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This Special Issue relates to the 18th biannual International Gap Junction Conference (IGJC2017),
held at the Crowne Plaza Hotel, Glasgow, U.K., from the 29 July–2 August 2017. The special issue,
entitled: Interplay of Connexins and Pannexins in Tissue Function and Disease focused on six key state
of the art reviews written by chairs of the sessions highlighting the assembly and functional interactions
of connexins and pannexins in diverse tissues and disease states, with translational outputs emerging.
A further 14 articles detail specific contributions that were presented as oral communications (Table 1).
The meeting was attended by over 200 delegates from 24 different countries and celebrated 50 years of
Gap Junction Research.
Table 1. Publication contents of this special issue.
Topic Reviews Participant Contributions
Trafficking, Assembly, Gating and Protein-Protein Interactions [1,2] [3–7]
Cardiovascular System [8] [9–13]
Connexins and Tumorigenesis [14] [15,16]
Epithelial Tissue, Wound Healing [17] [18,19]
Connexin Therapy Translates to Clinic [20]
Connexins and pannexins are tetramembrane spanning channel proteins with a shared topology
and related functional properties. They oligomerise to form channels in the plasma membrane
with two extracellular loops that project into the extracellular space and an intracellular carboxyl
tail is subject to post-translational modification. Within the connexin family (21 members in man),
these extracellular loops interdigitate and dockwith loops from neighbouring cells to form dodecameric
intercellular gap junction channels (GJCs) that link the cytoplasm’s of neighbouring cells. These
GJCs enable the regulated exchange of over 300,000 metabolites of less than 1000 Da in size, in so
doing co-ordinating specific cell and tissue homeostasis. Connexin compatibility is highlighted by
phylogenetic classification into three–four specific subgroups, with only specific heteromeric channel
combinations possible and in so doing facilitating the segregation of tissue compartments.
Over the last 15 years, it has emerged that connexin hemichannels can be triggered to
open under conditions of cell stress releasing signalling molecules such as ATP, glutamate and
Nicotinamide adenine dinucleotide (NAD) into the extracellular environment and subsequently
elicit localised extracellular signalling cascades via purinergic receptors. Pannexins, proteins forming
hemichannel-like structures, identified about 15 years ago, share a common topology but no sequence
homology with connexins, are thought to be evolutionary related to the innexins, gap junction forming
proteins in invertebrates. Unlike connexins (and innexins) pannexins are highly glycosylated proteins
and act to release ATP, engaging with downstream signalling pathways. In particular, pannexin
Int. J. Mol. Sci. 2018, 19, 2823; doi:10.3390/ijms19092823 www.mdpi.com/journal/ijms1
Int. J. Mol. Sci. 2018, 19, 2823
signalling has been closely linked with inflammatory mediated events, where caspase1 cleavage of the
carboxyl tail renders these channels constitutively open and triggers cell death ‘find me’ signals.
Due to the diversity of connexin and pannexin expression in tissue networks, their importance
cannot be underestimated and they are now firmly established as key proteins in diverse tissue
networks including the cardiovascular system, the skin, the nervous system, the liver, the ocular,
respiratory and immune system. Further, changes in connexin expression and function occur in disease
states associated with all of these tissues: Tumorigenesis, diabetic retinopathy, cardiac arrhythmia,
atherosclerosis, stroke, Alzheimer’s disease, chronic non–healing skin wounds, and inflammation
of epithelial tissue, to name a few. A range of mutations in connexins are associated with clinical
disease, where mutations in Cx26 are among the most common in recessively inherited hearing
impairment, Cx32 with the demyelinating disorder Charcot Marie Tooth-Linked disease, Cx43 with
oculodentodigital dysplasia, and Cx46 and Cx50 with familial cataract formation. All these diseases
impact on the quality of life, healthcare resources, ageing populations and many with conditions that
can be managed with current therapies, but not cured.
Thus, connexins and pannexins have emerged as prime therapeutic targets for a diverse range of
disease states. These channels are amenable to targeting therapeutically and a range of antisense and
peptidomimetic strategies have emerged as key regulators of channel function. Such regulators were
first identified over 25 years ago when Evans and Warner synthesised the first mimetic peptides and
antibodies that mimicked amino acid sequences on the extracellular loops. These tools are now widely
used by the research community to define the role of connexins and pannexins in tissue function
and are proving successful in translational research where the success of clinical trials of a connexin
targeted therapy, from bench to bedside, for improving wound healing events is reported in this
special issue.
The Editors thank all contributors to this special issue, delegates and in the conference support
team for the successful running of IGJC2017. The follow-up meeting will be held in Victoria, Vancouver
Island, July 2019 (#IGJC2019).
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Abstract: Connexins are tetraspan transmembrane proteins that form gap junctions and facilitate
direct intercellular communication, a critical feature for the development, function, and homeostasis
of tissues and organs. In addition, a growing number of gap junction-independent functions are
being ascribed to these proteins. The connexin gene family is under extensive regulation at the
transcriptional and post-transcriptional level, and undergoes numerous modifications at the protein
level, including phosphorylation, which ultimately affects their trafficking, stability, and function.
Here, we summarize these key regulatory events, with emphasis on how these affect connexin
multifunctionality in health and disease.
Keywords: connexins; gap junctions; transcription; translation; post-translationalmodifications; trafficking
1. Introduction
Since the cloning of the first connexins in the 1980s, steady progress towards elucidating their
regulation and function as signaling hubs and mediators of direct intercellular communication has
been made [1–3]. All connexins share a conserved four-transmembrane domain structure that
assembles into hexameric pores known as connexons that can integrate into the cell membrane
(Figure 1). Hundreds to thousands of these connexons typically dock with opposing connexons in
an adjacent cell, creating intercellular channels forming a clustered gap junction plaque that permits
direct flux of ions and small cytosolic signaling molecules between cells, commonly referred to as
gap junctional intercellular communication (GJIC) (Figure 1). More recently, connexons have been
shown to act as “hemichannels” to facilitate direct exchange of molecules between the cell cytosol
and the extracellular milieu under specific conditions [4]. Additionally, numerous noncanonical
channel-independent functions have been described, in particular for connexin 43 (Cx43), which are
mediated through direct protein interactions and modulation of signaling pathways [5]. The complexity
and isoform-specificity of the connexin gene family is reflected by their links to numerous human
diseases, many of which are rare syndromes with unique genotype–phenotype associations [6,7].
This latter phenomenon is underscored by the observation that mutations in different connexins
can cause the same disease, whereas varying mutations in one connexin gene can result in vastly
Int. J. Mol. Sci. 2018, 19, 1296; doi:10.3390/ijms19051296 www.mdpi.com/journal/ijms6
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divergent diseases and phenotypes. Dysregulation of connexins is also increasingly linked to many
common and often morbid medical conditions—such as stroke, heart attack, and cancer—which have
been linked to the discovery of an expanding number of new functional attributes through both
gap junction-dependent and -independent mechanisms [2,3,6–9]. As such, exploring the clinical and
therapeutic potential of connexins as drug targets is pertinent and ongoing [10–12]. Towards this,
a deeper understanding of how these genes and proteins are regulated and function is essential. This
review aims to summarize and underscore important and unique mechanisms that regulate connexin
function in healthy and diseased states, which ultimately shed light on clinical observations and future
therapeutic opportunities.
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Figure 1. Connexins form hexameric connexons permeable to small molecules acting either as
hemichannels or as intercellular channels. The human GJA1 gene, encoding for connexin 43 (Cx43),
contains two exons spanning a genomic region of 14,168 bp. Exon 1 contains 256 bp of the 5′ UTR
(untranslated region), whereas exon 2 encompasses 16 bp of the 5′ UTR, the entire coding region
(1149 bp), and the entire 3′ UTR region (1748 bp). Transcription of mRNA (3169 bp) is under regulation
by numerous transcription factors as indicated in this figure and in the main text. Notably, Sp-1 and
AP-1 are key regulators of Cx43 mRNA expression (grouped in blue). Multiple tissue-specific promoters
are active, which has been well described in the heart (grouped in red). Additional transcription factors
(grouped in light red) are derived from promoter analysis using the online Lasagna-Search tool (using a
very strict cut-off of p < 0.0001 and Transfac transcription factor binding sites) [13]. Epigenetics regulate
transcription, including through promoter hypermethylation by DNA methyltransferase enzymes
(DNMTs). Acetylation by histone acetyltransferase enzymes (HATs) promote transcription, and the
reverse reaction is mediated by histone deacetylases (HDACs). The transcript is also regulated by
numerous microRNAs (see main text for details). In addition to full-length Cx43 (43 kilodalton (kDa)),
the same mRNA can produce multiple truncated forms via internal translation initiation (indicated by
arrows within the CDS (coding DNA sequence) of the mRNA, most notably the 20 kDa form named
GJA1-20k). Truncated forms are also under translational regulation by a number of pathways such as
mechanistic target of rapamycin (mTOR) and mitogen-activated protein kinase (MAPK)-interacting
serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2), and can be induced by inhibitors of these
pathways as well as by other specific drugs such as cyclosporin A (the positive regulators are depicted
in green). GJA1-20k is also induced by pathological states such as hypoxia. The function of GJA1-20k
may include interaction with mitochondria and regulation of the actin cytoskeleton as well as regulation
of Cx43 oligomerization and trafficking to the membrane. See main text for further details related to
the figure.
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2. Connexins: From Gene to Protein
2.1. Gene Structure and Splicing
Twenty-one human genes and 20 mouse genes encoding for connexin proteins have been
identified, of which 19 are considered orthologous pairs [14,15]. The genes tend to have distinct
chromosomal locations, although there are some regions of the genome containing clusters of connexin
genes [14]. Most connexin genes share a common structure consisting of two exons separated by an
intron of variable size. The majority of the 5′ UTR (untranslated region) is localized on exon 1, whereas
the entire coding region and the 3′ UTR are found in exon 2. Some connexin genes contain more than
two exons (for the 5′ UTR of the transcript), such as human GJA5 (Cx40) [16], which contains three
exons producing two distinct and tissue-specific transcripts, and GJB6 (Cx30), described to contain
six exons that allows for tissue-specific splicing [17]. Mouse connexin genes with three or more exons
include Gjb1 (Cx32) [18], Gja1 (Cx43) [19], and Gjc1 (Cx45) [20]. In a few cases, the coding region is
also distributed over more than one exon [21–24]. A basal promoter (P1) is typically found within
300 bp upstream of the transcription initiation site of exon 1 [25]. However, splice isoforms have been
reported due to alternate promoter usage, yielding different transcripts with the coding region being
unaltered. As such, a deeper understanding of connexin gene structure, promoter usage, and splicing
pattern is required for a full understanding of their impact in connexin-related diseases. For example,
the human GJB1 gene encoding Cx32 contains at least three exons (E1, E1B, and the coding exon E2)
and produces two different alternatively spliced transcripts by using two tissue-specific promoters (P1
and P2) [26]. It is thus pertinent to include this region in mutational screening of dominant X-linked
Charcot-Marie-Tooth (CMTX1) disease, a type of neuropathy that can be caused by mutations in Cx32
leading to defects in Schwann cell function, at least in cases where no mutations are found in the
Cx32 coding region. Indeed, recent studies have identified mutations affecting GJB1 splicing [27],
and even deletion of the GJB1 P2 promoter [28], as underlying causes of CMTX1. Others have shown
that splicing mutations in GJC2 encoding Cx47 can cause a severe form of Pelizaeus-Merzbacher-like
disease [29]. Another splice-site mutation, in GJB2 encoding Cx26, has been suggested to cause a mild
postlingual onset form of hearing loss [30].
In addition to these more well-described biological phenomena, a few connexin pseudogenes
(genes thought to originate from decay of genes that stems from duplication through evolution)
have been identified in the human genome. The GJA1 pseudogene (GJA1P) is located on human
chromosome 5, whereas the regular GJA1 gene encoding for Cx43 is located on chromosome 6.
Although most pseudogenes are thought to be nonfunctional, GJA1P appears to be transcribed,
possibly even translated, and may regulate tumor growth [31,32]. Mutations in GJA1P have also been
associated with nonsyndromic deafness [33]. Functionally, GJA1P may influenceGJA1 expression levels
by acting as a microRNA sponge [34]. In contrast, GJA6P seems to be a nonfunctional pseudogene,
originated from the mouse Gja6 connexin gene encoding Cx33, which has no human counterpart
(Gene ID: 100126825). Another potential pseudogene has been inferred for GJA4 (Gene ID: 100421028)
encoding Cx37. The role of pseudogenes in disease is an emerging field, particularly among genes
causing multiple different diseases or syndromic diseases, such as connexins.
2.2. Transcription Factors and Epigenetics
Connexins are expressed distinctively in almost all vertebrate cell types (excluding erythrocytes,
mature sperm cells, and differentiated skeletal muscle cells) [35]. Some connexins (notably Cx43) are
expressed in numerous cell types, whereas others show a more restricted expression profile (e.g., Cx50
that is mainly found in lens cells). Most tissues express multiple connexins. The epidermis of the
skin, for example, is thought to express at least 10 different connexins whose expression partially
overlap during keratinocyte stratification and differentiation [36–38]. Five of these connexins underlie
11 clinically different cutaneous disorders [37,39]. This spatiotemporal expression pattern is in large
part controlled by transcription factors and epigenetic mechanisms. Several transcription factors acting
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as regulators of basal (ubiquitous) or cell-specific gene activity, and their upstream signal transduction
pathways, have been implicated in the control of connexin expression (Figure 1). Notably, specificity
protein 1 (Sp1), an important basal transcription factor that binds to GC box sequences in promoter
regions, has been reported to favor transcriptional initiation of several connexin genes, including
Cx26 [40], Cx32 [41,42], Cx40 [16,43–47], and Cx43 [45,48–53]. Examples of other important regulators
that control connexin gene expression include: (i) Activator protein 1 (AP1) transcription factor,
composed of proteins belonging to the c-Fos, c-Jun, activating transcription factor (ATF), and J domain
containing protein( JDP) families that typically promote positive regulation. AP-1 sites have mainly
been described in Cx43 [48,54,55], whereas putative sites have been identified in the Cx45 promoter [56].
(ii) The Wnt pathway: activation of this pathway leads to the formation of nuclear β catenin/TCF
(T-cell factor) complexes that act as transcription factors by binding to specific TCF/LEF (lymphoid
enhancer-binding factor) motifs present in the promoter of human GJA1 and mouse Gja1 encoding
Cx43 [57]. From a physiological and disease point of view, this may also be relevant. For example, one
study showed Wnt signaling could modulate Cx43-dependent GJIC in the heart, which ultimately may
contribute to altered impulse propagation and arrhythmia in the myopathic heart [58]. The importance
of GJIC in the heart is well documented and several cell-specific transcription factors have been
shown to either activate or repress connexin gene expression in this setting (Figure 1 (red box),
reviewed in [25,59]). These studies have revealed a role of: (i) homeobox proteins, transcription factors
with a unique DNA-binding domain that target gene promoter sequences by self-complementarity
(e.g., Nkx2.5, Hop, Shox2, Irx3); (ii) T-box (Tbx) proteins, transcription factors that possess a domain
that recognizes a DNA binding element (e.g., Tbx2, Tbx3, Tbx5, Tbx18); and (iii) GATA proteins,
important regulators of specific gene expression in different tissue (e.g., GATA-4) [25,59].
Besides the well-described transcriptional regulation of the cardiac connexins, other cases of
tissue-specific regulation have been reported (for an overview, see [25]). Cx32 transcription has been
found to be positively regulated by hepatocyte nuclear factor-1 (HNF-1) via Sp1 in liver cells [60], by
the transcription factor Mist1 in secretory pancreatic acinar cells [61], and by the Sox10 in synergy
with the early growth response-2 gene (Egr2) in Schwann cells [62]. This exemplifies how different
transcription factors act in a tissue-dependent fashion. Complex transcriptional control thus allows for
tissue-specific regulation of connexin expression. It also facilitates rapid response to environmental
changes, for example, progesterone and estrogen act as positive and negative regulators, respectively,
of Cx43 transcription in the myometrium during pregnancy and labor [63]. Transcription factors are
also important during pathological states, such as in ischemia, where multiple connexins are emerging
as important injury response mediators. Their roles in complex disease, such as cancer, are also being
unraveled. In breast cancer, for example, Cx43 has been proposed to play a biphasic role acting both as
a tumor promotor and a tumor suppressor depending on context such as cancer subtype and stage [3].
In this setting, the aforementioned role of progesterone and estrogen as regulators of Cx43 expression
may be of importance. Recent evidence also suggests that the transcription factor FOXP3 directly
binds to and inhibits RUNX1 in mammary epithelial cells, whereas in the absence of FOXP3 in breast
tumors, RUNX1 downregulates Cx43 expression [64]. Understanding the role of transcription factors
will provide further insight into loss and overexpression of connexins during tumor progression and
other pathological states.
Connexin expression is also under significant epigenetic regulation (for recent extensive reviews
see [25,65]). Two major epigenetic mechanisms have been described to regulate transcriptional control:
DNA methylation and histone acetylation. Connexin gene inactivation due to hypermethylation of
CpG islands in the promoter region has been described in various human carcinomas, including Cx26
in lung [66] and breast [67], Cx32 in a renal cell carcinoma cell line [68], and Cx43 in breast cancer [69].
In addition, a gradual decrease in Cx32 and Cx43 mRNA expression levels is associated with promoter
hypermethylation in Helicobacter pylori-associated gastric tumorigenesis [70]. Transcriptional silencing
via promoter hypermethylation is mediated by the enzyme DNA methyltransferase (DNMT). The
use of demethylating drugs (DNMTs inhibitors), such as 5-aza-2-deoxycytidine and 5-azacytidine,
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has been proposed as a potential therapeutic solution in cancer, as an increase connexin expression
and/or GJIC has been demonstrated in specific cases [68,71,72]. However, the correlation between
hypermethylation and gene expression is not always direct and differs between connexin isoforms [72].
Histone acetylation and deacetylation—causing chromatin decondensation and condensation,
respectively—constitute other important mechanisms of epigenetic regulation of connexin
transcription [25,65]. While acetylation is catalyzed by histone acetyltransferase (HAT) enzymes
and promotes transcription, the reverse reaction is mediated by histone deacetylase (HDAC) enzymes.
Histone acetylation also affects connexin expression, and inhibitors of HDAC enzymes (HDACi)—such
as trichostatin A, sodium butyrate, and 4-phenylbutarate—have been shown to enhance connexin and
GJIC in a variety of cell populations, including in cancer cells [73], in which therapeutic and preventive
roles for specific HDACi have been proposed. Histone deacetylase inhibition has also been shown to
reduce Cx43 expression and gap junction communication in cardiac cells [74], which has implications
with regards to potential side effects such as slow ventricular conduction or arrhythmias. Therefore,
the action of HDACi seems to be connexin- and cell type-dependent. Curiously, Cx43 has been shown
to influence histone acetylation of other genes; in a human pulmonary giant cell carcinoma cell line,
the follistatin-like 1 (FSTL1) promoter was shown to be associated with acetylated histones H3 and H4
upon Cx43 transfection. Cx43 was proposed to act as a “histone deacetylase inhibitor” that modulates
gene expression and inhibits tumor invasion [75].
The potential therapeutic role of epigenetic regulations has broad interest, particularly in
complex diseases such as cancer, as exemplified above. However, the nonspecific nature of this
gene regulatory mode complicates more direct and specific therapeutic targeting. Moreover, research
is needed to determine if connexin levels are mainly mediated via HDACi histone modification [73,76],
via non-histone protein modification of transcription factors, or via direct or indirect connexin protein
modification such as Cx43 acetylation or phosphorylation [77–79].
2.3. RNA Stability and MicroRNAs
MicroRNAs (miRNAs) are short single-stranded noncoding RNAs that can regulate expression at
a post-transcriptional level by base pairing to mRNA sequences (usually located at the 3′ UTR region),
reducing protein expression levels via mRNA degradation, translational inhibition, or transient mRNA
sequestration. Numerous microRNAs have been predicted to downregulate the expression of different
connexin genes (for recent reviews see [65,80]). Cx43 is by far the best studied connexin, and a number
of functional microRNAs targeting this gene have been identified, including miR-1, miR-23a, miR-186,
miR-200a, miR-206, and miR-381 in human breast cancer [81], miR-20a in human prostate cancer [82],
miR-221/222 in glioblastoma multiforme [83], and miR-206, miR-1, and miR-133 in cardiac myocytes
and during skeletal myoblast differentiation [84–86].
Regulation of connexin expression by miRNAs has been described to be active in various disease
states (for example, in cancer) by affecting hallmarks such as proliferation and invasion [82,83].
In therapeutic settings, options include targeting miRNAs that regulate connexins in order to reverse
the malignant phenotype. This has been shown in several studies, including in human glioblastoma
cells, where inhibition of miR-221/222 activity with antisense oligonucleotides led to the upregulation
of Cx43 and restoration of GJIC [83].
As mentioned above, miR-1 acts in cardiac muscle and downregulates Cx43 expression.
This has been related to several cardiopathologies in humans, including the regulation of cardiac
arrhythmogenic potential [86]. In contrast, loss of miR-1, and thus increased Cx43 expression, has been
linked to myotonic dystrophy [87]. Interestingly, a severe congenital heart defect, tetralogy of Fallot, is
associated with downregulation of miR-1 and miR-206, which is thought to lead to an increase in Cx43
protein levels [88]. miR-1 downregulation of Cx43 in the bladder musculature has also been reported
to have a role in overactive bladder syndrome [89].
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Connexins are implicated in joint and bone disease [90]. Cx43 has an important role in osteoblast
growth and differentiation, and various miRNAs (including miR-23a [91] and miR144-3p [92]) have
been shown to target Cx43 in this setting. Cx43 can also influence the expression of miRNAs
themselves, notably miR-21 in osteocytes, a pathway linked to osteocyte apoptosis and osteoclast
formation/recruitment [93]. Moreover, direct transfer of miRNAs—through gap junctions—has been
described, and is thought to play a role in bone development [94] as well as in aspects of tumor growth
and tumor dormancy [3].
In addition to miRNAs, connexin transcript stability can be regulated by RNA-binding
proteins (RBPs), such as human antigen R (HuR) that stabilizes the Cx43 mRNA by binding
adenylate/uridine-rich elements (AREs) present in the Cx43 3′ UTR [95]. Other examples include
S1516-binding protein elements, which may regulate Cx43 expression, particularly in Ras-transformed
cancers [96]. For further insight into the epigenetic regulation of connexins, including by miRNAs,
we refer to other more exhaustive recent reviews [65,80].
2.4. Translational Regulation
2.4.1. Internal Ribosome Entry Site (IRES)
Due to the key role of connexins in sustaining many cellular functions and tissue physiology, it has
been suggested that connexin expression needs to be maintained at all times, even under conditions
where the classical cap-dependent mRNA translation pathway is suppressed, such as during mitosis,
apoptosis, differentiation, senescence, or cell stress [97,98]. Several internal ribosome entry site (IRESs)
elements have been reported in the mRNA of connexins, notably in Cx43 [99] (Figure 1), Cx32 [100],
and Cx26 [101]. An IRES is a nucleotide sequence, usually located within the 5′ UTR of the mRNA,
which—in contrast with the canonical translation mechanism—allows for cap-independent translation
initiation, a process regulated by specific RBPs also known as IRES trans-acting factors (ITAFs) [102,103].
However, numerous other translation initiation mechanisms are thought to exist [104] and whether
true IRES-mediated translation occurs in the aforementioned connexins and other family members,
is subject to caution, and additional specific molecular assays are warranted [105]. Additional work is
also needed towards elucidating their functional relevance. One study suggests that IRES-mediated
translation of Cx26 and Cx43 occurs in density-inhibited cancer cells (where cap-dependent translation
is reduced), thus leading to the induction of GJIC and potentially reduced tumor growth [101]. Some
data also points towards an important role of IRES-translation of connexins in human physiology.
Notably, a specific mutation in the 5′ UTR IRES sequence of Cx32 is linked to neurodegenerative
Charcot–Marie–Tooth disease [100].
2.4.2. Alternative Translation of Truncated Connexin Forms
Most IRES sequences are located in the 5′ UTR, yet a few examples exist (notably Notch2 [106])
where an IRES sequence is located within the coding region, allowing translation of truncated protein
forms. A similar mechanism has been proposed for Cx55.5 in zebrafish, in which an 11 kilodalton
(kDa) truncated C-terminal form is produced and localizes to the nucleus of outer retina cells [107,108].
In mammalian cells, the presence of truncated forms of Cx43 is often observed in immunoblots.
In particular, a 20 kDa form (named GJA1-20k) is highly prevalent in cultured cells, which was
described to arise from the Cx43 coding sequence and correspond to the C-terminal tail [109]. More
recently, Smyth and Shaw described that GJA1-20k and several other less prevalent truncated forms
can occur in normal tissue, and is due to internal translation initiation events [110]. Multiple groups
have now confirmed this observation and further delineated key regulatory pathways, such as
the mechanistic target of rapamycin (mTOR) [110,111] and the mitogen-activated protein kinase
(MAPK)-interacting serine/threonine-protein kinase 1 (MNK1) and 2 (MNK2) [111] signaling cascades.
Additionally, regulation occurs in response to important physiological conditions such as hypoxia [112]
(Figure 1). Although an internal IRES element has been suggested [112], evidence suggests a
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highly unusual cap-dependent mechanism is critical for the efficient synthesis of these truncated
forms [80,111].
The C-terminus of Cx43 has been extensively studied and is implicated in the regulation of a
variety of biological events such as cell migration and proliferation, neuronal differentiation, and
cytoskeletal changes (for a recent review see [5]). However, functional roles for specific internally
truncated forms of Cx43 are currently being elucidated. Thus far, GJA1-20k has been shown to act as
a potential chaperone for Cx43 [110,113] that facilitates microtubule-based mitochondrial transport
and mitochondrial network integrity [114] (for details, see Section 4.3). Additionally, loss of GJA1-20k
(but not full-length Cx43) has been reported in early-stage human breast cancers, followed by its
re-expression in cell lines regulated by p53 activation via miR-125b [115]. Roles for these truncated
forms of connexins in complex genetic disease is of future interest considering recent advancements in
the potential for pharmacologic modulation of internal translation [80].
3. Post-Translational Regulation of Connexins
Post-translational modification of connexin proteins regulates many important aspects of
their life-cycle, including synthesis, trafficking, channel gating, and protein–protein interactions.
While highly conserved, variations occur throughout the connexin family in protein sequence, size
of intracellular N-/C-terminus, and loop regions. Connexin extracellular loop regions contain
disulfide bridges that form between cysteines to maintain membrane topology and facilitate
docking with opposing connexons, allowing the formation of gap junctions [116]. Unlike many
other membrane-bound proteins, connexins are not glycosylated, with membrane trafficking
and protein folding being regulated through alternative pathways (for details, see Section 4).
The relatively unstructured nature of intracellular connexin domains makes for an ideal environment
for post-translational modification to induce conformational changes that regulate protein–protein
interactions. The majority of connexins contain multiple consensus sites for modifications through
phosphorylation, S-nitrosylation, SUMOylation, and others. There have been several recent
and comprehensive reviews on connexin post-translational modifications [5,117–119]. Instead
of recapitulating these articles, we will highlight some of the main aspects of post-translational
modifications of connexins and discuss their relevance in human disease.
3.1. Phosphorylation
Phosphorylation is a key regulator of connexin proteins, hemichannels, and gap junction
channels [120–122]. The addition of phosphate groups to specific amino acids—including serine
(Ser, S), threonine (Thr, T), or tyrosine (Tyr, Y)—leads to changes in charge, hydrophobicity, and
potential alterations in protein structure resulting from formation of hydrogen bond networks [123].
These can alter the way the connexin protein interacts with itself (e.g., channel regulation) or with
other proteins (e.g., trafficking and protein–protein interactions).
Phosphorylation has been reported in a large number of connexins, e.g., Cx31 [124],
Cx32 [125–127], Cx37, Cx40 and Cx45 [128,129], Cx43 [130,131], Cx46 and Cx50 [132–134], and
Cx47 [135]. The majority of phosphorylation events are reported within the connexin C-terminus, with
the exception of Cx26, which is not phosphorylated in its short 11 a.a. C-terminus [136,137]. However,
mass spectrometry has demonstrated multiple potential Cx26 phosphorylation sites in the N-terminus,
which are differentially regulated by hydroxylation, and further putative sites in the cytoplasmic
loop, although the functions of these Cx26 phosphorylation sites are unknown [138,139]. There are
some reports of intracellular loop phosphorylation—such as Cx56 [140] and Cx35 [141]—although
this does not appear to be the case for Cx43 or other connexins [5,142,143]. There are no reports
of N-terminus phosphorylation in other connexins, although Cx43–Ser5 is a potential candidate
site [144]. The C-terminus of connexins are intrinsically disordered protein (IDP) regions with a high
Ser/Thr/Tyr content, as described for Cx32, Cx40, Cx43, Cx45, and Cx50 [145–149]. Stable α-helical
regions have been identified by nuclear magnetic resonance (NMR) and circular dichroism (CD) in
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the C-terminus of Cx43 [146,150] and other connexins, for example, Cx37, Cx45, and Cx50 [151–154].
However, stable alpha-helices are not a common feature of the connexin C-terminus. For instance,
Cx40 only forms dynamic alpha-helices between Cys267–Gly285 [155]. Several lines of evidence—such
as electrophoretic shifts on SDS-PAGE gels and NMR analysis—suggest that phosphorylation by
enzymes, such as MAPK and Protein Kinase C (PKC), result in differential, transient increases in
connexin C-terminal alpha-helical content [128,149,156–158].
The significance of the formation of alpha-helical domains is the potential for higher order
secondary structures that regulate channel gating and protein partner binding. In Cx43, it has been
demonstrated that the C-terminus interacts with the intercellular loop to regulate channel functions
in a “ball-and-chain” type mechanism [159,160], although other factors relating to phosphorylation
(e.g., charge and hydrophobicity) may also influence channel gating. Multisite phosphorylation
of proteins is known to alter protein half-life, docking, and intracellular localization, which may
also influence gap junction signaling [148,149,161]. Connexin 43, the most widely studied of the
connexin family, has 30 putative phosphorylation sites which have been extensively demonstrated
to be post-translationally modified, leading to alterations in gap junction signaling. For detailed
reviews of these phosphorylation sites and their effects on channel regulation see [5,143,144,162–164].
The effects of post-translational modifications on connexins are also shown in Table 1.
Table 1. Connexin post-translational modifications (PTMs) and functional effects.







N170/N176 Hydroxylation ND ND
E42/E47/E114 carboxylation ND ND
K61/R75/






263 b CK1 No change No change [124]
266 b CK1 No change No change [124]
Cx32:
S229 PKC Increase/Decrease Increase/Decrease [165]
S233 PKA/PKC Increase/Decrease Increase/Decrease [120,138,165,166]
S240 ND ND ND [138]
Y7/Y243 EGFR tyrosine kinase ND ND [167]
Cx35/Cx36:
S110 PKA/PKG No change Decrease [141,168–170]
S276/293 PKA/PKG No change Decrease [141,168–171]





PKC Increased Decrease [128]
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Table 1. Cont.
Connexin/Residue PTM GJIC Expression Refs.
Cx43:
S5 m.s. ND ND ND [144]
K144 SUMO Increase Increase [172]
K237 SUMO Increase Increase [172]
S244 m.s. CAMKII ND ND [173]
Y247 c Src Decrease Decrease c [120,146,174–178]
S255 m.s.
CAMKII ND ND [173]
P34cdc2 Decrease Decrease [179,180]
MAPK No change/Decrease No change [120,131,148,181]
S257 m.s. PKG/CAMKII ND ND [173]
S262 d
P34cdc2 Decrease Decrease [179,180]
MAPK Decrease Decrease/no change [120,131,148,182,183]
PKCε a Decrease Decrease [131,181,182]
Y265 c Src Decrease Decrease c [120,146,174–178]







MAPK Decrease Decrease/no change [131,148,174]
CDK5 Decrease Decrease [185]
S296 m.s. CAMKII ND No change [173,186]
S297 m.s. CAMKII/PKCε ND No change [173,186]
S306 m.s. CAMKII Decrease Decrease associatedwith De-Phosph. [173,186,187]
S314 m.s. CAMKII ND ND [173]
S325 m.s.
CAMKII ND ND [173]
CK1 Increase Increase [188]
S328 m.s.
CAMKII ND ND [173]
CK1 Increase Increase [188]
S330 m.s.
CAMKII ND ND [173]
CK1 Increase Increase [188]
S364 m.s.
CAMKII ND ND [173]
PKA Increase Increase [120,189–191]
S365 m.s.
CAMKII ND ND [173]
PKA Increase Increase
PKC Decrease Decrease [120,192–194]
S368 f
PKCα Increase/Preserved/ Increase [192–196]
PKCε Decrease g Decrease [120,193–199]
S369 m.s.
CAMKII ND ND
PKA Increase No change [173]
PKC Increase Increase [5,120,192–194]
S372 m.s.
CAMKII ND ND [173]
PKC Decrease Decrease [5,148,192,193,200,201]
S373 g,m.s.
Akt Increase Increase e [200,201]
CAMKII ND ND [173]
PKC Decrease Decrease
PKA Increase Increase [120,148,192–194]
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Table 1. Cont.





CAMKII ND ND [129]
S326/S382/S384/
S387/S393 m.s. CK1 ND ND [129]
Cx46 (Cx56 Chick homologue):
S118 PKCε ND Decrease [140,202]
Cx50:
S363 CK1 Increase Increase [120,193]
Notes: a mass spec identified a number of potential phosphorylation sites in Cx26 but did not test functions, although
mutations at many of these sites are associated with disease pathology [139]. b Direct phosphorylation not shown,
S263 and S266 on Cx31 contain consensus sequence for Ck1 which, when deleted, alters functions. c Src may not alter
function of formed gap junctions. d Currently debated as to whether Cx43-S262 is a CDK1/CDC2/PKC/MAPK site,
and several lines of evidence indicate that this is most likely an ERK-regulated site [148]. e Functions of S279/S282
typically shown by single phosphorylation antibodies or multiple site directed mutagenesis including both residues.
Decrease GJIC as a result of reduced open probability. f Phosphorylation of S368 by phorbyl esters, e.g., TPA,
are associated with PKCε phosphorylation and reduced communication. In ischemia, treatment by peptides, e.g.,
rotagaptide, increase S368 phosphorylation by PKCα, leading to increases in GJIC. g While initial phosphorylation
at S373 is associated with a temporal increase in GJ size, it is thought to be the start in the process that leads to
internalization. Abbreviations: ND, not demonstrated; (m), mouse; m.s., mass spectrometry-based identification
approach. GJIC, gap junction intercellular communication; EGFR, epidermal growth factor receptor; PKA/PKC,
Protein kinase A/ Protein kinase C; NO, nitric oxide; SUMO, small ubiquitin-like modifier.
Phosphorylation is a key regulator of physiological states in tissues, and changes in the
phosphorylation status has been observed in several disease states. Within the vasculature,
heterocellular endothelial cell–smooth muscle cell contacts, called the myoendothelial junctions (MEJs),
express Cx37, Cx40, and Cx43, allowing for the direct exchange of intercellular signaling ions and
molecules such as Ca2+ and IP3 [203,204]. At theMEJ, Cx43 and Cx37 are regulated by post-translational
modifications, including phosphorylation and S-nitrosylation (for details, see Section 3.2). In vitro and
ex vivo data demonstrate that gap junctions at MEJs allow for the movement of Ca2+ and IP3 between
endothelial and vascular smooth muscle cells, which is in part regulated via Cx43-Ser368 [205].
In the healthy heart, Cx43 is primarily localized to the intercalated disc region of cardiomyocytes.
Opening of Cx43-containing channels and signal conduction is facilitated by phosphorylation at
residues including Ser365, 325, 328, and 330 [206–208]. Phosphorylation acts as a molecular switch,
regulating gap junction opening. In ventricular arrhythmias following myocardial infarction, raised
intracellular Ca2+ concentration leads to de-phosphorylation of Cx43-Ser365, which acts as the
gatekeeper to phosphorylation of Cx43-Ser368. This resulting increase in Cx43-Ser368 reduces GJIC
and promotes a redistribution of Cx43 to lateral regions of the cardiac myocytes, disrupting signaling
in the heart [208–210].
Formation of large cardiac gap junction plaques at the intercalated disc is modulated through
Cx43 interactions with zonula occludens 1 (ZO-1) [211–214]. In turn, this protein–protein interaction is
regulated by PKC phosphorylation of Cx43 at Ser368, which inhibits ZO-1-mediated disassembly of
gap junctions [215]. In ischemic heart disease, Cx43 is lost at the intercalated disc, but Cx43-Ser368
phosphorylation can act to indirectly stabilize the protein [196]. Multiple studies have investigated the
effects of targeting the C-terminus of Cx43 in ischemia/reperfusion injuries, reducing infarct size, and
other diseases [11,216]. A peptide that mimics the terminal region of the Cx43 known as ACT1 can
disrupt Cx43/ZO-1 interaction [214,217]. This peptide promotes phosphorylation of Cx43-Ser368 via
upregulation of PKCε activity, inhibits Cx43-ZO-1 binding, and improves cardiac function following
ischemic insult in mice [215]. Similar results have been found for other connexin mimetic peptides
targeting the Cx43 C-terminus (e.g., antiarrhythmic peptide 10 (AAP10) and rotigaptide (ZP123)),
causing increases in Cx43-Ser368 phosphorylation through PKCα (reported to stabilize protein
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expression and increase GJIC) associated with improved cardiac functions in experimental animal
models and early tests demonstrating no adverse effects in humans [192,218–222]. However, it should
be noted that a similar peptide, danegaptide (a stabilized form of rotigaptide), failed to change
clinical outcomes in ischemic reperfusion injuries in human Phase II testing (NCT01977755, completed
2016) [223].
In vascular disease, phosphorylation-mediated connexin–protein interactions and GJIC have
been found to regulate disease state. Oxidized phospholipids found within atherosclerotic plaques
increase MAPK and PKC phosphorylation of Cx43 and are associated with increased inflammation and
cellular proliferation [130,224–227]. In response to the release of growth factors in disease, Cx43
is phosphorylated at MAPK residues (Cx43-Ser255, -Ser262, -Ser279, -Ser282), promoting direct
interactions with the cyclin E/CDK2 complex and enhancing smooth muscle cell proliferation [131].
Conversely, PKC phosphorylation of Cx37 alters GJIC, which is linked with growth suppressive effects
(e.g., reducing vasculogenesis and angiogenesis) [228–233]. Mutation of all seven Cx37 Ser > Ala
essentially closes Cx37 GJs and hemichannels and inhibits both proliferation and cell death, whereas
mutation of only three (Cx37-Ser275, -Ser302 and -Ser328) partially inhibits channel opening and
decreases cellular death in rat insulinoma cells [128].
Phosphorylation also plays an important role in altered localization and function of connexins
in cancer [3]. Several oncogenes and proto-oncogenes robustly inhibit GJIC, including HRAS [234],
c-Src [235], and v-Src [178]. Curiously, the tyrosine-protein kinase c-Src has a reciprocal relationship
with Cx43 that regulates its activity, where Cx43 is shown to bind with phosphatases (e.g., PTEN
and Csk) reducing c-Src activity [236]. Conversely, Src phosphorylation of tyrosine residues on Cx43
(Cx43-Tyr243/-Tyr265) mediates interactions with endosomal machinery, leading to internalization
of Cx43 and reduced expression [118,237]. Numerous tumor promoters, such as phorbol esters, also
rapidly inhibit Cx43-mediated GJIC [238–240] through PKC- and ERK-mediated phosphorylation
events [181,241]. On the contrary, loss of phosphorylation can also negatively affect GJIC. One
recent study showed that the levels of total Cx43 protein and Cx43 phosphorylated at Ser368
and Ser279/282 were high in normal tissue but low to absent in malignant pancreatic tissue [79].
Altered Cx43-phosphorylation can be indicative of prognosis in some tumors, such as gliomas [242].
Phosphorylation of other connexins can also affect GJIC and the cancer phenotype, notably
PKC-mediated phosphorylation of Cx37 [128]. Targeting dysregulated phosphorylation events of
connexins in cancer may be one therapeutic angle towards restoring connexin function or GJIC. Indeed,
the chemotherapeutic drug gefitinib has been suggested to upregulate GJIC by inhibiting Src and
PKC-modulated Cx43 phosphorylation [243]. However, resistance to cisplatin-based chemotherapy
has been suggested to be due to Src-induced Cx43 phosphorylation and loss of GJIC [244].
During wound healing, phosphorylation may also play a role in coordinating GJIC and connexin
redistribution [245–247]. Initial responses to wounding include a generalized loss in Cx43, which
may be modulated by increases in cyclic adenosine monophosphate (cAMP). In wound models,
8-bromo-cAMP-treated embryonic stem cells promote enhanced wound repair associated with reduced
membrane bound Cx43, disruption in Cx43-ZO-1 interactions, and reduced GJIC [248]. However,
the mechanisms regulating this are unclear, since cAMP-associated kinases have been previously
described to increase PKA-mediated Cx43 synthesis, phosphorylation (Cx43-Ser364), GJ assembly, and
GJIC in other model systems [189,249]. Phosphorylation is extremely dynamic within the wound and
appears to be coordinated with the stage of repair. Initial increases in Cx43-Ser373, driven by AKT,
can be seen between 1 and 30 min after wounding occurs, disrupting interactions with ZO-1, initially
stabilizing Cx43 at the membrane, but is followed by rapid internalization of Cx43 [200]. Following
wounding, transient increases (24–72 h) in PKC-mediated Cx43-Ser368 phosphorylation in regions
proximal to the injured sited are associated with a loss of GJIC [250,251]. These data and others suggest
that a combination of phosphorylation events sequentially regulate connexin signaling during wound
repair [252].
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In disease states such as diabetes, nonhealing wounds lead to complications, including ulcerations
in skin tissues. In streptozotocin-induced diabetic mice, Cx43 dynamics are different from normal
skin tissues, with increased expression of dermal Cx43 associated with reduction in keratinocyte
migration [253]. Similar observations have been made in human diabetic ulcers, with Cx43 found to
remain at elevated levels as compared to normal skin wounds [254]. In vitro and ex vivo evidence
suggests that peptides aimed at disrupting gap junction and hemichannel communication (e.g., Gap27)
can improve wound healing, which is associated with increased Cx43-Ser368 phosphorylation [251].
Recent studies have also shown that increases in Cx43-Ser368 phosphorylation following topical
application of the ACT1 peptide is associated with clinically significant improvements in scar reduction
and wound closure rates [255].
3.2. S-Nitrosylation
S-Nitrosylation occurs through covalent binding of nitric oxide (NO) to reactive cysteine(s) and can
result in structural alterations of proteins leading to functional changes [256]. Protein S-nitrosylation
is highly dependent on the cysteine oxidation state and surrounding amino acids, meaning that not
all cysteines in a protein can be S-nitrosylated. While there are cysteine residues on the extracellular
loops of all connexins, these have not been demonstrated to be S-nitrosylation targets [257]. Within
the C-terminus of Cx43, there are three cysteines (Cx43-Cys260, -Cys271, and -Cys298), but only
Cx43-Cys271 has been demonstrated to be S-nitrosylated, leading to an increase in GJ permeability
in endothelial cells and at the MEJ [184]. Direct S-nitrosylation of other connexins has not been
demonstrated, although there are multiple lines of evidence demonstrating that nitric oxide (NO)
activation leads to regulation of gap junction and hemichannel signaling [258]. Within the vasculature,
NO plays an important role in vasodilation. Figueroa et al. found that vascular connexins channels
formed by Cx37, Cx40, and Cx43 are activated by and directly permeable to NO, and have suggested
that this is an alternative method to NO transfer across plasma membranes [259]. Cx37 is enriched
at the MEJ of resistance arteries and is reported to be important in the regulation of NO-mediated
Ca2+ regulation via reducing Cx37-mediated gap junctional coupling between endothelial cells and
smooth muscle cells [260]. However, unlike Cx43, the effects of NO on Cx37 gap junction channels are
thought to be indirect, with no known cysteine modification occurring. Rather, the phosphorylated
tyrosine residue (Cx37-Tyr332) is protected from de-phosphorylation by Src homology region 2 (Shp2)
phosphatase, which is inhibited in the presence of NO, reducing MEJ transfer of Ca2+ signaling through
Cx37 GJ [261]. Thus, S-nitrosylation appears to have diverse effects, depending on GJ composition
particularly at the MEJ [261].
3.3. Other Post-Translational Modifications: SUMOylation, Ubiquitination, and Acetylation
A number of post-translational modifications are associated with regulation of connexin protein
turnover, for example, ubiquitination, SUMOylation, and acetylation. Small ubiquitin-like modifier
proteins (e.g., SUMO-1/-2/-3) interact with lysine residues on proteins, altering protein targeting
and turnover [262]. So far, there is only evidence for direct Cx43 SUMOylation at lysine residues
(Cx43-Lys144, -Lys237) within its intracellular loop and C-terminus [172]. Overexpression of all
three SUMO proteins in HeLa cells increases Cx43 expression, promotes gap junction formation,
and increases signaling. However, the exact mechanism by which SUMOylation regulates protein
expression is not known. The amino acids sequences surrounding Cx43-Lys144 and Cx43-Lys237
are not common motifs associated with SUMOylation, although the same motifs of a conserved
Lys144 followed by an upstream large hydrophobic amino acid (valine) are found in at least six other
connexins, suggesting a common regulatory pathway [172].
Once at the plasma membrane, the majority of connexins are rapidly turned over with half-lives
estimated between 1.5 and 5 h for Cx43 and Cx26 and up to 24 h for other isoforms such as
Cx46 [124,263–266]. While connexins use a multitude of pathways for internalization and degradation,
the process typically involves formation of an endosome (termed connexosome [267]), where older
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gap junctions are internalized to be targeted to the lysosome for degradation, although there is
also evidence for endosomal recycling back to the membrane [214,268,269]. Endosomal formation
is driven by multiple proteins in complex, including interactions with ZO-1, tubulin, and others.
In the case of Cx43, this interaction (with ZO-1) is regulated via Cx43-Ser373 and Cx43-Ser368
phosphorylation [200,214,270,271]. Monoubiquitinylation typically acts as a signal for internalization
of proteins via endosomes to lysosomes, leading to degradation [272,273]. Multiple covalently linked
ubiquitin molecules bind lysine residues within the target protein, which are then recognized by
receptors and targeted for degradation by the 26S proteasome [274–276] and by autophagy [277–279].
Recent evidence has demonstrated a complementary role for Cx43 in regulating autophagy, in that
Cx43 at the plasma membrane interacts with several pre-autophagosomal proteins, including Atg16,
but not other autophagosome proteins, such as LC3 [280]. When the cells are under stress, such
as nutrient depletion, Cx43 becomes ubiquitinylated and internalized, causing recruitment of other
factors (Atg5, Atg12, and LC3) to form fully functional autophagosomes. While regulated autophagy
can have a protective effect in stressed cells, there is also evidence linking aberrant autophagy and
Cx43 degradation from intercalated discs to heart failure [281], suggesting the potential for a novel
pharmacologic approach to treat cardiac failure.
Proteasomal–ubiquitin pathways have been proposed to indirectly regulate Cx43 through
interaction with the ZO-1 protein, thus disrupting part of the process that is critical for Cx43 membrane
organization [214,282]. Multiple studies suggest that other connexin proteins (e.g., Cx50, Cx43,
and Cx31.1) are regulated by ubiquitination [283]. Several studies show that ubiquitin regulates
internalization of Cx43 via clathrin-mediated endocytosis, by both tyrosine (Y)-dependent sorting
signal (YXXΦ, where X is any amino acid and Φ is an amino acid with a bulky hydrophobic side chain)
and tyrosine-independent, EPS15-dependent pathways [284,285]. However, the route through which
ubiquitin regulates the connexins has not been fully delineated, with studies in Cx43 demonstrating
that the C-terminal lysines are dispensable for protein turnover [286]. Despite this, there is increasing
evidence that Cx43 is modified in response to ubiquitin, and corresponding ligases are controlled
in part by phosphorylation events, such as MAPK and PKC phosphorylation [287,288]. A number
of ubiquitin-binding proteins (e.g., EPS15, p62, Hrs, and TSG101) are rec ruited to Cx43 to facilitate
its internalization and sorting to the lysosome [289,290]. In addition, TSG101 has been found to
interact with Cx30.2, Cx31, Cx36, and Cx45 [290]. While classic lysine-based motifs may not be
responsible for direct ubiquitin binding, more recent studies have shown that proline-rich regions
of the Cx43 C-terminus (xPPxY) bind to ubiquitin ligase. A number of ubiquitin ligases have also
been associated with direct binding, internalization, and degradation of Cx43 (e.g., Trim21 [291],
WWP1 [292], SMURF2 [293], and NEDD4 [287–289,294]). NEDD4 also has been directly associated
with loss of Cx43 at the plasma membrane in experimental models [287].
The process of degradation may be further regulated by connexin N-terminal acetylation, which
can act to regulate protein stability in the membrane. In mouse cardiac myocytes, N-terminal
acetylation through binding of P300/CBP-associated factor with Cx43 leads to a loss of Cx43 at
the intercalated disc, a lateral reorganization of the protein, reduced gap junction formation in
cardiac myocytes, and internalization in NIH-3T3 (mouse embryo) fibroblasts [77]. These patterns of
disorganization of Cx43 are similar to those seen in mouse models of Duchenne cardiomyopathies,
where NO and oxidative stress lead to an imbalance in acetylation/deacetylation and alterations in
cardiac conduction. Similarly in dogs, cardiac pacing leads to increased Cx43 acetylation, suggesting
that this mechanism is important in regulating signaling in physiology and pathology of the cardiac
system [77,295,296].
4. Connexin Trafficking
Formation of gap junctions by connexins is regulated by the delivery of newly synthesized channels
to the plasma membrane and is balanced by the removal of channels via endocytosis [263,297,298]. As
mentioned above, since connexin turnover is generally quite rapid and influenced by post-translational
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modifications, the dynamic regulation of connexins by secretion and turnover provides a means to
control gap junction formation, composition, and, thus, GJIC.
4.1. Control of Oligomerization
Secretion of newly synthesized connexins from the endoplasmic reticulum (ER) through the
Golgi apparatus is coordinately regulated with oligomerization into hexameric hemichannels [299].
Based on structural homology, connexins can be separated into two distinct oligomerization groups.
GJB1–GJB7 (so-called β connexins, including Cx26 and Cx32) follow a more traditional pathway,
where full oligomerization into hexamers is required prior to transport from the ER to the cis-Golgi
apparatus [300–302]. By contrast, other connexins are stabilized by a connexin-specific quality control
apparatus as monomers that are subsequently transported to the trans-Golgi network (TGN) where
they then have the capacity to oligomerize [301,303]. The best-studied connexin known to oligomerize
in the TGN is Cx43, although there is also experimental evidence for Cx40 and Cx46 oligomerization
late in the secretory pathway [304,305]. By homology, it is likely that most non-beta connexins will
also follow the late oligomerization pathway that has been demonstrated for Cx43 [299].
Several lines of evidence suggest that the transition from monomeric to hexameric Cx43 requires
a conformational change, largely centered on the third transmembrane domain (TM3) where it is
stabilized in a monomeric conformation by motifs containing charged amino acids on both ends
of the TM domain (Figure 2) [300,305]. At the cytoplasmic interface of the Cx43 TM3 domain is
an LR motif containing a highly charged arginine residue, and at the extracellular interface is a
glutamine-containing motif with a QYFLYGF amino acid consensus sequence. The extracellular loop
domain of Cx43 also interacts with a chaperone protein, ERp29, that is required to stabilize monomeric
Cx43 [300].
Figure 2. Differential connexin oligomerization. (A) Line diagram showing two key connexin motifs
adjacent to the third transmembrane domain. Connexins (such as Cx43), which oligomerize in the
Golgi apparatus (B), have a cytosolic LR and extracellular QYFLYGF motif that interacts with ERp29
(yellow) and other putative chaperones (grey ovals) that stabilize monomeric connexins until they
transition from the endoplasmic reticulum (ER) to the Golgi apparatus (delineated by the dashed lines).
In the Golgi apparatus, ERp29 dissociates from monomeric connexins and then recycles back to the
ER, enabling connexins to oligomerize into hexameric hemichannels. By contrast, connexins (such as
Cx32) that have a WW and a FYxLYxG motif cannot interact with ERp29—they are inserted into the ER
membrane as unstable monomers and thus immediately oligomerize (C).
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By contrast, beta connexins lack charged residues adjacent to the TM3 domain. They instead
have a di-tryptophan (WW) motif that is less stringently localized to the membrane/cytosol interface,
and they lack the ability to interact with ERp29. Thus, beta connexins are not stable as monomers
and instead oligomerize in the ER (Figure 2) [300–302]. Since motifs associated with the TM3 domain
also have been implicated in regulating connexin hetero-oligomerization [299,306], this implicates a
role for spatial separation of connexin oligomerization in regulating the extent and stoichiometry of
heteromeric channel formation.
4.2. Connexin Quality Control
The differences in quality control for Cx26 and Cx43 were directly observed for native connexins
in human airway epithelial cells derived from a cystic fibrosis (CF) patient expressing the CF
transmembrane conductance regulator (CFTR) protein harboring the Fdel508 mutation [307]. In these
cells, Cx43 trafficking and function is impaired, yet Cx26 transport and assembly into gap junction
channels is normal. Interestingly, CFTR also interacts with ERp29 [308], and Cx43-mediated
GJIC by Fdel508-CFTR-expressing cells is restored by treatment with 4-phenylbutyrate, a drug
that upregulates ERp29 expression [307,308]. In addition, 4-phenylbutyrate has been shown to
upregulate GJIC in several other contexts [309–314], further underscoring a role for ERp29 and other
4-phenylbutyrate-sensitive factors in connexin quality control.
Aberrant accumulation of connexins in the ER clearly decreases the pool of connexins available
to produce gap junction channels at the cell surface. However, ER accumulation of connexins has
also been found to induce an unfolded protein response (UPR) that, in turn, has the capacity to
impair cell function and lead to human disease. UPR induced by mutant connexins has been directly
demonstrated for Cx50 mutations associated with cataract [315–317] and Cx31 mutations that cause the
skin disease erythrokeratoderma variabilis (EKV) [318] or hearing impairment [319]. The association
of UPR with human diseases related to misfolded connexins suggests the possibility that treatments
alleviating ER stress, such as 4-phenylbutyrate, may have therapeutic value by promoting proper
protein folding and trafficking as well as increasing GJIC. Also, as mentioned above, the ability of
4-phenylbutyrate to enhance GJIC also may contribute to its potential as an anticancer therapeutic,
and may be related to increased ERp29 activity [320].
4.3. Connexin Cytoplasmic Domains and the Cytoskeleton
In addition to motifs adjacent to the TM3 domain, there are several lines of evidence in support
of connexin C-terminal domains in regulating connexin trafficking. As described above, in addition
to containing several motifs that can be post-translationally modified, the semi-structured nature
of the C-terminus [153,155,321] enables it to be conformationally labile and to interact with several
different classes of cytosolic scaffold proteins and the cytoskeleton that can influence connexin targeting
(reviewed in [5] for Cx43). For instance, several truncated connexins lack the ability to be efficiently
trafficked to the plasma membrane or be endocytosed [322,323]. The connexin C-terminal domains
also have the capacity to homo- and hetero-dimerize [153,155,159,324] as well as interact with other
connexin domains, including the cytoplasmic loop [155,325,326] that can influence connexin targeting,
oligomerization, and function.
Interestingly, it was determined that there is reciprocal regulation of Cx43 and Cx46 in the lens,
where conditions such as activation of PKC caused an increase in Cx46 transcription and expression
that was associated with a concomitant decrease in Cx43, via ubiquitination and proteasomal
degradation [327]. In fact, transfecting cells with Cx46 was sufficient to induce Cx43 degradation and
this effect required the C-terminus of Cx46, since a Cx46 tail truncation mutant had no effect on Cx43
expression. Increased Cx50 also had no effect on Cx43. However, transfecting cells with a soluble Cx46
tail construct had the ability to decrease Cx43 expression. Since the decrease in Cx43 was induced by
an intracellular pool of Cx46, this raises the possibility that crosstalk between Cx46 and Cx43 may be
related to differential oligomerization [304]. However, this remains to be determined.
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As another instance where the C-terminus plays a key role in regulating Cx43 trafficking, it has
been shown that amino N-terminal truncated forms of Cx43 are also expressed by cells, through
alternative internal translation via one of six different AUG initiation sites (see Section 2.4.2) [328].
The most prominent of these is GJA1-20k, which consists of a portion of the TM4 domain as well
as the entire C-terminus [110] (Figure 1). GJA1-20k expression promotes formation of Cx43 gap
junction channels, resulting in an increase in intercellular communication [110,113]. As discussed
in Section 2.4.2, alternative translation of Cx43, including production of GJA1-20k, is inhibited by
mTOR [110,111] and Mnk1/2 kinases [111], suggesting that metabolic stress regulates gap junctional
coupling through mTOR- and Mnk1/2-mediated pathways as a means to protect cells both by enabling
scarce metabolites to be distributed via intercellular communication as well as limiting damage by
restricting generation of reactive oxygen species [329].
How GJA1-20k regulates channel formation by Cx43 is still under investigation. One intriguing
possibility is that GJA1-20k acts as a chaperone protein that promotes Cx43 oligomerization, as was
recently demonstrated to regulate the decrease in gap junction formation and function that can occur
in the epithelial to mesenchyme transition [330] (Figure 1).
Another likely role for GJA1-20k relates to cytoskeletal control of Cx43 trafficking, since it has been
shown that the C-terminus of Cx43 and, therefore, GJA-20k as well, interacts with both microtubules
and filamentous actin [331–333]. Microtubules and actin perform complementary functions in
regulating connexin trafficking, where microtubules help facilitate rapid transport of Cx43-containing
vesicles to sites of junction formation [332], whereas actin has a more subtle role in regulating connexin
trafficking, since quantitative live cell-imaging shows that transport of Cx43-containing vesicles
temporarily pauses when they interact with actin filaments, perhaps as a means to enhance sorting
or to remodel vesicle composition [331]. Also, transfecting HeLa cells with GJA1-20k nucleates the
formation of actin filaments [113], suggesting a role for GJA1-20k in altering the itinerary of Cx43
trafficking in the cell. Reverse regulation is also suggested by studies where gap junction inhibitors
resulted in misalignment of actin filaments across the monolayer and reduced calcium signaling
in rat astrocytes [334]. Furthermore, treatment of astrocytes with an actin polymerization inhibitor
cytochalasin D or anti-actin antibodies reduced GJIC, as visualized by a reduction in the spread of
microinjected neurobiotin between cells [335].
4.4. Regulation of Gap Junction Plaque Morphology
Actin has also been implicated in regulating gap junction plaque morphology. Double knockout
of the actin capping protein tropomodulin 1 and intermediate filament protein CP49 in lens fiber cells
led to a significant decrease in Cx46 plaque volume and increase in plaque number, affecting gap
junction coupling and function in the lens tissue [336]. Regulation of plaque size by actin is likely to be
coordinated by interactions involving the C-terminus of connexins and zonula occludens 1 (ZO-1). For
example, enhanced green fluorescent protein (EGFP)-tagged Cx43 incapable of interacting with ZO-1
produces plaques that are not size regulated [337]. By contrast, the perimeter of gap junction plaques
(the perinexus) is ringed by Cx43/ZO-1 complexes, whereas the center of plaques is largely devoid
of ZO-1 [338]. Inhibition of Cx43/ZO-1 interactions cause an increase in gap junction plaque size.
Consistent with this possibility, Cx43 phosphorylation inhibits ZO-1 binding and facilitates connexin
channel endocytosis [339]. Additional roles for ZO-1, connexin phosphorylation, and ubiquitinylation
in regulating connexin endocytosis and degradation are described in Sections 3.2 and 3.3, above.
Although the precise mechanism whereby ZO-1 limits plaque formation is still under
investigation, it seems plausible that it may be analogous to the role of ZO-1 in regulating tight
junctions, where claudin/ZO-1/actin interactions have a junction-stabilizing influence on the apical
junctional complex, whereas, in the absence of ZO-1, there is increased access of myosin that increases
tight junction dynamics and tension [340,341]. Consistent with this possibility, myosin VI has also been
found to have a specific role in increasing gap junction plaque size, analogous to treatments inhibiting
Cx43/ZO-1 interactions [342].
22
Int. J. Mol. Sci. 2018, 19, 1296
Whether regulation of plaque assembly strictly follows the perinexus model has recently been
challenged by observations of Cx36 plaque formation [343]. Pulse-chase experiments with Cx36
indicated addition of Cx36 to both the ends and the middle of preexisting gap junction plaques, with
diffusion of Cx36 throughout the plaque. When the experiments were repeated with Cx43, there
appeared to be less diffusion of newly added Cx43 in preexisting plaques [343]. Targeted delivery
of connexins has only recently been observed. Through interactions with plus-end binding protein
EB1 and the dynein/dynactin complex, microtubule plus-ends are tethered to adherens junctions at
the plasma membrane, leading to the targeted deposition of connexin hemichannels and gap junction
plaque formation [332]. These two models begin to bring to light the vast complexity of connexin
trafficking and gap junction formation, suggesting a network of cytoskeleton and protein-binding
partners tailored to specific connexins that was previously unrealized.
A less understood but intriguing role for the cytoskeleton in gap junction biology is the creation
of unique junctional subregions involved in gap junction dynamics. Using an EGFP-tagged Cx32
construct, particularly dynamic regions at the edges of gap junction plaques were observed as
invaginated tubular structures, where plaque fragments pinched off into the cytoplasm [344]. These
tubulovesicular extensions of gap junction plaques were recently observed with Cx36 and termed
filadendrites [345]. Filadendrites at the edges of gap junction plaques appeared to be the same
thickness as the plaque, suggesting that the filadendrites were a continuation of the gap junction
plaques themselves. Filadendrites were also observed in interior regions of the gap junction plaques,
but appeared to be much thinner than the gap junction plaques. From pulse-chase labeling of Cx36,
it was observed that filadendrites exhibited some of the same dynamic properties as the earlier observed
Cx32 invaginations, constantly pinching off and fusing with the gap junction plaque. Labeling of
actin filaments showed colocalization with Cx36 filadendrites, suggesting that the actin cytoskeleton
could be one of the drivers behind the formation of these dynamic structures. Treatment with the actin
polymerization inhibitor Latrunculin A or actin depolymerization inducer cytochalasin D reduced the
presence of filadendrites, indicating that the driving force behind the dynamic gap junction plaques
requires actin polymerization [345].
Similar structures have been noted at other junctions. Primary human keratinocytes treated
with pemphigus vulgaris (PV) IgG containing antibodies targeted to the adherens junction protein
desmoglein 3 (Dsg3) exhibited reorganized Dsg3 at the membrane into projections perpendicular to the
membrane plane. These projections, termed linear arrays, are similar to the filadendrites in that they
are sites of disassembly of junction components and active endocytosis at the junctions. Linear arrays
also colocalized with actin filaments oriented perpendicular to the plasma membrane, similar to those
observed in filadendrites. Furthermore, linear arrays were associated with decreased cell adhesion,
suggesting a functional effect of these junctional subregions [346,347]. A comparable structure formed
by tight junction proteins, termed tight junction spikes, have been observed to correlate with treatments
that enhance junction disassembly and paracellular leak, including oxidative stress induced by chronic
alcohol exposure, transforming growth factor (TGF)-β1 treatment, and inhibition of NF-κB [348–350].
In alveolar epithelial cells, actin filaments colocalized with the tight junction protein claudin-18 in tight
junction spikes. Spikes were also found to be sites of budding and fusion of vesicles carrying tight
junction proteins, both indicators of active tight junction remodeling. Treatment of lung alveolar
epithelial cells with granulocyte-macrophage colony-stimulating factor (GM-CSF) reduced actin
filament colocalization with claudin-18 containing tight junction spikes, whereas keratinocyte growth
factor treatment inhibited spike formation and instead promoted formation of cortical actin as opposed
to actin stress fibers [350,351]. Taken together, these findings indicate that these similar junctional
subregions observed universally across several different classes of intercellular junctions, including
gap junctions, could represent a common mechanism of junction protein turnover, where the junctions
partition themselves into unique filamentous structures. Whether these structures serve to restrict
turnover of junction proteins to specific subdomains or whether they nucleate the formation of signaling
complexes that recruit specialized subsets of cytosolic binding partners remains to be determined.
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5. Conclusions and Future Perspectives
In order to fully understand the complex role of connexins in health and disease, it is essential to
elucidate their regulation at all steps, from gene transcription, protein synthesis, post-translational
modifications, and trafficking to their regulation at the cell membrane. This review is intended to
highlight some of the progress made in these areas in relation to health and disease, giving examples
of how this knowledge is pertinent for future therapeutic applications. Going forward, understanding
how modulation of connexins occurs at any of these stages will require additional work and insight,
which over time may lead to more fruitful and safer strategies to alleviate patient suffering. For
example, the danegaptide trials that were based on strong preclinical data suggested that alterations to
the trafficking and increased Cx43 signaling in the heart would have a profound effect in reducing
ischemic reperfusion injury and reduce cardiac tissue damage. However, Phase II clinical trials in
humans failed to show an effect, highlighting the complex nature of targeting gap junctions as a
treatment modality including differences in how connexins are regulated in model systems as opposed
to human disease. Additional caution is also needed for therapeutic approaches in cancer, where it is
now clear that connexins have distinct roles that both promote and inhibit cell growth and metastasis.
Despite substantial progress, it is important to acknowledge the complexity of gap junctions
that serve as a conduit that enables cells to share thousands of different signaling molecules.
Additionally, the complex connexin protein interactome underscores the non-junctional functions of
connexins, including their ability to act as a signaling platform. In particular, it is critical to identify
connexin-specific functions that are unique and targetable. This is best approached by understanding
how connexins are regulated at multiple levels by multiple mechanisms, from gene transcription and
translation to post-translational modification, and as a specifically localized multiprotein complex.
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Abstract: Connexins are integral membrane building blocks that form gap junctions, enabling direct
cytoplasmic exchange of ions and low-molecular-mass metabolites between adjacent cells. In the
heart, gap junctions mediate the propagation of cardiac action potentials and the maintenance of
a regular beating rhythm. A number of connexin interacting proteins have been described and
are known gap junction regulators either through direct effects (e.g., kinases) or the formation of
larger multifunctional complexes (e.g., cytoskeleton scaffold proteins). Most connexin partners
can be categorized as either proteins promoting coupling by stimulating forward trafficking and
channel opening or inhibiting coupling by inducing channel closure, internalization, and degradation.
While some interactions have only been implied through co-localization using immunohistochemistry,
others have been confirmed by biophysical methods that allow detection of a direct interaction.
Our understanding of these interactions is, by far, most well developed for connexin 43 (Cx43) and
the scope of this review is to summarize our current knowledge of their functional and regulatory
roles. The significance of these interactions is further exemplified by demonstrating their importance
at the intercalated disc, a major hub for Cx43 regulation and Cx43 mediated effects.
Keywords: gap junction; connexin; protein–protein interaction; intrinsically disordered protein;
post-translational modification; intercalated disc
1. Introduction
The Cx43 carboxyl terminal (Cx43CT) domain plays a role in the trafficking, localization,
and turnover of gap junction channels via numerous post-translational modifications and
protein–protein interactions [1–5]. The Cx43CT is also important for regulating junctional conductance
and voltage sensitivity [6–9]. Structural studies from our laboratory revealed that the Cx43CT as
well as the CT domain from other connexins are predominately unstructured [10–13]. Intrinsically
disordered domains are now well recognized to be loci for regulation of protein function because their
conformation can be readily modulated by the local environment, phosphorylation, and interaction
with proteins and small-molecules. We and others have shown that the Cx43CT binds multiple proteins,
some of which have been shown to modulate channel function (for review see [14]). These data
strongly suggest that protein–protein interactions mediated by any part of the CT are likely to have
regulatory effects. Numerous excellent reviews have summarized the functional significance of these
Cx43-interacting proteins [15–17]; here we provide a different perspective. We separated the proteins
known to affect Cx43 function into three categories. The first are those proteins that directly interact
Int. J. Mol. Sci. 2018, 19, 1428; doi:10.3390/ijms19051428 www.mdpi.com/journal/ijms42
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with the CT and are associated with trafficking Cx43 to the gap junction plaque and open gap junction
channels. Cx43-protein interactions identified from cell biology studies (e.g., immunoprecipitation
and co-localization) that have been confirmed using different biophysical techniques (e.g., nuclear
magnetic resonance, X-ray crystallography, and surface plasmon resonance) are considered a “direct”
interaction. The second are those proteins that directly interact with the CT and are associated
with channel closure, disassembly, and degradation. The third, which will not be a focus of this
review, are those proteins that can affect all aspects of the Cx43 life cycle, but no evidence exists
they directly interact with the Cx43CT (Table 1; albeit we realize a number of the proteins in Table 1
will eventually be shown to directly interact with Cx43 or may never be identified because binding
requires a connexin embedded within the membrane or in context of a connexon, thus posing extreme
challenges to performing in vitro assays). Additionally, we will not focus on those post-translational
modifications such as ubiquitination, sumoylation, methylation, phosphorylation, and hydroxylation
that form covalent bonds with connexins to modify function (for review see [18]). For the proteins
that directly interact, we provide their location on the Cx43CT domain, residues (de)phosphorylated
where necessary, and their diameter as estimated from their molecular weight (Available online:
http://www.calctool.org/CALC/prof/bio/protein_size). Of note, these values are on the conservative
side because proteins like ZO-1 and 14-3-3 have multiple modular domains and would have a larger
diameter. For the Cx43CT, we combined the knowledge that the intrinsically disordered Cx43CT
domain (length of 3.8 Å per residue; [19]) can contain as high as 35% α-helical structure (length of
1.50 Å per residue) depending on the level of phosphorylation [20]. The rationale for this perspective
is to visually illustrate that only a small number of proteins can bind at any one time. The importance
of Cx43 cellular localization (spatial), Cx43CT phosphorylation state, as well as the cellular condition
(temporal) will help determine which proteins will bind the Cx43CT domain.
Table 1. Proteins suggested to interact with Cx43, but where no evidence currently exist for a direct
protein–protein interaction. Abbreviations: IP, immunoprecipitation; co-Loc, co-localization; PLA,
proximity ligation assay; TEM, transmission electron microscopy; PD, pull-down; IV, in vitro assay;
FW, Far-Western.
Interacting Protein Type of Detection References
Actin co-Loc [21–23]
AGS8 IP, co-Loc [24]
A-kinase anchoring protein 95 IP, co-Loc [25]
Ankyrin G IP [26]
Apoptosis-inducing factor IP, co-Loc, PLA [27]
Atg16L/Atg14/Atg9/Vps34 IP, co-Loc [28]
Bax IP, co-Loc [29]
β-arrestin IP, co-Loc [30]
β-subunit of the electron-transfer protein IP, co-Loc, PLA [27]
Brain-derived integrating factor-1 IP, co-Loc [31]
CASK (LIN2) IP, co-Loc [32]
Caveolin-1,2,3 IP, co-Loc [33–35]
Clathrin IP, co-Loc [36]
Claudin 5 IP, co-Loc [37]
CIP85 IP, co-Loc [38]
Consortin IP, co-Loc [39]
Cyclin E IP, PLA, TEM [40]
Desmocollin-2a PD [41]
Dlg co-Loc [42]
Dynamin IP, co-Loc [43]
EB1 IP [44]
Eps15 IP, co-Loc [45]
43
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Table 1. Cont.
Interacting Protein Type of Detection References
ERp29 IP, co-Loc [46]
Hrs co-Loc [47]
HSP70 IP, PD [48]
HSP90 IP, co-Loc [49]
Light chain 3 IP, co-Loc [50,51]
Lin-7 PD [52]
Myosin-VI co-Loc [53]
DMPK IP, co-Loc [54]
NaV1.5 co-Loc [55]
N-cadherin co-Loc [56]
NOV/CCN3 IP, PD [57]
Occludin IP, co-Loc [37]
p120ctn co-Loc [58]




PP1/PP2A IP, co-Loc [63]
RPTPμ IP [64]
Smurf2 IP, co-Loc [65]
STAMBP (AMSH) IP, co-Loc [66]
TOM20 IP, co-Loc [49]
TRIM21 IP, co-Loc [67]
USP8 IP [68]
Vinculin IP, co-Loc [60]
Wwp1 IP [69]
ZO-2 IP, co-Loc, PD, FW [52,70]
2. Direct Interactions with Cx43 and Their Functional Consequence
2.1. Interactions that Promote Synthesis, Trafficking to the Gap Junction Plaque, and Channel Opening
Intercellular coupling is eventually determined by the number of open channels in gap junction
plaques, which is governed by the synthesis, forward trafficking, and channel open probability.
A number of protein partners affect these processes (Figure 1).
Cx43 is translationally integrated into the endoplasmic reticulum (ER) and oligomerization
occurs only after exit of the ER in the trans-Golgi network [71]. One of the first proteins likely to
directly interact with Cx43 is the Connexin Interacting Protein of 75 kDa (CIP75). CIP75 interacts with
Cx43CT residues K264-Q317 through its ubiquitin-associated (UBA) domain [72,73]. The importance
of CIP75 is to mediate ER associated degradation of Cx43 for quality control and fine-tune the level
of expression through dislocation of Cx43 from the ER and proteasomal degradation [73–76]. Use of
cellular denaturants increased the association of CIP75 with Cx43, suggesting only pools of Cx43
lacking association with CIP75 escape ER dislocation and travel to the Golgi [75]. Upon exiting the
trans-Golgi network, Cx43 containing vesicles are transported via the microtubular network to the
plasma membrane [77].
Microtubular transport of connexons coincides with the recruitment of a number of protein
interactors to the Cx43CT, a number of which have been implicated, however a direct interaction was
not confirmed (Table 1; for review see [4,78,79]). In addition to microtubules, the actin cytoskeleton
aids in connexon delivery to the gap junction plaque (for review see [80]). Curiously, regulation of Cx43
forward trafficking may in part be regulated by internally translated fragments of the Cx43CT [81].
One of these fragments, GJA1-20k, was recently shown to stabilize filamentous actin and suggested
to help target microtubules to cell–cell junctions [82]. Full length Cx43 did not stabilize actin and the
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relation between the ability of GJA1-20k and Cx43 (see below) to target microtubules to the membrane
remains to be established.
Figure 1. Protein partners that directly interact with the Cx43CT domain to promote intercellular
communication. The black line represents Cx43CT domain residues 234–382. Provided for each Cx43CT
protein partner (circle) is its diameter (in Å) as estimated from their molecular weight, and number of
amino acids (aa), and the Cx43CT residues affected as a result of the interaction (lines). If the protein
partner is a kinase or phosphatase, the Cx43CT residues affected are labeled on the Cx43CT (circle or
triangle). Abbreviations are as follows: β-tubulin (β-tub), T-cell protein tyrosine phosphatase (TC-PTP),
Connexin interacting protein 75 kDa (CIP75), Ubiquitin-associating domain (UBA), Casein kinase 1
(CK1), Protein kinase A (PKA), Zonula Occludens 1 (ZO-1), and Protein kinase B (AKT). Kinases have
been highlighted (shaded circle).
In proximity of the plasma membrane, the actin- and protein kinase A (PKA)-binding protein
Ezrin, binds the Cx43CT and enables PKA to phosphorylate Cx43CT serine residues. In particular,
phosphorylation of S364 is a likely precursor to binding with the tight junction protein Zonula
occludens 1 (ZO-1), another actin scaffolding protein [83]. Functional studies demonstrating increased
gap junction intercellular communication following activation of PKA support this hypothesis [84,85].
Work by Pidoux et al. 2014, identified the minimal binding motif of Cx43CT for Ezrin as 366RASSR370
using a peptide screening approach [86]. Furthermore, PKA and ZO-1 interact with the Cx43CT
over the same region as Ezrin (S364-I382), however phosphorylation by PKA (S365, S369) did not
appear to alter binding of Ezrin to Cx43, nor binding of ZO-1 [86,87]. Work from Thévenin et al. 2017,
and others have highlighted phosphorylation of S373 as a critical modulator of ZO-1 binding, a site
phosphorylated by both PKA and protein kinase B (AKT) [83,87–89]. Association with ZO-1 is a critical
mediator of gap junction plaque size; when bound to ZO-1 Cx43 is retained in the perinexal region
“poised” for docking with apposing connexons, and upon release Cx43 is incorporated into the gap
junction plaque proper [88–91]. Whether Ezrin and ZO-1 simultaneously bind the Cx43CT remains to
be determined, but based on their size and location of binding on the Cx43CT, it seems unlikely.
Capture and incorporation of Cx43 containing vesicles at the plasma membrane (gap junction
periphery) has been attributed to 14-3-3 [92–94]. Like Ezrin, 14-3-3 interacts with the Cx43CT in the
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same region as ZO-1, hovering over S373 [94]. Unlike the reduced binding of ZO-1, phosphorylation
of S373 by PKA enhances 14-3-3 binding and likely serves as a switch of perinexal Cx43 to junctional
Cx43 through tethering to integrins (specifically integrin α5; [88,89,94]). Taken together these studies
highlight the intricacy of spatial-temporal and post-translational regulation of Cx43 trafficking to
the gap junction plaque and suggest that association of Ezrin (and PKA) with the Cx43CT precedes
association with ZO-1. This is further advanced by phosphorylation of S373 promoting the exchange
of ZO-1 for 14-3-3 and incorporation into the gap junction plaque [88,89,94]. Of note AKT and
14-3-3 proteins are also involved in gap junction disassembly, a topic covered in the next section.
Once incorporated into the plaque a number of interactions serve to stabilize and maintain Cx43 and
control channel maturation (opening; for review see [95]).
Fully open channels require phosphorylation by casein kinase 1 (CK1) on residues S325, S328,
S330 [96]. Interestingly, Cx43 knock-in mice in which Cx43CT residues S325, S328, and S330 were
replaced with glutamic acids (phospho-mimicking) were immune to acute and chronic pathological
gap junction remodeling and ventricular arrhythmias after transverse aortic constriction [97].
In addition to channel opening, stability of the gap junction plaque regulates gap junction intercellular
communication. Direct protein interaction with microtubules via β-tubulin and association with
the actin cytoskeleton through the scaffolding protein Developmentally Regulated Brain Protein 1
(Drebrin) are two key interactions, which stabilize gap junctions (for review see [98,99]). β-tubulin
binds the Cx43CT over Y247, a known site of phosphorylation by Src kinase, and Drebrin binds over
Y265 and Y313, two other substrates for Src phosphorylation [100–106]. Importantly, the interaction of
β-tubulin with the Cx43CT likely occurs subsequent to plasma membrane incorporation as a direct
interaction prior to plasma membrane incorporation would prevent Cx43 trafficking to the membrane
(no motor proteins). This hypothesis is supported by data from Francis et al. 2011, indicating that
Cx43 regulates microtubule dynamics at plasma membrane [107]. NMR and cell based work from
our laboratory identified a phosphatase T-cell Protein Tyrosine Phosphatase (TC-PTP) which directly
interacts with the Cx43CT and dephosphorylates the Y247 and Y265 reversing the down-regulating
effects of Src kinase (described further in the next section; [108]).
Finally, β-catenin is another protein identified to interact with Cx43. In response to Wnt signaling,
β-catenin can interact with the Cx43 gene to increase transcription as well as modulate gap junction
stability at the plaque [109–112]. Works from several laboratories have shown indirect evidence of
this interaction at the plaque by reciprocal co-immunoprecipitation as well as co-localization [109,113].
β-catenin was added in this section because we recently identified a direct interaction with the Cx43CT
domain over three areas (residues G261-T275, S282-N295, and N302-R319) using a combination of
surface plasmon resonance (SPR) and NMR experiments [114].
2.2. Interactions that Promote Channel Closure, Gap Junction Disassembly, Internalization and Degradation
Similarly, to facilitating coupling, down regulation of Cx43-mediated intercellular communication
requires a number of direct protein interactions and phosphorylation events (Figure 2). Indeed,
phosphorylation of Cx43 by Src is a key initiator of gap junction closure, internalization, and
turnover [103,104,115–119]. Src-induced phosphorylation of Cx43 has been correlated with channel
closure [101]. Current research suggests a “particle–receptor” mechanism for Src-mediated channel
closure similar to that proposed for pH gating of Cx43 channels [7,104,120]. The impact of Src
phosphorylation on channel activity is decreased electrical coupling by reducing open probability and
changes in selectivity [121]. Work from our laboratory and others support an additional mechanism of
Src to decrease gap junctional intercellular communication: the altering of Cx43 protein partners to
enhance degradation. A commonality between the proteins that link Cx43 to the cytoskeleton is that
Src can inhibit their interaction. For example, Cx43CT residues Y247 and Y265 phosphorylated by Src
inhibit the binding of β-tubulin and Drebrin, respectively [122].
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Figure 2. Protein partners that directly interact with the Cx43 CT and CL domains to impede
intercellular communication. The black lines represents Cx43CT domain residues 234–382 and
Cx43CL domain residues 100–158. Provided for each Cx43 CT and CL protein partner (circle) is
its diameter (in Å) as estimated from their molecular weight, and number of amino acids (aa),
and the Cx43CT residues affected as a result of the interaction (lines). If the protein partner is a
kinase, the Cx43CT residues affected are labeled on the Cx43CT (circle). Abbreviations are as follows:
Calmodulin (CaM), Src homology 3 domain (SH3), Tyrosine kinase 2 (Tyk2), Mitogen-activated protein
kinase (MAPK), Neural precursor cell expressed developmentally down-regulated protein 4 (Nedd4),
Cyclin-dependent kinase 1 (CDK1), Tumor susceptibility gene 101 protein (Tsg101), Ubiquitin E2
variant domain (UEV), Protein kinase B (AKT), Protein kinase C (PKC), matrix metalloproteinase-7
(MMP7), and Ca2+/calmodulin-dependent protein kinase II (CaMKII). Kinases have been highlighted
(shaded circle).
In the case of β-tubulin, at the gap junction plaque, this may be a mechanism in the disassembly
process; at the trans-Golgi network, in cardiomyocytes this may re-route trafficking from the
intercalated disc to lateral membranes; or inhibit trafficking to the plasma membrane altogether,
leading to increased proteasomal and/or lysosomal degradation. For Drebrin, depletion in cells
results in impaired cell–cell coupling, internalization of gap junctions, and targeting of Cx43 for
degradation [123]. While phosphorylation of the Cx43CT by Src does not inhibit ZO-1 binding,
we found that active c-Src can compete with Cx43 to directly bind ZO-1 [124]. Studies from the
Gourdie and Lampe laboratories would suggest blocking these protein partners would transition
Cx43 from the non-junctional plasma membrane into the gap junction plaque, and then through the
degradation pathway(s) [91]. Finally, Src activation also indirectly leads to serine phosphorylation by
AKT (S373), PKC (S368), and MAPK (S255, S279, and S282) that contributes to reduced Cx43 at the
plasma membrane. AKT may act in a similar manner as Src in that phosphorylation of S373 inhibits
the Cx43 interaction with ZO-1 [88]. In addition, phosphorylation of S373 enables the binding of
14-3-3 leading to gap junction ubiquitination, internalization, and degradation during acute cardiac
ischemia [94]. Altogether, the data point to Src playing a significant role in inhibiting Cx43-mediated
cell-to-cell communication by channel closure and enhanced degradation.
In addition to Src, another tyrosine kinase identified to directly interact with and phosphorylate
the Cx43CT was the Janus kinase family member non-receptor tyrosine-protein kinase 2 (Tyk2; [125]).
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Interestingly, Tyk2 can functionally substitute for Src as work from our laboratory identified that
it phosphorylates Cx43CT residues Y247 and Y265 and results in concomitant loss of coupling and
disassembly of gap junction plaques [125]. While phosphorylation of these sites by either Tyk2
or Src would result in disruption of the direct binding of β-tubulin and Drebrin, one difference
is that Tyk2 unlikely disrupts the Cx43/ZO-1 interaction as Tyk2 does not contain a SH3 domain
(for review see [126]). Whether Tyk2 binds to Cx43 via its SH2 domain or FERM domain remains to
be determined [127–129]. It is becoming clear that overlap in the phosphorylated residues of Cx43 by
a number of kinases provides the cell with a highly dynamic ability to alter gap junction function in
response to various initial stimuli. In addition, like Src, activation of Tyk2 coincides with increased
phosphorylation of S279/282 by MAPK and S368 by PKC [125]. MAPK also phosphorylates Cx43
residues S255 and S262, all of which alter the secondary structure of the Cx43CT to increase α-helical
content, a mechanism which can promote or inhibit interactions with other protein partners [20].
One protein partner that undergoes recruitment following MAPK activation, is the E3 ubiquitin
ligase Neural precursor cell expressed developmentally down-regulated 4 (Nedd4; [130]). Specifically,
work by Leykauf et al. 2006, demonstrated that phosphorylation of S279/282 increased the affinity
(KD pS279/282 585 μM vs non-pS279/282 1064 μM) of Nedd4 for Cx43 [131]. Our laboratory confirmed
this approximate 2-fold increase in the binding affinity for Nedd4 via NMR [132]. Furthermore, we
determined that Nedd4 binds to the Cx43CT primarily through its WW2 domain via the PPXY motif
(P283-Y286; [132]). Importantly, other proteins also interact with the Cx43CT in proximity to the PPXY
motif, these are tumor susceptibility gene 101 (Tsg101) and the AP2 adaptor protein complex (AP2)
both of which are involved in the endocytosis and retrograde trafficking of Cx43 [133,134]. In addition
to MAPK, Src phosphorylation also primes Cx43 for phosphorylation by PKC at S368 [102]. A point
worth noting is that phosphorylation of Cx43 S368 requires dephosphorylation of S365, as work from
Solan et al. 2007, demonstrated that phosphorylation of these sites is mutually exclusive [135].
Phosphorylation of Cx43 by PKC occurs via indirect mechanisms following phosphorylation
by Src [102]. Cx43 residue S368 is well established as a site for PKC phosphorylation and this
site is correlated with a decrease in unitary conductance of approximately 50% (~100 pS down to
~50 pS; [136]). This decrease works together with phosphorylation by MAPK on S262 to close the
channel completely. Since MAPK and PKC interact with and phosphorylate Cx43 over different
regions it is likely, they can both interact simultaneously. Indeed, time course experiments following
the changes in levels of site-specific phosphorylations (MAPK and PKC sites) following treatment of
porcine aorta endothelial cells with vascular endothelial growth factor (VEGF) revealed a concomitant
increase in phosphorylation on S255, S262, S279/282, and S368 [137]. However, the same study
demonstrated that inhibition of PKC by GF109203X also resulted in a decrease in phosphorylation
of S255, S279/282, and S368. The authors suggest it is likely the PKC phosphorylation may precede
MAPK phosphorylation at least in VEGF activated cells to create a binding site for AP2 [137].
Similar phosphorylation patterns occur in a number of other cell types with different initiating
stimuli suggesting this as a likely critical kinase program for the closure and internalization of
Cx43 gap junctions [138–140]. Furthermore, in the same study the authors demonstrated that the
phosphomimetic Cx43CT S365D mutation resulted in a significant change in structure of CT residues
(T275-A276, G285-Y286, L356-S368, and R370-D379) as indicated by significant changes in chemical
shift as observed in a heteronuclear single quantum coherence experiment [135]. Taken together these
two lines of data suggest that phosphorylation of Cx43 by PKA on S365, induces a shift in structure
which precludes binding of and phosphorylation by PKC. Finally, activation of PKC can halt the
assembly of new gap junctions and its phosphorylation on S368 has been implicated in affecting gating
and/or disassembly [141,142].
AP2 is one protein member of a family of five adaptor protein complexes (AP1-5) that are
involved in both clathrin and non-clathrin (AP4/5) mediated trafficking events (for review see [143]).
AP2 associates specifically with its cargo proteins via either two tyrosine based sorting motifs (YXXΦ or
NPXY) or dileucine based sorting motifs ([D/E]XXXL[L/I]) (for review see [144]). The Cx43CT domain
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contains three tyrosine based sorting motifs (S1-Y230VFF, S2-Y265AYF, and S3-Y286KLV; [134,145]).
Only S2 and S3 interacted with AP2 to initiate clathrin-mediated internalization [134]. S1 was not
involved due to its membrane juxtaposition. Furthermore, the study by Thomas et al. 2003, illustrated
that the Cx43 AP2 S3 overlaps with the proline rich PPXY motif which Nedd4 recognizes [145].
This suggests that it is unlikely both Nedd4 and AP2 bind Cx43 at the same time, indicating potential
diverging roles for ubiquitin and clathrin mediated internalization. The significance of Cx43 containing
two tyrosine based sorting signal is unclear, however, work by Johnson et al. 2013, using yeast
two-hybrid analysis indicated that the Cx43CT with a Y286A mutation (abolishing S3) did not
function as bait for the μ2 subunit of the AP2 complex [140]. Although they suggest a requirement
for post-translational modification [140], most likely, coordination of the tyrosine ring is important
for binding AP2 as tyrosine phosphorylation within the Yxxφ-type-binding motif of other proteins
inhibits the interaction with AP2 (e.g., [146]).
Two additional proteins that directly interact with Cx43 are calmodulin (CaM) and
CaM-dependent kinase 2 (CaMKII). Ca2+/CaM activates CaMKII leading to autophosphorylation
and subsequent phosphorylation of target proteins, including Cx43 [147–149]. In vitro work using
mass spectroscopy identified extensive phosphorylation of the Cx43CT by CaMKII (15 Cx43CT
residues; [147]). Whether all of these sites identified occur in vivo remains to be determined as
this high degree of phosphorylation could be a result of non-specific binding under in vitro conditions
as the only identified CaMKII consensus is R-X-X-S/T (only four in the Cx43CT domain; for review
see [150]). However, of the sites identified by Huang et al. 2011, phosphorylation of S306 has
been shown to increase rather than decrease coupling [148]. NMR experiments showed that CaM
directly binds the Cx43 cytoplasmic loop residues K136-S158 [151]. This occurs in a Ca2+ dependent
manner and leads to gap junction channel closure, perhaps via occlusion of the pore (for review
see [152]). We recently identified that CaM also binds Cx43CT residues K264-T290 [153]. It is
tempting to speculate that this may be the mechanism by which Cx43 channels close, but remain at
the plasma membrane, unlike the effects of Src phosphorylation. Along with regular turnover, gap
junctions disassemble during cell division as they serve as a source of cell–cell adhesion (for review
see [154]). During mitosis Cx43 phosphorylation patterns change with phosphorylation detected
on S255 and S262 [155]. These changes in phosphorylation correlate with reduced intercellular
communication as well as increased concentration of Cx43 in intracellular structures [156–158].
Interestingly, a pool of this internalized Cx43 can be recycled to nucleate the formation of new gap
junction channels [155]. Similar to phosphorylation of S255 and S262 by MAPK, cyclin-dependent
kinase 1 (CDK1) phosphorylates these same residues to closes the gap junction channel [156,157].
In addition to the phosphorylation-mediated changes in protein partner associations described
above, new studies have begun to illustrate Cx43 as a potential target for proteolytic cleavage in
various pathologies [159–162]. Lindsey et al. 2006, using in vivo, in vitro, and in silico methods
demonstrated that Cx43 is a substrate for matrix metalloproteinase-7 (MMP-7; [159]). The Cx43CT
domain contains two putative MMP-7 cleavage sites (G350-R362 and R374-I382); however, biochemical
analysis using epitope-mapped antibodies (antibody 1: 252-270, antibody 2: 363-382) suggested
cleavage was occurring only at the R374-I382 site [159]. A direct MMP-7 interaction with Cx43 was
shown by SPR, in proximity to S373, suggesting potential regulation by PKA/AKT [83,88,89,159].
3. The Intercalated Disc as a Hub of Cx43 Mediated Protein–Protein Interactions
Cx43 is expressed in a large variety of cells [5], where it may interact with the proteins discussed
above as well as yet unidentified binding partners. The expression and localization of the interacting
partners vary between cell types, which possibly underlie the bewildering number of contradictory
findings on the role and regulation of Cx43. In the following, we will give examples from the current
knowledge about interactions and regulation of Cx43 at the intercalated disc (ID) of cardiomyocytes.
The ID is a region of particular interest since it contains large amounts of Cx43 in close contact with
several known interaction partners [163]. Although we only have evidence of direct interaction with
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a few of the nearby proteins, the list of possible partners is growing. Using a proteomics approach,
Girao and coworkers showed that 236 proteins precipitated with Cx43 isolated from rat hearts [164].
Even if a lot of these are not direct or may occur outside the ID, the number of potential partners
is overwhelming.
3.1. Nedd4 Regulates the Cx43 Content of Cardiac Gap Junctions
The ubiquitin ligase Nedd4 interacts directly with Cx43 [132] and both proteins co-localize in
cardiomyocytes [165,166]. Studies indicate that multiple pathways may induce Cx43 ubiquitination in
cardiomyocytes, such as activation of G-protein coupled receptors [166] and cardiac ischemia [165],
and that the underlying mechanism may differ between experimental models. In the case of
G-protein-coupled receptor activation, ubiquitination was achieved via a depletion of PIP2 without
a measurable change in Cx43-Nedd4 co-IP [166,167], whereas cardiac ischemia increased both
co-localization at the ID and increased co-IP [165]. Rather than closing the channel per se, ubiquitination
most likely targets Cx43 to internalization [131] that may involve binding to the adaptor protein
Eps15 [45] followed by endocytosis and lysosomal degradation [168].
3.2. Cx43 Regulates the Forward Trafficking of the Cardiac Sodium Channel NaV1.5
In contrast to the binding of Nedd4 that primarily regulates the Cx43-dependent coupling,
other binding partners may be important for the regulation of nearby partners. This has proven
particularly crucial at the ID, as evidenced by the fact that mutations in a number of ID components
lead to wide spread dysregulation of ID function [169]. Although the exact nature of cross regulation
remains obscure for many ID interactions, the interdependence of Cx43 and the cardiac sodium channel
NaV1.5 has recently been unraveled in some detail.
Knock out of Cx43 in the heart leads to severe arrhythmias [170,171], originally believed to rely
solely on the lack of intercellular coupling. However, several lines of evidence suggested a co-regulation
of Cx43 and NaV1.5 [26,172]; and van Rijen and coworkers demonstrated that Cx43 knock out indeed
reduces sodium channel expression in mice in vivo [173], a result that was reproduced in the cardiac
HL-1 cell line, where Cx43 knock down reduces sodium current [173]. Intriguingly, the deletion of
the last five amino acids of the Cx43CT (D378stop), which interact with the scaffolding protein ZO-1,
also induced a highly arrhythmogenic phenotype in mice, despite an apparently normal intercellular
coupling [174]. As for the complete loss of Cx43 described above, sodium current as well as NaV1.5
expression were reduced in cardiomyocytes from D378stop mice [174], showing that an intact CT is
needed for full NaV1.5 expression at the membrane. The lack of NaV1.5 at the ID suggested that forward
trafficking of NaV1.5 might be compromised. Using super resolution microscopy Agullo-Pascual et al.
demonstrated that the plus end microtubule marker EB1 was partially dislocated from the ID in mice
expressing Cx43-D378stop, which correlated with the presence of NaV1.5 clusters that came very close
to the ID membrane without reaching it properly [175]. This led to the hypothesis that Cx43 acts as an
anchoring point for microtubules and thereby regulates the forward trafficking of other proteins to the
ID. Such an anchoring function was already demonstrated by Lo and coworkers, who showed that
KO of Cx43 reduces fibroblast motility and destabilizes the microtubular network [107]. Deletion of
the tubulin binding domain between amino acids 234 and 243 in the Cx43-CT recapitulated the effect
of removing Cx43 altogether [107], demonstrating the important functional role of the Cx43-tubulin
interaction. The role of the Cx43-tubulin interaction was also demonstrated in the cardiac HL1 cell
line. As mentioned above, knock down of Cx43 in HL1 cells reduces the sodium current by ~50% and
re-transfection with Cx43 restores the sodium current [173]. In contrast, transfection of the same HL1
cells with Cx43 with the tubulin binding domain truncated, failed to restore sodium current [175],
supporting a role for Cx43 as a microtubule anchoring point and thereby for guiding in sodium
channels. Using the HL1 cells, it was also demonstrated that Cx43-D378stop channels were unable
to restore the sodium current [175], indicating that both the tubulin- and ZO-1-binding domains are
needed for proper transportation of sodium channels to the membrane.
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3.3. Cx43, the Area Composita and the Connexome
There is overwhelming evidence indicating that the functions of Cx43 extend beyond that of
forming gap junction channels. Studies from various laboratories indicate that in fact, Cx43 is not
only localized at the gap junction or in the perinexus [176], but also as part of a molecular/structural
conglomerate named the “area composita” [177]. This term was coined to describe the fact that in
the heart cells, in addition to well-defined desmosomes, there are structures with features of both,
desmosomes and adherens junctions. Work of Agullo-Pascual et al. 2014 showed that Cx43 can be
localized to these structures [178]. Furthermore, loss of Cx43 can decrease intercellular adhesion
strength [179]. Finally, changes in desmosomal molecules can affect the integrity of gap junctions [180].
All of these complex interactions have brought us to the conclusion that in the heart, desmosomes,
gap junctions, and sodium channel complexes are not separated and apart from each other. Instead,
they form a protein interacting network where molecules classically defined as belonging to one of
these groups, interact with others and together bring about excitability, adhesion, and intercellular
coupling in the heart. This protein interacting network (dubbed “the connexome” [178,181,182])
provides for a coordinated response between the different elements that are necessary for an integrated
functional syncytium.
4. Conclusions
It has been over 30 years since the description by Beyer, Paul, and Goodenough of Cx43 as the
major gap junction protein in the heart [183]. Since this description, there has been abundant research
demonstrating that Cx43 is far from a lonely and aloof piece of the intercalated disc, geared for only
one function. Rather, Cx43 is part of a complex interacting protein network, not only as a recipient of
interactors that modify gap junctions, but also as a component of complexes that exert other functions.
As such, the view of Cx43 as a single-function molecule (to make gap junctions) is now changed to
that of a multi-tasking protein, webbed into other networks to synchronize cell coupling. The extent to
which those functions are involved in disease remains a matter of controversy. Whether gap junctions,
or Cx43, participate in arrhythmia syndromes, or in limiting the size of infarcts, or as good (or bad?)
pharmacological targets, remains incompletely defined. These last 30 years have brought us a long
way in understanding Cx43 as part of a molecular ecosystem. Hopefully, the next 30 years will help us
improve our ability to forecast the storms that may result from Cx43 deficiency.
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Abbreviations
AA amino acids
AGS8 Activator of G protein signaling 8
AKT protein kinase B
AMSH associated molecule with the SH3 domain of STAM




CaMKII Ca2+/calmodulin-dependent protein kinase II
CASK Ca2+/calmodulin-activated serine kinase
CCN3 CYR61/CTGF/NOV
CDK1 Cyclin-dependent kinase 1
CIP75 connexin interacting protein 75 kDa
51
Int. J. Mol. Sci. 2018, 19, 1428
CIP85 Cx43-interacting protein of 85-kDa




Cx43CT Cx43 carboxyl terminal
Dlg Discs-large
DMPK dystrophia myotonica protein kinase
Drebrin Developmentally Regulated Brain Protein 1
EB1 End binding 1
Eps15 Epidermal growth factor receptor substrate 15
ER endoplasmic reticulum
ERp29 Endoplasmic reticulum protein 29
FERM domain Domain found in 4.1 protein (F), Ezrin, Radixin and Moesin
FW Far-Western
Hrs hepatocyte growth factor-regulated tyrosine kinase substrate
HSP70 heat shock protein 70
HSP90 heat shock protein 90
ID intercalated disc
IP immunoprecipitation
IV in vitro assay
Lin-7 linage-7
MAPK Mitogen-activated protein kinase
MMP7 matrix metalloproteinase-7
Nedd4 Neural precursor cell expressed developmentally down-regulated protein 4





PKA protein kinase A
PKC protein kinase C
PKG protein kinase G
PLA proximity ligation assay
PP protein phosphatase
RPTPμ receptor-like protein tyrosine phosphatase μ
SH3 Src homology 3 domain
Smurf2 Smad ubiquitination regulatory factor-2
SPR surface plasmon resonance
STAMBP Signal transducing adapter molecule 1 binding protein
TC-PTP T-cell protein tyrosine phosphatase
TEM transmission electron microscopy
TOM20 mitochondrial outer membrane receptor 20
TRIM21 Tripartite motif-containing protein 21
Tsg101 Tumor susceptibility gene 101 protein
Tyk2 Tyrosine kinase 2
UBA Ubiquitin-associating domain
UEV Ubiquitin E2 variant domain
USP8 Ubiquitin specific protease 8
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Abstract: Connexin 43 (Cx43), a gap junction protein seemingly fit to support cardiac impulse
propagation and synchronic contraction, is phosphorylated in normoxia by casein kinase 1 (CK1).
However, during cardiac ischemia or pressure overload hypertrophy, this phosphorylation fades,
Cx43 abundance decreases at intercalated disks and increases at myocytes’ lateral borders, and the
risk of arrhythmia rises. Studies in wild-type and transgenic mice indicate that enhanced
CK1-phosphorylation of Cx43 protects from arrhythmia, while dephosphorylation precedes
arrhythmia vulnerability. The mechanistic bases of these Cx43 (de)phosphoform-linked cardiac
phenotypes are unknown. We used patch-clamp and dye injection techniques to study the channel
function (gating, permeability) of Cx43 mutants wherein CK1-targeted serines were replaced by
aspartate (Cx43-CK1-D) or alanine (Cx43-CK1-A) to emulate phosphorylation and dephosphorylation,
respectively. Cx43-CK1-D, but not Cx43-CK1-A, displayed high Voltage-sensitivity and variable
permselectivity. Both mutants showed multiple channel open states with overall increased
conductivity, resistance to acidification-induced junctional uncoupling, and hemichannel openings in
normal external calcium. Modest differences in the mutant channels’ function and regulation imply
the involvement of dissimilar structural conformations of the interacting domains of Cx43 in electrical
and chemical gating that may contribute to the divergent phenotypes of CK1-(de)phospho-mimicking
Cx43 transgenic mice and that may bear significance in arrhythmogenesis.
Keywords: casein kinase 1; phosphorylation; channel gating; gap junction permeability; arrhythmia
1. Introduction
Gap junction channels made of Connexin (Cx) proteins support the propagation of electrical
impulses from cell to cell, and are therefore indispensable for synchronic heart contractions. Cx43,
the most widely distributed cardiac Cx and abundant in all four chambers [1], can compensate for
atrial Cx40 deficiency and prevent fibrillation [2]. However, replacing or supplementing Cx43 with
other Cx isotypes promotes arrhythmia vulnerability [3,4]. These data suggest that Cx43 is optimally
endowed to support cardiac conduction. While such uniqueness may derive from Cx43 amenability
to regulation by multiple kinases [5,6], the functional ramifications of such regulation remain poorly
defined. To address this deficit, we aim to outline the operational profiles of Cx43 modified by specific
phosphorylation events.
In normal heart, Casein Kinase 1 (CK1) phosphorylates serines 325, 328 and 330 of the Cx43
protein residing at gap junctions (GJs) of intercalated disks (ID) [7,8]. During acute ischemia or chronic
pressure overload hypertrophy (induced by transverse aortic constriction, TAC), phosphorylation of
these serine residues is greatly reduced, while total Cx43 protein decreases at the ID and increases
at the lateral sides of cardiomyocytes [8,9]. This gap junction remodeling (GJR) alone might slow
Int. J. Mol. Sci. 2018, 19, 1659; doi:10.3390/ijms19061659 www.mdpi.com/journal/ijms63
Int. J. Mol. Sci. 2018, 19, 1659
impulse propagation and contribute to arrhythmia. In accordance, spironolactone, an aldosterone
antagonist with beneficial effects in patients with heart failure [10], prevents dephosphorylation
of the CK1 sites and reduces or reverses pathological GJR [11]. These data suggest that reversible
CK1-phosphorylation is a pivotal regulatory event that establishes the fate of Cx43 protein/channels
during the transition from physiological to pathological states. In agreement, hearts from transgenic
mice expressing a CK1-dephospho-mimicking mutant of Cx43 (substitutions S325,328,330A, named
S3A) exhibit enhanced GJR and high propensity to arrhythmias after ischemia or TAC-induced
hypertrophy. A converse CK1-phospho-mimicking mutant (substitutions S325,328,330E, named S3E)
had opposite effects, that is, hearts were resistant to arrhythmia induction and to pathological GJR
after ischemia or TAC [9]. Despite the clinical interest of such Cx43 (de)phosphoform-linked cardiac
phenotypes their mechanistic (functional) bases remain unknown.
We hypothesized that differences in channel gating/permeability, linked to the phosphorylation
status of Cx43, contribute to the cardiac phenotypes of S3A and S3E mice. Therefore, we assessed
gating and permeability of mutant Cx43-S325,328,330D (here dubbed Cx43-CK1-D), where aspartates
supply the charge effect of phosphorylation, and mutant Cx43-S325,328,330A (dubbed Cx43-CK1-A),
where non-phosphorylatable alanines provide a stable “dephosphorylated” state. While both
mutants displayed properties typical of wild-type Cx43 (Cx43WT), they also showed unexpected
properties that challenge current models of channel function and may be significant for the cardiac
phenotypes of the (S3A, S3E) transgenic mice, as well as for the pathophysiology of cardiac ischemia
and arrhythmogenesis.
2. Results
2.1. Cx43-CK1-D Displays Stronger Vj-Sensitivity than Cx43-CK1-A
The decrease in junctional current (Ij) observed in GJs subjected to large transjunctional
voltages (Vj) is called Vj-gating (Figure 1A,B) and is quantified by fitting the ratio of steady state
and instantaneous junctional conductance (gjss/gjinst) through a broad Vj range with a Boltzmann
function [12,13], with half-maximal response reported as V0 (see Section 4). When measured in rat
insulinoma (Rin) cells, Cx43 Vj-gating (Figure S1, Table 1, Tables S1 and S2 and [14]) was similar to that
reported for Cx43WT expressed in other cell types [15–17]. Cx43-CK1-A showed Vj-gating comparable
to Cx43WT (Figure 1; Table 1, Tables S1 and S2). In contrast, Cx43-CK1-D showed a faster response
to Vj (Figure 1A,B) and smaller V0 values (Figure 1C,D, Table 1, Tables S1 and S2), revealing a more
sensitive closure mechanism than Cx43-CK1-A. This suggests that Cx43 phosphorylation by CK1
enhances junctional Vj-gating, and that highly Vj-dependent gap junction channels (GJChs) populate
the intercalated disks.
Table 1. Boltzmann parameters of Cx43 WT and mutants.
Mutant Gj max Gj min V0 (mV) A
Cx43WT 0.98/0.99 0.32/0.34 −64/+70 4.8/4.1
Cx43-CK1-D 1.1/1.0 0.21/0.34 −49/+46 12.1/5.4
Cx43-CK1-A 1.0/0.98 0.35/0.40 −71/+70 8.4/4.1
Boltzmann fit parameters are shown as rounded values for both negative and positive polarities. Exact values are
reported on Table S2. Cx43WT values obtained from experiments are displayed in Figure S1.
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Figure 1. Cx43-CK1-D displays stronger Vj-sensitivity than Cx43-CK1-A. (A) Five individual Ij
responses to Vj = ±80 mV pulses (left) and sum (right) of 38 similar traces from Cx43-CK1-A cell
pairs; (B) Five individual Ij responses to Vj = ±80 mV pulses (left) and sum (right) of 30 similar traces
from Cx43-CK1-D cell pairs. For (A,B), tau values of Ij inactivation (2nd order exponential decays)
are shown and the fits (white) displayed over the corresponding sum traces; (C) Vj-dependence of Gj
from individual experiments in Cx43-CK1-A (gj = 2.8 ± 1.0; n = 5) cell pairs; (D) Vj-dependence of Gj
from individual experiments in Cx43-CK1-D (gj = 1.7 ± 1.1; n = 7) cell pairs. For (C,D), gj from each
experiment was normalized as described in the Methods and the Boltzmann fits are shown in solid
black lines; (E) Average Vj-dependence for CK1-A (gray circles) and CK1-D (black triangles) and their
corresponding Boltzmann fits (dashed lines). Fast inactivation and V0 values were different between
Cx43-CK1-D and Cx43-CK1-A. For fitting parameters, see Table 1, Tables S1 and S2.
2.2. Cx43-CK1-D and Cx43-CK1-A Display Highly Conductive, Vj-Sensitive, Channel Transition Amplitudes
As deduced from their unitary conductances (γj) at Vj < V0, Cx43 GJChs exist in multiple states:
closed (C), fully open (O), residually open (R), and several intermediate open states, or substates
(S) [16,18–22]. Thus, while only one fully open state may exist, channels can occupy multiple
less conductive configurations. These multiple configurations could result from variable structural
conformation of the connexin molecules comprising each channel. Transitions between multiple
channel states yield a broad range of apparent γj values that seem to vary with the cell type and with
the Cx phosphorylation state (cf. [23,24]). In addition, the presence of other Cxs can modify both
the γj profile and function of predominantly Cx43-comprised GJs [25,26]. It is thus important that
recording conditions are standardized and that cells express only the protein of interest. In our current
experimental settings [14,22,27,28] and at Vj < V0, the γj values for Cx43WT channels are C = 0,
O = 100–125, R = 17–35, and S = 55–70 pS. Transitions between these states would produce transition
amplitudes of approximately (in pS) 100–125 (O↔C), 17–35 (R↔C), 55–70 (S↔C), 83–90 (O↔R), 45–50
(O↔S), and 35–40 (S↔R). Given the conductance ranges for each transition type, distinguishing each as
a distinct peak is generally not possible. Vj > V0 brings GJChs to the residual state (O↔R) from which
full closure (R↔C) may occur. Hence, at Vj < V0 Cx43WT displays many transition amplitudes, and at
Vj > V0 most likely O↔C, O↔R and R↔C transitions (Figure S2; cf. [16,18,28]). Because Cx43-CK1-D
emulates a Cx43 phosphoform found in normoxic hearts (Cx43-pCK1), we expected the distribution of
channel transition amplitudes of this mutant to resemble that of Cx43WT. In comparison, Cx43-CK1-A
emulates a Cx43 phosphoform (Cx43-dpCK1) found during hypoxia and displays a decreased incidence
of fully open channels when expressed in mesenchymal cells [8].
In Rin cells both mutants showed multiple transition amplitudes, including those consistent with a
fully open channel (Figure 2A,B,D,E). Differences in transition amplitudes and distribution with respect
to each other and to Cx43WT were documented as follows (Figure 2C,F; cf. Figure S1D): At Vj = 40 mV
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(<<V0), main transitions in Cx43-CK1-D were 90–150 pS, and in Cx43 CK1-A, 75–140 pS. In both
mutants, R↔C transitions (≤30 pS) were rare. Transitions >150 pS were sporadically observed in
Cx43-CK1-D, extending the range of apparent channel amplitudes to values not present in Cx43-CK1-A
and unreported for Cx43WT. At Vj = 80 mV (>>V0), Cx43-CK1-D mostly displayed 35–55 and 75–120 pS
transitions, and a few >150 pS transitions. In comparison, Cx43 CK1-A displayed 25–40 and 60–105 pS
transitions, but essentially no >150 pS transitions. Note that while both mutants showed transition
amplitudes above the typical 120 pS fully open state, they also displayed intermediate transitions
compatible with a substate (80 > S > 40 pS), particularly at Vj = 80 mV. Thus, in contrast to Cx43WT [14]
both mutants preferentially displayed O↔C and O↔R transitions at small Vj gradients, and O↔R
and R↔C transitions at large Vj gradients. On the whole, the data indicate that in the absence of Vj
gradients, mutant (and WT) channels may favor a fully open state. In addition, transition amplitude













































































































Figure 2. Cx43-CK1-A and Cx43-CK1-D display fully open, Vj-sensitive gap junction channels.
(A,B,D,E) Illustrative traces of channel activity from Cx43-CK1-A (A,B) and Cx43-CK1-D (D,E) expressing
cell pairs, at 40 mV (A,D) and 80 mV (B,E) transjunctional gradients. For all traces: zero current
(long-dashed line) and the most evident Ij levels (short-dashed lines) are indicated; when present,
downward arrows mark the beginning (black) and end (gray) of pulses; plots at right are the all-points
histogram for the displayed record segment, showing the fraction of time at each Ij level; numbers indicate
the conductance change between current levels. Notice that channel transitions often occur between
the identified levels. (C,F) Average transition amplitude histograms at 40 and 80 mV Vj values from
Cx43-CK1-A (C) and Cx43-CK1-D (F). Peak fits indicated by solid black lines. Likely transitions between
channel states (see main text for further explanation) are indicated by double arrowed vertical lines.
Transition amplitude distributions of Cx43-CK1-D and Cx43-CK1-A differed from each other and from
Cx43WT, at both Vj values of 40 and 80 mV. However, at Vj = 40 mV, both mutants displayed transitions
amplitudes compatible with O↔C and O↔R transitions (if O = 150 pS and R = 30 pS). Transitions larger
than 150 pS were documented for Cx43-CK1-D. At Vj = 80 mV, O-R and R-C transitions were more evident
for both mutants. However, at both 40 and 80 mV, transitions between closed and levels smaller than
fully open states were observed, suggesting substates (S). For each group, the number of experiments (n)
and measured transitions (N) were respectively, as follows: For CK1-A, 6 and 1867 at 40 mV, 5 and 1080 at
80 mV. For CK1-D, 4 and 1369 at 40 mV, 6 and 1032 at 80 mV.
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2.3. Cx43-CK1-A Displayed Lower Permselectivity than Cx43-CK1-D
The appearance of highly conductive channels in the CK1-(de)phospho-mimicking mutants raised
the possibility of these mutants displaying higher GJ permselectivity (molecular/atomic permeability:
Pj-NBD/gj) than Cx43WT [14,28]. Thus, NBD transjunctional diffusion (illustrated in Figure S3) and gj
were measured in cell pairs expressing either mutant (see Section 4). Cx43-CK1-D expressing cells
displayed (~three-fold) larger electrical coupling (gj = 30.86 ± 7.81 nS; n = 21) than those expressing
Cx43WT (gj = 10.49± 1.48 nS; n = 53); however, permselectivity (Figure 3) of Cx43-CK1-D (0.074± 0.022
and Cx43WT (0.094 ± 0.018; [28]) expressing cells was similar. Cx43-CK1-A cells also displayed
(~2 fold) greater electrical coupling (gj = 24.56 ± 8.79 nS; n = 12) than Cx43WT cells, but showed lower
permselectivity (0.017 ± 0.001) than Cx43-CK1-D or Cx43WT (Figure 3), in agreement with previous
studies [8]. It is noteworthy that the variability in permselectivity of Cx43-CK1-A was far less than
either Cx43WT or Cx43-CK1-D (6% vs. 19% and 30%, respectively). These data suggest a link between
Cx43 phosphorylation by CK1 and variable permselectivity; in contrast, low Cx43 permselectivity may


































Figure 3. Permselectivity of dephospho-mimicking Cx43-CK1-A GJs is lower and less variable than
that of phospho-mimicking Cx43-CK1-D GJs. (A) Rate constant of transjunctional dye diffusion
vs. junctional conductance for the indicated mutants. Each symbol represents a single experiment;
(B) Distribution (box plots) of collected permselectivity values for Cx43-CK1-D (0.074 ± 0.022; n = 16)
and Cx43-CK1-A (0.017 ± 0.001; n = 7); Cx43WT data (from [14]) shown in light gray for comparison.
Note that permselectivity values of Cx43-CK1-D (and Cx43WT) do not display a normal distribution.
** Median and variance of Cx43-CK1-A are different from Cx43-CK1-D and Cx43-WT (p < 0.05). See
text for further explanation.
2.4. Cx43-CK1-D and Cx43-CK1-A GJs are Resistant to Intracellular Acidification
In ischemic tissue, internal pH (pHi) falls to very acidic values (pH ~6.0) [29–31], and low
pH-induced uncoupling can be arrhythmogenic [32–35]. To determine whether decreased
pH-sensitivity of the Cx43 CK1-phosphoform confers the arrhythmia-resistant phenotype of S3E
transgenic mice, we documented the response of Cx43-CK1-D gj to acidification. Unlike Cx43WT GJs,
which typically close within ~5 min of exposure to low external pH (pHo), Cx43-CK1-D GJs remained
open for > 5 min (Figure 4): ~54% and ~40% of initial gj lingered at 15 and 20 min, respectively, after
the start of acidification. The overall delayed uncoupling reveals a major reduction of pH-sensitivity,
suggesting that phosphorylation influences pH-gating of Cx43. In particular, phosphorylation by
CK1 may decrease Cx43 susceptibility to low pH-induced uncoupling. Unexpectedly, however, the
same acidification protocol also failed to uncouple Cx43-CK1-A GJs (Figure 4). Indeed, Cx43-CK1-A
gj was ~93 and ~90% of initial at 15 and 20 min, respectively, and remained essentially unchanged
following 25 min of low pH exposure, suggesting that dephosphorylation of CK1 targeted serines of
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Cx43 renders GJChs unable to close upon acidification. These data show that resistance of GJ coupling
to acidification alone cannot explain the divergent cardiac phenotypes of transgenic S3A and S3E mice.
time (min)















Figure 4. Cx43-CK1-D and Cx43-CK1-A mutants form gap junctions resistant to closure by low pH.
Superfusion (starting at time 0) with a bicarbonate solution buffered at pH = 6.0–6.2 caused slow gj
decrease in Cx43-CK1-D (black triangles; n = 6), and no gj decrease in Cx43-CK1-A (gray circles; n = 4)
during an observation period of ≥ 20 min. The response of Cx43WT junctions to similar treatment
(white triangles; n = 5) is reproduced from [14] for comparison.
2.5. Cx43-CK1-D and -CK1-A Hemichannels Open Frequently
In Cx43WT-expressing cells at normal external calcium ([Ca2+]o) = 1–2 mM (and internal
calcium, ([Ca2+]i) from nominally 0 to ~40 nM), connexin hemichannel (HCh) openings are rare
and may require depolarization >+60 mV [36–39]. In Rin cells under our experimental conditions (see
Section 4), this rarity is exacerbated, and few HCh-like transitions from Cx43WT have been recorded
at Vm = 80–100 mV (Figure S4). In contrast, membrane current (Im) transitions suggestive of HCh
openings were seen in several, but not all cells transfected with Cx43-CK1-D (43 out of 127 explored, or
~33%) or Cx43-CK1-A (11 out of 62 explored, or ~18%). The amplitude of presumptive HCh transitions
varied for both Cx43-CK1-D (140–280 pS; Figure 5A–C) and for Cx43-CK1-A (100–240 pS; Figure 5D–F).
HCh activity of mutant Cx43-CK1-D varied from only a few events per second to profuse transitions
(Figure 5A,B), not inactivated during >50 s pulses. In contrast, Cx43-CK1-A displayed less organized,
harder to detect HCh activity (Figure 5D,E). Clear step-wise openings could be found in Cx43-CK1-D
(Figure 5C), but less often in Cx43-CK1-A expressing cells. However, in three Cx43-CK1-A expressing
cells, sudden Im increases suggesting multiple HCh openings, were seen during prolonged depolarizing
pulses. One such Im increase (and recovery) occurred before the trace shown in Figure 5F, under well
controlled Vm clamp. The variability of HCh activities, in particular the infrequent appearance of
Cx43-CK1-A events, encumbers wider comparisons between the mutants. Nevertheless, the records
suggest that HChs formed by Cx43-CK1-D or Cx43-CK1-A can open under physiological conditions of
internal and external Ca2+.
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Figure 5. Cx43-CK1-D and Cx43-CK1-A expressing cells display frequent connexin HCh activity.
Plasma membrane channel transitions compatible with opening of undocked connexons from single
cells expressing Cx43-CK1-D (A–C) or Cx43-CK1-A (D–F). Lines, marks, plots, and numbers as in
Figure 2. (A,D) are 20 s samples of longer recordings; (B,E) are expanded displays of the 2 s interval
marked by black lines at the bottom left of (A,C); (C,F) Further examples of transitions recorded during
5-s pulses. Hemichannel activity from Cx43-CK1-D is usually well defined (as in A–C), in contrast to
Cx43-CK1-A (D–F).
2.6. Cx43-CK1-D and -CK1-A are Phosphorylated at S368
Our published data suggest PKC phosphorylation at residue S368 increases the dye
permselectivity (Pj-NBD/gj) of Cx43 GJs [28]. Hence, we pondered whether the discrepancy
between Cx43-CK1-D and Cx43-CK1-A permselectivity might be consequential to differences in S368
phosphorylation. To address this possibility, we used phospho-specific antibodies to determine the
presence and location of Cx43 phosphorylated at S368 (Cx43-pS368) in Cx43WT- and mutant-expressing
cells. Representative images of this scrutiny show that the Cx43-pS368 epitope was present both at
junctional (mainly) and non-junctional membranes, abundantly and in multiple spots in Cx43WT
cells (Figure 6A,B). Although fewer cells in the Cx43-CK1-A clone were Cx43 positive, Cx43-pS368
signal was also present in this mutant (Figure 6D,E), with distribution comparable to Cx43WT. In
Cx43-CK1-D expressing cells, Cx43-pS368 signal was readily found decorating long cell contacts
(Figure 6G,H). Total Cx43 was profusely expressed, with a significant fraction located to junctional
plaques, in all cell groups (Figure 6C,F,I, green). In addition, an antibody against CK1-phosphorylated
Cx43 demonstrated the presence of this phosphoform in Cx43WT plaques, confirming that Rin cells
are able to properly process and place this junctional protein (Figure 6C). These data demonstrate that
phosphorylation of S368 occurs in both Cx43 mutants, but the data do not preclude the possibility that
high permselectivity (in Cx43-CK1-D) is due to higher phosphorylation of S368 by PKC, and in turn,
low permselectivity (in Cx43-CK1-A) results from lower pS368-Cx43.
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Figure 6. Residue S368 of Cx43 is phosphorylated in Rin cells expressing Cx43-WT, Cx43-CK1-A or
Cx43-CK1-D. (A,B,D,E,G,H) Fluorescent (upper) and fluorescent merged with the corresponding
differential interference contrast (DIC, lower) images of cells stained with a Cx43-pS368
phospho-specific antibody (pS368). Cx43-pS368 (green) was found in junctional plaques in groups
and isolated pairs of Cx43WT (A,B), Cx43-CK1-A (D,E) and Cx43-CK1-D (G,H) cells. (C,F,I) DIC
and fluorescent images of cells stained simultaneously with a polyclonal Cx43 antibody (“total”
Cx43, tCx43) and a phospho-specific antibody against Cx43-pCK1 (pCK1). In all groups, total Cx43
(green) was found in junctional plaques and other cell areas (C,F,I, upper left panels). Bona fide
CK1-phosphorylated Cx43 (red) was found only in Cx43WT cells (C, bottom right) colocalized with a
membrane fraction of total Cx43 at junctional plaques (C, upper right, yellow). The pCK1 antibody
labels a non-specific nuclear signal in the dephospho- (F) and phospho-mimicking (I) mutant expressing
cells that is also found in parental Rin cells, devoid of connexins (Figure S5). Calibration bars (pink
lines, 25 μm) apply to each column.
3. Discussion
3.1. On the Role Cx43 of Phosphorylation
The cytoplasmic carboxyl terminus (CT) domain of Cx43 harbors several kinase consensus
sites [5,40], but whether phosphorylation at these sites occurs independently or in tandem, transiently
or continuously, alternately or progressively, remains unclear. Nevertheless, (de)phosphorylation at
specific sites has been linked to specific Cx43 cellular locations [41–47]. How these phosphorylation
differences and their associated structural modifications translate into functional changes in the context
of cellular phenomena where Cx43 plays a role (e.g., cell cycle progression and proliferation [48–51],
healing [52–54], migration [55–58]; differentiation [59–61] and electrical coupling [34,35,41,62,63]),
remains undetermined. Here, we studied the electrical/chemical gating and the permselectivity
70
Int. J. Mol. Sci. 2018, 19, 1659
of Cx43 (de)phospho-mimicking mutants associated to disparate cardiac phenotypes in transgenic
mice (arrhythmia susceptibility vs. arrhythmia resistance). We found differences in channel
function/regulation that may contribute to these cardiac phenotypes. Our data may be relevant
to the pathophysiology of cardiac ischemia.
3.2. What the Data Suggest
3.2.1. Voltage Gating and Channel States
Cx43-CK1-D and Cx43-CK1-A display differences in GJ Vj-sensitivity and channel behavior. The
fast exponential component of Vj-gating may involve an interaction of the Carboxyl Terminus (CT)
domain with a receptor-like structure near the pore mouth, formed by a region of the Cytoplasmic
Loop (CL) [19,64,65]. Our Vj-gating data suggest that CK1-phosphorylation enhances Vj-sensitivity
of Cx43 residing at the ID, and that the residual state would be more readily occupied by this
phosphoform (Cx43-pCK1) when subjected to high Vj gradients. In turn, the channel data suggest that
at low Vj gradients (the most likely environment of GJs), both the dephospho-(Cx43-dpCK1) and the
phosphoform exist in either fully open or closed states, and at high Vj gradients, both transit frequently
between fully open and residual states, from which they can close.
Because at low Vj and despite their charge differences, both mutants show larger channel
transitions than Cx43WT, it is possible that high conductivity results from structural modifications
of the mutated region rather than different charge polarity/density. Alternatively, the large unitary
conductance (γj) of mutant channels could reflect the “homomeric” nature of these channels (at least in
regard to the CK1 targets) compared to Cx43WT, where differences in phosphorylation state between
Cx subunits certainly must exist. Large γj values in mutants representing the extremes of Cx43
phosphorylation by CK1 cannot readily explain their opposite cardiac phenotypes. However, the
Cx43-CK1-D data suggest that phosphorylation by CK1 enhances conductivity of Cx43 channels,
as evinced by the larger O↔C and O↔R transitions (at low Vj), and the wider residual state
range (at high Vj), than either Cx43-CK1-A or Cx43WT. Of note, oversized transitions were not
observed in all Cx43-CK1-D cell pairs and did not establish a predominant γj peak, suggesting that
CK1-phosphorylation alone is not sufficient to yield this highly conductive channel configuration.
Another possibility is that large transitions are double channel events brought about by the high
Vj-sensitivity of the mutant, which cannot be discriminated under our recording conditions.
It is important to consider here the possible meaning of multiple channel transition amplitudes
and their relative abundance. Such multiplicity is observed at Vj < V0 as well as > V0, in Cx43WT as
well as Cx43-CK1-D and Cx43-CK1-A mutants. This multiplicity of transition amplitudes indicates that,
in the absence of Vj gradients, Cx43 channels reside stably (≥50 ms) in multiple open configurations,
each of which can display Vj sensitivity. If the only function of GJChs were to establish an electrical
pathway between cells, the only relevant measure would be the absolute value of gj, irrespective of
the multiple channel states that inhabit the junctional plaque. What, then, is the benefit of supporting
multiple open states? It has been shown that electrical coupling and dye coupling are not linearly
correlated [28,66]; perhaps we should ask whether and how multiple channel states regulate the
intercellular flux of the “metabolites and second messengers” so often mentioned in the literature.
3.2.2. pH-Gating
Susceptibility to acidification-induced uncoupling is a common trait of GJs, but pH-sensitivity
varies among connexins [67–70]. As with Vj-gating, a CT-CL interaction has also been proposed
as the pH-gating mechanism [64]. Uncoupling of Cx43 GJs is quickly induced by superfusing
cells with weak acid solutions buffered at pHo ~6.0–6.2 [68,71], which pHi readily follows [72].
In ischemic tissue, pHi may fall to similar low values [29–31,73]. Therefore, during myocardial
ischemia low pHi could contribute to the decreased electrical coupling in damaged tissue, setting the
stage for arrhythmogenesis [32–35]. In this scenario, delayed closure upon acidification and transient
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preservation of electrical coupling at the cells’ end-to-end GJs could temporarily protect impulse
conduction, cardiac anisotropy, and metabolic rescue of failing cells, all favoring preservation of
function early in an ischemic episode. However, during continuous ischemia, complete GJ uncoupling
could limit tissue damage, to the detriment of the still living cells in the infarct area, but to the benefit
of the organ. Thus, the transient resistance to acidification of Cx43-CK1-D would be consistent with the
arrhythmia-resilience of S3E mice. On the other hand, persistent junctional coupling during prolonged
acidification would negate the advantages of a transient preservation of coupling, by allowing the
steady diffusion of noxious substances from the damaged area to surrounding tissue [32,33]. If this
were the case, the imperviousness of Cx43-CK1-A to acidification-induced closure would be consistent
with the arrhythmia-vulnerability of S3A mice, where increasingly larger lesions may facilitate
arrhythmia. This possibility does not necessarily exclude TAC-induced arrhythmia susceptibility, a
chronic condition where acute acidification is not a known factor, but where junctional permselectivity
to regulatory molecules may play an important role.
3.2.3. Channel Selectivity
The permselective variability of homomeric, homotypic Cx43 GJs has been linked to variable
phosphorylation of the Cxs comprising the channels [28]. Results from Cx43-CK1-D and Cx43-CK1-A
support the notion that permselectivity is an inherent property of Cx43 channels, not directly linked to
the level of electrical coupling, but to the phosphorylation-induced functional states of the channels
comprising the junction. Explicitly, CK1 phosphorylation may provide part of, or be permissive
to, the permselective variability of Cx43 junctions. In turn, dephosphorylation of CK1 sites may be
less permissive to, or limit (but not completely prevent) such variability. It was also proposed that
decreasing permselectivity with unchanging gj was due to a decreasing proportion of highly permeable
channels within the junction [74]. Our results from Cx43-CK1-A and previous data showing low dye
(LY) coupling in mesenchymal cells expressing this mutant [8], are in agreement with that idea.
At this point, we should consider possible differences between the transgenic models and the
fate of Cx43WT phosphoforms during pathological events. First, Cx43-CK1-A showed lower and less
variable permselectivity (Pj-NBD/gj) than Cx43WT, suggesting that despite its likely contribution to
persistent electrical coupling (in the mouse model), this mutant’s ability to support transjunctional
diffusion of organic ions (e.g., signaling molecules, nutrients, and waste products) may be limited.
Whether this reduced permselectivity would make Cx43-CK1-A (or Cx43-dpCK1) in the infarct border
zone more liable to propagating damage (bystander effect) or efficient in protecting non-injured tissue
(metabolic rescue) requires further study. Interestingly, in transgenic mice with cardiac-selective
Cx45 overexpression, increased arrhythmia vulnerability was linked to altered permselectivity (lower
LY and higher biotin coupling) between myocytes [4], suggesting that positively charged junctional
permeants in the molecular size range of biotin may be of interest in arrhythmogenesis.
Second, during ischemia (or pressure overload hypertrophy), Cx43WT dephosphorylated at
the CK1 sites may be phosphorylated or dephosphorylated at other sites as it moves away from the
IDs. Judging by its electrophoretic mobility alone, the Cx43-CK1-A mutant would appear overall as
dephosphorylated [9]; but despite being a “CK1-dephosphoform” this mutant generates (electrically)
stable GJs, even in conditions of low pHi, and therefore, may not accurately represent the Cx43-dpCK1.
Possible functional effects of kinases targeting other Cx43 sites (see below) during ischemia and GJR,
and the fate of Cx43-dpCK1 remain subjects of study.
3.2.4. Hemichannels
Cardiac ischemia- and TAC-induced GJR involve an apparent mobilization of Cx43 from IDs
to lateral membranes of myocytes [8,11]. It is uncertain whether this lateralized protein pool makes
functional channels (as docked connexons or undocked HChs), but reports suggest that massive
HCh opening is a pathophysiological occurrence in the aftermath of myocardial ischemia [75–79].
Cx43-CK1-D and Cx43-CK1-A HChs can display high activity in the presence of normal [Ca2+]o.
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To date, only one other Cx43 construct, Cx43*NT37 [14], has displayed robust HCh activity in our
experimental settings, but this chimera, with exceptional inability to respond to several gating triggers,
is an unnatural construct made to explore the interaction of Cx domains. In contrast, Cx43-CK1-D
and Cx43-CK1-A emulate natural states of the protein. This raises the questions of whether the massive
HCh opening during metabolic inhibition or ischemia is indeed linked to stable CK1-dependent
Cx43 phosphoforms or, alternatively, the mutants’ HChs are artifactual. As shown previously [8,
11], Cx43-pCK1 disappears from IDs during GJR. In contrast, CK1-A and CK1-D mutants seem to
exist (and stay) in junctional and in non-junctional membranes ([9] and our current data), even in
pathological conditions.
If the Cx43-CK1-D and Cx43-CK1-A mutants replicate phosphorylated states of Cx43WT, then the
corresponding alternate Cx43 phosphoforms make HChs that open at different cellular locales. Thus,
Cx43-pCK1 HChs would open toward the “gap” (the virtual space containing the extracellular regions
of Cx43) or the perinexus, but it is unclear whether their opening would be consequential (e.g., modify
the ionic composition of perinexus or cytoplasm; cf. [80]). In contrast, HChs made by Cx43-dpCK1 may
open at the lateral membranes, where they would contribute to arrhythmia propensity by facilitating
collapse of the membrane potential, decreasing (Na+ channel) excitability and mediating leak of
substances into and out of the cells [75,81,82].
3.2.5. Further Cx43 Phosphorylation
The cardioprotective S3E phenotype may be linked to a stable presence of Cx43 at the ID, and/or
to a permissive/protective role of the mutation itself for phosphorylation at other Cx43 sites ([9], their
Figures 1–4). Without conflict with these interpretations, arrhythmia resilience might be partly due to
the temporary resistance of the CK1-phospho-mimicking Cx43 mutant to low pH-induced gating.
Slowly migrating electrophoretic Cx43 bands, perhaps representing phosphorylated isoforms,
are preserved in the S3E hearts [9]. This observation poses an interesting line of thought: In Cx43WT,
dephosphorylated S365 (Cx43-dpS365) is permissive to S368 phosphorylation by PKC [83], an event
linked to smaller γj and higher permselectivity [15,18,28] of the remaining active GJChs [50,84].
Because spironolactone and the S3E mutation yield parallel effects on Cx43 distribution and arrhythmia
susceptibility [9,11], one can speculate that the Cx43-pS365 isoform, protected by the hormone inhibitor,
is also protected in the transgenic S3E hearts. Were this the case, the rise of Cx43-pS368 and the shift
toward smaller γj and higher GJ permselectivity would be deterred in the S3E hearts and in the CK1-D
expressing cells. Our results partially concur with this possibility, as the CK1-D mutant displayed lower
frequency of small GJCh transitions and no higher permselectivity values than Cx43WT. However,
Cx43-pS368 was readily found in cells expressing Cx43-CK1-D, and less abundantly in Cx43-CK1-A
expressing cells; high permselectivity was observed in some Cx43-CK1-D, but not in Cx43-CK1-A cell
pairs. These data demonstrate that S368 remains a target of PKC in both Cx43-CK1-D and Cx43-CK1-A,
but leaves the possibility open that differences between these mutants may be due to differences in
the level of S368 phosphorylation. To address this issue, one possible strategy would involve Cx43
constructs carrying both the CK1- and PKC-(de)phospho- mimicking mutations.
Despite their possible drawbacks, and because of their relative ease, mutational techniques contribute
importantly to the study of phosphorylation [85,86]. However, alternate mutant (mimicking) forms of
single phosphorylation siteswith outcomes equally differing fromCx43WThave been reported [87]. These
and some of our data (e.g., single channel transitions, pH-gating) suggest that (de)phospho-mimicking
amino acid substitutions may not recapitulate all features of biological (de)phosphorylation. It is
also possible that similar outcomes indicate that the mutated residues are not absolutely essential,
or that complementary or sequential changes at other sites are necessary, for the explored/expected
outcomes. Thus, in addition to S368, PKC-phosphorylation of S262 was linked to cardioprotection
and prevention of Cx43 lateralization in the context of preconditioning and reperfusion injury [88–91].
Also during ischemia, Cx43 can be phosphorylated at S373, which activates a 14-3-3 mode-1 binding
domain in Cx43; pS373 may disrupt Cx43/ZO-1 interaction, while the complex Cx43/14-3-3 facilitates
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ubiquitination, internalization and degradation of Cx43 [84]. The role of phosphorylation in Cx43/ZO1
binding/releasewas recently further explored using (de)phospho-mimicking amino acid substitutions [87].
Results suggest that Cx43/ZO-1 interaction is set within a series of sequential and hierarchical
phosphorylation/dephosphorylation steps that involve not only residue S373, but also S365, S368,
S279/S282, S255, and S262. Specific phospho-antibodies against these and other important sites (e.g.,
S262, S279, S365) are not widely available. However, it would be interesting to explore the channel from
(de)phospho-mimicking amino acid substitutions of all these sites.
3.2.6. Implications of CK1-Phospho-Mimicking Mutants for a Channel Gating Model
Overall, the data shown here strongly suggest that the gating of gap junction channels cannot
be explained with a simple/unique closure mechanism. The data also confirm that the CT domain
plays a role in channel closure, and demonstrate that such a role is modified by phosphorylation.
To illustrate these points, let us assume that the various triggers that cause GJCh closure shared a
single gating mechanism. Because modifications to the mechanism itself must affect its response to
any trigger, then, weak pH-gating, for instance, would be expected to match weak Vj-gating. We
showed strong Vj-gating paired with weak pH-gating (opposite), and “WT-like” Vj-gating paired with
absence of pH-gating (opposite). Thus, in contrast to the chimera Cx43*NT37, which inhibited both pH-
and Vj-gating in the presence of an intact Cx43CT [14], the CK1-(de)phospho-mimicking mutations
differentially modulate the response of GJs to gating triggers through Cx43CT. These observations can
only be understood if the (CT-CL) interactions involved in Vj- and pH-induced channel closure are
dissimilar, at least for Cx43. In other words, while different triggers may share common elements, the
specific molecular structures involved in electrical and chemical gating may not always be identical.
Moreover, the availability and readiness of the gating elements are amenable to modification by
phosphorylation, and thus by the changing cellular conditions.
4. Materials and Methods
4.1. Plasmid Construction
pcDNA3 neo plasmid (Thermo Fisher Scientific, Waltham, MA, USA) containing
the rat Cx43 sequence was mutated at the N341 site to convert the amino acid
sequence to mouse using the Stratagene’s QuikChange Lightning kit (Stratagene, San
Diego, CA, USA) according to the manufacturer instructions and the following primers
(mutations shown in bold): 341S F 5′ gatttccccgacgacagccagaatgccaaaaag3′ and N341S R 5′
ctttttggcattctggctgtcgtcggggaaatcg 3′. After verifying the sequence at the University of Arizona’s
UAGC sequencing facility, mutations S325,328,330D (dubbed CK1-D) and S325,328,330A
(dubbed CK1-A) were introduced also with the QuikChange kit (Stratagene, San Diego,
CA, USA) and the primers (mutations shown in bold): CKIDx3 F 5′ catggggcaggccggagaca
ccatcgacaacgatcacgcccagccgttcg 3′ and CKIDx3 R 5′ cgaacggctgggcgtgatcgttgtcgatggtgtctccggcct
gccccatg 3′; CK1-Ax3 F 5′ catggggcaggccggagccaccatcgccaacgcacacgcccagccgttcg 3′ and CKIAx3 R
5′ cgaacggctgggcgtgtgcgttggcgatggtggctccggcctgccccatg 3′. pcDNA containing each mutation was
amplified with the QIAgen Maxiprep kit (QIAgen, Hilden, Germany)) as per manufacturer instructions
to produce material for transfection. Sequence was confirmed at the University of Arizona UAGC
Sequencing Facility (Local University Services).
4.2. Cell Culture, Transfections and Protein Expression
Rat insulinoma (Rin) cells [51] were transfected with the Lipofectamine 2000 (Life Technologies,
Grand Island, NY, USA) and pcDNA3 plasmid containing Cx43-CK1-D. Subclones were isolated by
dilution cloning and tested for gene expression by Western blotting. GJ coupling was examined
in subclones or recently transfected cells. Control experiments were performed in cells stably
transfected with Cx43WT (Rin43). Protein expression of Cx43-CK1-D and CK1-A was confirmed
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by immunofluorescence and Western blot. Immunocytochemistry (ICC) was performed using
primary antibodies against total Cx43 (Sigma-Aldrich, St. Louis, MO, USA), pS368-Cx43 (AbCam,
Cambridge, MA, USA) and pS325/328/330-Cx43 (generous gift from Paul Lampe). Secondary
antibodies (Jackson ImmunoResearch, West Grove, PA, USA) labeled with Alexa488 or Alexa647
were used for fluorescence detection.
4.3. Electrophysiology
Electrical recordings were performed as described [14]. Briefly, junctional (Ij) or membrane (Im)
currents were recorded with square voltage pulses using dual or single whole-cell (WC) patch clamp
and osmotically matched (300–330 mOsm) external (in mM: 142.5 NaCl, 4 KCl, 1 MgCl2, 5 Glucose,
2 Na-pyruvate, 10 HEPES, 15 CsCL, 10 TEA-Cl, 1 CaCl2), and pipette solutions (in mM: 124 KCl, 3
MgCl2, 5 Glucose, 9 HEPES, 9 EGTA, 14 CsCl, 9 TEA-Cl, 5 Na2-ATP, 0.5 CaCl2; calculated [92] free
cytosolic Ca2+ ≤ 20 nM). Macroscopic junctional conductance (gj) was measured with repeated, 2-second
transjunctional voltage (Vj) pulses of ±10 mV. Vj-gating was assessed with 5-s Vj pulses of increasing
magnitude from 0 to±100 mV in 10 mV increments (step protocol) or with repeated pulses of±80 mV (for
Vj-dependent fast Ij inactivation). To quantify Vj-gating, normalized gj (Gj = steady state/instantaneous
gj (gjss/gjinst)) values obtained with the Vj step protocol were fit with a Boltzmann function, which
depicts distribution of two channel states: maximally/minimally open, over the Vj range [12,13,16];
from these Gj/Vj relationships, the following parameters were obtained: Gjmax and Gjmin (maximum
and minimum normalized gjss), V0 (Vj at which Gjss is halfway between Gjmax and Gjmin) and z, a value
representing gating charges [12,13]. To quantify fast Ij inactivation, the decrease of composite Ij during
repeated ±80 mV pulses were fit with exponential decays of 1st or 2nd order (cf. [13]). Channel transition
amplitudes (γj) were documented with Vj = ±40 or 80 mV in poorly-coupled cell pairs with or without
halothane treatment. Transitions (see Supplemental Figure S1) were considered to occur between fully
open (O), residual (R) and closed (C) states; transitions with values intermediate between O↔R and R↔C
point to the existence of a substate (S). To reveal the presence of hemichannels, repeated, 5-second or
longer depolarizing pulses (Vm = 80 mV, WC configuration) were applied to non-coupled or single cells.
All-points histograms were made from short (5–12 s) fragments of extended recordings. As intracellular
pH (pHi) closely follows the extracellular pH (pHo) when buffered with weak acid solutions [72], gj
uncoupling was achieved by superfusing cells with bicarbonate-containing solution adjusted to pH = 6.0
to 6.4 (when bubbled with 95% CO2/5% O2).
4.4. Permselectivity
Measurements of the ratio of permeation to dye vs. current carrying ions (Pj-dye/gj) were fully
described [14,27]. Briefly, dyes NBD-m-TMA (NBD, a junctional permeant) and rhodamine-labeled
3000Da dextran (rhodex3000, unable to permeate junctions, Molecular Probes, Eugene, OR, USA)
were delivered through a patch pipette in Whole Cell Voltage Clamp (WCVC) mode to one cell of a
pair; total NBD fluorescence was timely imaged for up to 17 min or until NBD equilibrated in both
cells; the second cell was then accessed in WCVC mode to document gj. For each pair, a rate constant
(k ≡ junctional permeability to dye, Pj-dye) representing the speed of transjunctional dye diffusion, was
calculated and plotted vs. the associated gj (thus, permselectivity ≡ Pj-NBD/gj). Rhodex3000 images
(Molecular Probes, Eugene, OR, USA) and/or halothane-induced uncoupling helped to discard dye
diffusion through cytoplasmic bridges.
4.5. Statistical Analysis
Analyses were performed in Excel (Office 2010, Microsoft Corp., Redmond, WA, USA), Origin
(Version 7, OriginLab Corp., Northampton, MA, USA) and GraphPad Prism (Version 7, GraphPad
Software, La Jolla, CA, USA). Values are reported as Mean ± SEM. Comparisons were performed with
ANOVA and unpaired t-Test (significance at p < 0.05). For permselectivity and channel distribution,
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Kruskal-Wallis (ANOVA on ranks) and Mann-Whitney U test (significance at p < 0.05) were used.
Graphics were created with SigmaPlot 2001 (Version 7.101, Systat Software, San Jose, CA, USA).
5. Conclusions
Our data suggest that phosphorylation of Cx43 by CK1 (normoxia) yields GJChs with strong
Vj-gating, large γj values, variable permselectivity, and resistance to low pH-induced uncoupling, all
of which may be compatible with arrhythmia-resistance. In contrast, dephosphorylation of the CK1
sites (hypoxia) yields GJChs with near “wild type” (as seen in Rin cells) Vj-gating, large γj values, low
permselectivity and imperviousness to low pH-induced gating. These data suggest that persistently
open GJChs may be deleterious during ischemia, despite (or because of) their low permselectivity.
In addition, Cx43-dpCK1 HCh openings at the lateral membranes (rather than the ID) may worsen
the arrhythmic propensity of the afflicted myocardium. While phosphorylation of S368 was shown
in Cx43WT and in the CK1-(de)phospho-mimicking mutants, a role for pS368 levels in determining
permselectivity remains possible. The data offer possible explanations for the cardiac phenotypes of
S3A and S3E mice, and for the pathophysiological events that attend the development of ischemia-
or TAC-induced GJR and arrhythmias. Gap junction channel gating cannot be described with a
single closure mechanism; instead, the role played by the CT in channel closure can be modified
by phosphorylation.
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S3A Transgenic mouse line expressing mutant Cx43-S325,328,330A
S3E Transgenic mouse line expressing mutant Cx43-S325,328,330E
TAC Transverse Aortic Constriction
GJR Gap Junction Remodelling
ID(s) Intercalated disc(s)
GJCh(s) Gap Junction Channel(s)
HCh(s) Hemichannel(s)
Rin Rat insulinoma





DIC Differential Interference Contrast
CT Carboxyl Terminus
CL Cytoplasmic Loop
ZO-1 Zonula Occludens 1
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Abstract: Activation of Wnt signaling induces Connexin43 (Cx43) expression via the transcriptional
activity of β-catenin, and results in the enhanced accumulation of the Cx43 protein and the formation
of gap junction channels. In response to Wnt signaling, β-catenin co-localizes with the Cx43 protein
itself as part of a complex at the gap junction plaque. Work from several labs have also shown indirect
evidence of this interaction via reciprocal co-immunoprecipitation. Our goal for the current study
was to identify whether β-catenin directly interacts with Cx43, and if so, the location of that direct
interaction. Identifying residues involved in direct protein–protein interaction is of importance
when they are correlated to the phosphorylation of Cx43, as phosphorylation can modify the
binding affinities of Cx43 regulatory protein partners. Therefore, combining the location of a protein
partner interaction on Cx43 along with the phosphorylation pattern under different homeostatic and
pathological conditions will be crucial information for any potential therapeutic intervention. Here,
we identified that β-catenin directly interacts with the Cx43 carboxyl-terminal domain, and that this
interaction would be inhibited by the Src phosphorylation of Cx43CT residues Y265 and Y313.
Keywords: Cx43; β-catenin; phosphorylation
1. Introduction
Gap junctions are intercellular channels that permit the passage of ions, small metabolites,
and signaling molecules between neighboring cells [1]. They are important in a number of physiological
processes, including cellular development, growth, and differentiation. In the heart, gap junctions
mediate the propagation of cardiac action potentials and the maintenance of a regular beating
rhythm [2]. Dysfunctional intercellular communication via gap junctions has been implicated in
causing many human diseases [3]. Gap junctions are formed by the apposition of connexons from
adjacent cells, where six connexin proteins form each connexon. Although the 21-connexin isoforms
(e.g., 43-kDa isoform, Cx43) share significant sequence homology, differences in the amino acid
sequence occur in the cytoplasmic loop and carboxyl terminal (CT) domains.
The CT domain is involved in regulating the trafficking of connexons to and from the plasma
membrane, as well as the level of gap junction intercellular communication via a number of
post-translational modifications and interactions with protein partners [4–11]. The CT domain
is predominately unstructured (i.e., intrinsically disordered), making it an ideal substrate for the
regulation of intercellular signaling by facilitating both high specificity and low affinity interaction
with many different binding partners to allow the rapid feedback to cytoplasmic signals [12–15]. Over
20 protein partners have been identified to directly interact with Cx43, which can be categorized
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according to those that can promote or inhibit intercellular communication (for review see [16,17]).
For example, connexin localization and stability at the gap junction plaques are strongly determined
by interaction with cytoskeletal-associated proteins; these interactions are modulated by specific
phosphorylation events [18,19]. The demonstration that Src phosphorylates Y247 and Y265 of
Cx43 [20,21] enabled subsequent findings that pY247 inhibits the Cx43 interaction with β-tubulin [22]
and that pY265 inhibits the Cx43 interaction with drebrin [23]. At the gap junction plaque, inhibiting
the β-tubulin interaction could be a mechanism involved in the disassembly process. If this
inhibition occurs after connexon formation in the trans-Golgi network, trafficking may be re-routed
for degradation or to the lateral membrane [24]. The depletion of drebrin results in impaired gap
junction intercellular communication, also by targeting Cx43 for degradation [25]. Further, while
Cx43CT phosphorylation by Src does not inhibit Zonula occludens-1 (ZO-1) binding, active Src directly
competes with Cx43 to bind ZO-1 [26]. Studies from the Gourdie and Lampe labs suggest that
interaction with ZO-1 transitions Cx43 from the non-junctional membrane into the gap junction plaque,
and that Src inhibits this process [27,28]. Thus, even though our knowledge is no doubt incomplete,
it is clear that for Cx43, there exists a network of integrated processes involving phosphorylations
and binding partners that control junctional Cx43 [19]. Another protein that has been identified to
modulate both Cx43 expression and gap junction intercellular communication is β-catenin [29].
β-catenin is a critical protein in the canonical Wnt signaling transduction cascade. β-catenin
(781 amino acids) consists of a well-structured central region made up of 12 armadillo repeats that
are flanked by intrinsically disordered N-terminal and C-terminal domains [30,31]. β-catenin is a
multi-functional protein whose activity depends on its subcellular localization. β-catenin at the plasma
membrane is a component of cell adhesion junctions, while cytosolic accumulation leads to increased
nuclear localization and transcriptional activity [32]. The activation of Wnt signaling induces Cx43
expression via the transcriptional activity of β-catenin, which leads to the increased formation of
gap junction channels [29,33–38]. In response to Wnt signaling, β-catenin co-localizes with the Cx43
protein itself as part of a complex at the gap junction plaque [29]. Unfortunately, none of these studies
was able to determine whether the β-catenin and Cx43 interaction is direct, or instead requires other
protein partners.
2. Results
2.1. β-Catenin CT Domain Directly Interacts with the Cx43CT
The domain architecture of β-catenin includes a disordered N-terminal domain (~150 residues;
binds α-catenin, glycogen synthase kinase 3β (GSK3β), and is phosphorylated by casein kinase I),
a well-structured central armadillo repeat domain (~530 residues; major protein partner binding
domain; e.g., binds axin, adenomatous polyposis coli protein, 14-3-3ζ, and E-cadherin), and a
disordered C-terminal domain (~100 residues; binds several transcriptional coactivators) [39,40].
To determine whether β-catenin directly interacts with the Cx43CT domain, we performed a
15N-heteronuclear single quantum coherence (HSQC) nuclear magnetic resonance (NMR) experiment
using purified 15N-lableled Cx43CT (V236–I382) and unlabeled full-length β-catenin (Figure 1A, top).
Each chemical shift (or peak) in this two-dimensional experiment corresponds to one amide group;
thus, the number of peaks should correspond to the number of Cx43CT residues (except proline). We
have previously published the 15N-HSQC assignment for the Cx43CT domain [41]. These chemical
shifts are sensitive to their environment and small changes in structure and/or dynamics, such as
those that would occur from a direct protein–protein interaction, can influence the chemical shift (i.e.,
change the location or broaden beyond detection) of an amino acid. The advantage of using NMR
to study direct protein–protein interactions over cellular assays such as immunoprecipitation is its
specificity. As only two proteins are present in the solution, any detected interaction is the result of
a direct interaction, as opposed to the possibility that both are part of a larger molecular complex
(limits of immunoprecipitation). Moreover, because the chemical shifts of the affected amino acids
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drift or diminish, the specific residues involved in the interaction can be determined. The addition
of β-catenin affected a subset of Cx43CT residues (Figure 1A, top). When mapped onto the Cx43CT
sequence, they were located within three areas: K259–T275, S282–N295, and N302–R319 (Figure 1A,
bottom). The data indicates that the Cx43CT domain and β-catenin directly interact.
Figure 1. Nuclear magnetic resonance spectra showing the direct interaction between the Cx43CT and
β-catenin. 15N- heteronuclear single quantum coherence (HSQC) spectra of Cx43CT alone (black) and
in the presence of (A) full-length β-catenin (red); (B) the β-catenin carboxyl-terminal (CT) domain (red);
or (C) the β-catenin ΔCT domains (red). Molar ratio for each experiment is indicated in the figure.
In panel B, provided is a subset of residues used to calculate the KD of the interaction by fitting their
decrease in signal intensity according to β-catenin CT concentration. Below each 15N-HSQC spectra is
the Cx43CT amino acid sequence. Highlighted are the affected residues (yellow—peaks broadened
beyond detection; green—peaks decreased in intensity). Black boxes delimitate the three areas of
interaction with β-catenin. Asterisks denote that amino acids that were used to calculate the binding
affinity for the β-catenin CT. Two of the residues phosphorylated by Src and affected by β-catenin are
also highlighted (red letters).
To identify the β-catenin domain mediating the direct interaction with Cx43CT, we initially
focused on the β-catenin CT domain (S681–L781). The N-terminal domain is the primary locus for Wnt
signaling (GSK3β/E3 ubiquitin ligase), and armadillo repeat domains have been well characterized for
binding partners involved in cell adhesion. Moreover, most of the binding partners to the C-terminal
domain occur in the nucleus, thus potentially leaving the CT domain free to associate with a different
set of proteins in the cytoplasm [42]. Upon purification, circular dichroism was used to determine
whether the β-catenin CT domain contains any secondary structure (Figure 2). Analysis of the
circular dichroism spectrum by Dichroweb (London, UK) determined that the protein is predominately
intrinsically disordered with between 18–21% α-helical content [43,44]. The low amount of secondary
structure is consistent with the low peak dispersion (<1 1H ppm) that was previously seen in the
β-catenin CT domain 15N-HSQC [32]. The addition of the unlabeled β-catenin CT domain affected
the same subset of 15N-Cx43CT residues as full-length β-catenin (Figure 1B, top). These have been
highlighted on the Cx43CT sequence (Figure 1B, bottom). Next, a titration of the unlabeled β-catenin
CT domain was performed to determine the binding affinity (KD). The decrease in signal intensity
caused by increasing the β-catenin CT domain concentration was fit according to the nonlinear
least-square method (Figure 1B, inset). The KD was determined to be 210 μM (±90 μM). A surface
plasmon resonance (SPR) experiment confirmed the NMR results (Figure 3). When the Cx43CT domain
was immobilized onto a carboxymethyl-dextran 5 chip, the addition of the β-catenin CT domain
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resulted in a direct interaction. A peptide to the Cx43 first extracellular loop (EL1, residues G38–R76)
served as a negative control, and the Cx43CT domain itself served as a positive control (specific areas
of dimerization include M281–N295, R299–Q304, S314–I327, and Q342–A348, [45]). To ensure that
the β-catenin CT is the only β-catenin domain interacting with the Cx43CT, we purified a β-catenin
construct containing the N-terminal and armadillo repeat domains (β-catenin ΔCT, i.e., deleted the
CT domain). The addition of the unlabeled β-catenin ΔCT had no effect on the 15N-Cx43CT residues
(Figure 1C). Of note, the N-terminal domain of β-catenin has poor expression and degraded during
purification, which prevented any attempt to test this domain only. Altogether, the data indicate that
the β-catenin CT is the domain that directly interacts with Cx43CT.
Figure 2. Circular dichroism spectrum showing the secondary structure of the β-catenin CT domain.
The spectrum is represented as mean residue ellipticity as a function of wavelength. Data were analyzed
using Dichroweb.
Figure 3. Surface plasmon resonance spectra showing direct interaction between the Cx43CT and
β-catenin CT domains. Cx43CT was immobilized onto a CM5 chip by amine coupling (Biacore;
GE Healthcare, Uppsala, Sweden) and either β-catenin CT (500 response units), Cx43EL1 (negative
control), or Cx43CT (residues S255–I382, positive control) were flown over the chip as indicated on the
top of the graph. The chip was regenerated after an interaction was observed. Repeat of an injection of
β-catenin CT was performed to confirm the interaction.
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2.2. Phosphorylation of Y265 and Y313 Inhibits Cx43 Binding with β-Catenin
Previous studies have identified that Src phosphorylates Cx43CT residues Y247 and Y265 [21,46].
Additional studies have identified that Src also phosphorylates Cx43CT residues Y313 (Li et al., 2018,
Journal of Molecular and Cellular Cardiology, publication under revision; PhosphoSitePlus, [47]).
Since the β-catenin CT domain affected Cx43CT residues Y265 and Y313, we addressed whether the
phosphorylation of both sites could dissociate β-catenin from Cx43. A number of gap junction studies
have determined that an aspartic acid can mimic a phosphate for Cx43 [41,48,49] and responds to the
need to purify enough protein for biophysical studies. Therefore, NMR titration experiments were
performed using purified soluble 15N-labeled Cx43CT single or double phosphomimetics (Y313D or
Y265,313D) and different concentrations of either an unlabeled β-catenin CT domain (Figure 4A,B) or
full-length β-catenin (Figure 4C). The 15N-HSQC spectrum of each control (no β-catenin, black) has
been overlaid with spectra when either the β-catenin CT domain or full-length β-catenin (red) were
added at a single molar ratio. For the single phosphomimetic construct, among the three areas where
the β-catenin CT domain interacted with Cx43CT wild type (WT), binding was completely inhibited for
area three (N302–R319), significantly reduced in area two (S282–N295), and mostly preserved in area
one (K259–T275). A titration of the unlabeled β-catenin CT domain was performed to determine the KD.
The interaction with β-catenin decreased by approximately two-fold compared to WT (KD = 341 μM
vs. 202 μM) (Figure 4A, inset). When both Cx43CT Y265 and Y313 sites were mutated to mimic
Src phosphorylation, the Cx43CT interaction with β-catenin was completely inhibited. These results
confirm the direct interaction between Cx43CT and CT portion of β-catenin, and strongly suggest that
Src phosphorylation of Cx43CT regulates this interaction.
Figure 4. Mimicking phosphorylation of Cx43CT residues Y265 and Y313 inhibits the interaction with
the β-catenin CT domain. 15N-HSQC spectra of (A) Cx43CT Y313D alone (black) and in the presence
of the β-catenin CT domain (red) or Y265,313D alone (black), and in the presence of the (B) β-catenin
CT domain and (C) full-length β-catenin (red). The molar ratio for each experiment is indicated in
the figure. In panel A, provided is a subset of residues used to calculate the KD of the interaction by
fitting their decrease in signal intensity according to β-catenin CT concentration. Also represented
below the 15N-HSQC spectra is the Cx43CT amino acid sequence. Highlighted are the affected residues
(yellow—peaks broadened beyond detection; green—peaks decreased in intensity). Asterisks denote
amino acids used to calculate the binding affinity for the β-catenin CT interaction with the Cx43CT.
Tyrosine residues 265 and 313 phosphorylated by Src are indicated in red.
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3. Discussion
The Cx43CT domain binds multiple proteins, many of which have been shown to regulate Cx43
function through altering trafficking to the gap junction plaque, opening/closing gap junction channels,
disassembly, and degradation (for review see [16,50]). Numerous excellent reviews have summarized
the functional significance of these Cx43-interacting proteins [50–53]. These proteins can be partitioned
into those that directly interact with the Cx43CT, and those proteins that can affect all aspects of the
Cx43 life cycle, but no current evidence exists that they directly interact with the Cx43CT. One of
the proteins in the latter category is β-catenin. Work from several labs has shown indirect evidence
of this interaction, including reciprocal co-immunoprecipitation as well as co-localization of Cx43
with β-catenin [29,35]. Additionally, β-catenin segregates in triton insoluble fractions with Cx43 [29].
Our goal here was to identify whether β-catenin directly interacts with Cx43, and the location of that
direct interaction.
β-catenin is an intracellular signal transducer in the Wnt signaling pathway that is involved in the
regulation and coordination of cell–cell adhesion and gene transcription [54]. Ai et al. first identified
that in response to Wnt signaling by the addition of Li+, β-catenin interacts with the Cx43 gene GJA1
(contains three transcription factor 4 (TCF)/lymphoid enhancer binding factor binding sites; [55]) to
increase transcription expression [29]. The accumulating Cx43 in the junctional membrane increased
neonatal rat cardiomyocyte cell-to-cell coupling and co-localization with β-catenin [29]. Cx43 and
β-catenin co-localization also occurs at the intercalated discs of adult rat cardiomyocytes [56]. A
similar response to Li+ elicited Wnt/β-catenin signaling, which increased Cx43 expression and gap
junction intercellular communication in skeletal myoblasts [57]. Additionally, the rapid electrical
stimulation of cardiomyocytes had a similar effect as Li+, leading to the increased nuclear localization
of β-catenin and subsequent Cx43 expression [58]. The suggested sequestering of β-catenin by Cx43
would serve to reduce the transactivation potential of β-catenin [29]. This observation is consistent
with the increase in the active form of β-catenin with the knockdown of Cx43 seen in human neural
progenitor cells [35], and the decrease in the nuclear localization of β-catenin with Cx43 overexpression
in breast adenocarcinoma cell lines [36]. Conversely, Moorer et al. observed in a Cx43CT truncation
(K258stop) mouse model that osteoblasts had reduced active β-catenin (along with protein kinase C δ
and extracellular signal-regulated kinase 1/2), leading to altered proliferation, differentiation, collagen
processing, and organization [34]. While the phenotype observed from loss of the Cx43CT matches that
from the complete loss of Cx43 in bone cells, the same is not true in the cardiovascular system [34,59].
This suggests the influence of Cx43 on the activity and cellular localization of β-catenin may be tissue
specific [34,59].
Shaw et al. put forth a model for connexin trafficking to the plasma membrane [56]. Cx43
oligomerizes into connexons in the trans-Golgi network [60]. Upon exiting, they use microtubules to
travel to adherens junctions, which capture the microtubules allowing for connexon offloading to the
plasma membrane [56,61–64]. Based upon the co-localization of Cx43 and β-catenin at the gap junction
plaque, at some point in the trafficking, either to or at the adherens junctions, the interaction occurs. The
β-catenin interaction occurs at Cx43 residues K259–T275, S282–N295, and N302–R319. Interestingly,
similar residues directly interact with drebrin [23]. A commonality with these proteins is they would
both help Cx43 indirectly interact with F-actin (β-catenin indirectly through α-catenin; drebrin directly)
and stabilize gap junctions to favor intercellular communication. Conversely, they both cannot interact
at the same time. Therefore, the available data would suggest that β-catenin binds first, and then at
some point in the maturation of the gap junction plaque, Cx43CT switches to interact with drebrin.
Since the phosphorylation of Y265 and Y313 also inhibits the Cx43 interaction with drebrin, this would
not be the mechanism [23]. The possibility exists that regulation from the β-catenin perspective inhibits
the interaction with Cx43. Consistent with this is that: (1) the phosphorylation of β-catenin at S552
by protein kinase B increases the association between β-catenin and 14-3-3ζ, leading to β-catenin
translocation into the cytosol and nucleus [65]; (2) the phosphorylation of β-catenin by casein kinase 1
is necessary for subsequent glycogen synthase kinase-3 phosphorylation and then degradation [66]; (3)
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the protein kinase A phosphorylation of β-catenin leads to the nuclear localization of β-catenin [67].
Interestingly, protein kinase B, casein kinase 1, and protein kinase A also phosphorylate Cx43 to
promote synthesis, trafficking to the gap junction plaque, and channel opening.
The importance of identifying if and where a direct protein interaction occurs is in relationship
to the phosphorylation of Cx43, because phosphorylation modifies the binding affinities of the
Cx43 protein partners that regulate assembly, disassembly, and channel function [68]. For example,
we demonstrated that mitogen-activated protein kinase phosphorylation of Cx43 increases the binding
affinity for the E3 ubiquitin ligase neural precursor cell expressed, developmentally down-regulated
4 [69], which leads to Cx43 degradation [70,71]. Therefore, combining the location of a protein
partner interaction on Cx43 along with the phosphorylation pattern under different homeostatic and
pathological conditions will be crucial information for any potential therapeutic intervention. Here,
we identified that β-catenin directly interacts with the Cx43CT domain, and that this interaction would
be inhibited by Src phosphorylation of Cx43CT residues Y265 and Y313.
4. Material and Methods
4.1. Expression and Purification of Recombinant Proteins
The rat Cx43CT (V236–I382) (or (S255–I382) for the SPR study) polypeptide (unlabeled
or 15N-labeled) cloned into the bacterial expression vector pGEX-6P-2 (GST-tagged; Amersham
Biosciences, Little Chalfont, UK) was expressed and purified in 1× phosphate-buffered saline (PBS),
as previously described [72,73]. Y313D and Y265,313D mutations in the Cx43CT plasmid were
incorporated using the Quick Change Lightning kit (Qiagen, Hilden, Germany). Human β-catenin
in pET-28a (+) was purchased from Addgene, expressed (unlabeled), and purified by Nickel affinity
column (Buffer A: 50 mM Tris, 150 mM NaCl, 10 mM Imidazole, 2 mM β-mercaptoethanol (BME), pH
8.0; Buffer B: 50 mM Tris, 150 mM NaCl, 600 mM Imidazole, 2 mM BME, pH 8.0) followed by Anion
exchange (Buffer A: 50 mM Tris, 2 mM BME, pH 8; Buffer B: 50 mM Tris, 1 M NaCl, 2 mM BME, pH 8).
β-catenin ΔCT (M1-S680) was obtained by introducing a stop codon after serine 680 using the Quick
Change Lightning kit (Agilent, Santa Clara, CA, USA). Purification was identical to the full-length
β-catenin. β-catenin CT (S681–L781) was subcloned into the pET-16b vector, expressed (unlabeled),
and purified by Nickel affinity column similarly to the full-length β-catenin. Purity and analysis for
degradation was assessed by SDS-PAGE, and all of the polypeptides were equilibrated by dialysis in
Slide-A-Lyzer G2 Dialysis Cassettes (Thermo Scientific, Waltham, MA, USA) in 1× PBS at pH 7.8 in
presence of 2 mM dithiothreitol.
4.2. Nuclear Magnetic Resonance (NMR)
NMR data were acquired at 7 ◦C using a 600-MHz Varian INOVA spectrometer (Agilent,
Palo Alto, CA, USA) upgraded with a Bruker Avance-III HD console (Bruker, Billerica, MA, USA)
and outfitted with a Bruker z-axis PFG “inverse” triple-resonance cryogenic (cold) probe (Bruker).
Gradient-enhanced two-dimensional 15N-HSQC experiments were used to obtain the binding
isotherms of the 15N-labeled Cx43CT WT, Y313D, and Y265,313D at a constant concentration (35 μM) in
the absence or presence of increasing amounts (up to 285 μM) of β-catenin, β-catenin CT, or β-catenin
ΔCT. Data acquisition, processing, and analysis, including calculation of the dissociation constants
(KD), have been previously described [14,46,69].
4.3. Circular dichroism (CD)
The CD experiment was performed on a JASCO J-815 CD spectrometer (JASCO, Mary’s Court,
Easton, MD, USA) at 7 ◦C in the far UV (260–190 nm). Spectra of the β-catenin CT were collected in
1× PBS at pH 7.4, with a 0.1-mm path length quartz cell, using a bandwidth of 1 nm, an integration
time of 1 s, and a scan rate of 50 nm/min. The final spectrum was obtained from the average of five
scans. All of the spectra were corrected by subtracting the solvent spectrum acquired under identical
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conditions. CD data were processed and converted to mean residue ellipticity using Spectra Analysis
from the Jasco Spectra Manager software, Version 2.05.01 (JASCO, Mary’s Court, Easton, MD, USA).
4.4. Surface plasmon resonance (SPR)
The SPR experiments were performed on a Biacore (GE Healthcare) 1000 at 25 ◦C. The Cx43CT
(S255–I382) was immobilized onto a CM5 sensor chip by amine coupling, and the flow cell was
equilibrated with the reaction buffer at a flow rate of 5 μL/min (213 mM phosphate buffer, pH 7.1).
Then, 5 μL of either the β-catenin CT (4 μM), the Cx43EL1 (residues G38–R76, 10 μM, negative control),
or the Cx43CT (10 μM, positive control) were injected over the chip, and the responses were recorded
as resonance units (RU).
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Abstract: Pannexins (Panx1, 2, 3) are channel-forming glycoproteins expressed in mammalian
tissues. We previously reported that N-glycosylation acts as a regulator of the localization and
intermixing of Panx1 and Panx3, but its effects on Panx2 are currently unknown. Panx1 and
Panx2 intermixing can regulate channel properties, and both pannexins have been implicated in
neuronal cell death after ischemia. Our objectives were to validate the predicted N-glycosylation
site of Panx2 and to study the effects of Panx2 glycosylation on localization and its capacity to
interact with Panx1. We used site-directed mutagenesis, enzymatic de-glycosylation, cell-surface
biotinylation, co-immunoprecipitation, and confocal microscopy. Our results showed that N86 is
the only N-glycosylation site of Panx2. Panx2 and the N86Q mutant are predominantly localized
to the endoplasmic reticulum (ER) and cis-Golgi matrix with limited cell surface localization was
seen only in the presence of Panx1. The Panx2 N86Q mutant is glycosylation-deficient and tends to
aggregate in the ER reducing its cell surface trafficking but it can still interact with Panx1. Our study
indicates that N-glycosylation may be important for folding and trafficking of Panx2. We found
that the un-glycosylated forms of Panx1 and 2 can readily interact, regulating their localization and
potentially their channel function in cells where they are co-expressed.
Keywords: pannexin; Panx1; Panx2; post-translational modification; traffic; N-glycosylation;
channels; subcellular localization
1. Introduction
Pannexins (Panx1, Panx2, and Panx3) are membrane-spanning glycoproteins capable of forming
large pore channels that allow the passage of ions and macromolecules involved in paracrine and
autocrine signaling [1,2]. Panx1 is the most widely expressed pannexin and the most studied, with
evidence supporting that its channels act as ATP and Ca2+ conduits [3–6] and are implicated in critical
cellular processes such as cell death after brain ischemia [7] and inflammation [8]. On the other hand,
Panx2 is the largest member of the family and its expression was thought to be restricted to the central
nervous system (CNS). Recently, it has been reported that Panx2 can also be expressed in other tissues
such as skin, kidney and liver [9,10], while Panx3 is predominantly expressed in skin, cartilage and
bone [4,5,11–13]. In contrast to the hexameric type of channels formed by Panx1, it has been suggested
that Panx2 can form octameric or heptameric channels [14] and it is still unclear whether its channel
function would be similar to the other family members. Interestingly, Panx1 and Panx2 expression
have been found to overlap in adult rodent brains although they are inversely regulated throughout
development, with Panx1 being more abundant in neonatal and young tissues, whereas Panx2 is more
abundant in the adult [15–18]. Under ischemic conditions, both Panx1 and Panx2 are expressed in the
brain and their overlapping channel functions contribute to neurodegeneration. In fact, the deletion
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of Panx1 and Panx2 in a double knockout mouse model was necessary to observe a reduction in cell
death after ischemia, perhaps due to their redundant and/or complementary functions [19].
N-glycosylation is a posttranslational modification that occurs in the endoplasmic reticulum (ER)
and is recognized to have profound effects on protein folding and trafficking of membrane-bound
proteins [20]. The prediction of putative N-linked glycosylation sites for pannexins has been done in
the past, and it has been demonstrated that Panx1 and Panx3 have sites for N-linked glycosylation at
Asn (N) 254 and N71, respectively. These studies comprised further characterization using enzymatic
digestion with endoglycosidases that confirmed that all three members of the pannexin family are
differentially N-glycosylated but not O-glycosylated [11,21]. However, for Panx2 the predicted site of
N-glycosylation at residue N86 remains to be validated [22].
Unlike other pannexins, Panx2 is only modified to a high-mannose glycosylation species (termed
as Gly-1) and presents a predominantly intracellular localization that has been associated with
this lower level of N-glycosylation [22–26]. Previous evidence supports the concept that complex
glycoprotein species (Gly-2) (further processed at Golgi) present in Panx1 and Panx3 traffic readily to
the cell surface [22]. However, our group and others have stated that under certain circumstances Panx2
can also translocate to the plasma membrane [14,17,22], but it is still unclear whether glycosylation
plays a role in regulating Panx2 trafficking.
Panx2 has been shown to interact with Panx1, and when co-expressed together they can
form heteromeric channels with reduced channel properties compared to homomeric ones [22,27].
Although this has only been tested in ectopic expression systems it has been suggested that it might
function as a mode of regulation in cells that endogenously express both proteins. Interestingly, the
Panx1/Panx2 interaction only occurs with the Gly-0 and Gly-1 species of Panx1 [22] and it is unknown
whether Panx2 glycosylation has any impact on the formation of these intermixed channels. Since
previous studies have shown that Panx1 and Panx2 are often co-expressed in the same cells under
normal conditions [15,18,27–30], and that their co-expression modulates important processes such as
ischemia-induced neurodegeneration and brain damage in vivo [31], it is important to understand how
these channels may be regulated by post-translational modifications (PTMs) such as N-glycosylation,
and how this PTM may regulate their interaction.
The present study aimed to validate the predicted N-linked-glycosylation site of Panx2 and
determine its role in the regulation of the subcellular localization and intermixing of Panx2 with
Panx1. We generated a Panx2 mutant protein completely devoid of N-glycosylation that, when
overexpressed, exhibits a high level of intracellular aggregation with decreased traffic to the plasma
membrane compared with wild-type Panx2. We found that N-glycosylation of Panx2 is not required
for Panx1/Panx2 intermixing but facilitates Panx2 trafficking and localization at the plasma membrane
when co-expressed with Panx1. The intracellular localization of un-glycosylated Panx2 reduces its
co-localization with Panx1 at the cell surface and may impact their channel function in cells that
co-express both glycoproteins, such as neurons. Collectively, we propose that N-glycosylation may
be necessary for proper processing of Panx2 at the endoplasmic reticulum, regulating its intracellular
distribution, but it is not required for interacting with Panx1.
2. Results
2.1. Characterization of the Panx2 N-Glycosylation Site at Asparagine 86
Previous research has shown that ectopic expression of full-length mouse Panx2 presented
N-glycosylated species with high-mannose modification [22]. Based on the analysis of the canonical
sequence of Panx2 (UniProt ID: Q6IMP4-1), this modification might occur at asparagine 86 (Asn86 or
N86) that is located in the first extracellular loop of Panx2 [20] (Figure 1A). To validate this prediction,
we generated a full-length Panx2 mutant (Panx2N86Q, referred here as N86Q) with the substitution of
the N86 with a glutamine (Gln, Q) that prevents the attachment of N-linked glycans to this specific site.
As shown in Figure 1B, Western blotting (WB) of overexpressed constructs of N86Q and wild-type
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Panx2 (as glycosylated control) indicated that the electrophoretic band corresponding to N86Q mutant
migrated faster than its wildtype counterpart, characteristic of a reduction in molecular weight.
Figure 1. Asn86 is the N-glycosylation site of Panx2. (A) Based on sequence analysis, Panx2 (Uniprot
ID: Q6IMP4-1) is predicted to contain four transmembrane domains, one intracellular (IL) and two
extracellular loops (EL). The predicted N-glycosylation site is located at Asn86 in the first extracellular
loop (EL1) (red residue). (B) Western blot (WB) comparing wildtype Panx2 and mutant N86Q, the
latter shows a faster migrating band than the wildtype counterpart, indicative of decreased molecular
weight. (C) Cell lysates of HEK293T transiently expressing Panx2 and N86Q mutant were subjected to
enzymatic digestions with PNGase F and EndoH N-glycosidases. WB analysis confirmed that N86
is the only glycosylation site for Panx2 since only the wildtype protein exhibited a band shift after
treatment with both glycosidases, and the de-glycosylated Panx2 band ran to the same position as the
N86Q mutant. GAPDH was used as loading control. Molecular weights are noted in kDa.
To analyze whether N-glycosylation was prevented in the N86Q mutant, enzymatic
de-glycosylation with endoglycosidase H (Endo H) and Peptide-N-Glycosidase F (PNGase F) were
applied to the protein lysates and analyzed by WB (Figure 1C). Both de-glycosylation treatments
did not cause any shift in migration of the N86Q band. Yet, wild-type Panx2 exhibited a small shift
after treatment which relocated the migration of this band to the same position as that of the faster
migrating N86Q mutant. Thus, the differences in the electrophoretic migration of the N86Q compared
with the wild-type (WT) Panx2 can be explained by differences in molecular weight due to the absence
of N-glycosylation. These findings validate N86 as the only N-glycosylation site present in Panx2 as
was predicted by Penuela and others [22].
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2.2. N86Q Forms Intracellular Aggregates
To determine whether glycosylation of Panx2 has any effect on its subcellular localization, we
ectopically expressed Panx2 WT and N86Q in different reference cell lines and evaluated whether
the intracellular distribution observed was dependent on the cell type as has been reported for
Panx1 and Panx3 [32]. Because our group has demonstrated before [21] that Panx1 influences
Panx2 trafficking, we selected Normal Rat Kidney cells (NRK), that in our experience have very
low expression of endogenous Panx1 (Figure 2D), and “adherent” human embryonic kidney cells
(AD293) that endogenously express the human ortholog PANX1 (Figure 3D). Likewise, these cell lines
were selected as they are suitable transfection hosts with a relatively large cytoplasm which facilitates
the visualization of the subcellular localization of proteins.
Figure 2. Panx2 has a predominantly intracellular localization, and its N-glycosylation-deficient mutant
(N86Q) forms aggregates in NRK cells with low endogenous Panx1 protein expression. (A) Confocal
micrographs of Panx2 and N86Q ectopically expressed in NRK cells, immunolabeled with anti-Panx2
antibody (green), revealed that Panx2 is predominantly localized intracellularly. Themutant N86Q is also
localized intracellularly but appeared mostly as punctate aggregates. Nuclei (blue) were counterstained
with Hoechst 33342. Scale bars = 20 μm. (B) Representative images of a small subpopulation of NRK cells
expressing Panx2 or N86Q that showed minimal apparent localization at the cell surface (indicated with
white arrows). Scale bars = 5 μm. (C) Western blot analysis of cell-surface-biotinylated proteins with
EZ-Link™ Sulfo-NHS-SS-Biotin pulled down with NeutrAvidin® beads showed very low detection of
Panx2 but not the N86Q mutant at the cell surface of NRK cells. E-cadherin was used as a positive control
of cell surface protein labeling and GAPDH was used as a negative control of intracellular proteins (no
biotin internalization). Non-transfected NRKs (nt) were used as a negative control. (D) Western blot of
protein lysate from NRK cells indicated that these cells have very low detectable levels of endogenous
Panx1. Overexpressed Panx1 was used as positive control (Ctrl +) and endogenous α-tubulin was used
as protein loading control. Molecular weights noted in kDa.
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Figure 3. Analysis of Panx2 and N86Q localization in AD293 and HEK293T cells expressing endogenous
PANX1. (A) Immunolabeling of Panx2 and N86Q mutant (green) showed that both localized mostly
intracellularly, but the N86Q mutant aggregated intracellularly in AD293 cells. Scale bars = 20 μm.
(B) A subpopulation of AD293 cells displayed Panx2 localization at the cell surface, less evident
with the N86Q mutant (indicated with white arrows) Scale bars = 5 μm. Nuclei (blue). (C) Cell
Surface Biotinylation Assays on AD293 cells showed a weak detection of the Panx2 wildtype but not
N86Q mutant in surface-labeled fractions. GAPDH was used as a control for biotin internalization.
(D) Immunoblots of AD293 and HEK293T cells confirmed that both cell lines express endogenous
PANX1. Overexpressed human PANX1 served as positive control (Ctrl +) and endogenous α-tubulin
was used as loading control. Line dividing upper panel of PANX1 WB indicates differences in exposure
of the same blot to show a better detection of endogenous PANX1 compared to the overexpressed
positive control. (E) Cell surface biotinylation experiments performed on HEK293T cells showed that
overexpressed Panx2 and themutant N86Q are detectable at the cell surface. Protein disulfide-isomerase
(PDI) was used as a control for biotin internalization. (F) Densitometric analysis and quantification of
cell surface biotinylation experiments performed in HEK293T cells revealed a significant reduction of
N86Q cell surface detection compared to Panx2. Cell surface detection was calculated relative to the
total protein in input lanes. Statistical significance was considered when p < 0.05 (* p = 0.0286, N = 4
independent experiments), Mann Whitney U test. Error bars denote mean ± S.E.M. Molecular weights
are noted in kDa. 98
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Confocal immunofluorescence imaging revealed an intracellular localization of ectopic Panx2
(Figures 2A and 3A, top panel), with perinuclear distribution and spread in intracellular compartments.
Interestingly, in both cell types assayed, the mutant N86Q localized intracellularly with large
subpopulations forming punctate aggregates (Figures 2A and 3A, bottom panel).
2.3. Limited Panx2 Localization at the Cell Surface Is Reliant on N-Glycosylation Status and the Level of Panx1
Despite the predominant intracellular localization, in a subpopulation of cells, Panx2 and the
N86Q mutant (to a lesser extent) were apparent in limited regions of the cell surface (Figures 2B and
3B, arrows). To corroborate these results, cell surface biotinylation assays followed by immunoblotting
were conducted using a cell-impermeable biotinylation reagent (Sulfo-NHS-SS-Biotin). Cell-surface
biotinylation experiments in NRKs (low endogenous Panx1, Figure 2D) showed a faint band of
Panx2 and no detection of N86Q at the cell surface in the neutravidin pull-downs (Figure 2C). Also,
AD293 cells (with a higher level of endogenous PANX1, Figure 3D) exhibited low Panx2 and no
detectable N86Q mutant protein at the cell surface (Figure 3C). However, in subsequent experiments
we also used human embryonic kidney (HEK293T) cells (Figure 3D) that have been used in previous
studies [11,22], because of their increased transfection efficiency and enhanced protein expression
due to the SV40 T-antigen [33]. After ectopic expression in HEK293T cells, we performed the same
cell-surface biotinylation assays and noticed that Panx2 WT protein was detected (approximately 4%
of the total Panx2 expression) at the cell surface (Figure 3E). Under these overexpression conditions,
the N86Q mutant was also detected in the biotinylated-protein fractions (Figure 3E) but there was a
significant (p = 0.0286, N = 4) reduction (to ~1% of its total amount) in the cell surface protein pool
of the mutant (Figure 3F). Therefore, although the Panx2 cell membrane trafficking is reduced when
Panx2 is not N-glycosylated at N86, its cell surface localization is not completely abrogated when
overexpressed in HEK293T cells.
2.4. Panx2 and N86Q Aggregates Localize to the Endoplasmic Reticulum and Golgi Apparatus
Because of the prominent intracellular localization of both Panx2 and the mutant N86Q, we were
interested in determining the subcellular compartments to which these proteins could be trafficking.
We transiently expressed these proteins in AD293 cells and used immunolabeling with different
organelle markers to assess their intracellular location by confocal microscopy (Figures 4 and 5).
As shown in Figure 4A, Panx2 immunolabeling exhibits a broad cytoplasmic distribution highly
overlapping (Pearson’s Colocalization Coefficient (PCC)Panx2-PDI = 0.49 ± 0.02; n = 41, N = 3) with the
chaperone protein disulfide-isomerase (PDI), a known marker of the endoplasmic reticulum (ER). The
mutant N86Q had significantly (p < 0.0001) less overlap (PCCN86Q-PDI = 0.34 ± 0.03, n = 57, N = 3) with
PDI although there was also a more punctate distribution of PDI that co-localized with N86Q. These
observations suggest that N86Q is being confined to some punctate regions enriched in PDI, along
with other subcellular organelles. We also observed an apparent alteration of the ER morphology
when N86Q was expressed.
Quantitation of colocalization with cis-Golgi marker (GM130) (Figure 4B) showed a significantly
(p = 0.0001) higher colocalization with the N86Q mutant (PCCN86Q-GM130 = 0.43 ± 0.04; n = 41, N = 3)
than with Panx2 WT (PCCPanx2-GM130 = 0.23 ± 0.03; n = 30, N = 3). In this case, cells that overexpressed
Panx2 WT exhibited changes in the distribution of GM130 compared to un-transfected ones (in the
same field of view, Figure 4B). These changes were more pronounced in AD293 cells overexpressing
the mutant N86Q, in which not only the cis-Golgi morphology changed, but GM130 also appeared to
accumulate within N86Q aggregates.
On the other hand, lysosome-associated membrane protein 2 (Lamp-2) and the fixable and
cell permeant Mitotracker™ Red CMXRos were assayed to label lysosomes/late endosomes,
and active mitochondria, respectively. We did not observe colocalization with Lamp-2
(PCCPanx2-Lamp-2 = −0.08 ± 0.01; n = 59, N = 3; PCCN86Q-Lamp-2 = −0.05 ± 0.02; n = 49, N = 3) or
Mitotracker (PCCPanx2-Mitotracker = −0.08 ± 0.03; n = 25, N = 3; PCCN86Q-Mitotracker = −0.13 ± 0.06;
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n = 31, N = 3), and there was no difference in the distribution of both markers upon overexpression of
Panx2 WT or N86Q.
Figure 4. Panx2 and N86Q colocalize with markers of the endoplasmic reticulum and Golgi.
Representative confocal micrographs of Panx2 and N86Q ectopically expressed in AD293 cells.
Co-immunolabeling with anti-Panx2 antibody (green) and organelle markers (magenta): (A) PDI,
endoplasmic reticulum (ER); (B) GM-130, cis-Golgi matrix. Panx2 has a perinuclear localization and is
spread intracellularly in the cytoplasm partially colocalizing with markers of the endoplasmic reticulum
and Golgi. N86Q aggregates also overlap with ER and Golgi markers and disrupt their distribution.
Yellow arrowheads indicate representative regions of colocalization. Nuclei (blue) were counterstained
with Hoechst 33342. Scale bars = 20 μm. Pearson Correlation Coefficients (right) were calculated for
multiple regions of interest (ROI)s corresponding to double-labeled cells. Statistical significance was
considered when p < 0.05 (*** p ≤ 0.0001, N = 3 independent experiments), using unpaired two-tailed t
test with Welch’s correction. Error bars denote mean ± S.E.M.
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Figure 5. Panx2 and N86Q do not localize to late endosomes/lysosomes or mitochondria. Confocal
micrographs of Panx2 and N86Q ectopically expressed in AD293 cells. Co-immunolabeling with
anti-Panx2 antibody (green) and organelle markers (magenta): (A) Lamp-2, lysosomes and late
endosomes, and (B) Mitotracker® Red, mitochondria showed that neither Panx2 or N86Q mutant
exhibited significant overlap with the markers. Nuclei (blue) were counterstained with Hoechst 33342.
Nuclei (blue) were counterstained with Hoechst 33342. Scale bars = 20 μm. Pearson Correlation
Coefficients (right) were calculated for multiples ROIs corresponding to double-labeled cells. There
was no statistical significance (p > 0.05, N = 3, unpaired two-tailed t test with Welch’s correction) in the
degree of colocalization between Panx2 and N86Q with the markers. Error bars denote mean ± S.E.M.
2.5. Panx2 N-Glycosylation Is Not Required for the Interaction with Panx1
Due to our previous report [22] in which we showed that glycosylation regulates intermixing of
pannexins and that Panx2 interacts only with the core (non-glycosylated, Gly-0) and high-mannose
species (Gly-1) of Panx1, we were interested in determining what would be the outcome with the
un-glycosylated species of Panx2. For these experiments, Panx1 was ectopically co-expressed with
either Panx2 or non-glycosylated N86Q mutant in HEK293T cells. Using co-immunoprecipitation
assays (co-IP, Figure 6A), we observed that both Panx2 and N86Q can co-IP in a complex with Panx1
and occasionally, although not statistically significant (p > 0.05, N = 4) (Figure 6B,C), N86Q pulled
down more Panx1 than the WT Panx2. In addition, consistently with what was reported before by
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Penuela et al. (2009), we noticed that only Gly-0 and Gly-1 Panx1 species interacted with both variants
of Panx2.
Figure 6. Panx2 glycosylation is not required for the interaction with Panx1 by immunoprecipitation.
(A) Reciprocal co-immunoprecipitation (co-IP) experiments showed that both Panx2 and N86Q co-IP
in a complex with overexpressed Panx1 in HEK293T cells. Colored arrowheads denote bands of co-IP
proteins detected in WB. (B,C) Quantitative analysis (see Materials and Methods Section 4.8) of co-IP
shows that the interaction of N86Q with Panx1 is not significantly different (p > 0.05, N = 4) than with
Panx2, and in both cases the complexes only involved the lower glycosylated species of Panx1 (Gly-0
and Gly-1). Beads Ctrl denote control IPs done in parallel without antibodies. Protein sizes in kDa.
Due to the lack of available antibodies from different species to perform double immunolabeling
of both pannexins, we used C-terminal FLAG-tagged Panx2 and N86Q that were co-expressed with
Panx1 in HEK293T cells. Confocal imaging of Panx2-FLAG or N86Q-FLAG co-expressed with Panx1
(Figure 7A) showed that Panx2-FLAG exhibits both an intracellular and cell surface localization overlap
with Panx1 (see Linescan analysis, Figure 7A). N86Q-FLAG formed mostly intracellular aggregates
like its untagged counterpart (Figure 3A). A small subpopulation of N86Q-FLAG could still be seen at
the cell surface colocalizing with Panx1 (see Linescan analysis, Figure 7B), but to a lesser degree than
Panx2-FLAG. Taken together, these findings suggest that the glycosylation of Panx2 is not required
for the interaction of Panx1/Panx2 but can determine the differential localization of glycosylated and
un-glycosylated species.
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Figure 7. N-glycosylation may enhance plasma membrane localization of Panx2 when co-expressed
with Panx1. Confocal micrographs of (A) Panx2-FLAG or (B) N86Q-FLAG (magenta) ectopically
co-expressed with mouse Panx1 (green) in HEK293T cells. 72 h post-transfection Panx2-FLAG
partially colocalized with Panx1 at the cell membrane (see black arrows in Linescan, panel A) with a
subpopulation still in intracellular compartments. N86Q-FLAG formed intracellular aggregates and
showed limited colocalization with Panx1 at the plasma membrane (see black arrows in Linescan, panel
B). Yellow arrowheads denote regions of colocalization of Panx1 and FLAG labeling also depicted with
black arrows in the corresponding linescans. Insets: Linescans showing the overlapping (black arrows)
between fluorescence peaks to denote colocalization. Nuclei (blue, Hoechst 33342). Scale bars = 20 μm.
3. Discussion
Pannexins are a family of channel proteins implicated in important physiological and pathological
functions and most of the current research has been conducted to analyze their level of expression
and distribution within mammalian tissues and their role in diverse diseases [34]. However, there
is still a need to understand the biophysical properties of these channels and the different ways
of regulation that prevent the detrimental effects of their exacerbated channel activity. Pannexins
are N-glycosylated and as integral membrane proteins, this modification seems to be essential in
regulating their trafficking, as was demonstrated formerly for Panx1 and Panx3 [11,22]. Unlike
the other pannexins, Panx2 is modified only to a high-mannose glycosylation (Gly-1) which is
known to be an early post-translational modification occurring in the ER lumen. For many other
glycoproteins, this step is generally followed by further oligosaccharide editing in the Golgi (complex
glycosylation). To date, there is no evidence showing further processing of Panx2 in Golgi and
only studies in Panx1 and Panx3 showed that trafficking of these two pannexins to the plasma
membrane is mediated by Sar1-dependent COPII vesicles [35] with N-glycosylation affecting their
final delivery [11,36,37]. This suggests that N-glycosylation regulates the route of pannexin trafficking
and modifies their localization and channel formation in immortalized culture cells. A previous report
of Panx2 localization pointed to a predominantly intracellular distribution that can also be modified
by other PTMs like palmytoilation, which can determine its subcellular localization in neurons [17].
Panx2 seems to be mostly intracellularly localized, but in some instances, it can also translocate to
the plasma membrane [14,17]. However, the exact site of N-glycosylation and whether this modification
affects Panx2 trafficking was unknown. In this study, we sought to determine the N-glycosylation site
by generating a glycosylation-deficient mutant (N86Q) based on the predicted N-linked glycosylation
site reported by Penuela et al. [22]. For our experiments we transfected constructs encoding mouse
Panx2 and an N86Q mutant into HEK293T cells. Our results showed that N86Q substitution generated
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a Panx2 mutant with a faster-migrating electrophoretic band compared to Panx2 WT, that does not
shift after specific N-glycosidase digestion with endoglycosidases, thus confirming that N86 is the
only N-glycosylation site for Panx2. In the other cell lines assayed (NRK and AD293) we also observed
that overexpression of the same Panx2 WT and N86Q constructs exhibited the same electrophoretic
properties seen with HEK293T (Figures 2C and 3C).
Independently of the cell-type used for ectopic expression, the N86Q mutant appeared to form
punctate aggregates that were localized to intracellular compartments along with the ER-chaperone
PDI, and the cis-Golgi matrix marker GM130. Compared to the N-glycosylation-deficient mutants
of Panx1 and Panx3 [11], un-glycosylated Panx2 exhibited an exacerbated abnormal intracellular
aggregation. This raises the possibility that the lack of N-glycosylation may have affected proper
protein folding of Panx2, which is the largest member of the pannexin family. We cannot rule out that
the intracellular accumulation of N86Q could be an artifact of overexpression, that concomitant with
the lack of glycosylation of the Panx2 mutant, might have induced misfolding and ER-stress [38].
A previous study in murine postnatal hippocampal neural progenitor cells (NPC)s [17] showed
that treatment with glycosidases had no effect on endogenous Panx2 electrophoretic mobility,
suggesting that they were un-glycosylated. That study relied on antibody detection of endogenous
Panx2, and the protein bands identified were of lower molecular weight than the predicted full-length
Panx2 used in this study (677 aa, [39]). Further studies are needed to determine first, if the expression
of certain un-glycosylated endogenous isoforms of Panx2 is cell-type specific, and second, whether
glycosylation has measurable effects on the Panx2 cellular function. To date, there are no reports of
mutations in the Panx2 gene, but our results would predict significant changes in Panx2 behavior if its
glycosylation is affected. It is also possible that the un-glycosylated form of Panx2 may be preferentially
expressed in some cells and tissues determining the primary function of the Panx2 channel and its
subcellular localization.
In our study, we detected large intracellular subpopulations of Panx2 likely localized in the ER,
and partially colocalized with cis-Golgi marker. Interestingly, we found that overexpression of the
N86Q mutant changed the distribution of PDI and GM130 compared to Panx2 WT, suggesting that
the formation of aggregates may disrupt the morphology of ER and cis-Golgi. GM-130 is a peripheral
membrane protein in cis-Golgi matrix that is important for maintenance of Golgi structure [40], and the
regulation of ER-to-Golgi transport of proteins and glycosylation [41]. It is possible that the aggregation
of N86Q may interfere with the mutant protein transport from the ER causing accumulation of GM130.
As reviewed by Boyce et al. [42], pannexins contain putative recognition sequences for endocytic
and endo-lysosomal targeting which could account for the control of pannexin trafficking. Interestingly,
recently published work by Boassa et al., described the localization of a recombinant Panx2 fused
to mini-SOG tag that was transiently expressed in HeLa cells [26]. These authors used correlated
light and electron microscopy imaging to detect Panx2 localization at cytoplasmic protrusions. Also,
immuno-colocalization in HEK293T cells using assorted vesicular markers displayed Panx2 WT
(untagged) localized to early or recycling endosomes rather than ER. Although, they mentioned
in the manuscript that when the ER marker calnexin was used they detected colocalization with
overexpressed Panx2 in HEK293T cells. Our findings are consistent with these reports [24], since we
found Panx2 primarily in the ER (Figure 4A). However, we did not find conclusive evidence of Panx2
in endo-lysosome compartments (Figure 5A) as others have reported [25,26]. Based on our results, it
is possible that Panx2 may have an intracellular channel function in the ER, similar to the proposed
calcium-leak channels formed by Panx1 and Panx3 [6].
In some instances, Panx2 distribution exhibited limited cell surface localization that was more
apparent when higher endogenous or ectopic Panx1 protein was expressed in the studied cell lines. This
is consistent with our previous observation of increased Panx2 at the cell surface when co-expressed
with Panx1 under overexpression conditions [22]. Here, we used three different cells lines with varying
levels of endogenous Panx1 and a different capacity of protein production. We noticed that in cells
with low endogenous Panx1 (e.g., NRKs), there was barely any Panx2 at the cell surface based on
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immunolabeling and cell surface biotinylation pull-downs. In the case of AD293 and HEK293T cells,
it was possible to detect low levels of overexpressed Panx2 at the cell surface, while the mutant
Panx2 (N86Q) had a detectable but significantly decreased presence only at the cell membrane of
HEK293T cells. This result could be attributed to the increased protein expression in HEK293T cells
that contains the SV40 T-antigen and have high transfection efficiency. This feature might have allowed
the overexpressed Panx2 to bypass mechanisms of protein quality control resulting in more Panx2
trafficking to the plasma membrane [43].
Further research is needed to evaluate endogenous Panx2 in terms of N-glycosylation and
subcellular localization of its isoforms, and to examine if Panx2 can form channels at the plasma
membrane under physiological conditions. To date, limited studies have attempted to evaluate the
Panx2 channel function [14,15] and several factors make it difficult to test Panx2 channel activity, such
as its intracellular localization, the lack of evidence of in vivo functional channel formation [27] and
the unknown mechanisms of activation [14].
Work done by Bruzzone et al. [15], showed that Panx1 and Panx2 were abundantly expressed
in the CNS, and co-injection of both pannexin RNAs in paired Xenopus oocytes resulted in the
formation of heteromeric channels with functional characteristics different from those formed by
Panx1 monomers but with similar pharmacological sensitivity [27]. Ambrosi et al. [14] suggested
that Panx1/Panx2 heteromeric channels tend to be unstable and they attributed that to differences in
monomers size and oligomeric symmetry between these two pannexins. We have previously shown
that Panx1 and Panx2 do form a complex as determined by co-IP experiments. Interestingly, when
both pannexins are co-expressed, the level of interaction between Panx2 and glycosylated-species of
Panx1 is dependent of the glycosylation of the latter [22]. Here, we showed in vitro, that the Panx2
glycosylation-deficient mutant can readily form complexes with Panx1, thus Panx2 glycosylation is not
required for intermixing of the two pannexins. In fact, although it was not statistically significant, N86Q
seemed to pull-down Panx1 more efficiently than the WT Panx2. However, in confocal images the
N86Q aggregates did not show higher overlap with Panx1-immunolabeling than Panx2 WT. Consistent
with our previous report [22], complex N-glycosylation of Panx1 hinders their interaction, since both
Panx2 and N86Q interacted only with the Gly-0 and Gly-1 forms of Panx1. Taken together, these results
suggest that in an ectopic expression system, glycosylation of Panx2 is not required for Panx1/Panx2
intermixing, but it does help with the transport of Panx2 to the cell surface, which is also increased by
the presence of Panx1.
Finally, we propose that N-glycosylation of pannexins is an important post-translational
modification that partially regulates their subcellular localization. Whether N-glycosylation represents
a post-translational mechanism that regulates trafficking and Panx1/Panx2 interactions in vivo would
be important questions to address in future studies. In cells where both pannexins are co-expressed,
glycosylation may act as a form of regulation defining whether these channels will serve as intracellular
or plasma membrane channels with different physiological and pathological functions.
4. Materials and Methods
4.1. Cell Lines, Constructs and Transient Transfections
Media, supplements and reagents were obtained from GIBCO® and Invitrogen™ (Carlsbad, CA,
USA). Normal rat kidney (NRK) (ATCC® CRL-6509™) and human embryonic kidney cells (HEK293T)
(ATCC® CRL-3216™) were obtained from ATCC (Manassas, VA, USA). Adherent HEK293 cells (AD293,
Cat# 240085) were obtained from Agilent Technologies, Inc. (Santa Clara, CA, USA). Cell cultures were
grown in high-glucose DMEM supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin,
100 μg/mL streptomycin and 2mM L-Glutamine. At ~50% of confluency, cells were transfected
adding Lipofectamine 3000 (Invitrogen™) following manufacturer directions. 2 μg of pcDNA3.1
(Invitrogen™) plasmids encoding mouse Panx2 [22] or Panx2N86Q or their respective FLAG-tagged
versions were used for transfections in 35 mm culture plates. After 48 h for single transfections and 72 h
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for co-transfections, proteins were extracted, and expression levels were determined by Western blot.
For co-transfections experiments with mPanx1 plasmid [11], levels were reduced to 0.5 μg of DNA.
4.2. Mutagenesis and Cloning of New FLAG-Tagged Panx2 Constructs
As described previously [11], Panx2 has a predicted N-glycosylation consensus site
located at asparagine (N) 86 on the first extracellular loop. Site-directed mutagenesis service
(NorClone Biotech Labs, London, ON, Canada) was used to generate a new expression Panx2
construct encoding a replacement of asparagine by glutamine at position 86, referred to as
Panx2 N86Q. FLAG-tagged Panx2 was obtained by inserting a single FLAG sequence with
In-Fusion HD Cloning Kit (Clontech Laboratories, Inc., Takara Bio, Inc., Mountain View,
CA, USA) at the end of the coding region of the Panx2 C-termini. Primers used for FLAG
insertion were Forward: 5′-GTTTAAACTTAAGCTTCATGCACCACCTCCTGGAG-3′ and Reverse:
5′-GCCCTCTAGACTCGAGCTCACTTGTCATCGTCGTCCTTGTAATCAAACTCCACAGTACT-3′.
All the constructs were verified by sequencing.
4.3. Protein Extractions and Western Blots
For co-immunoprecipitation (Co-IP) assays, cell lysates were obtained using a Triton-based
extraction buffer (IP buffer) (1% Triton X-100, 150 mM NaCl, 10 mM Tris, 1 mM EDTA, 1 mM EGTA,
0.5% NP-40). The rest of the protein extractions were performed with SDS-based buffer (RIPA buffer)
(0.1% SDS, 50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 1% NP-40 and 0.5% Sodium Deoxycholate). In each
case, lysis buffers were complemented with a final concentration of 1 mM NaF, 1 mM Na3VO4, and
one tablet of cOmplete™-mini, EDTA-free Protease Inhibitor Cocktail (Roche, Mannheim, Germany).
Total protein concentrations were quantitated with Pierce™ BCA Protein Assay Kit (Thermo Scientific,
Rockford, IL, USA). For Western Blots, 50 μg of total protein were resolved in 8% SDS-PAGE and
transferred onto nitrocellulose membranes using an iBlot™ Blotting System (Invitrogen, Carlsbad,
CA, USA). Membranes were blocked with 3% bovine serum albumin (BSA, Burlington, ON, Canada)
and 0.05% Tween 20-Phosphate Buffer Saline (T-PBS) for 45 min at room temperature and probed
overnight with a 1:1000 dilution of the rabbit affinity-purified antibodies anti-Panx2-CT-523 [22].
Mouse monoclonal anti-FLAG® M2 (Sigma, St. Louis, MO, USA, Cat# F3165), monoclonal mouse
anti-GAPDH (Millipore, Burlington, MA, USA, Cat# MAB374, RRID: AB_2107445), and anti-α-Tubulin
(Millipore-Sigma Cat# 05-829, clone DM1A) antibodies were used at 1:2000, 1:1000 and 1:5000 dilutions,
respectively. For detection, IRDye-800 and -680RD (Life Technologies™, Carlsbad, CA, USA) were used
as secondary antibodies at 1:10,000 dilution and the membranes were scanned on a Li-Cor Odyssey
infrared system (Li-Cor, Lincoln, NL, USA). In most cases, GAPDH was used as a loading control.
4.4. Immunofluorescence, Confocal Imaging, Linescans and Colocalization Analysis
Cells were grown on coverslips at ~70% of confluency and were transfected as described
previously in Section 4.1. After 48 h of transfection, coverslips were washed with D-PBS (Gibco®) and
fixed with ice-cold 80% methanol and 20% acetone for 15 min at 4 ◦C. Coverslips were blocked with
2% BSA-PBS for 1h and primary antibodies were used diluted in blocking buffer as follows: polyclonal
anti-Panx2-CT (2 mg/mL, 1:100 dilution), polyclonal anti-Panx1-CT (1 mg/mL, 1:100 dilution),
anti-PDI monoclonal antibody (1 mg/mL, 1:400 dilution) (1D3, Enzo® Life Sciences, Burlington,
ON, Canada, ADI-SPA-891-D), cis-Golgi marker anti-GM130 (1 mg/mL, 1:300) (Abcam, Toronto,
ON, Canada, Prod#: ab169276), anti-FLAG® M2 (1 mg/mL, 1:500) (F3165, Sigma, St. Louis, MO,
USA), mouse monoclonal anti-Lamp-2 (1 mg/mL, 1:300) (DHSB, clone H4B4). Coverslips were
incubated with primary antibodies for 1 h at room temperature, then washed with PBS and incubated
with the secondary antibodies: Alexa Fluor 488 goat anti-rabbit IgG (2 mg/mL, 1:700) or goat
anti-mouse antibody Alexa Fluor 647 (2 mg/mL, 1:400) (Life Technologies), that were selected to
avoid bleed-through between dyes. Mitochondrial labeling was performed by using MitoTracker™
Red CMXRos (M7512, Thermofisher, Life Technologies, Eugene, OR, USA) as per manufacturer
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directions, and cells were fixed with freshly prepared paraformaldehyde (4%) and then permeabilized
with 0.1% Triton X-100 before the blocking step. Coverslips were rinsed with PBS followed by
water once and counterstained with Hoechst 33342 (H3570, Life Technologies™, Eugene, OR, USA)
(1:1000, in water) for 5 min to stain nuclei and then were mounted with the custom-made Airvol
mounting medium. Imaging was performed with an LSM 800 Confocal Microscope (Carl Zeiss,
Oberkochen, Germany) using a Plan-Apochromat 63x/1.40 Oil DIC objective (Carl Zeiss, Oberkochen,
Germany). Image acquisition for colocalization was performed with sequential laser scanning and
with the multitracking feature of the Zeiss software with settings to avoid wrong excitation-crosstalk
and bleed-through of the channels. Colocalization was quantitated with the colocalization plug-in
of the Zeiss software (ZEN, version 2.3, blue edition). Regions of interest (ROI) were drawn in
dual-labeled cells selecting individual cells expressing Panx2 or the mutant and co-stained with
organelle markers. Controls of single-labeled cells were used to determine thresholds of intensities for
each single channel and a manual thresholding was used to determine the region of pixels colocalized
in the intensities scatterplots. Pearson correlation coefficient was determined for each cell as a measure
of colocalization and was expressed as means ± S.E.M., representative of at least three independent
transfections. Linescans using Zeiss software tool were used to detect overlaps of fluorescence peaks
in cells co-transfected with Panx1.
4.5. Cell Surface Biotinylation Assays
Cell surface biotinylation assays were performed as described in Reference [22]. Briefly, cells were
grown in 60 mm plates and used for biotinylation 72 h following transfection with Panx2 or N86Q
constructs. After, culture media was aspirated, the cell monolayer was rinsed twice with ice-cold
D-PBS supplemented with Ca2+ and Mg2+ (Gibco®). Then, cells were incubated only with D-PBS
(non-labeling as a negative control) or with a solution of 1.5 mg/mL EZ-Link™ Sulfo-NHS-SS-Biotin
(Thermo Scientific, Rockford, IL, USA) in D-PBS for 30 min on ice and covered from light. Plates
were washed once again with D-PBS and then incubated with 100 mM glycine dissolved in D-PBS
for 30 min to quench the remaining labeling biotin washed once more with D-PBS. Lysates were
prepared using RIPA buffer as described before. For pull-down of cell surface biotinylated proteins,
250 μg of total protein was incubated overnight with 50% slurry of 50 μL NeutrAvidin agarose beads
(Thermo Scientific, Rockford, IL, USA). Samples from lysates and initial flow-through wash were
collected, the beads were spun down (at 500× g, 4 ◦C) and then washed three times with RIPA buffer.
The samples and the beads were then mixed with 2X Laemmli buffer and 10% β-mercaptoethanol and
placed at 95 ◦C in heat block for 5 min. 50 μg of total protein from lysates and the beads supernatant
were resolved in parallel with 8% SDS-PAGE gel and then transferred to nitrocellulose membranes
as previously described. PDI or GAPDH were used as controls of non-specific biotinylation of
intracellular/cytoplasmic proteins and E-cadherin was used as positive control of cell surface protein.
4.6. Co-Immunoprecipitation (Co-IP) Assays
Co-immunoprecipitation (Co-IP) of protein complexes was performed at 4 ◦C by incubating
overnight 1 mg of total protein from pre-cleared (with Protein A/G beads alone) lysates with 5 μg/mL
of rabbit polyclonal anti-Panx2-CT or anti-Panx1-CT affinity-purified antibody crosslinked to Pierce
Protein A/G-Agarose beads (Thermo Scientific); the same amount of beads (~30 μL) were used for
IP in each case. Control experiments to evaluate unspecific binding to the beads were performed in
parallel using beads with no antibody. To remove un-bound proteins, four washes with 500 μL of
ice-cold IP buffer were performed. Then, beads were dried by aspiration and re-suspended in 2X
Laemmli buffer (10% (v:v) β-mercaptoethanol), boiled for 5 min, spun down and the supernatants
(IP samples) were used for WB. For WB analysis, 50 μg of protein of each lysate was loaded into
the INPUT lanes and ran along with the IP samples. The intensities of the bands in each lane were
obtained by densitometry and were used for quantitation.
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4.7. De-Glycosylation Assays
Lysates from HEK293T cells ectopically expressing mouse Panx2 and the N86Q were used for
validation of N-glycosylation site of the mouse Panx2 construct. Enzymatic de-glycosylation with
Peptide-N-glycosidase F (PNGase F) and Endoglycosidase H (EndoH) were used to detect the presence
of all complex forms of N-glycosylation and high-mannose modification, respectively. PNGase F
(Roche, Indianapolis, IN, USA) and EndoH (New England Biolabs Ipswich, MA, USA) digestions
were performed according to their manufacturer’s instructions. Briefly, at least 35 μg of total protein
was denatured at 100 ◦C for 5 min in denaturing buffer (0.1% (v/v) SDS, 0.05 M 2-mercaptoethanol,
50 mM phosphate buffer, pH 7.5) and subsequently incubated for 1h at 37 ◦C with 10 units of the
PNGase F, 0.7% (v/v) of Triton X-100 or 2500 U of Endo H in supplier’s digestion buffer. In the parallel
control, samples were assayed without endoglycosidases. Protein samples were separated on an
8% SDS-polyacrylamide gel electrophoresis gel (PAGE) and transferred to nitrocellulose membranes
for WB.
4.8. Densitometric Analysis of Western Blots
Densitometry analysis was performed in the Odyssey Application Software Version 3.0.16 (LI-COR
Biosciences, Lincoln, NL, USA) as follows: For cell surface biotinylation experiments, the fraction
of biotinylated-protein detected at the cell surface was calculated using the integrated intensity (I.I.)
of protein bands detected in the Neutravidin lanes divided by the I.I. of protein bands detected in
their corresponding input-lysate lanes. For Co-IP experiments, quantitative analysis was performed
by calculating the ratio of the I.I detected for Co-IP protein divided by the I.I of the IP-target
protein. Quantitation results were expressed as means ± S.E.M. representative of at least three
independent experiments.
4.9. Statistics
Statistical analysis was performed using the statistical package of GraphPad Prism® Ver. 5.03
(GraphPad Software, Inc., San Diego, CA, USA). Cell surface biotinylation data were analyzed with
non-parametric Mann-Whitney U test for unpaired data. Data derived from quantitation of Co-IP
assays and colocalization were analyzed with a two-tailed unpaired t test with Welch’s correction.
A probability of p < 0.05 was considered as statistically significant.
Author Contributions: R.E.S.-P. devised and performed the experiments, analysis of data. R.E.S.-P. and S.P. wrote
the manuscript. D.J., assisted on the design of mutagenesis, and provided technical help in immunostaining and
imaging and revised the manuscript. S.P. designed the original project, devised experiments, served as scientific
advisor and provided critical revision of results and manuscript.
Funding: This work and the cost of publication was funded by the Natural Sciences and Engineering Research
Council of Canada with an NSERC Discovery Grant RGPIN-2015-06794 to Silvia Penuela.
Conflicts of Interest: The authors declare no conflict of interest.
108
Int. J. Mol. Sci. 2018, 19, 1837
Abbreviations
AD293 Adherent human embryonic kidney cells
ATP Adenosine triphosphate nucleotide
CNS Central nervous system
Co-IP Co-immunoprecipitation
Endo H Endoglycosidase H
ER Endoplasmic reticulum
GAPDH Glyceraldehyde 3-phosphate dehydrogenase
GM130 Golgi matrix protein 130 kDa
HEK293T Human embryonic kidney cells with SV40 T-antigen
IP Immunoprecipitation
LAMP2 Lysosome-associated membrane glycoprotein 2
NPC Neural progenitor cells
NRK Normal rat kidney cells
PDI Protein disulfide isomerase
PNGase F Peptide-N-glycosidase F
PTM Posttranslational modification
SV40 Simian vacuolating virus 40
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Abstract: GJB2 mutations are the leading cause of non-syndromic inherited hearing loss. GJB2
encodes connexin-26 (CX26), which is a connexin (CX) family protein expressed in cochlea, skin,
liver, and brain, displaying short cytoplasmic N-termini and C-termini. We searched for CX26
C-terminus binding partners by affinity capture and identified 12 unique proteins associated with
cell junctions or cytoskeleton (CGN, DAAM1, FLNB, GAPDH, HOMER2, MAP7, MAPRE2 (EB2),
JUP, PTK2B, RAI14, TJP1, and VCL) by using mass spectrometry. We show that, similar to other
CX family members, CX26 co-fractionates with TJP1, VCL, and EB2 (EB1 paralogue) as well as the
membrane-associated protein ASS1. The adaptor protein CGN (cingulin) co-immuno-precipitates
with CX26, ASS1, and TJP1. In addition, CGN co-immunoprecipitation with CX30, CX31, and CX43
indicates that CX association is independent on the CX C-terminus length or sequence. CX26, CGN,
FLNB, and DAMM1 were shown to distribute to the organ of Corti and hepatocyte plasma membrane.
In the mouse liver, CX26 and TJP1 co-localized at the plasma membrane. In conclusion, CX26
associates with components of other membrane junctions that integrate with the cytoskeleton.
Keywords: connexin; connexin 26; GJB2 gene; deafness; protein-protein interaction; TJP1; CGN;
FLNB; DAAM1; organ of Corti
1. Introduction
The GJB2 gene encodes connexin 26 (CX26), which is a protein that plays central roles in hearing,
promoting cochlear development, and sustaining auditory function in the mature cochlea [1–4].
In addition to the cochlea, expression of CX26 is also observed in the skin, the liver, the brain, the
mammary gland, the salivary gland, the uterus, testis, the pancreas, lungs, the stomach, the thyroid,
and the parathyroid [5]. GJB2 mutations are the most frequent cause of non-syndromic recessive
hearing loss across diverse populations [6–9]. In addition, some heterozygous GJB2 mutations behave
in a dominant fashion, which leads to non-syndromic autosomal dominant hearing loss or to the
keratitis-ichthyosis-deafness syndrome [10].
In vertebrates, connexins (CX) assemble intercellular gap junctions (GJ), which result from
the interaction between two distinct hemi-channels from adjacent cells with each composed of six
CX units. GJ directly allows the passage of various small (<2 kDa) molecules between two cells
such as ions, secondary messengers, nucleotides, amino acids, and short RNAs [11]. GJ are highly
organized structures in which CX interact among themselves as well as with a number of other cellular
components including cytoskeleton-associated elements and adhesion and signaling molecules [12–14].
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While, among CX family members, the C-termini are dissimilar and present unique binding partners
and signaling, they may share common protein interactors [15–17]. The C-terminus from CX26 is
strikingly different from that of other CX [18]. Among mouse CX family members, CX26 has the
second lowest molecular mass due to shorter segments outside the four transmembrane domains
(the extracellular and intracellular loops as well as N-termini and C-termini). Due to its limited
length, few binding partners have been identified for CX26 cytosolic segments, e.g., amino-termini
and carboxyl-termini and the loop between the second and third transmembrane domains [19–21].
The aim of this study was to search for proteins that interact with the cytoplasmic ten-residue
carboxyl-terminal tail of CX26. Employing two distinct biochemical approaches, we disclosed a
cytoskeleton and membrane junction-associated protein network that co-fractionates with CX26.
CX26 interaction with the molecular complex depends on its C-terminus. Additionally, our results
revealed that proteins from this macromolecular complex may also associate with CX30, CX31,
or CX43, which indicates that assembly of CX in the macromolecular complex is independent of
the CX C-terminus length or sequence.
2. Results
We employed affinity precipitation assays to search for proteins that interact with the cytoplasmic
carboxyl-terminal tail of CX26. To that end, the portion of the GJB2 mouse gene coding for the 10 most
C-terminal amino acids of Cx26 was cloned and expressed in Escherichia coli as a peptide in fusion
with the glutathione-S-transferase (GST) C-terminus (GST–CX26). The purified fusion protein or GST
was submitted to affinity capture assays. Mass spectrometry analyses identified 447 proteins from
the mouse brain or liver that precipitated in sepharose beads conjugated to glutathione and bound
by affinity to the GST–CX26 fusion protein or only GST. After exclusion of potential contaminants,
39 proteins were found to co-fractionate in the GST–CX26 assay but not in the negative control
(GST-only assay). The number of peptides identified by mass spectrometry for each of the 39 proteins
varied from two to seven and the protein coverage by peptides ranged from 1% to 15%. The number
of unique interactor candidates was reduced from 39 to 26 proteins when the following exclusion
criteria were applied: redundancy of representation within the GST–CX26 group, discrepancy between
the observed and expected molecular weights, and inconsistency in tissue/cell spatial distribution.
For instance, biglycan, canstatin, and fibronectin were excluded because, as secreted fibrous proteins,
the interaction results would probably be false-positive due to unspecific precipitation or a transient
association during synthesis and trafficking in the secretory pathway. As a result, we retrieved a total
of 26 candidate proteins to interact with the cytosolic C-terminus of CX26.
Gene ontology and scientific literature searches allowed us to classify the 26 interactor candidates
in the following groups: (i) 12 proteins with direct or indirect association with cell junctions and/or the
cytoskeleton (Table 1); (ii) seven proteins from the secretory pathway; (iii) four mitochondrial proteins;
(iv) two chaperone proteins; and (v) one nucleus-cytoplasm shuttling protein. Two proteins from the
mitochondrion group and one protein from the secretory pathway have been detected at the plasma
membrane. Therefore, 15 out of 26 proteins may be directly or indirectly associated with the plasma
membrane (12 from cell junctions or the cytoskeleton, two from the mitochondrial group, and one from
the secretory group). A general subcellular classification of the 26 proteins is illustrated in Figure 1A.
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Figure 1. (A) Venn diagram representing the distribution of 26 candidate proteins to interact with CX26.
The subcellular classification and the number of proteins in each of the five distinct groups are indicated
as well as their overlapping sorting; (B) The network of protein-protein interaction (PPI) is predicted
at http://string-db.org. Acronyms are according to the genes listed on Table 1 in addition to actin B
(ACTB), α-tubulin (TUBA1A), and arginine succinate synthase 1 (ASS1). Black circles represent proteins
absent from the list of interactors fed by the user to the software input list. Asterisks indicate protein
interactions manually added to the PPI network according to the literature (MAP7, RAI14, Homer2).
Striped circles denote the four CX26 interactor candidates previously demonstrated to associate with
other CX. Thicker lines indicate experimentally demonstrated associations that may be either more
reproducible or a direct interaction. A dashed line indicates inference of an intermediate interactor.
Table 1. Candidate proteins to interact with CX26 are classified as a cell junction or
cytoskeleton-associated proteins.
Human Gene Acronym Human Gene Protein Name, Aliases, and Acronyms
CGN Cingulin Cingulin
DAAM1 Disheveled-associated activator of morphogenesis 1 DAAM1
FLNB Filamin B Filamin-B, Filamin-3, β-filamin
GAPDH Glyceraldehyde-3-phosphate dehydrogenase GAPDH
HOMER2 Homer scaffold protein 2 Homer-2, cupidin
JUP Junction plakoglobin Plakoglobin, γ-catenin, desmoplakin-3
MAP7 Microtubule-associated protein 7 MAP7, EMAP-115, ensconsin
MAPRE2 Microtubule-associated RP/EB family member 2 EB2
PTK2B Protein tyrosine kinase 2β Focal adhesion kinase 2, FAK2, PYK2, PTK2B
RAI14 Retinoic acid-induced 14 RAI14, ankycorbin, NORPEG
TJP1 Tight Junction Protein 1 Zonula occludens 1, ZO-1, TJP1
VCL Vinculin Vinculin, VCL
2.1. A Membrane-Cytoskeleton Protein Network Associated with CX26
We continued the in silico analyses by verifying the potential ability of the 26 proteins to assemble
protein-protein interaction (PPI) networks according to data from literature reports on the interaction
and co-expression experiments [22]. Nine out of 26 proteins comprised a single PPI network (ASS1,
CGN, DAAM1, FLNB, GAPDH, JUP, PTK2B, VCL, and TJP1). When cytoskeleton proteins α-tubulin
and actin were included on the protein list, the PPI network encompassed 10 out of the 26 proteins
(EB2 was included). A further individual literature data search allowed for the manual inclusion
of three additional proteins in the PPI network (HOMER2, MAP7, and RAI14) (Figure 1B) [23–27].
Consequently, among the 26 proteins, 13 constitute a single PPI network along with α-tubulin and actin
(Figure 1B). The PPI network contains all 12 proteins classified as cell junction/cytoskeleton (Table 1,
Figure 1B) and one from the mitochondrion group (argininosuccinate synthase 1—ASS1, Figure 1A),
which has been reported to interact with the plasma membrane in addition to the mitochondrial outer
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membrane [28]. In the present study, we report the analysis of the group of 13 proteins present in the
PPI network.
2.2. Known CX Binding Partners in the CX26 Molecular Complex
Four of the 13 proteins present in the PPI network (Figure 1B, striped circles) have been
described to interact with other members from the CX family. They are ASS1, microtubule-associated
RP/EB family member 2 (EB2), tight junction protein 1/zonula occludens protein 1 (TJP1),
and vinculin (VCL) [29–34]. While the former classifies as mitochondria-associated and plasma
membrane-associated, the latter three proteins are cell junction or cytoskeleton proteins. As CX
interaction with TJP1 appears to be direct for the majority of family members studied [29–31,35–40],
we adopted the yeast two-hybrid split-ubiquitin system to search for direct, pairwise interaction
between full-length CX26 individually with TJP1, ASS1, EB2, and VCL.
In the yeast split-ubiquitin system, the interaction is expected to take place at the membrane
and cleavage of the fusion protein by a ubiquitin-specific processing protease and then releases the
transcription factor lexA-VP16. The reporter genes lacZ, HIS3, and ADE2 were employed in this
study as they are responsive to lexA-VP16 binding after its nuclear translocation. As presented
in Figure 2A, no specific activation of the reporter genes was observed for any test bait-prey pair
(CX26–TJP1, CX26–VCL, CX26–EB2, or CX26–ASS1). Leaky activation was observed for the lacZ
gene expression for all pairs and the ADE2 gene was activated by the preys themselves. No test pair
allowed for yeast growth in minimal medium without histidine when compared to the positive control
(Figure 2A). Therefore, we concluded that, under these conditions, we did not obtain data indicating
direct interaction between full-length CX26 and TJP1, VCL, EB2, or ASS1.
Antibodies that recognize each of the four CX interactors including TJP1, VCL, EB2, and ASS1
were employed in immunofluorescence assays of adult mouse liver with double staining for CX26
in all four experiments. CX26, TJP1, VCL, and EB2 all presented staining patterns consistent with
plasma membrane distribution in hepatocytes (Figure 2B). TJP1 and CX26 co-localized in different
points at the plasma membrane (Figure 2B, arrows). On the other hand, although in double staining
assays, there were sporadic merged signals between CX26 and either EB2 or VCL (Figure 2B, arrows),
we considered that VCL and EB2 do not co-localize with CX26 in the mouse liver under our assay
conditions. ASS1 disclosed a cytoplasmic staining pattern and no co-localization with CX26 under the
conditions employed (Figure 2B). However, in a control experiment, ASS1 did not co-localize with the
mitochondrial cell marker mtHSP70 (data not shown), which suggests that the anti-ASS1 antibody
employed should be unspecific in our immunofluorescence assays of mouse liver sections.
Figure 2. Cont.
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Figure 2. (A) Results of the yeast two-hybrid split ubiquitin assay has, in column 1, interaction tests
with GJB2 full-length sequence as bait and the preys non-recombinant vector (nr, control), EB2, TJP1,
ASS1, or VCL. Column 2 has the non-recombinant (nr) vector as bait. Therefore, it leads to testing
for leaky activation of the reporter gene by each prey fusion protein. Column 3 presents different
controls: untransformed, positive, and negative controls for each vector (coding for either N- (N-Ub)
or C-terminal (C-Ub) ubiquitin moieties in fusion with known strong (+) or negative (−) interactors.
Different media respectively select for the presence of both vectors (SD, Leu−, Trp−), activation of the
reporter gene ADE2 (SD, Leu−, Trp−, Ade−), HIS3 (SD, Leu−, Trp−, His−), or β-galactosidase (X-Gal
test); (B) Indirect immunofluorescence of adult (P60) mouse liver cryosections with anti-CX26 antibody
(green) and ASS1, VCL, EB2, and TJP1 (all in red). DNA is in a pseudo white color, according to DAPI
staining. The analysis was performed at confocal microscopy with z-sections of 0.5 μm (LSM880, Carl
Zeiss, Oberkochen, Germany). Arrows: merged signals. Scale bar: 10 μm.
2.3. Expanding the Protein Interaction Network with Cx26
Since some CX26 interactor candidates retrieved in our affinity capture assay are common to
other CX and do not appear to be in direct association with CX26, we looked for adaptor proteins
in the PPI network that could play roles in bringing TJP1, VCL, ASS1, or EB2 to proximity to CX26.
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Among the 13 proteins from the PPI network, there are four adaptor/scaffolding proteins: cingulin
(CGN), filaminB (FLNB), dishevelled-associated activator of morphogenesis 1 (DAAM1), and homer
scaffolding protein 2 (HOMER2). As the N-terminal globular domain of the adaptor protein CGN
associates with TJP1 PDZ domain [41], we performed immunoprecipitation experiments with anti-CGN
antibodies in RIPA or EGTA buffer lysates of neonate mouse liver tissue and confirmed that CGN,
as expected, co-immunoprecipitates with TJP1. We confirmed co-immunoprecipitation of CGN
and CX26 in both buffer compositions employed, RIPA buffer (Figure 3), and EGTA buffer (data
not shown). ASS1 and EB2 were disclosed to co-immunoprecipitate with CGN. Data presented in
Figure 3 are clear evidence for CGN co-immunoprecipitation with TJP1 and ASS1. The faint band
observed for EB2 in a CGN immunoprecipitation lane led us to consider it may be due to weak and
indirect association with proteins from any CGN protein complex. We did not observe VCL in CGN
immunoprecipitates in either buffer condition (Figure 3 and data not shown) even though it may still
bind CX26 through an additional intermediate interactor. Although CX43-specific blot band migrates
very close to an unspecific band observed in the negative control, its co-immunoprecipitation with
CGN is demonstrated (Figure 3). Lastly, we show that CGN co-immunoprecipitates with CX30 and
CX31 (Figure 3).
Figure 3. Immunoprecipitation of cingulin from adult mouse liver and its co-immunoprecipitation
with CX26, CX30, CX31, CX43, EB2, TJP1, and ASS1, which is indicated by the respective arrows.
No co-immunoprecipitation is observed with VCL. The protein molecular mass is indicated in
kiloDaltons (kDa).
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The adult mouse liver was co-labeled for Cx26 and three adaptor proteins known as CGN,
FLNB, or DAAM1. The four proteins were detected in hepatocytes and in patterns consistent with
plasma membrane localization (Figure 4, arrowheads) as well as cytoplasm organelles (Figure 4).
Few overlapping signals were observed in hepatocytes for CX26 and DAAM1 at the plasma membrane
(Figure 4, arrows). The paucity of these observations led us to exclude co-localization of those proteins.
CX26 co-localization with CGN or FLNB was not observed under those conditions. Moreover, we show
that all three adaptor proteins including CGN, FLNB, and DAAM1 are expressed in key regions of
P14 mouse cochlea such as the organ of Corti (OC), stria vascularis, spiral ligament, spiral limbus,
and external sulcus cells (Figure 5). DAAM1 is also present in spiral ganglion cells (Figure 5). Likewise,
in stria vascularis DAAM1, staining appeared more evident than CGN and FLNB staining. On P14,
CX26 distributed to the OC, stria vascularis, spiral ligament, spiral limbus, and the spiral ganglion.
The tectorial membrane is acellular and known to yield unspecific staining due to spontaneous
fluorescence. CX26 and all three adaptor proteins seem to be co-expressed in the OC even though OC
cell identity could not be precisely defined since distinct cell type markers have not been employed.
?
Figure 4. Indirect immunofluorescence of adult (P60) mouse liver cryosections with anti-Cx26 antibody
(green) and CGN, FLNB, and DAAM1 antibodies (all in red). DNA is in a white pseudo color,
according to DAPI staining. The analysis was performed at confocal microscopy with z-sections of
0.5 μm (LSM880, Carl Zeiss, Oberkochen, Germany). Each image consists of the maximum intensity
projection of all z-sections obtained. Arrowheads: signal at the plasma membrane. Arrows: merged
signals. Scale bar: 10 μm.
118
Int. J. Mol. Sci. 2018, 19, 2535
?
Figure 5. Indirect immunofluorescence of P14 mouse cochlea cryosections and zooming-in at the organ
of Corti (OC) indicated by a rectangle. The sections highlight the spiral ligament (SL), stria vascularis
(SV), spiral limbus (SLm), spiral ganglion (SG), external sulcus cells (ES), OC, and tectorial membrane
(TM). Labeling by anti-Cx26 antibody (green) and antibodies for CGN, FLNB, and DAAM1 (all in
red) are presented. DNA is in a white pseudo color, according to DAPI staining. The analysis was
performed at confocal microscopy with z-sections of 1 μm (LSM880, Carl Zeiss, Oberkochen, Germany).
Each image consists of maximum intensity projection of all z-sections obtained. Scale bar: 50 μm.
3. Discussion
CX26 assembly as heteromeric hemi-channels and heterotypical gap junctions has been
demonstrated in particular through its association with CX30 [42]. CX26 association with other
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CX has also been disclosed by global interactome analyses [33]. CX26 physical interaction with
paralogues is, therefore, a common feature since it is for other family members [43]. Few additional
binding partners have been reported for CX26. The trans-Golgi network protein consortin interacts
with CX26 in the secretory pathway [21]. At the plasma membrane, CX26 binding to caveolin-1 is
necessary for its localization in caveolae from lipid rafts [44]. Lastly, CX26 association with dynamin-2
has been implicated in its turnover by endocytosis [45]. The finding of CX26 interaction with the SCF
E3 ubiquitin ligase component known as the F-box protein OCP1 has also contributed to clarify its
turnover mechanism [46]. As seen, few proteins are known as binding partners of CX26. Therefore, we
employed the CX26 C-terminus as bait and sought for interacting proteins from the adult mouse brain
or liver.
In this paper, we presented 13 proteins that have been identified by mass spectrometry analysis
of the CX26 C-terminus affinity precipitation assays with 12 of them having been classified as cell
junction and cytoskeleton-associated proteins (Table 1). Four proteins have previously been identified
as other CX interactors (ASS1, EB2, TJP1, VCL, Figure 1B). Three proteins from this subgroup are part
of cell junctions and the cytoskeleton (EB2, TJP1, and VCL). TJP1 directly interacts with the C-termini
of CX30, CX31.9, CX32, CX35, CX36, CX43, CX45, CX46, CX47, and CX50 [29–31,35–40] as well as with
VCL (Figure 1B) [34] and is important to stabilize CX43 gap junctions [34]. Moreover, EB1, which is
a paralogue of EB2, has been shown to be necessary for targeting CX26 and CX43 to the plasma
membrane and co-immunoprecipitates with CX43 [32].
TJP1 is a large protein with three tandem N-terminal PDZ domains, which mediate its interaction
with CX. TJP1 binding to CX C-terminus is an important regulatory step in a gap junction assembly,
internalization, and degradation [47]. Apparently, TJP1 binding needs a CX C-terminus to be anchored
at the membrane or protein complex. For affinity capture, we employed CX26 C-terminus in fusion
with the GST C-terminus. This configuration may have contributed to in vitro binding of TJP1 to the
GST–CX26 C-terminus. However, contrary to other connexins such as CX43, CX26 does not have
a PDZ-binding motif in its C-terminus (data not shown). In fact, PDZ-binding motifs need to be
internal at the C-terminus to properly mediate protein interaction [48] and the CX26 C-terminus is only
11-amino acids long. Therefore, it was not surprising that the yeast two-hybrid system did not reveal a
direct interaction between TJP1 and CX26 (Figure 2A). We then looked at indirect interactions between
these proteins and employed CGN in immunoprecipitation assays. There is a direct association between
the N-terminal globular domain of the adaptor protein CGN and the TJP1 PDZ domain [41] and we
demonstrated that CX26 co-immunoprecipitates with CGN (Figure 3). No extensive co-localization
was observed between CGN and CX26 in the liver (Figure 4) or cochlea (Figure 5). Therefore, a direct
interaction between these proteins is not suggested by our data.
Due to the limited length of the CX26 C-terminus, other scenarios could be considered to speculate
how CX26 interactions described here would take place. Each hemi-channel displays six CX N-termini,
six intracellular loops, and six C-termini at the cytosolic face of the plasma membrane. Hence, it is
plausible that the CX26 C-termini combine in specific configurations that allow for protein interactions,
which individually would not be possible. Those segments could be stabilized through an interaction
with other membrane proteins or the lipid content from the plasma membrane in a stoichiometric ratio
likely different from one-to-one.
Multiple sequence alignments among CX C-termini display limited similarity between the short
cytosolic C-termini of CX26 and other B-group CX paralogues (data not shown). On the other hand,
manual alignments between human and mouse CX26 11-residue C-terminus and up to 42 residues
of the C-termini from the A-group and the B-group CX disclosed enrichment (30% to 50%) in basic
amino acids in the first 21 cytosolic amino acids of all CX analyzed (Figure 6). Functional roles in the
gap junction sensitivity have been proposed for the CX32 C-terminus basic residues [49]. Although
basic residues are commonly observed in cytosolic protein segments contiguous with transmembrane
domains and by balancing the net negative charge of the lipid bilayer, they may also mediate common
interactions with scaffolding proteins [50]. Therefore, an additional scenario would be that the basic
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amino acids of at least two CX26 C-termini help to stabilize molecular interactions in the PPI network
in close adjacency to the membrane. This network could be assembled on the cytoplasmic face of
membranes at any point along the secretory pathway.
?
Figure 6. Pairwise alignments of human (h) and mouse (m) CX orthologues as indicated by
comprehending part of the last transmembrane domain (TM4) and 42 amino acids that follow that
domain. Basic amino acids are underlined and their counting indicated on the two right columns,
respectively, for the first and second 21-residue initial segments of C-termini. (*) identical residues;
(+) amino acids with lateral chains from the same biochemical group.
Our results do not indicate a specific interactor that could be a direct binding partner for CX26.
Hence, themacromolecular assembly hypothesis is corroborated and it contributes to a protein platform
at the cytosolic face of CX26 hemi-channels associated with the membrane and other junction proteins.
While interaction between tight junctions and CX has previously been observed solely for CX32 [51],
we could detect co-localization of CX26 and TJP1 at the plasma membrane of hepatocytes from the
mouse liver (Figure 2B). It is also a possibility that CX26 hemi-channels would associate in vivo with
tight junction proteins if composed of heteromeric assemblies. Alternatively, the tight junction proteins
could associate with CX26 C-terminus during trafficking at the Golgi cytoplasmic face.
EB2 and VCL disclosed no convincing co-localization with CX26 in the mouse liver (Figure 2B).
Specifically, microtubule plus end-binding proteins, EB1 and EB3, have been implicated in microtubule
dynamics promoting microtubule growth and inhibiting its catastrophe [52]. In microtubule-assisted
disassembly of focal adhesions, microtubule growth is believed to take place on underlying actin
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microfilaments and associated proteins. It has been demonstrated that EB2 knocking-down decreases
cell motility and causes aberrant focal adhesion dynamics. EB2 has been shown to be essential for focal
adhesion disassembly as a direct microtubule interactor and through its interaction with MAP4K4
(mitogen-activated protein kinase 4) [53]. Moreover, EB1 plays roles in CX43 trafficking to regions of
the plasma membrane where adherens junctions had already been formed [32,54,55].
VCL is a membrane-cytoskeletal protein in focal adhesion plaques involved in the linkage of
integrin adhesion molecules to the actin cytoskeleton. It is a cytoskeletal protein associated with cell-cell
and cell-matrix junctions where it is thought to function as one of several interacting proteins involved
in anchoring F-actin to the membrane [56]. VCL binding to CX43 has already been demonstrated
by in vivo and in vitro studies including co-immunoprecipitation and co-localization [57]. Therefore,
focal adhesions are cytoskeleton-membrane association sites where CX26 interaction with VCL and
EB2 could be investigated.
ASS1 is the fourth protein from the CX26 PPI network that has previously been identified as a CX
interactor since it has been detected in the CX32 interactome [33]. Although ASS1 is not part of the
cell junction or the cytoskeleton, it has been analyzed in this report since it distributes to the plasma
membrane of endothelial cells. More specifically, associated with endothelial nitric oxide synthase in
caveolae from lipid rafts [28], where CX26 has also been identified [44]. However, most commonly,
ASS1 is described in the vicinity of the mitochondria outer membrane [58]. ASS1 and other enzymes
from the urea cycle are believed to form a macromolecular complex that facilitates and concentrates
arginine metabolism components near mitochondria. Since ASS1 gene expression and ASS1 protein
localization have been demonstrated to be regulated by hormones and amino acids [58], it is logical to
assume that, when driven to caveolae, ASS1 association to cell membrane junction proteins such as CX
and paralogues would be more pronounced. On the other hand, a few reports have implicated CX in
mitochondrial functions. CX43 has been shown to localize in the mitochondria inner membrane [59]
where it is assembled as a hemi-channel and functions in homeostasis and cell death [33,60]. Therefore,
on the one hand, plasma membrane caveolae are a likely address for interaction between CX and
ASS1. On the other hand, although CX43 and ASS1 have been reported in different mitochondria
compartments including mitochondrial inner and outer membranes, indirect interaction could take
place between CX and ASS1 during the transport to mitochondria. This is probably a considerable
alternative since we did not observe co-localization of CX26 and ASS1 at the plasma membrane
(Figure 2B).
We showed that CGN, DAAM1, and FLNB distribute to the organ of Corti (Figure 5). Moreover,
all 13 proteins from the CX26 PPI network have been reported to be expressed in the inner ear,
according to databases [61–65]. Among the 13 genes that encode CX26 interactors, the HOMER2 gene
has been related to autosomal dominant hearing loss in humans with the description of a missense
mutation [66]. In addition, tricellulin, which is a protein encoded by the TRIC gene, presents in
its C-terminal region a domain for binding to occludin, which is known as a TJP1 direct binding
partner [67]. Protein-truncating mutations in the TRIC gene led to the loss of the occludin-binding
domain and autosomal recessive hearing loss in humans [68]. In the inner ear, tricellulin is in cell
junctions of supporting and ciliated cells. These data corroborate our results on TJP1 as part of
the CX26 interactome. Lastly, the localization of CX26 and adaptor proteins belonging to its cell
junctional network in the cochlea confirms their potential for physiological roles in hearing. Their
corresponding genes are unveiled as good candidates to be explored in hearing loss studies. Among
other functions, they may participate in the mechano-electrical transduction of sound vibrations in
the organ of Corti [69] or in the maintenance of cochlear ion homeostasis regulated through stria
vascularis [70].
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4. Materials and Methods
4.1. Animals and Tissue
The experimental protocol was previously approved by the Internal Review Board on Ethics
in Animal Research from the Institute of Biosciences of the University of São Paulo (CEP 062/2007,
3 April 2007). All experiments were conducted in accordance with the guidelines for the care and use
of laboratory animals established by the American National Research Council. Postnatal day 3 (P3)
Balbc mice (Mus musculus), postnatal day 14 (P14), and 60 (P60) CBL57/6 mice (Mus musculus) were
obtained from specialized breeders from the University of São Paulo (São Paulo, Brazil). Animals
presenting acute or chronic ear infection or congenital malformations were excluded from the study.
The P60 CBL57/6 mouse brain and liver were obtained for affinity precipitation assays. P3 mouse
liver was employed in immunoprecipitation assays. To obtain the biological material of interest, the
animals were submitted to profound anesthesia with ketamine and xylazine (0.17 and 0.03 mg/g
of body mass, respectively) followed by decapitation. The heads and abdomen were bathed in 70%
ethanol, which was followed by the removal of the liver and sagittal incision of the skull to remove
all brain tissue. Tissues were snap-frozen in liquid nitrogen and later stored at −80 ◦C. P14 CBL57/6
mice provided cochlea for immunofluorescence assays. The animals were sacrificed as described
above. The heads were bathed in 70% ethanol, temporal bones were removed, labyrinth dissected,
and cochleae was harvested with micro tweezers (Dumont #5 and #54, Electron Microscopy Sciences,
Hatfield, PA, USA), under a trinocular stereomicroscope (Discovery V12, Carl Zeiss, Oberkochen,
Germany) and incubated in 4% paraformaldehyde. For immunofluorescence assays, P60 CBL57/6
mice were submitted to profound anesthesia with ketamine and xylazine (0.17 and 0.03 mg/g of body
mass, respectively), which was followed by trans-cardiac perfusion with 4% paraformaldehyde in
phosphate-buffered saline solution (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, and 1.76 mM
KH2PO4, pH 7.4) at 4 ◦C.
4.2. DNA Clones
To obtain a recombinant pGEX-4T-1 clone containing the DNA coding sequence for
glutathione-S-transferase (GST) in fusion with that encoding CX26 C-terminus, genomic DNA from
mouse liver was used as a template for a polymerase chain reaction (PCR) amplification of human GJB2
gene DNA from base chr13:2018852 to 20188933 (GRCh37/hg19) with the following pair of primers:
(1S) 5′ CGA GGC CCG GGT TAT TGC TCA GGA AAG TCC A 3′ and (1AS) 5′ CGA GGG CGG CCG
CTG GGT TCC TCT CTC CTG TC 3′, with the 5′-end having restriction sites respectively for SmaI
and NotI (underlined). The undigested, purified PCR product was cloned in a pCR2.1-TOPO vector
(Invitrogen, Carlsbad, CA, USA) in DH5α E. coli. Plasmid DNA from one recombinant clone with
its insert sequence confirmed by Sanger sequencing was digested with SmaI and NotI (Invitrogen).
A released insert was subcloned in the pGEX-4T-1 vector (GE Healthcare, Little Chalfont, UK) and the
final recombinant clone was named PGEX-GST–CX26. For the yeast two-hybrid interaction test, the bait
construct was obtained after a cloning mouse GJB2 full-length coding sequence (present in a single
exon) into the vector pBT3-N (MoBiTec, Göttingen, Germany) while prey constructs (full-length coding
sequence for mouse VCL, TJP1, ASS1, or MAPRE2) were sub-cloned into the vector pPR3-N (MoBiTec).
4.3. Antibodies
The antibodies from Santa Cruz Biotechnology (Santa Cruz, CA, USA) used to detect the following
proteins were: CX26 (GJB2, goat polyclonal antibody N-19, and rabbit polyclonal antibody O-24),
CX30 (GJB6, rabbit polyclonal antibody C20), CX31 (GJB1, rabbit polyclonal antibody H-43), CX43
(GJA1, mouse monoclonal antibody F-7), ASS1 (rabbit monoclonal antibody H-231), CGN (cingulin,
mouse monoclonal antibody G-6), DAAM1 (disheveled-associated activator of morphogenesis 1,
mouse monoclonal antibody WW-3), FLNB (filamin B, mouse monoclonal antibody F-8), and TJP1
(zonula occludens 1 protein, ZO-1, rat polyclonal antibody R40.76). Antibodies from Abcam
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(Cambridge, MA, USA) were as follows: MAPRE2 (EB2, rat polyclonal antibody K52), VCL
(vinculin, mouse monoclonal antibody SPM227), and TJP1 (rabbit polyclonal antibody ab59720).
An additional anti-CX26 (Zymed mouse monoclonal antibody, Thermo Fisher Scientific, Waltham,
MA, USA) was employed in immunofluorescence assays. Western blot secondary antibodies were
conjugated to horseradish peroxidase (GE Healthcare, Wauwatosa, WI, USA). Immunofluorescence
secondary antibodies were conjugated to Alexa488 or Alexa594 (Jackson ImmunoResearch Laboratories,
West Grove, PA, USA).
4.4. Bacteria Expression of Fusion Protein
For fusion protein expression, pGEX-GST–CX26 or pGEX-GST plasmid DNA was used to
transform BL21 E. coli. Recombinant clones were grown at 37 ◦C in liquid LB medium supplemented
with 50 μg/mL ampicillin (TEUTO, Anapólis, Brazil) and 0.5 mM IPTG (Invitrogen) until optic
density (600 nm) reached values between 0.4 and 0.6. For soluble protein isolation, a bacteria pellet
was suspended in PBS with a protease inhibitor (Pefabloc, Roche Applied Science, Indianapolis, IN,
USA), 10 mg/mL lysozyme (Sigma-Aldrich, St Louis, MO, USA), and incubated on ice for 15 min.
After two quick cycles of freezing and thawing, lysates were centrifuged at 10,000× g, for 15 min at
4 ◦C. One-hundred μL of the supernatant were mixed with 40 μL of GST-Bind™ resin (glutathione
(GSH)-sepharose, Novagen, Darmstadt, Germany) under agitation at 4 ◦C for 30min. After washing the
pellet, samples of sepharose beads containing glutathione-bound proteins were boiled and submitted
to SDS-PAGE for protein quantification in comparison to bovine serum albumin (BSA) standards.
Bacterium soluble protein fractions containing 600 pmols of GST–CX26 or GST were aliquoted and
stored at −80 ◦C.
4.5. Affinity Capture Assay
Three different lysis buffers named EDTA, EGTA, or PHEM were employed for obtaining mouse
tissue lysates. For each one, 10 to 20 mg of mouse liver or brain were homogenized in 1 mL of the lysis
buffer using a Douncer homogenizer (40 slow strokes). The basic composition of EDTA and EGTA
buffers was the same: 50 mM Tris-HCl pH 7.4, 150 mM NaCl, 0.75% triton X-100, 2 mM Na3VO4, 10
mM NaF, 1× protease inhibitor (cOmplete, EDTA-free, Sigma-Aldrich, St Louis, MO, USA). EDTA and
EGTA buffers differed on a divalent cation composition with the former having 1 mM EDTA and the
latter 10 mM EGTA and 2 mM MgCl2. PHEM buffer was composed of 60 mM piperazine-N,N′-bis
[2-ethane-sulfonic acid] (PIPES) pH 6.9, 25 mM N-2-hydroxyethylpiperazine-N′-2-ethane-sulfonic acid
(HEPES), 2 mM MgCl2, 10 mM EGTA, 0.75% triton X-100, 5 μM phallacidin (Sigma-Aldrich, St Louis,
MO, USA), 2 mM Na3VO4, 10 mM NaF, 1× protease inhibitor (complete, EDTA-free, Sigma-Aldrich).
After tissue homogenization in EDTA or EGTA buffers, the suspension was incubated on ice for 30 min
and then centrifuged for 30 min at a temperature of 4 ◦C at 14,000× g. The supernatant was transferred
to a new tube, the protein was quantified, and the lysate was aliquoted and stored at −80 ◦C. After
Douncer homogenization of tissue in PHEM, the suspension was incubated for 2 min at 37 ◦C and
centrifuged for 5 min at a temperature of 4 ◦C at 14,000× g. The pellet was re-suspended in PHEM
buffer and, after a novel centrifugation, both supernatants containing soluble proteins were pooled.
For affinity precipitation, 600 pmoles of GST–CX26 or GST were bound to 200 μL of 50%
GST™Bind Resin sepharose beads (Novagen) and incubated at RT for 30 min under agitation.
After three washes with PBS and protease inhibitor (Pefabloc, Roche Applied Science), lysates were
added to the beads and the samples were maintained under rocking at 4 ◦C for 16 h. The samples were
washed in a lysis buffer without triton-X-100, centrifuged and submitted to SDS-PAGE, and followed
by Coomassie blue staining, according to standard procedures.
4.6. Mass Spectrometry Analyses
Gel bands identified after Coomassie blue staining were compared between the two lanes of
SDS-polyacrylamide in which precipitates from GST–CX26 or GST-only had been electrophoresed side
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by side. Lanes with apparently similar total protein loading had specific gel bands visually compared.
Bands with discrepant intensities between the two lanes were excised from the whole gel, which led to a
total of 11 gel band pairs. The in-gel digest and mass spectrometry experiments were performed by the
Proteomics platform of the Research Center at the Quebec University Hospital Center (CHUQ, Laval
University, QC, Canada). Protein from the excised gel bands were digested with trypsin on a MassPrep
liquid handling robot (Waters, Milford, CT, USA), according to the manufacturer’s specifications and
to the protocol of Shevchenko et al. [71] with the modifications suggested by Havlis et al. [72]. Proteins
were reduced with 10 mM DTT and alkylated with 55 mM iodoacetamide. Trypsin digestion was
performed using 126 nM of modified porcine trypsin (Sequencing grade, Promega, Madison, WI, USA)
at 58 ◦C for 1 h. Digestion products were extracted using 1% formic acid, 2% acetonitrile followed by
1% formic acid, and 50% acetonitrile. The recovered extracts were pooled, vacuum centrifuge-dried,
and then suspended into 7 μL of 0.1% formic acid and 2 μL were analyzed by mass spectrometry.
The resulting peptides were separated by online reversed-phase (RP) nanoscale capillary
liquid chromatography (nanoLC) and analyzed by electrospray mass spectrometry (ES MS/MS).
The experiments were performed with a Thermo Surveyor MS pump connected to a LTQ linear ion
trap mass spectrometer (Thermo Fisher, San Jose, CA, USA) equipped with a nano-electrospray ion
source (Thermo Fisher). Peptide separation took place on a self-packed PicoFrit column (New Objective,
Woburn, MA, USA) packed with a C18 Jupiter HPLC column (5-μm particle size, 300-Å pore size;
Phenomenex, Torrance, CA, USA). Peptides were eluted with a linear gradient of 2–50% acetonitrile,
0.1% formic acid in 30 min at 200 nL/min (obtained by flow-splitting). Mass spectra were acquired
using a data-dependent acquisition mode using Xcalibur software (Version 2.0, Thermo Fisher
Scientific). Each full scan mass spectrum (400 to 2000 m/z) was followed by collision-induced
dissociation of the seven most intense ions. The dynamic exclusion (30-s duration) function was
enabled and the relative collisional fragmentation energy was set to 35%.
All MS/MS samples were analyzed using Mascot (Version 2.3.0; Matrix Science, London, UK).
The Mascot was set up to search the Uniref100 mouse database (release of June 2010; 80,419 entries)
when assuming the digestion by trypsin. Mascot was searched with a fragment ion mass tolerance of
0.50 Da and a parent ion tolerance of 2.0 Da. Iodoacetamide derivative of cysteine was specified as a
fixed modification and oxidation of methionine was specified as a variable modification. Two missed
cleavages were allowed.
Scaffold (Version 3.6.2; Proteome Software Inc., Portland, OR, USA) was used to validate MS/MS
based peptide and protein identifications. Protein identifications were accepted if they could be
established at greater than 95% probability and contained at least two identified peptides, which is
specified by the Peptide Prophet algorithm [73]. Proteins that contained similar peptides and could
not be differentiated based on the MS/MS analysis alone were grouped to satisfy the principles
of parsimony.
4.7. NCBI Protein Reference Sequence Accession Numbers
Initial protein identification was completed according to Uniprot (http://www.uniprot.org/)
accession numbers. Corresponding NCBI mouse protein RefSeq accession numbers were as
follows: ASS1 (argininosuccinate synthase, NP_031520.1), CGN (cingulin, NP_001032800.2), DAAM1
(disheveled-associated activator of morphogenesis, NP_766052.2), FLNB (filamin-B, NP_001074896.1),
GAPDH (glyceraldehyde-3-phosphate dehydrogenase, NP_001276675.1), Homer2 (homer protein
homolog 2 isoform 1: NP_036113.1), JUP (junction plakoglobin, NP_034723.1), MAP7 (ensconsin,
NP_032661.2), MAPRE2 (microtubule-associated protein RP/EB family member 2, NP_694698.3),
PTK2B (protein tyrosine kinase 2β, NP_001155838), RAI14 (ankycorbin, NP_001159880.1), TJP1 (tight
junction protein, NP_033412.2), and VCL (vinculin, NP_033528.3). RefSeq accession numbers
for human and mouse CX protein paralogues employed in multiple sequence alignments were:
connexin 26 (hCX26 NP_003995.2, mCX26 NP_032151.1), connexin 30 (hCX30 NP_001103689.1,
mCX30 NP_001258592.1), connexin 30.3 (hCX30.3 NP_694944.1, mCX30.3 NP_032153.1), connexin
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31 CX31 (hCX31 NP_001005752.1, mCX31 NP_001153484.1), connexin 32 (hCX32 NP_000157.1,
mCX32 NP_032150.2), connexin 37 (hCX37 NP_002051.2, mCX37 NP_032146.1), connexin 40 (hCX40
NP_859054.1, mCX40 NP_001258557.1), connexin 43 (hCX43 NP_000156.1, mCX43NP_034418.1),
connexin 46 (hCX46 NP_068773.2, mCX46, NP_001258552.1), and connexin 50 (hCX50 NP_005258.2,
mCX50 NP_032149.1).
4.8. In Silico Analyses
Computational analyses of nucleic acids and proteins were performed at the following web sites,
according to their recommendations: EMBL-EBI [74], ExPASy Proteomics server [75], Hereditary
Hearing Loss Homepage [76], Kyte Doolittle Hydropathy [77], Mouse Genome Informatics [64],
NCBI [62], PSORT [78], The Connexin-Deafness Homepage [79], SWISSPROT [80], STRING [22],
BioGRID [81], and WebGestalt [82].
The Connexin family (pfam00029) comprises 215 members (updating of August, 2016, https:
//www.ncbi.nlm.nih.gov/Structure/cdd/cddsrv.cgi?uid=pfam00029). RefSeq accession numbers
from protein full-length sequences of five human and five mouse paralogues from each CX group
A or B were retrieved and used in multiple sequence alignments at Clustal Omega [83]. The last
transmembrane domain of each CX was identified at pfam00029. Alignment of the following 42 amino
acids as available was manually finalized and basic residues were highlighted.
4.9. Yeast Two-Hybrid Assay
The sequence-verified bait or prey constructs were used in self-activation testing by individually
transforming the strain NMY51 (MATa his3Δ200 trp1-901 leu2-3,112 ade2 LYS2::(lexAop)4-HIS3
ura3::(lexAop)8-lacZ ade2::(lexAop)8-ADE2 GAL4) using standard procedures. For the yeast
two-hybrid interaction test, bait and prey were employed in co-transformation of the yeast strain
NMY51. Interaction was verified by testing for His and Ade activation. Lastly, both bait and prey
plasmids were used to co-transform yeast Y2HGold. In the case of bait-prey interaction, the reporter
genes (HIS3 and ADE2) were activated and yeast was able to grow on SD–Leu− Trp–His− medium
and activate the β-galactosidase expression in the X-gal assay (Creative BioLabs, Shirley, NY, USA).
4.10. Immunoprecipitation and Western Blotting
Whole livers from P2–P3 mice were lysed in EGTA buffer as described above or in RIPA buffer
[50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 50 mM NaF, 5 mM Na3VO4, 2 mM EGTA, 1% NP-40, 0.1% SDS,
0.5% sodium deoxycholate, 1X protease inhibitor (cOmplete, EDTA-free, Sigma-Aldrich)]. The protein
quantity was estimated using a Bradford reagent at 595-nm absorbance. For immunoprecipitation,
lysates were precleared in a 1:1 mixture of protein-A and protein-G conjugated to sepharose beads
(GE Healthcare) and 1:50 volume of normal mouse serum. Nearly 500 μg of precleared lysates were
submitted to incubation with 2 μg of anti-CGN specific antibodies or normal mouse serum for 16
h at 4 ◦C under rocking. The antibody-lysate mix was then transferred to a microtube containing
a 1:1 mixture of protein-A plus protein-G beads (GE Healthcare). Further agitation was at 4 ◦C
for two hours. Beads were pelleted at 8000× g for three minutes at 4 ◦C, washed twice in 50 mM
Tris-HCl, pH 7.4, 150 mM NaCl, 50 mM NaF, 5 mM Na3VO4, and suspended in sample buffer (2%
SDS, 100 mM dithiothreitol, 10% glycerol). Western blotting was performed by submitting samples to
electrophoresis (6% or 14% SDS-PAGE) and electro-transferring proteins to a 45-μm nitrocellulose filter
(BioRad, Hercules, CA, USA) for 16 h at 25 Volts. Transfer efficiency was observed after 1.5% Ponceau
S staining. Proteins were blocked for one hour in 1% casein (Novagen) and was followed by 10 min in
3% hydrogen peroxide. Blots were incubated with primary antibody followed by secondary antibody
for 1 h each at room temperature. Antibody dilutions were in 2% immunoglobulin-free bovine serum
albumin (BSA, Jackson ImmunoResearch Laboratories) in TBS-T (20 mM Tris pH 7.6, 135 mM NaCl,
0.05% Tween-20). All washes were in TBS-T. The filter was incubated in ECL™ Plus (GE Healthcare)
and exposed to Amersham Hyperfilm™ ECL film (GE Healthcare).
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4.11. Indirect Immunofluorescence
Isolated P60 mouse livers were post-fixed in 4% paraformaldehyde for 6 h at 4 ◦C and then
incubated in increasing concentrations of sucrose up to 30% sucrose for 48 h at 4 ◦C. After inclusion
immersion in Jung Tissue Freezing Medium (Leica Biosystems, Buffalo Grove, IL, USA) for two
hours, the tissue was frozen and cryo-sectioned in 12-μm histological sections. Isolated cochleae were
punctured in the apex for perfusion of 4% paraformaldehyde and was followed by fixation in 4%
paraformaldehyde at 4 ◦C for 16 h. The tissues were then immersed in decalcification solution (10%
EDTA and 1% paraformaldehyde) at 4 ◦C for four days. After washing in PBS, all cochleae were
immersed in 10% sucrose solution until the tissue sunk and then all cochleae were incubated in 20%
sucrose solution at 4 ◦C for 20 h. Lastly, the cochleae were immersed in Jung Tissue Freezing Medium
(Leica Biosystems) for two hours. The tissue was frozen and cryo-sectioned in 12-μm histological
sections (Leica CM-1850, Leica Biosystems).
The histological slides were incubated in acetone at −20 ◦C for ten minutes and permeabilized
in 0.3% triton-X-100 for 20 min, which was followed by 20 min in 0.1 M glycine. Blocking was
performed in 5% normal donkey serum in PBS, supplemented with 1× donkey anti-mouse Fab’
(Jackson ImmunoResearch Laboratories). Primary antibody incubation was for 16 h and secondary
antibody incubation followed for three hours. All washes were in PBS and antibody dilutions were
in 5% normal donkey serum and 0.1% triton-X-100. After the final wash, slides were mounted in
DAPI-containing mounting medium (Invitrogen) and sealed after a coverslip was placed. Images
were captured in a LSM 880 confocal microscope (Carl Zeiss) after a background fluorescence intensity
subtraction from a negative control section (omission of primary antibody) obtained in the same
experiment. Pseudo colors and zooming-in were obtained by the ZEN software (Version 2.5, Zeiss
Efficient Navigation, Oberkochen, Germany).
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Abstract: Gap junction channels and hemichannels formed by concatenated connexins were analyzed.
Monomeric (hCx26, hCx46), homodimeric (hCx46-hCx46, hCx26-hCx26), and heterodimeric
(hCx26-hCx46, hCx46-hCx26) constructs, coupled to GFP, were expressed in HeLa cells. Confocal
microscopy showed that the tandems formed gap junction plaques with a reduced plaque area
compared to monomeric hCx26 or hCx46. Dye transfer experiments showed that concatenation allows
metabolic transfer. Expressed in Xenopus oocytes, the inside-out patch-clamp configuration showed
single channels with a conductance of about 46 pS and 39 pS for hemichannels composed of hCx46 and
hCx26 monomers, respectively, when chloride was replaced by gluconate on both membrane sides.
The conductance was reduced for hCx46-hCx46 and hCx26-hCx26 homodimers, probably due to the
concatenation. Heteromerized hemichannels, depending on the connexin-order, were characterized
by substates at 26 pS and 16 pS for hCx46-hCx26 and 31 pS and 20 pS for hCx26-hCx46. Because
of the linker between the connexins, the properties of the formed hemichannels and gap junction
channels (e.g., single channel conductance) may not represent the properties of hetero-oligomerized
channels. However, should the removal of the linker be successful, this method could be used to
analyze the electrical and metabolic selectivity of such channels and the physiological consequences
for a tissue.
Keywords: oligomerization; concatenated connexins; gap junction; channel stoichiometry; heteromeric
connexons; human connexin46; human connexin26; inside-out patch-clamp configuration; dualwhole-cell
patch-clamp; dye transfer
1. Introduction
Gap junction channels (GJC) are formed between adjacent cells by docking of two hemichannels.
The hemichannels are formed by oligomerization of connexins (Cx). Connexins are membrane proteins
encoded by a gene family which in the human genome comprises 21 members [1]. In many tissues,
different connexins are concurrently expressed and the formation of heteromeric connexons and
heterotypic gap junction channels has been postulated. It is assumed that by forming heteromeric
connexons and heterotypic gap junction channels, the cells in a tissue could achieve a rectification of
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gap junctions as it is observed in tissue [2,3]. Using expression systems such as the Xenopus oocytes, the
formation of heterotypic gap junction channels could be unequivocally demonstrated by coupling two
oocytes expressing two different connexins [4]. With such experiments, it was possible to specify which
connexins were able to form heterotypic gap junction channels with each other. In combination with
molecular biology and protein modeling, it was possible to classify the connexins into two different
groups depending on some residues found in the second extracellular loop (EL2). One group is
represented by Cx26 and named K-N group with the sequence φ(K/R)CXXXPCPNXVDCΩψS and a
second group is represented by Cx43 called H group with the sequence φXCXXXPCPHXVDCΩψS.
In the sequences, φ represents a hydrophobic residue, X is any residue, Ω an aromatic residue, and
ψ indicates a residue with a large aliphatic side chain [5–10]. Within a group the connexins formed
compatible connexons. An asparagine residue in position 168 of Cx26 or in a homologous position in
other connexins belonging to the K-N group was shown to form hydrogen bonds and was therefore
essential for the docking between hemichannels of this group [11–13]. The analysis of hCx26, for which
a crystal structure was generated, revealed that each asparagine residue at position 176 (N176) in a
hemichannel formed three hydrogen bonds with a lysine residue at position 168 (K168), a threonine
residue at position 177 (T177), and an aspartic acid residue at position 179 (D179) in the E2 domain of
the counterpart hCx26 in the hemichannel of the adjacent cell [6–9,11,14–18]. For hCx32 and hCx46,
homologous N residues to N176 were described [12,13,19,20]. For hCx32, the central N residue was
N175, which interacted with K167, T176, and D178. For hCx46, the N188 formed corresponding
hydrogen bonds with R180, T189, and D191. The importance of N176 and K168 for the docking
interaction was recently demonstrated by Karademir et al. (2016) [21]. The authors showed that by
adapting the homologous residues, heterotypic docking between Cx26 and Cx40 connexons could
be achieved.
With respect to oligomerization in connexons, the first transmembrane domain (TM1) and the
transition between the cytoplasmic loop (CL) and the third transmembrane domain (TM3) were
identified as the critical regions [10,22,23]. Analyzing Cx26 mutants, the sequence V37-A40 (VVAA)
of the wild type Cx26 was identified as an important motive for Cx26 oligomerization. However, as
stated in Jara et al. (2012), the motive did not determine hetero-oligomerization of connexins [10,22,23].
Concerning the hetero-oligomerization of different connexin types within a connexon, the compatibility
between connexins was mostly related to the amino acid residues in the region of the transition
between the cytoplasmic loop (CL) and the third transmembrane domain (TM3) [10]. According to the
sequence of these regions, the connexins were classified into the R-type connexins, which contain a
conserved arginine or lysine motif in this region, and the W-type connexins with a di-tryptophan motif.
In compliance to this classification, only connexins belonging to the same type can hetero-oligomerize.
However, even if the motif in this region is important for the oligomerization, it was proposed that
indirect mechanisms associated with the motif were necessary to achieve the discrimination between
connexins that do not belong to the same type. Cx43 proteins, for example, are maintained asmonomers
in the endoplasmic reticulum (ER) by the chaperone protein ERp29, which is associated with the second
extracellular loop, thereby avoiding oligomerization. After the transport to the trans-Golgi network,
the Cx43 proteins are separated from ERp29 for oligomerization [24]. Therefore, it was suggested that
the sequence did not per se hinder the oligomerization between connexins belonging to different types.
The sequence was rather an element involved in recruiting quality control proteins like ERp29 that in
turn regulated the oligomerization.
Concatenation of subunits of the GABA, Ach, and P2×7 ionotropic receptors has been used to
analyse the architecture of these membrane channels [25–28]. In these studies, it was shown that
concatenated proteins were completely inserted in the cell membrane. In the present report, we
concatenated hCx26 and hCx46 (Figure 1). Cx26 and Cx46 are concurrently expressed in trachea and
alveolar epithelium type 1 and 2 cells [29,30]. With respect to the docking they belong to the K-N group.
Therefore, they form hemichannels that can dock to each other. But with respect to the oligomerization
behavior, Cx26 belongs to the W-type while Cx46 belongs to the R-type so that they are not supposed
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to oligomerize [10]. The analysis of the formed gap junction channels with imaging methods and
functional assays, as well as electrophysiological characterization, showed that the concatenated
proteins were able to form functional hemichannels and gap junction channels. Although aspects
of the channels e.g., single channel conductance might be affected by concatenation, aspects such as
docking of hetero-oligomerized connexins in variable and clearly determined stoichiometry could be
analyzed using concatenation of connexins. For an accurate analysis of the biophysical properties of
the concatenated channels, it would be desirable to cleave the linkers of the concatenated connexins in
a connexon to reintroduce the full C- and N-terminal flexibility (and thus the natural functionality),































































Figure 1. Structural organization of connexins and gap junctions. A gap junction channel is composed of
two hemichannels or connexons, which consist of six connexins. Connexins have four transmembrane
domains (TM), two extracellular loops (EL), one cytoplasmatic loop (CL), as well an intracellularly
localized N- and C-terminus. Homomeric connexons and homotypic gap junction channels are formed
by a single connexin isoform. In the postulated heteromeric connexons and heterotypic gap junction
channels, different connexin isoforms are expected. The lower right pictogram shows the constructed
concatemeric connexins as heterodimeric tandem.
2. Results
2.1. Gap Junction Plaques Formed by Concatenated Variants of hCx26 and hCx46
Molecular cloning was used to generate concatenated hCx26-hCx26-GFP (green fluorescent
protein), hCx46-hCx46-GFP, hCx26-hCx46-GFP, and hCx46-hCx26-GFP. In order to concatenate two
neighboring connexins, a 19-amino acid long linker was inserted into the sequence. The linker, which
was used between the connexin and the GFP tag, was 23 amino acids long (Table 1).
Table 1. The amino acid linkers (one-letter code) between the two concatenated connexins and between
the connexin and the GFP tag. The GFP tag was always located at the C-terminus.
Linker Amino Acid Sequence
Cx-Cx GGNLQSTVPR ATTLYTKVV
Cx-GFP GGNLQSTVPR AHPAFLYKVV RSR
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The concatenated constructs, as well as hCx26-GFP and hCx46-GFP, were expressed in HeLa cells
to analyze their capacity to form gap junction plaques. Confocal laser scanning microscopy showed
that the GFP labeled constructs formed gap junction plaques between neighboring cells (Figure 2A
and Figure S1 in the Supplemental Materials). Compared to the expressed monomeric hCx26-GFP or
hCx46-GFP, the dimeric connexins formed gap junction plaques with a reduced surface, suggesting
a possible reduction of the protein synthesis for both heterodimeric and homodimeric tandems
(Figure 2B). Moreover, western blotting of the hCx46 monomer and hCx46-hCx46 homodimer seems to
corroborate the suggestion (Figure 2C). When quantifying the protein amount of the hCx46 monomer
and the hCx46-hCx46 homodimer using an anti-Cx46 antibody, cells expressing the homodimer

































































































Figure 2. Expression of the GFP-labeled monomeric and concatemeric connexins in HeLa cells.
(A) Representative micrographs of cell pairs expressing GFP-labeled hCx46, hCx26, hCx46-hCx46,
hCx26-hCx26, hCx46-hCx26, and hCx26-hCx46 are shown. The cells were imaged 24 h after transfection
using a confocal laser scanning microscope. The nuclei (blue) were stained with Hoechst 33342. Gap
junction plaques are indicated by arrows. Gap junction plaques were found in HeLa cells expressing
hCx46, hCx26, and the four different tandems. In cells expressing the tandems, a trend to accumulate
the proteins in intracellular organelles was observed. (B) Quantification of the gap junction plaque area
formed by the monomers and the four different tandems in HeLa cells. The plaque area was calculated
using the particle analyzer of ImageJ and normalized to the number of transfected cell pairs. At least
three transfections were performed per construct. The results are given as average plaque area per
cell pair [μm2]. Error bars represent the SEM. The data were evaluated by a one-way ANOVA and
a post-hoc Tukey test (** p ≤ 0.01, *** p ≤ 0.001) in comparison to hCx46 and hCx26 (### p ≤ 0.001).
(C) Quantification of the relative protein amount in HeLa cells expressing the monomeric hCx46-GFP
or the homodimeric hCx46-hCx46-GFP. An anti-Cx46 antibody was used for the western blotting.
For the quantification, four independent replicates were analyzed by using the gel analyzer tool of the
FiJi software [32]. The data was normalized to the intensity of the hCx46 monomer.
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To test the physiological functionality of the built gap junction channels, dye transfer experiments
with the monomeric and the tandem connexins in all variations were performed in HeLa and N2A
cells (Figure 3). HeLa cells, transfected with either a GFP-labelled monomeric connexin or a homo-
or heterodimeric tandem, showed a degree of Lucifer Yellow dye coupling of about 45%, while
mock-transfected HeLa cells showed a significantly reduced degree of dye coupling (11%). When
using AMCA (7-amino-4-methyl-3-coumarinylacetic acid) as tracer dye in Neuro2A (N2A) cells,
expressing the untagged homo- or heterodimeric tandems or the monomeric variants together with
soluble GFP (IRES-GFP plasmids), a dye transfer rate between 32% and 46% could be observed, while
N2A cells expressing only the soluble GFP showed a significantly reduced dye coupling ability of
about 5%. Interestingly, the concatenation did not alter the formation of the functionally coupled gap
junction channels.
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Figure 3. Analyzing the gap junction functionality by dye transfer experiments. A whole-cell
patch-clamp configuration with a pipette solution containing 1 mg/mL Lucifer yellow was established
on a HeLa cell pair expressing GFP-labelled monomeric hCx26 or hCx46 or one of the concatemeric
variants. Mock transfected cells were used as control. The first row of the micrographs shows the phase
contrast images of example experiments. In the second row, the GFP fluorescence signal before a dye
transfer experiment is shown. The third and fourth rows show the fluorescence signal of the tracer dye
5 min and 10 min after establishment of the whole cell configuration. For the sake of clarity, the image
in the fourth row was taken after removal of the dye filled capillary. Likewise, the experiments were
performed with N2A cells. The cells were transfected with IRES-GFP constructs resulting in the
expression of untagged constructs in the membrane and GFP in the cytosol. As control, cells expressing
only GFP were used. The experiments were performed with a pipette solution containing 1 mg/mL
AMCA, which could easily be distinguished from GFP under the fluorescence microscope. The cells
were considered as coupled if the fluorescence intensity, which was measured in the unpatched cell
of a cell pair after 10 min, was at least twice as bright as the background, which was measured at the
beginning of the experiment. The probability of coupling (bar diagrams) was estimated as ratio of
the sum of coupled cell pairs per the sum of tested pairs. The results are given as average. Error bars
represent the SEM. The data were evaluated by a one-way ANOVA and post-hoc Tukey test (* p ≤ 0.05,
** p ≤ 0.01, *** p ≤ 0.01) in comparison to the control cells.
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2.2. Single Channel Activity of Connexons
Cx46 is known to form gap junction hemichannels when expressed in Xenopus oocytes [33–35].
Therefore, Xenopus oocytes were used as expression system to measure the single channel activity of
connexons formed by the single connexins, as well as the variant tandems. In inside-out patch-clamp
experiments, we found that the open probability p of channels composed of the monomeric connexins,
as well as the homodimers and heterodimers, was increased by suppression of Ca2+ on both side of the
channels (Figure 4). Moreover, we observed that all configurations were sensitive to the gap junction
channel inhibitor carbenoxolone (CBX). With respect to CBX, the Cx26 connexons were less sensitive to the
agent than the hCx46 connexons (Figure 4). The insensitivity to CBX was even more pronounced for the
hCx26-hCx26 homodimer, while the hCx46-hCx46 heterodimeric hemichannels were almost completely
closed by CBX (Figure 4B). For the hemichannels formed by the heterodimers in either configuration,
the sensitivity to CBXwasmore similar to that observed for hCx46 connexons than that of hCx26 connexons.
For a further characterization of the hemichannels, we analyzed the single channel conductance in absence
of Ca2+ (Figure 4A). Under our experimental conditions, in which the chloride was completely replaced by
gluconate at both sides of the membrane, a single channel conductance of 46.0 ± 5.3 pS and 39.2 ± 5.5 pS
was found for hCx46 and hCx26, respectively. For the homodimers, the conductance was reduced to
24.5 ± 3.3 pS and 32.9 ± 6.3 pS for hCx46-hCx46 and hCx26-hCx26, respectively. For the heterodimers,
two substates were observed for each configuration: A conductance of 15.7 ± 0.8 pS and 26.2 ± 1.8 pS
for hCx46-hCx26, and 20.1 ± 1.4 pS and 31.2 ± 3.0 pS for the hCx26-hCx46 configuration (Table 2,
Figure 4). The changes in conductance are also related to the concatenation. A successful cleavage of the
linker to separate the connexins in the channels is needed in order to evaluate changes solely caused by




















































































Figure 4. Analysis of single hemichannels formed by concatemeric connexins. The stripped membrane
of Xenopus oocytes, which were injected with hCx46, hCx26, or the four different concatemeric
constructs, as well as the AS38 (control) cRNA 24 h before, was used to perform the inside-out
patch-clamp recordings. The measurements were performed in presence of Cs+ and in absence of Cl−
on both sides of the membrane. (A) Examples of single channel currents elicited by a depolarizing
voltage pulse of +50 mV in absence of Ca2+ in the bath solution are shown. (B) The open probability
of all measured single channels was analyzed. The error bars represent the SEM. The data were
evaluated by a one-way ANOVA followed by a Tukey test (* p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, ns: not
significant). The statistical comparison showed that the presence of Ca2+ or carbenoxolone (CBX) in
the bath solution significantly reduced the open probability of all tested variants.
Table 2. Conductance states of the hemichannels expressed in Xenopus oocytes as measured in inside
out patch-clamp configuration. n gives the number of analyzed oocytes.
Injected cRNA Large Substates ± SEM Small Substates ± SEM
hCx46 (n = 5) 46.0 ± 5.3 pS
hCx26 (n = 5) 39.2 ± 5.5 pS
hCx46-hCx46 (n = 4) 24.5 ± 3.3 pS
hCx26-hCx26 (n = 7) 32.9 ± 6.3 pS
hCx46-hCx26 (n = 4) 26.2 ± 1.8 pS 15.7 ± 0.8 pS
hCx26-hCx46 (n = 5) 31.2 ± 3.0 pS 20.1 ± 1.4 pS
AS38 (n = 6) 0 pS
2.3. Dye Uptake through Hemichannels
Using ethidium bromide (Etd), we observed the dye uptake by HeLa cells expressing
hemichannels formed by the different variants in order to clarify how the constructed tandems
could affect the function of the channels. First, we found that the cells expressing the monomers
or the tandems in different variations did not differ from mock cells in their capacity to absorb
ethidium bromide as long as external Ca2+ was present (Figure 5). The dye uptake in presence of
external Ca2+ was therefore considered as background uptake. Specific hemichannel uptake of the
dye was initialized when the cells were superfused with a Ca2+-free external solution (Figure 5).
To determine a possible mechanical effect on the dye uptake, the cells were first superfused with a
2 mM Ca2+-containing solution. In cells expressing the homodimeric hCx26-hCx26, a tendency to
increase the rate of dye uptake during the perfusion with the Ca2+-containing solution was observed.
However, this mechanical sensitivity of the channel was not statistically significant when analyzed
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by a two-way ANOVA and a post-hoc Tukey test. For cells expressing the GFP control or the other
variants, the tendency to respond to a mechanical stimulus was not observed (Figure 5). For all
variants, the ethidium bromide uptake was accelerated by the superfusion of the cells with Ca2+-free
external solution compared to cells expressing the GFP control (Figure 5A,B and Figure S2: Table in
the Supplemental Materials). In the context of low external Ca2+, only the hCx26-hCx26 homodimer
showed an increased rate of dye uptake compared to the monomeric hCx26 and hCx46, as well as the
hCx46-hCx46 homodimer and both heterodimers (S2). These changes in the ethidium bromide dye
uptake rate seems to be an artifact due to the concatenation. For hCx46 however, the hCx46-hCx46
homodimer as well as the hCx46 monomer showed a comparable rate of dye uptake, and this uptake
rate of hCx46 was also measured for the heterodimers in either order. Additionally, dye uptake by
hemichannels in all variants except for the hCx26 monomer (and the GFP control cells) was significantly
reduced by the superfusion with a La3+-containing medium. When using a two-way ANOVA and
a post-hoc Tukey test for the comparison of the different variants, neither the perfusion with the
Ca2+-containing solution nor the perfusion with a Ca2+-free and La3+-containing solution showed a
significant difference to another variant or the GFP expressing control cells. Only the perfusion with
the Ca2+-free solution led to significant differences, as described above (S2).
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Figure 5. Dye uptake through hemichannels using ethidium bromide. HeLa cells were grown on
coverslips to a confluency of about 40–50% and transfected with IRES-GFP-plasmids. The GFP allowed
the identification of transfected cells by fluorescent microscopy. (A) Time course of dye uptake
experiments by cells expressing the different variants when perfused with bath solutions containing
2 mM Ca2+, no Ca2+, and no Ca2+ but 1 mM La3+. The fine lines show the SEM spread for all measured
points. The symbols indicate the average for data points measured every 1 min. The solid lines indicate
the part of the curves that was used to estimate the dye uptake rate. (B) Quantification of the dye
uptake rate (Etd AU/min) for all tested variants and the backbone control in absence or presence of
Ca2+ or La3+. The error bars represent the SEM. The data were evaluated by a one-way ANOVA and a
post-hoc Tukey test (* p ≤ 0.05, *** p ≤ 0.001, ns: not significant).
2.4. Activity of Single Gap Junction Channels
The activity of single gap junction channels was analyzed by dual whole-cell patch-clamp
experiments [36,37] applied on N2A cells expressing hCx26 and hCx46, as well as the different dimeric
variants. Compared to HeLa cells, which were used for the analysis of gap junction plaques, N2A cells
did not form a monolayer, which offered the advantage of an easy identification of unambiguous cell
pairs suitable for the dual whole-cell patch-clamp experiments. Moreover, probably due to their round
morphology, the cells formed small gap junction plaques with less gap junction channels allowing a
better observation of single gap junction channel activity (Figure 6).
Cells expressing the different variants were found to form gap junction channels with a total
macroscopic conductance of up to 1000 pS. In some of these cell pairs, it was possible to follow the
closing and opening of single gap junction channels at different transjunctional voltages, and to
estimate the conductance of the single gap junction channels in dependency of the expressed variant.
Although multiple simultaneously opened channels were recorded, it was possible to follow the
opening and closing of single gap junction channels (Figure 6).
Considering the clear opening and closing of the single channels, maximal conductance levels of
202 pS, 198 pS, 138 pS, 184 pS, 137 pS, and 371 pS were estimated for the Cx46 monomer, Cx46-Cx46
homodimer, Cx26 monomer, Cx26-Cx26 homodimer, Cx46-Cx26 heterodimer, and Cx26-Cx46
heterodimer, respectively. The mean of the large conductance ± SEM of these variants is given
in Table 3. Besides these large conductance levels, low subconductance states were observed (Figure 6
and Figure S3 in the Supplemental Materials). However, because of the rapid flickering, a clear
estimation of the numeric values was not possible.
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Figure 6. Recordings of dual whole-cell patch-clamp experiments. N2A cells were cultured and
transfected with the different IRES-GFP-plasmids. As control, cells expressing only soluble GFP in the
cytosol were used. Twenty-four hours post transfection, the dual whole-cell patch-clamp experiments
were performed. The resting membrane potential was set to −40 mV for both cells. One cell of a
cell pair was alternatingly stepped from −120 mV to +60 mV, while the junctional currents were
recorded in the other cell. The junctional currents (ΔI2) recorded during the 250 ms-long voltage
pulses at different transjunctional potentials are shown above the current responses. Magnification
of the Vj +70 mV traces of the hCx46 monomer, as well as of the hCx46-hCx46 homodimer, showed
several simultaneously open channels, with a large conductance of ~193 pS (13.5 pA step), and low
conductance of ~72 pS (5.05 pA step) and ~121 pS (8.49 pA step). Similar steps were observed for Cx46
by other authors [38–41]. The control cells showed only the background noise, which was below 2 pA
(grey band), indicating that the fluctuations of about 5 pA were conducting substates.
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Table 3. Large conductance states of the gap junction channels expressed in transfected N2A cell pairs.
n gives the number of analyzed cell pairs for each variant.
Expressed Variant Large Conductance ± SEM
hCx46 (n = 7) 175.5 ± 5.7 pS
hCx26 (n = 7) 182.8 ± 1.0 pS
hCx46-hCx46 (n = 14) 193.5 ± 2.4 pS
hCx26-hCx26 (n = 9) 125.1 ± 4.0 pS
hCx46-hCx26 (n = 18) 110.5 ± 8.5 pS
hCx26-hCx46 (n = 11) 281.2 ± 24.7 pS
GFP control (n = 8) 0 pS
3. Discussion
In cells, different connexin isoforms are concurrently expressed. The formation of heteromeric
connexons and heterotypic channels with a variable stoichiometry offers the cell a mode for fine
tuning the gap junction coupling, thereby producing a flux rectification and selectivity [3,4]. The goal
of the present report was to test whether concatenated connexins form heteromeric connexons and
heterotypic gap junction channels with clearly determined stoichiometry (Figure 1). This could be a
promising method to study the physiological consequences of the hetero-oligomerization of connexins
in hemichannels and gap junction channels.
By expressing GFP labeled hCx46 and hCx26 monomers, hCx46-hCx46 and hCx26-hCx26
homodimers, as well as hCx46-hCx26 and hCx26-hCx46 heterodimers in HeLa cells, we found that the
monomers as well as the homodimers and heterodimers were transported to the cell membrane and
were able to form gap junction plaques (Figure 2A). However, as shown for the hCx46 monomer and
the hCx46-hCx46 homodimer, the concatenation reduced the quantity of the produced protein. This
might contribute to the reduction of the gap junction plaque area formed by the tandems (Figure 2B).
The results suggest that concatenation might induce changes in the synthesis or the trafficking of
the proteins to the membrane. Furthermore, a tendency to retain the proteins in the ER and Golgi
apparatus was observed in cells expressing the hCx46-hCx46 tandem compared to cells expressing
the hCx46 monomer (Figure 2; cells expressing the hCx26 per se showed a higher intracellular signal,
which limited the possibility to compare trafficking of homomers and dimers). Although this trend
was not statistically significant, it could indicate a possible concatenation-related problem with protein
trafficking. Nevertheless, the different tandem proteins as well as the monomers formed functional
gap junction channels, as demonstrated by the dye transfer experiments (Figure 3). Consequently,
the concatenation of connexins might be helpful for the analysis of hetero-oligomerization of connexins
and, inter alia, opens the possibility to prospectively study metabolite selectivity, which could not
be predicted so far. Oligomerization, trafficking to the membrane, and the assembly to gap junction
plaques were not affected when GFP was coupled to the N-terminus. However, the fusion of
a fluorescent protein tag to the N-terminus of a connexin has been shown to block the channel
conductance of hemichannels and gap junction channels [42,43]. The mechanism responsible for
this is still a matter of speculation. The crystal structure of Cx26 led to the prediction that the
N-termini folded in the pore of the channel [11]. We can assume that the hydrophilic GFP subunits
coupled to the N-termini might stay in the cytosol. They might hinder the correct folding of the
N-terminus or form a lid on the cytosolic mouth of the channel. In case of the concatenated connexins,
the hydrophobic transmembrane domains of the two linked connexins led to the formation of a
protein with eight transmembrane domains. How the connexin C-terminus is structured is not
fully understood. However, experimental data showed that the C-terminus is highly flexible [44]
and interacts with cytoskeleton-associated proteins to structure the gap junction plaques in the
cell membrane, suggesting that the C-terminus does not form a barrel like GFP [45]. We therefore
assume that, by interacting with these associated proteins and in combination with the high flexibility,
the C-terminus of the first connexin of the concatemer could be close enough to the membrane to
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allow a correct structure formation of the linked N-terminus of the following connexin. However, the
NMR (nuclear magnetic resonance) data also showed disorders in the C-termini that can be affected by
binding to partners. Additionally, the NMR data showed the capability of dimerization in some parts
of the C-termini [44]. Consequently, it is possible that the concatenation, even if it is compatible with
the formation of hemichannels and gap junction channels, may affect the properties of the channels
e.g., single channel conductance. Therefore, concatenation offers the possibility to form hemichannels
with a determined stoichiometry and gap junction channels with manageable variabilities. However,
a tool for the removal of the linker between the connexins after formation of the hemichannels is still
needed to allow an exploitation of the potentialities of the method.
Considering the single channel conductance, the inside-out patch-clamp analysis of connexons
formed in the membrane of Xenopus oocytes showed conductance values of about 46 pS and 39 pS
for hCx46 and hCx26 monomers, respectively. In isolated lens fibers (Cx46) of rodents, a conductance
of about 240 pS was measured [46]. Similarly, for Cx46 hemichannels expressed in Xenopus oocytes,
HeLa, or N2A cells, main conductance levels of 250–300 pS could be identified [47–50]. For Cx26
expressed in Xenopus oocytes, HeLa, or N2A cells, a main conductance of 320 pS [51] and even a higher
conductance above 400 pS was found [52]. In our inside-out patch-clamp experiments, we could not
identify these large conductance values. However, the conductance values presented in this report
of about 39 pS and 46 pS for hemichannels composed of hCx26 and hCx46 monomers are similar
to measured subconductance states of these channels that were published by other authors [38–41].
For Cx26, Gaßmann et al. (2009) reported three conductance states with G1 = 34 ± 8 pS, G2 = 70 ± 8 pS,
and G3 = 165 ± 19 pS. G1 represents the vast majority of the detected events [39]. Moreover, the
conductance values were measured after the replacement of chloride by the less mobile gluconate
and acetate ions on both sides of the membrane. This allowed silencing the background currents
and thereby isolating specific currents that were only observed in patches from oocytes expressing
connexons (Figure 4). It is known that the replacement of chloride by less mobile ions leads to lower
conductance values [53,54]. We therefore assume that the measurement of hemichannels formed
by hCx46 and hCx26 monomers in our experimental conditions, where chloride was replaced by
gluconate and acetate ions, only allowed the recording of substates with a low conductance.
The conductance values measured for the hCx46-hCx46 (24.5 ± 3.3 pS) and hCx26-hCx26
(32.9 ± 6.3 pS) homodimers were slightly lower than the conductance values found for the
hemichannels formed by the respective monomers. Although the shown differences are comparably
slight, concatenation-related artifacts might need to be suppressed by successfully removing the linker
between the proteins within the hemichannels to reveal the properties of heteromerization-related
changes. However, by allowing the generation of channels with a defined stoichiometry, concatenation
could allow studying the aspects of heterodimerization of connexins. Correspondingly, we found that
heterodimerization of hCx26 and hCx46 introduced two new substates with ~16 pS and ~26 pS for
hCx46-hCx26, and ~20 pS and ~31 pS for hCx26-hCx46. The conductance of hemichannels formed
by hCx46-hCx46 or hCx26-hCx26 homodimers was clearly different to that of hemichannels formed
by hCx46-hCx26 or hCx26-hCx46 heterodimers, respectively. This result suggests that both parts of
the concatenated connexins participated in the hemichannels. Further non-published data showed
that concatenation of the hCx46 and the hCx46N188T mutant, which did not form gap junction
plaques [13], reduced the formation of gap junction plaques compared to the homodimer hCx46-hCx46,
suggesting that in concatenated form the hCx46N188T participated to formation of gap junction
channels. The observation that concatenated connexins are inserted in the membrane as whole is an
agreement with other experiments in which subunits of membrane proteins such as Ach, GABA, or
ATP ionotropic receptors channels were concatenated [25–28]. As for the changes in conductance
observed in the present report, the results indicate that the formation of heterodimeric hemichannels
would change the conductance and opening properties of the channels in comparison to the respective
homomeric hemichannels. A separation of the two connexins in a concatemer is desirable for the
analysis of the biophysical properties of the channel.
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Dual whole-cell patch-clamp experiments were performed to analyze the corresponding gap
junction channels. The hCx46 and hCx26 homomers formed gap junction channels with a maximal
conductance of ~200 pS for hCx46 and ~140 pS for hCx26. In other expression systems, similar
conductance values were found for the gap junction channels formed by these connexins [41,55]. Beside
these main conductance levels, other open substates and other residual substates with conductance
values of about 20 pS for Cx46 and 17 pS for hCx26 were observed, suggesting that the conductance
values (40 pS for hCx46 and 35 pS for hCx26) observed in the membrane of oocytes might represent
the residual substates of the hemichannels. The concatenation of hCx46 did not change the maximal
conductance of the channels (Figure 6). For hCx26, the concatenation resulted in channels with a
slightly increased maximal conductance of about 180 pS. Similar to the hemichannels, the analysis
of gap junction channels formed by the heterodimers revealed changes in the channel properties
compared to the homodimers. Therefore, these changes, such as the strong increase of the maximal
conductance, might be more related to heteromerization than to the concatenation. To confirm this
hypothesis, a cleavage of the linker between the connexins in a concatemer is necessary.
The comparison of the electrophysiological data obtained from hCx46-hCx26 and hCx26-hCx46
heterodimers showed some unexpected variability with respect to hemichannels and gap junction
channel activity, as well as to conductance states. The hCx26-hCx46 showed a higher activity as
hemichannels and as gap junction channels in comparison to homodimers. In the case of gap junction
channels, we found that channels formed by hCx26-hCx46 had a more elevated conductance (371 pS)
than the channels composed of hCx46-hCx26 (137 pS). It shows that the concatenation might affect
some properties of the channels, especially the electrical conductance, in a way that we cannot explain.
We presume that this might be related to the short C-terminus of Cx26, which might affect the
following N-terminus of Cx46. In their model, Maeda et al. (2009) suggested that the N-termini form
a voltage-sensitive funnel in the cytoplasmic mouth of the pore [11]. In our experiments with the
tandems, three N-termini were free while the other three termini were linked to the C-termini of
the preceding molecule. If the C-terminus of Cx46 is linked, the length of this terminus may allow
more flexibility to the linked N-terminus than if the C-terminus is given by Cx26, which is very short.
The observation that the homodimer hCx26-hCx26 formed hemichannels and gap junction channels
with more activity, as well as gap junction channels with higher conductance levels than those of
the Cx26 homomers, is compatible with this presumption. Additionally, the presumed model could
explain the difference in the trend of insensitivity to the inhibition by La3+. Using ethidium bromide,
Jara et al. (2012) already showed a degree of insensitivity of Cx26 hemichannels to La3+ [22]. This
insensitivity was transferred to the hemichannels formed by hCx46-hCx26 heteromers and did not
affect the hCx26-hCx46 heteromers (Figure 5). This trend might be related to the number of free
N-termini. Because the C-terminus of Cx46 in hCx46-hCx26 is long, the N-terminus of the following
hCx26 has more freedom to move. As result, we have three N-termini of hCx26, which are almost free
to interact with the completely free N-termini of hCx46. In hCx26-hCx46, three N-termini of hCx46
are linked to the short C-termini of hCx26, thereby limiting the interaction of these N-termini with
the free N-termini of hCx26. At that point, the concatenation limits the bearing of the information
shown in this report. However, it will be a valuable method if the cleavage of the linker is successful.
An increase of the conductance would be a good indication of a successful removal of the linker.
Using different methods, in this report we showed that concatenation could be a technique to
understand the consequences of formation of heteromeric gap junction hemichannels, as well as of
heterotypic gap junction channels built between cells. Concerning the oligomerization of connexins,
two critical motifs, which were not mutually exclusive, have been identified: The end of the first
transmembrane domain (TM1) and the transition between the cytoplasmic loop (CL) and the third
transmembrane domain (TM3) [10,22,23]. The motif in TM1 which was found to be critical for
the oligomerization of Cx26 was not important for hetero-oligomerization [10,22,23]. On the other
side, the amino acid dendrogram showed that the compatibility of different connexin isoforms to
hetero-oligomerize into a connexon was related to a motif situated at the transition region between CL
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and TM3 [10]. According to the sequence of these regions, the connexins were classified between the
R-type connexins, which contain a conserved arginine or lysine residue, and the W-type connexins
with a di-tryptophan motif. According to this classification, connexins belonging to different types do
not oligomerize.
In our experiments, we showed that Cx26 (W-type) and Cx46 (R-type), which are also different in
the TM1 region, could form heteromeric connexons with each other. Thereby, our results support the
assumption that the control of hetero-oligomerization is not regulate by the TM1 [10,22,23]. Moreover,
the residues R and W of the connexins in the transition between the cytoplasmic loop (CL) and the
third transmembrane domain (TM3) are indirect control and not an intrinsic property of the connexins
that regulate the hetero-oligomerization. Our results show the importance of indirect controls for
hetero-oligomerization above the sequences in the different parts of the connexins.
4. Materials and Methods
4.1. Molecular Cloning
In order to express various concatemers in HeLa cells, as well as in N2A cells and in Xenopus laevis
oocytes, the multisite gateway cloning system with three different destination plasmids was used.
For the transfection of the cell lines, the destination plasmids pEF-I-GFP GX, which has an IRES
element between the gateway cassette and the reporter GFP, and the psDEST47 were used. pEF-I-GFP
GX [56] was a gift from John Brigande (Addgene plasmid # 45443). psDEST47 was created by using a
“reverse” BP-cloning reaction with the expression clone pcDNA-DEST47-GFP-GFP and the pDONR221
linearized with EcoNI. pcDNA-DEST47-GFP-GFP [57] was a gift from Patrick Van Oostveldt (Addgene
plasmid # 36139). The psDEST47 was transformed into ccdB survival Escherichia coli BD3.1 cells and
selected on ampicillin- and chloramphenicol-containing LB-Agar plates. The purified psDEST47,
which is similar to the commercially available pcDNA™-DEST47 vector (#12281010, Thermo Fisher
Scientific, Waltham, MA, USA), was used to create a C-terminally GFP-labeled fusion protein via the
LR-cloning reaction.
The vector psGEMHE-GW was used for in vitro transcription to produce the cRNA for the
Xenopus oocytes. The vector was created by restriction enzyme cloning with XbaI and HindIII using
the pGEMHE [35] as backbone. As insert the gateway cassette was amplified with the attR1-ccdB-attR2
XbaI F and attR1-ccdB-attR2 HindIII R primers (see Table 4). Escherichia coli BD3.1 cells (invitrogen,
Carlsbad, CA, USA) were used to host the three different destination vectors.
Table 4. Primers used for restriction enzyme cloning to produce the destination vector psGEMHE-GW
and for the BP-cloning to generate the various Entry clones.
Primer 5’-3’ Sequence
attR1-ccdB-attR2 XbaI F CTTCATCTAGACACGCTCGAGATCACAAGTTTGTAC
attR1-ccdB-attR2 HindIII R CTTCGAAGCTTTTACATCTCGAGCACCACTTTGTACAAG
GW_BP-cloning hCx46 attB1 F GGGGACAAGTTTGTACAAAAAAGCAGGCTCCATGGGCGACTGGAGCTTTCTGG
GW_BP-cloning hCx46 attB2 R GGGGACCACTTTGTACAAGAAAGCTGGGTGGGCCCGCGGTACCGTCGAC
GW_BP-cl. hCx46 stop attB2 R GGGGACCACTTTGTACAAGAAAGCTGGGTTCTAGATGGCCAAGTCCTCCGGT
GW_BP-cloning hCx46 attB5r R GGGGACAACTTTTGTATACAAAGTTGTGGCCCGCGGTACCGTCG
GW_BP-cloning hCx46 attB5 F GGGGACAACTTTGTATACAAAAGTTGTAATGGGCGACTGGAGCTTTCTGG
GW_BP-cloning hCx26 attB1 F GGGGACAAGTTTGTACAAAAAAGCAGGCTTAATGGATTGGGGCACGCT
GW_BP-cloning hCx26 attB2 R GGGGACCACTTTGTACAAGAAAGCTGGGTTGGCCCGCGGTACCG
GW_BP-cl. hCx26 stop attB2 R GGGGACCACTTTGTACAAGAAAGCTGGGTTCTAAACTGGCTTTTTTGACTTCCCAGAAC
GW_BP-cloning hCx26 attB5r R GGGGACAACTTTTGTATACAAAGTTGTGGCCCGCGGTACCG
GW_BP-cloning hCx26 attB5 F GGGGACAACTTTGTATACAAAAGTTGTAATGGATTGGGGCACGCT
The various Entry vectors were built by amplifying hCx46 or hCx26 with the primers listed in
Table 4 with a proofreading DNA polymerase (Phusion, Thermo Fisher Scientific, Waltham, MA, USA)
followed by the BP-clonase reaction (Thermo Fisher Scientific, Waltham, MA, USA) with the donor
plasmids pDONR™221, pDONR™221 P1-P5r, and pDONR™221 P5-P2 (Thermo Fisher Scientific,
Waltham, MA, USA). For the psGEMHE-GW and the pEF-I-GFP GX plasmids, the stop attB2 R primers
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were used. Escherichia coli MachI (Thermo Fisher Scientific, Waltham, MA, USA) was used to host the
ten different Entry plasmids. The purified Entry and destination plasmids were used to perform the
multisite LR reaction (LR clonase II plus, Thermo Fisher Scientific, Waltham, MA, USA). Escherichia coli
MachI was used to host the 18 different expression clones (three different destination plasmids, each
with monomeric hCx46 and hCx26, homodimeric hCx46-hCx46 and hCx26-hCx26, as well as the
heterodimeric hCx46-hCx26 and hCx26-hCx46). The BP-clonase II and LR-clonase II plus reactions
were successfully performed in a total volume of only 2.5 μL. Restriction enzyme cloning and gateway
cloning were verified by sequencing (Seqlab, Göttingen, Germany).
4.2. Cell Culture
HeLa cells (DSMZ no.: ACC 57, Leibniz Institute DSMZ-German Collection of Microorganisms
and Cell Cultures, Braunschweig, Germany) were cultured in DMEM/Ham’s F12 (1:1) medium
(FG 4815, Biochrom, Berlin, Germany) supplemented with 10% fetal calf serum (Biochrom), 1 mg/mL
penicillin, and 0.1 mg/mL streptomycin (Biochrom). The mouse neuroblastoma cells N2A, abbreviation
for Neuro-2A (DSMZ no.: ACC 148), were cultured in DMEM with 1.0 g/L D-glucose (FG 0415,
Biochrom) supplemented with 10% heat inactivated fetal calf serum (Biochrom), 1x non-essential
amino acids (Biochrom), 1 mg/mL penicillin, and 0.1 mg/mL streptomycin (Biochrom). The cells were
cultured in a humidified atmosphere with 5% CO2 at 37 ◦C. Every two to three days the cell culture
medium was renewed.
4.3. Quantification of the Expression Behavior
To analyze the formation of gap junctions, 7 × 104 HeLa cells were seeded on collagen I-coated
glass coverslips with a diameter of 1 cm into a well of a 24-well plate 24 h before transfection to reach
a confluency of about 70–80%. Prior to the transfection, the cell culture medium was replaced by
500 μL OptiMEM I medium (Thermo Fisher Scientific). The transfection was performed as described
before [13,58,59]. In brief, per well, 500 ng purified plasmid and 1.5 μL FuGene HD (Promega,
Mannheim, Germany) transfection reagent were incubated in 25 μL OptiMEM I medium for 15 min
at room temperature and added to the prepared cells. After 4–6 h, the transfection medium was
exchanged to the penicillin- and streptomycin-free culture medium.
For the quantification of the expression behavior, the psDEST47 constructs were used, which
resulted in C-terminally labeled GFP fusion proteins. The cells were fixed 24 h after transfection with
3.7% formaldehyde. The nuclei of the cells were stained with Hoechst 33342 (1 μg/mL; Sigma Aldrich,
St. Louis, MO, USA) and the cell membranes were stained with Alexa 555-conjungated Wheat Germ
Agglutinin (5 μg/mL; Molecular Probes, Eugene, OR, USA) to improve the visibility of the cell-cell
contact regions. The cells were imaged with a confocal Nikon Eclipse TE2000-E C1 laser scanning
microscope (Nikon, Düsseldorf, Germany) as described previously [13,58,59]. For each variant, at least
five different transfections and coverslips were evaluated. Four images were taken of different regions
of each coverslip.
To analyze the plaque area per cell pair, the micrographs were evaluated using FiJi [32].
The resulting plaque areas per cell pair of the concatemers were evaluated in comparison to the
monomeric hCx46 and hCx26 by using a one-way ANOVA, followed by a Tukey test and are given as
mean ± SEM.
4.4. Western Blot
HeLa cells were grown to about 80% confluence in a 100 mm diameter cell culture plate. The cells
were transfected with the psDEST47 hCx46 or the psDEST47 hCx46-hCx46 plasmids and cultivated for
further 24 h. For the transfection of a 100 mm diameter cell culture plate, 5 μg plasmid DNA and 15 μL
FuGene HD were used (details are described above in Section 4.3). For the protein isolation, the cells
were washed twice with ice-cold PBS and were removed from the culture plate with a cell scraper
in presence of 1 mL ice-cold PBS. After a centrifugation step at 750× g for 3 min at 4 ◦C, the pellet
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was resuspended in 50 μL RIPA buffer containing 25 mM Tris HCl pH 7.6, 150 mM NaCl, 1% nonidet
P-40, 1% sodium desoxycholate, 0.1% SDS, freshly added 0.5% protease inhibitor cocktail (Roche,
Waiblingen, Germany), 10 mM NaF, 1 mM PMSF, and 1 mM Na3VO4. After an incubation for 15 min
on ice, a centrifugation at 14,000× g for 15 min at 4 ◦C was used to separate the protein solution from
the cell debris. A Bradford assay (Sigma Aldrich) was used to determine the protein concentration of
the supernatant using BSA as standard. 1 × Laemmli buffer (13 mM Tris HCl, 10 mM DTT, 2% glycerol,
0.4% SDS, 0.002% Bromphenol Blue, pH 6.8) was added to the protein solution and incubated for 10 min
at 70 ◦C. Next, 100 μg protein per lane were separated in a 5% SDS-polyacrylamide stacking gel and a
10% separation gel. The proteins were transferred to a nitrocellulose membrane using a semi-dry blot
(transfer buffer: 25 mM Tris HCL, pH 8.3, 192 mM glycine, 0.1% SDS, and 20% methanol). Afterwards,
the membrane was blocked with 5% non-fat dry milk powder in PBS containing 0.1% Tween 20
(PBS-T) for 2 h at room temperature. Anti-Cx46 antibody (sc-365394, Santa Cruz Biotechnology,
Heidelberg, Germany) was diluted 1:1000 in PBS-T and applied to the membranes for an overnight
incubation at 4 ◦C. After washing, the secondary anti-mouse antibody (A9044, Sigma Aldrich) was
diluted 1:100,000 and applied for 1 h at room temperature. For the detection, the SuperSignal West
chemiluminescent reagent (Thermo Fisher Scientific) was used. The blot was imaged with a CCD
camera system (Intas Science Imaging, Göttingen, Germany). For the quantification, four independent
replicates were analyzed by using the gel analyzer tool of the FiJi software [32]. Data are displayed
normalized to the intensity of the hCx46 monomer.
4.5. Dye Transfer Experiments
To test the functionality of the formed gap junction channels, dye transfer experiments with Lucifer
Yellow and 7-amino-4-methyl-3-coumarinylacetic acid (AMCA) in HeLa and N2A cells were performed,
respectively. HeLa cells were prepared and transfected with the different psDEST47-plasmids as
described above in Section 4.3. As control, mock transfected HeLa cells were used. For the dye
transfer experiments with the N2A cells, the cells were transfected with the different pEF-I-GFP
GX-plasmids. For control experiments, the N2A cells were transfected with the empty destination
vector pEF-I-GFP GX. Coverslips with transfected cells were transferred to a perfusion chamber
containing 400 μL of a bath medium consisting of (in mM) 140 NaCl, 5 KCl, 10 HEPES, 10 glucose, 1
MgCl2, and 2 CaCl2 at pH 7.4 and osmolarity (π) of 295 mosmol/L. The chamber was mounted on
an inverted fluorescence microscope (Ti-E, Nikon GmbH, Duesseldorf, Germany) equipped with a
Polychrome V monochromator (T.I.L.L. Photonics GmbH, Planegg, Germany), a CCD Orca-Flash 4.0
camera (Hamamatsu Photonics Deutschland GmbH, Herrsching, Germany), and the NIS-Elements AR
4.4 software (Nikon GmbH).
For the dye transfer experiments, a whole-cell patch-clamp configuration was established on one
cell of a transfected cell pair using an EPC 10 USB double patch-clamp amplifier (HEKA Elektronik
Dr. Schulze GmbH, Lambrecht/Pfalz, Germany) coupled to the PatchMaster 2.9 software (HEKA
Elektronik Dr. Schulze GmbH). For the pipette filling solution used for the HeLa cells, 1 mg/mL
Lucifer Yellow (LY) lithium salt (Biotium, Hayward, CA, USA) was diluted in a pipette medium
containing (in mM) 145 K gluconate, 5 KCl, 10 HEPES, 2.5 MgATP, 5 glucose, 0.5 Na2ATP, 1 EGTA, and
0.2 CaCl2 at pH 7.4 and π 295 mosmol/L. For the experiments with N2A cells, the LY was replaced
by 1 mg/mL AMCA (Sigma Aldrich, St. Louis, MO, USA). The Polychrome V was used to excite the
GFP-labeled connexin variants at 488 nm, LY at 410 nm, and AMCA at 350 nm. For each dye transfer
experiment, micrographs of the GFP and LY or AMCA fluorescence were taken before the whole-cell
configuration was established, during the experiment, and after 10 min with prior removal of the LY
or AMCA containing pipette. For each variant, the degree of dye coupling was estimated as the ratio
of the number of coupled pairs to the total number of tested pairs expressing the particular variant.
The results are given as mean values ± SEM. The significance of the difference was evaluated by a
one-way ANOVA and a post-hoc Tukey test (*** for p ≤ 0.001, ** for p ≤ 0.01, and * for p ≤ 0.05).
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4.6. Expression in Xenopus Oocytes
For the in vitro transcription, the mMESSAGE mMACHINE® T7 (Thermo Fisher Scientific,
Waltham, MA, USA) and the PeaI-linearized (Thermo Fisher Scientific) psGEMHE vectors were
used to generate the artificial cRNA. The cRNA was purified by a phenol/chloroform extraction and
an isopropanol precipitation.
Xenopus laevis oocytes were harvested from an anaesthetized female frog. After mechanical
disruption of the tissue, the oocytes were separated by an incubation (1 h at room temperature) in
190–240 U/mL collagenase type II (Worthington, Berlin, Germany) containing oocyte control medium
composed of (in mM) 88 NaCl, 1 KCl, 10 Tris-HCl, and 0.82 MgCl2 (pH 7.4 and π 180 mosmol/L).
During the tissue digestion with collagenase, the tissue was shaken at 100 rpm. After the collagenase
treatment, the oocytes were washed with oocyte control medium supplemented with 2 mM CaCl2.
The oocytes were stored and used for injection for up to three days after isolation.
Stage V and stage VI oocytes were injected with 23 nL of an aqueous solution containing 1 μg/μL
connexin mRNA and 400 ng/μL antisense to the endogenous Cx38 (AS38) using the Nanoliter Injector
(World Precision Instruments, Berlin, Germany). The antisense DNA (AS38) with the sequence
C*T*GACTGCTCGTCTGTCCACAC*A*G* (* indicates phosphorothioate modification) was purchased
from Microsynth AG (Balgach, Switzerland). The injected oocytes were incubated at 16 ◦C in
the Ca2+-containing oocyte medium and used for the measurement of single channels 18 to 48 h
post injection.
4.7. Single Channel Recordings of the Connexons
For the recording of the single channels, the vitelline membrane of a connexin expressing oocyte
was mechanically removed. The oocyte was incubated for at least 3 min in a stripping solution
containing (in mM) 88 NaCl, 1 KCl, 10 Tris-HCl, 0.82 MgCl2, 2 CaCl2, and 200 D-mannitol (pH 7.4
and π 444 mosmol/L) to release the vitelline membrane from the oocyte membrane. The released
vitelline membrane was removed using two Dumont no. 5 forceps (Manufactures D’Outils Dumont SA,
Montignez, Switzerland) under a LEICA GZ4 binocular (Leica Mikrossysteme Vertrieb GmbH, Wetzlar,
Germany). The stripped oocyte was transferred into a perfusion chamber containing 400 μL of a control
bath solution consisting of (in mM) 88 Na gluconate, 1 K gluconate, 10 Tris, 2 Ca acetate, 0.82 Mg
acetate, and 20 Cs acetate (pH 7.4 and π 220 mosmol/L) and mounted on an inverted fluorescence
microscope described in Section 4.4. The patch-clamp experiments were performed using an EPC 10
USB double patch-clamp amplifier (HEKA Elektronik Dr. Schulze GmbH). The data were recorded
with filter 1 (Bessel) at 10 kHz and filter 2 (I_Bessel) at 1 kHz. The patch pipettes were made from
PG150T-7.5 glass capillaries (Clark Electromedical Instruments, Pangbourne, UK). Filled with the
pipette filling solution composed of (in mM) 80 Na gluconate, 20 Cs acetate, and 10 HEPES (pH 7.4
and π 220 mosmol/L) the pipettes had an electrical resistance of about 5 MΩ. The reference electrode
was filled with K gluconate solution to avoid problems related to Ag/AgCl junction [60].
Three minutes after the formation of a gigaseal, the inside-out patch-clamp configuration [61] was
established. To measure the single channels, test voltage pulses between −70 mV and 60 mV were
applied for 20 s in 10 mV steps. Between the voltage pulses, the membrane was clamped at 0 mV for
30 s. Thereafter, the bath solution was changed to a Ca2+-free solution composed of (in mM) 88 Na
gluconate, 1 K gluconate, 10 Tris, 0.82 Mg acetate, and 20 Cs acetate at pH 7.4 and π 220 mosmol/L.
After application of the test voltages, the membrane was perfused with a Ca2+-free solution supplied
with 100 μM carbenoxolone (CBX) and the voltage pulses were applied again.
For the data analysis and the example curves, the data were filtered with the digital filter at
100 Hz in the FitMaster 2.90 software (HEKA Elektronik Dr. Schulze GmbH). The software was also
used to generate an amplitude histogram, which was fitted using a multi Gaussian fit to calculate the
single channel conductance states. The single channel open probability was estimated by using the
single channel event detection tool of the FitMaster software. Simultaneous opening of channels was
rarely observed. If it was observed this event was excluded in the calculation of the single channel
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open probability. For the calculation, only the +40 mV to +60 mV traces, which had an unambiguous
signal-to-noise ratio, were used. A measurement time of at least 4 min for at least four injected oocytes
of each variant was used for the estimation. For the comparison of the data a one-way ANOVA
followed by a Tukey test was used.
4.8. Dye Uptake through Hemichannels
The hemichannel activity was analyzed by measuring the ethidium bromide (Etd) uptake slightly
modified from Schalper et al. (2008) [62]. A day before the experiment, subconfluent HeLa cells
grown on collagen I-coated coverslips were transfected with the pEF-I-GFP variants. For the control
group experiments, the empty destination plasmid pEF-I-GFP GX was used to transfect the cells.
A coverslip with transfected cells was placed in a perfusion chamber with a chamber volume of
approximately 400 μL mounted on an inverse Nikon Ti-E fluorescence microscope, as described in
Section 4.4. The ISMATEC REGIO ICC peristaltic pump (Cole-Parmer GmbH, Wertheim, Germany)
controlled by the software ISMATEC® Pump Control (Cole-Parmer GmbH) allowed the constant
exchange of the medium with a flow rate of 1 mL/min. Prior to the experiment, the GFP fluorescence
of the transfected cells was used to define the regions of interest (ROIs) for the Etd uptake measurement.
During the first 10 min of a 30-min long dye uptake experiment, the cells in the chamber were
perfused with a prewarmed (37 ◦C) bath solution composed of (in mM) 121 NaCl, 5.4 KCl, 25 HEPES,
0.8 MgCl2, 5.5 glucose, 6 NaHCO3, 2 CaCl2, and 5 μM ethidium bromide (pH 7.4 and π 296 mosmol/L).
After 10 min, the medium was exchanged for additional 10 min to a Ca2+- and Mg2+-free solution,
which was consisting of (in mM) 121 NaCl, 5.4 KCl, 25 HEPES, 5.5 glucose, 6 NaHCO3, and 5 μM
ethidium bromide (pH 7.4 and π 295 mosmol/L). In the last 10 min of a dye uptake experiment, 1 mM
La3+ was added to the Ca2+/Mg2+-free solution. Before starting an experiment, regions of interest
(ROIs) were selected in a fluorescent micrograph of the cells taken by an Orca flash 4.0 CCD camera
(Hamamatsu Photonics Germany, Herrsching am Ammersee, Germany). During the entire experiment,
fluorescent images were taken every 15 s with an exposure time of 700 ms. The images were used to
assess the changes of the fluorescence intensity of the ROIs during an experiment. For the recording
of the images and the measurement of fluorescence intensity in the ROIs, the NIS-Elements AR 4.4
software (Nikon GmbH) was used. The dye uptake rate (Etd AU/min) was calculated with OriginPro
2017 (OriginLab Corporation, Northampton, MA, USA) fromminute 4–9, 14–19, and 24–29, respectively
(stationary rate). The results are given as mean values ± SEM. The significance of the difference was
evaluated by a one-way ANOVA and a post-hoc Tukey test (*** for p ≤ 0.001, ** for p ≤ 0.01, and
* for p ≤ 0.05). For the comparison between the groups a two-way ANOVA followed by a Tukey test
was used.
4.9. Dual Whole-Cell Patch-Clamp Experiments
For the dual whole-cell patch-clamp experiments, approximately 3 × 104 N2A cells were cultured
on a collagen I-coated coverslip in a well of a 24-well plate and were transfected as described above with
the pEF-I-GFP variants, which resulted in the separate expression of the different connexin-variants
and GFP as the reporter. For the control experiments, the N2A cells were transfected with the empty
pEF-I-GFP destination vector. The coverslip with the transfected cells was transferred into a perfusion
chamber filled with 400 μL of a bath solution composed of (in mM) 121 NaCl, 5.4 KCl, 25 HEPES,
0.8 MgCl2, 5.5 glucose, 6 NaHCO3, 2 CaCl2 and mounted on the inverse Nikon Ti-E fluorescence
microscope described in Section 4.4. The patch pipettes were filled with a pipette solution containing
(in mM) 125 K gluconate, 15 CsCl, 0.2 CaCl2, 2.5 MgCl2, 1 MgATP, 5 glucose, 0.5 EGTA, 4 Na2ATP,
0.1 cAMP, and 10 HEPES (pH 7.4 and π 295 mosmol/L). The patch pipettes were made from 40A502
glass capillaries (Kimble Chase Life Science and Research Products, Rockwood, TN, USA). Filled with
the pipette solution the pipettes had an electrical resistance of 2–5 MΩ.
Dual whole-cell patch-clamp experiments were performed with the EPC 10 USB double
patch-clamp amplifier described in Section 4.6. After establishing a whole-cell configuration on
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both cells of a cell pair, both cells were clamped at −40 mV. For the measurements, one cell of the cell
pair (cell 1) was alternatingly stepped from −120 mV to +60 mV (V1) for a duration of 250 ms, while
the junctional currents were recorded in the other cell (cell 2), which was maintained at −40 mV (V2).
The transjunctional voltage gradient (Vj = V2 − V1) was calculated.
5. Conclusions
In summary, the present paper shows that the expression of concatenated connexins leads to
a reduced plaque area between cells. However, concatenation of connexins was compatible with
trafficking of the hemichannels to the membrane and the formation of functional gap junction
hemichannels in the cell membrane and gap junction channels between cells. It could be used to
generate hemichannels and gap junction channels with a determined stoichiometry. Because of the
linker between the connexins, the properties of the formed hemichannels and gap junction channels
(e.g., single channel conductance) do not represent the properties of hetero-oligomerized channels.
However, should the removal of the linker be successful, this method could be used to analyze the
electrical and metabolic selectivity of such channels and the physiological consequences for a tissue.
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Abstract: Connexins (Cxs) and pannexins (Panxs) are ubiquitous membrane channel forming proteins
that are critically involved in many aspects of vascular physiology and pathology. The permeation
of ions and small metabolites through Panx channels, Cx hemichannels and gap junction channels
confers a crucial role to these proteins in intercellular communication and in maintaining tissue
homeostasis. This review provides an overview of current knowledge with respect to the
pathophysiological role of these channels in large arteries, the microcirculation, veins, the lymphatic
system and platelet function. The essential nature of these membrane proteins in vascular homeostasis
is further emphasized by the pathologies that are linked to mutations and polymorphisms in Cx and
Panx genes.
Keywords: connexin; pannexin; vascular physiology; vascular disease
1. Introduction
The cardiovascular system consists of the heart pumping the blood to a closed circuit of
interconnected blood vessels, allowing for the indispensable and constant supply of O2 and vital
nutriments to every single tissue throughout the human body. The blood contains components, such as
coagulation factors and platelets, that are essential to keeping the cardiovascular circuit closed after
injury by initiating haemostasis and formation of a platelet clot. The systemic circulation is composed
of large elastic arteries such as the aorta, serving as high-pressure conduits for the blood to smaller
muscular arteries and arterioles. Arterioles are resistance arteries controlling blood flow into capillary
beds by their high vasodilatory and vasoconstrictive ability. In the capillary beds, the actual exchange
of O2/CO2, nutriments, catabolites and fluid takes place between the blood and the surrounding tissue.
The blood returns to the heart via venules and veins. The excess of interstitial fluid returns to the
systemic circulation via lymphatics, a blind-ended system of lymphatic capillaries converging into
collecting vessels and ending into the subclavian vein. Much evidence has demonstrated an important
role for connexins (Cxs) and pannexins (Panxs) in many aspects of vascular physiology and pathology.
In this review, we will focus on the role of Cxs and Panxs in the physiology/pathophysiology of the
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vascular system by systematically following the route of the blood from the left ventricle through the
systemic circulation to its way back to heart.
2. Connexins and Pannexins
Cxs belong to a family of 20 to 21 proteins expressed in a wide variety of tissues [1]. Cx genes
are separated into 5 subfamilies according to their sequence homologies [2]; most cardiovascular
Cxs are found in the α subfamily (for instance, GJA4). The names of Cx proteins, on the other hand,
are determined by their specific molecular weight in kDa (for instance, Cx37). Structurally, Cxs
comprise 4 α-helical transmembrane domains (TM1–TM4) and two extracellular loops (EL1 and EL2)
that are highly conserved among the family members. Substantial differences among Cxs, both in
length and composition, are found in their cytoplasmic amino-terminal (NT) and carboxy-terminal (CT)
parts, as well as in the intracellular loop (IL). The synthesis of Cxs occurs in the endoplasmic reticulum
(ER) and their oligomerization in the ER/Golgi or trans-Golgi network results in the formation of
hexameric connexons [3,4]. Then, connexons traffic to the plasma membrane along microtubules.
When the membranes of two cells are in close proximity, connexons from one cell can connect with
their corresponding parts in the adjacent cell and form gap junction channels, which permit the
intercellular exchange of ions and metabolites up to ~1kDa. Connexons are normally closed but may
operate in a pathological setting as hemi-channels enabling the transmembrane passage of Ca2+, ATP
and glutamate for instance [5,6]. Cx channel gating is critically regulated by a number of factors,
including voltage, pH and Ca2+ and post-translational modifications such as phosphorylation [7,8].
The “connexin interactome”, a protein interacting network with the Cx as central mediator [9,10],
has been receiving increasing attention in recent years. For example, an interacting complex of gap
junctions, desmosomes and Na+ channels that cooperate to control excitability, electrical coupling
and intercellular adhesion are found at intercalated discs in the heart [10,11]. The plethora of diseases
associated with mutations and polymorphisms in Cx genes further underlines the crucial role of these
structures in tissue homeostasis [12,13].
Pannexins (Panxs) represent a smaller family of 3 transmembrane proteins (Panx1–3) exhibiting a
topology similar to Cxs but no sequence homology [14–16]. The glycosylation of specific sites in the ELs
of Panx1 and Panx3 likely prevents docking of pannexons [16,17], and it is presumed that pannexons act
as single-membrane channels connecting the cytoplasm to the extracellular compartment. While Panx2
and Panx3 display a rather limited expression pattern (central nervous system for Panx2 and bones
and skin for Panx3), Panx1 shows a ubiquitous expression pattern and is thus also found in vascular
cells. Similar to Cx hemi-channels, pannexons serve as “communication channels” by permitting
the release of small molecules, for instance purines, that subsequently signal via the activation of
membrane receptors in neighboring cells or even at distance. An important difference between Cx
hemi-channels and Panx channels is that the latter can be opened at physiological membrane potential
and physiological intra- and extra-cellular Ca2+ concentration by, for example, mechanical stretching
or upon activation of purinergic P2 receptors [18]. Instead, Cx hemi-channels only become functional
under conditions associated with pathologies such as hypoxia or ischemia and will be only briefly
mentioned in this review. Excellent reviews on Cx hemi-channels have been published recently [19–21].
3. Role of Cxs and Panxs in Distributing Arteries and Atherosclerosis
The largest distributing arteries are elastic vessels, which allows them to receive a high and
pulsatile pressure from the heart. The elastic properties of the distributing vessels further contribute to
the so-calledWindkessel effect, transforming a pulsatile flow at the entry into a constant flow at the level
of the capillaries. The aorta, pulmonary trunk, carotids as well as the illiac and subclavian arteries are all
examples of elastic arteries. As elastic arteries have such fundamental roles in the vascular physiology,
any pathology affecting the function of these vessels by inducing a stiffening of their wall may exert
dramatic effects on the supply of vital substances to organs. Atherosclerosis principally impacts
on large and medium-sized arteries and is the leading cause of mortality worldwide [22]. In brief,
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the pathogenesis of the disease initiates with the dysfunction of endothelial cells (ECs) characterized by
expression of adhesion molecules, secretion of chemokines and increased permeability to low-density
lipoproteins (LDL), which will subsequently accumulate in the sub-endothelial space where they get
oxidized. The expression of adhesion molecules and secretion of chemokines promotes the entry of
inflammatory cells such as monocytes, T lymphocytes and neutrophils into the intimal layer [23,24].
After their infiltration into the intima, monocytes differentiate into macrophages that will take up
oxidized LDL and convert it into foam cells. Inflammatory cells secrete metalloproteinases that degrade
extracellular matrix (ECM), as well as growth factors stimulating the proliferation and migration of
smooth muscle cells (SMCs) from the media to the intima. Intimal SMCs synthesize collagen and their
further proliferation eventually leads to the formation of a fibrous cap segregating the necrotic core of
the plaque from the luminal blood flow. Plaques with a large necrotic core, a thin fibrous cap, many
inflammatory cells and a few SMCs display increased propensity to rupture [25]. Upon rupture, ECM
and tissue factor (TF) present in atherosclerotic lesions are exposed to the bloodstream, which initiates
a coagulation cascade leading to the formation of a fibrin monolayer covering the site of injury [26,27].
In parallel, the activation of platelet receptors by atherosclerotic plaque components leads to platelet
activation and aggregation [26]. If platelet aggregation is not limited, thrombus formation may
compromise the arterial lumen and provoke acute ischemic events such as myocardial infarction
and stroke.
3.1. Connexins and Atherosclerotic Disease
The integrity of the endothelial barrier is warranted by various types of endothelial junctions
including gap junctions [28]. During atherosclerotic plaque development pro-inflammatory molecules
induce a progressive deterioration of EC junctions and an increase in endothelial permeability.
ECs are, for instance, responsive to TNF-α, which induces the expression of adhesion molecules
and inflammatory cell recruitment. It has been shown that treating ECs with TNF-α dampens the
expression of some Cxs, in particular Cx37 and Cx40, suggesting a possible implication of Cxs in
the pathogenesis of atherosclerosis [29]. Moreover, increased vascular permeability is associated
with an elevation of Cx43 expression in ECs [30,31]. The first support for the hypothesis that
Cxs may participate in the development of atherosclerotic disease came from studies analyzing
atherosclerotic lesions at different disease stages in specimen of human, rabbit or mouse origin.
In summary, it has been reported that Cx43 was generally absent in ECs of large arteries, but
that its expression was induced in ECs at the shoulder region of advanced atherosclerotic plaques,
a localization known to experience disturbed blood flow [32]. In addition, high expression of Cx43
was found in macrophages and SMCs of young atherosclerotic lesions, whereas Cx43 levels were
downregulated in SMCs of more mature plaques [32–35]. Interestingly, the oxidized phospholipid
derivative 1-palmitoyl-2-(5′-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) has been shown to
decrease Cx43 expression in SMCs, to increase its phosphorylation, and to promote SMC proliferation
in vitro and in vivo in a mouse model of atherosclerosis [36]. Besides Cx43, the expression patterns of
Cx37 and Cx40 have also been reported to be affected during atherosclerotic plaque development in
humans and in mice [32]. In fact, Cx40 and Cx37 expression was abolished in ECs covering advanced
plaques, while Cx37 levels were increased in foam cells. Moreover, long-term hypercholesterolemia in
mice decreased Cx37 and Cx40 expression in aortic ECs. Interestingly, this outcome could be reversed
exclusively for Cx37 by a one-week treatment with simvastatin, a well-known lipid-lowering drug [37].
Collectively, these observations support the idea that Cxs expression or their post-translational
modifications might evolve in atherosclerotic plaques over time, depending on the stage of the
lesion, and might thus affect atherogenesis.
As the ubiquitous deletion of Cx43 is lethal [38], Cx43+/− mice were crossed with atherosclerosis-
prone LDL receptor-deficient (Ldlr−/−) mice and fed a high cholesterol diet to study atheroma
formation. These initial studies revealed that Cx43 has an overall atherogenic effect, and that reducing
Cx43 might be beneficial by both reducing plaque burden as well as stabilizing the lesions [39].
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However, the exact scenario by which global reduction in Cx43 ultimately led to this dual benefit was
unclear, due to Cx43 expression in multiple atheroma-associated cell types. To examine specifically the
role of Cx43 in immune cells, Ldlr−/− mice were lethally irradiated and reconstituted with Cx43+/+,
Cx43+/− or Cx43−/− hematopoietic fetal liver cells [40]. Intriguingly, the progression of atherosclerosis
was lower in Cx43+/− chimeras compared with Cx43+/+ and Cx43−/− chimeras, and their plaques
contained fewer neutrophils. It turned out that chemoattraction of neutrophils, which did not
themselves express Cx43, was reduced in response to supernatant secreted by Cx43+/− macrophages
in comparison with the ones of Cx43+/+ and Cx43−/− macrophages. Thus, titration of Cx43 levels in
macrophages might regulate their chemoattractant secretion, leading to reduced atherosclerosis [40].
Recently, it was shown that an upregulation of Cx43 expression in human umbilical vein ECs resulted
in enhanced adhesion of monocytes via a mechanism involving increased vascular adhesion molecule-1
and intercellular cell adhesion-1. This effect was independent from the expression of other Cxs such as
Cx37 and Cx40 [41].
In contrast to Cx43, Cx40 expression has been reported to protect against atherosclerosis in mice
by synchronizing endothelial anti-inflammatory signaling thus inhibiting leukocyte recruitment to the
atherosclerotic lesion [42]. Interestingly, Cx40 expression is induced in arterial ECs by high laminar
shear stress, as normally observed in straight parts of arteries that are known to be protected from
atherosclerosis [43]. IκBα, a member of a protein complex inhibiting the activation of the transcription
factor NFκB, was recently identified as a binding partner of Cx40-CT. The Cx40 interactome may be
relevant for the control of NFκB activation in arterial ECs and the initiation of atherogenesis [43].
Deletion of Cx37 has been shown to promote atheroma formation in atherosclerosis-susceptible
apolipoprotein E-deficient (Apoe−/−) mice. Mechanistically it was demonstrated that Cx37
hemichannels in monocytes modulate the initial steps of atherosclerosis by regulating their adhesion
to the endothelium [44]. Even in later stages of the disease, Cx37 deletion also reduced the stability of
shear stress-induced atherosclerotic plaques in Apoe−/− mice by increasing macrophage contents of
the advanced plaques [45]. As the Cx37-CT directly binds to the NO reductase domain of endothelial
nitric oxide synthase (eNOS), thereby influencing the function of the enzyme and NO production [46],
absence of Cx37 in ECs covering the atherosclerotic lesion may contribute to the dysfunctionality of
these cells. Of note, a single nucleotide polymorphism (SNP) in the human Cx37 gene (Cx37 1019C > T)
associates with an increased risk for coronary artery disease, myocardial infarction, stroke and
peripheral artery disease [47]. This Cx37 1019C > T SNP results in a non-conservative Proline-to-Serine
substitution in the CT of Cx37 and appeared to have a significant impact on channel function
under basal and phosphorylating conditions [46,48,49]. When transfected in HeLa or N2A cells,
both polymorphic channels are efficiently transported to the cell membrane, where they may function
both as hemi-channels and gap junction channels; however, the unitary conductance of channels
formed by the Cx37-Proline isoform appeared 1.5 times larger than the one of the Cx37-Serine
isoform [48]. In addition, it was shown that monocytic cells expressing Cx37-319P were markedly
less adhesive than cells expressing Cx37-319S. Thus, Cx37-319P polymorphic hemi-channels may
function as a protective genetic variant by specifically retarding recruitment of monocytes to human
atherosclerotic lesions [44].
Altogether, these studies revealed important and diverse contribution of vascular Cxs to the
development of atherosclerosis. Before we may consider Cx-based strategies to fight atherosclerotic
disease, more work is needed to discriminate between beneficial effects of reduction of (hemi-) channel
function and alteration of the Cx interactome of atherogenesis. Moreover, it remains to be determined
whether Cxs may play a role in the mechanisms linked to plaque regression.
3.2. Panx1 and Atherosclerosis
As illustrated in the next section, Panx1 channels are important regulators of microvascular
physiology, mostly through their capacity to release purines, including ATP [50,51]. As such, Panx1
channels were long time hypothesized to play a role in atherosclerotic disease via their effects on
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inflammasome activation, neutrophil and macrophage chemotaxis and the activation of T cells [52].
Moreover, Panx1 may play a potential role in macrophage apoptosis and clearance from atherosclerotic
lesions by allowing the release of “find me” signals from apoptotic cells to recruit phagocytes at the
initial steps of programmed cell death [53–55]. Examination of Panx1 expression in carotid arteries
of Apoe−/− mice fed with high cholesterol diet revealed Panx1 in the arterial endothelium and in
macrophage foam cells in atherosclerotic lesions, and confirmed its absence in the SMCs of the media
in these large arteries [56] (Figure 1).
Figure 1. Panx1 expression in healthy and atherosclerotic arteries. (A) Panx1 (in green) is expressed in
ECs (arrowheads) separating the arterial wall from the lumen (L) of a healthy mouse carotid artery;
(B) Panx1 is found in lipid-laden macrophages (asterisks) present in atherosclerotic lesions. Of note,
Panx1 is absent from the SMC-rich media of non-diseased and diseased conduit arteries. Nuclei are
stained with DAPI (in blue) and elastic laminae are counterstained with Evans Blue (in red). Scale bar
represents 25 μm.
To investigate the potential contribution of Panx1 in endothelial and monocytic cells to
atherosclerosis, mice with a conditional deletion of Panx1 were generated. Atherosclerotic lesion
development in response to high cholesterol diet was enhanced in Tie2-CreTgPanx1fl/flApoe−/− mice
as compared to Panx1fl/flApoe−/− controls, pointing to a protective role for Panx1 in endothelial
and/or monocytic cells in atherosclerosis. Unexpectedly, atherogenesis was not altered in mice with
ubiquitous Panx1 deletion (Panx1−/−Apoe−/−), but these mice displayed reduced body weight, serum
cholesterol, triglycerides (TG) and free fatty acids (FFA), suggesting altered lipid metabolism in mice
with ubiquitous Panx1 deletion. As it is well known that lowering serum cholesterol and TG levels
protects against atherosclerosis in human, it was hypothesized that the lack of effect of ubiquitous
deletion of Panx1 on the extent of atherosclerosis may be explained by simultaneous opposite effects
of Panx1 on lipid metabolism and inflammation. Interestingly, Panx1-deficient mice show impaired
lymphatic function [56] (see Section 6). Future work should unravel the mechanisms linking the
lymphatic system, lipid metabolism and atherosclerosis.
4. Coordination of Microvascular Function by Gap Junctions
The arterial vascular system supplies oxygen and nutrients to peripheral tissues by controlling
blood flow distribution through a complex network of vessels. Resistance to blood flow is a function of
the lumen diameter of the vessels, which depends on the degree of vascular smooth muscle constriction
(i.e., vasomotor tone). Most of the total resistance to blood flow resides on feed arteries and arterioles;
therefore, coordination of changes in vasomotor tone in the microvascular network plays a central role
in the regulation of blood flow distribution and arterial blood pressure [57].
The endothelium plays an essential role in the tonic control of vascular function by Ca2+-dependent
production of vasodilator signals such as NO and prostaglandins [58–60]. Although NO is the
primary endothelium-dependent vasodilator signal in large conduit vessels, the inhibition of NO
or prostaglandin production only attenuates the relaxation initiated by endothelium-dependent
vasodilators in small resistance arteries [61–63]. The NO- and prostaglandin-independent response
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observed in these arteries is associated with the hyperpolarization of SMCs, which leads to smooth
muscle relaxation by the consequent reduction in the open probability of L-type voltage-dependent Ca2+
channels. In addition to the complex EC signaling, the appropriate control of blood flow distribution
also relies on the direct cell-to-cell communication via gap junctions, which has emerged as a key
pathway to coordinate vascular wall function in resistance arteries by radial (among ECs and SMCs)
and longitudinal (along the vessel length) conduction of vasomotor signals [62,64–66].
4.1. Radial Conduction in the Vascular Wall
Gap junctions play a central role in the intercellular communication of the endothelium-generated
vasodilator signals. Although ECs and SMCs are physically separated by the internal elastic lamina
in resistance arteries, these cells can make contact through cell projections that penetrate the
internal elastic lamina and reach the other cell type at discrete points known as myoendothelial
junctions [62,67–69]. These points of contact appear to constitute highly specialized subcellular
signaling microdomains and gap junctions located at myoendothelial junctions (i.e., myoendothelial
gap junctions) provide a critical pathway for fine regulation of vasomotor responses through the radial
transmission of current, Ca2+ and small signaling molecules such as IP3 [68,70–72].
The endothelium-mediated NO-independent smooth muscle hyperpolarization was first
attributed to a diffusible factor released by ECs and, in consequence, this vasodilator signal was termed
endothelium-derived hyperpolarizing factor (EDHF) [61,62]. Several EDHF candidates have been
proposed, such as K+ ions [73], epoxyeicosatrienoic acids [74,75], hydrogen peroxide [76], and C-type
natriuretic peptide [77,78]. Although the NO-independent smooth muscle hyperpolarization is likely
to rely on a combination of these signals, depending on the vascular territory [61,79] and experimental
preparation used in the study [80], this vasodilator component is however typically paralleled
by the hyperpolarization of ECs [61,62]. In addition, it has been consistently observed that the
endothelium-dependent smooth muscle hyperpolarization is sensitive to simultaneous inhibition
of Ca2+-activated K+ channels (KCa) of small (SKCa) and intermediate (IKCa) conductance [61,63,81].
In the vessel wall, these K+ channels are only expressed in ECs [81,82], which prompted the proposal
that a prominent component of the EDHF signaling is the simple direct electrotonic transmission from
ECs to SMCs via myoendothelial gap junctions of a hyperpolarizing current initiated by SKCa and
IKCa activation [61,81,83–85]. In which case, the release of a diffusible factor is not consistent with
this signaling mechanism, which led to replacing the term abbreviated as EDHF with the expression
endothelium-derived hyperpolarization (EDH) [86]. Consistent with this notion, the contribution of
the EDH-mediated responses and the expression of myoendothelial gap junctions increase as the vessel
size decreases [87,88] and the EDH-associated vasodilator signaling has been shown to be attenuated or
abolished by the Cx-mimetic peptides 37,40Gap26, 40Gap27 and 37,43Gap27 [89,90]. These peptides are
homologous to specific domains of EL1 (Gap26) or EL2 (Gap27) and were designed to block channels
formed by Cx37 or Cx40 in the case of 37,40Gap26, Cx40 in the case of 40Gap27, and Cx37 or Cx43 in
the case of 37,43Gap27. In addition to these findings, EC-selective loading with antibodies directed
against the carboxyl-terminal region of Cx40 [91] or deletion of Cx40 specifically in ECs also leads
to a reduction in the EDH pathway [80], which highlight the functional relevance of this Cx in the
endothelial cell signaling and in the control of vasomotor tone.
Interestingly, a pool of eNOS is also found at myoendothelial junctions [92], which provide a
subcellular location that is coherent, not only with the vasodilator function of the enzyme, but also
with the intercellular signaling pathway of NO. Although the biophysical properties of NO are
compatible with the assumption that it can diffuse freely across cell membranes, blockade of gap
junction communication in mesenteric resistance vessels with 18β-glycyrrhetinic acid was shown to
prevent the NO transfer from ECs to SMCs and the associated NO-dependent vasodilation observed
in response to acetylcholine (ACh) [93], suggesting that myoendothelial gap junctions provide a
directional pathway for effective NO signaling in the wall of small arteries. The Cx isoforms involved
in the gap junction-mediated NO signaling have not been identified, but, as NO-induced relaxation
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is mediated by a reduction in the Ca2+ sensitivity of smooth muscle contractile machinery [94,95]
and EDH signaling decreases the intracellular Ca2+ concentration of SMCs [61,94], regulation of
myoendothelial gap junctions may play a pivotal role in the balance of these two complementary
vasodilator components.
4.2. Longitudinal Conduction of Vasomotor Responses
Control of peripheral vascular resistance and blood flow distribution is a dynamic process that
depends on coordination of changes in diameter between different segments and cellular elements
of the vascular resistance network [57,96]. Vasomotor signals generated in a short arteriolar segment
(100 μm) rapidly spread (<1 s) several millimeters along the vessel length without apparent delay,
demonstrating functional coupling between distal and proximal segments of the vasculature [97,98].
Therefore, longitudinal conduction of vasomotor signals endows the microvascular network with a
mechanism that is most likely to contribute to integrate function within the arteriolar network and
between arterioles and feed arteries [96,99,100]. Direct measurements of membrane potential indicate
that conducted vasomotor responses are associated with changes in the membrane potential of cells of
the vessel wall [97,101,102]. As gap junctions provide a low-resistance intercellular pathway between
ECs and SMCs, the conduction of vasomotor responses along the vessel length is thought to be the
result of electrotonic spread of changes in membrane potential generated at the stimulation site through
gap junctions connecting cells of the vessel wall [103,104]. Then, in the case of endothelium-dependent
vasodilators, such as ACh, the conduction of the vasodilation is thought to be the result of the
electrotonic spread along the vessel length of an EDH-initiated vasodilation [62,64,105]. In contrast,
in the case of vasoconstrictor signals, such as those activated by phenylephrine (PE), a depolarization
is conducted [101,106].
The cellular pathway of conducted vasomotor signals seems to depend on the cell type that
initiates the response, and vasoconstrictor responses activated by the stimulation of SMCs are
consistently conducted by SMCs [107,108]. In contrast, vasodilator signals have been shown to
spread either exclusively by the endothelium in feed arteries [97,109] or by both SMCs and ECs in
arterioles [107,108], which led to the proposal that the cellular pathway for conduction of vasodilations
depends on the functional location of the vessel in the microvascular network [66]. However,
the cellular pathway of vasodilator signals may also depend on the stimulus that initiated the response,
because, in contrast to ACh, selective damage of the endothelium blocked the vasodilation induced by
bradykinin in arterioles [104,108].
Conduction of vasomotor responses may be mediated by interaction of one or more of the five Cx
isoforms that are expressed in the vascular system: Cx32, Cx37, Cx40, Cx43, and Cx45 [100,110–112].
Although the contribution of each of these Cxs to the longitudinal coordination of the changes in
diameter has not been clearly determined, it has been consistently observed that global deletion of
Cx40 results in the development of an irregular arteriolar vasomotion and in a reduced spread of
vasodilator signals activated by ACh or bradykinin in feed arteries as well as in arterioles of the
cremaster muscle microcirculation [98,113,114]. In blood vessels of the mouse, the expression of
Cx40 is restricted to the endothelium [98,115,116], which raises an apparent disagreement with the
participation of SMCs in the conducted vasodilation in arterioles. However, the involvement of Cx40 in
the transmission of the EDH signaling may explain the detriment of the alternative conduction through
SMCs observed previously in response to ACh [80]. In addition, ablation of Cx40 is also associated
with a decrease in Cx37 expression and the development of a hypertension caused by a dysregulation
of renin production [98,99,114,116,117]. As with Cx40, the expression of Cx37 is also confined to ECs in
the vessel wall of mice [98,116], and then, the decline in Cx37-mediated communication in the absence
of Cx40 and the development of hypertension may contribute to the reduction in the conduction of
vasodilator signals observed in Cx40 knockout animals. Nevertheless, conducted vasodilator responses
are intact in Cx37 knockout mice [98] and in animals with an angiotensin-dependent hypertension
evoked by deletion of Cx40 in the renin-producing cells [116]. Furthermore, the disruption in the
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propagation of the response to endothelium-mediated vasodilators attained after global deletion
of Cx40 was also observed in EC-specific Cx40 knockout mice [116] and in animals expressing a
mutated Cx40 (Cx40A96S) that exhibits a substantially lower junctional conductance [116,118–120].
Although the mutation Cx40A96S causes a renin-dependent hypertension, as that observed with global
deletion of Cx40, the endothelial Cx37 levels are normal in these mice [116]. Therefore, these findings in
conjunction confirm the critical role of Cx40 in the control and coordination of microvascular function
by ECs.
5. Coordination of Microvascular Function by Pannexins
There are three different pannexin isoforms (Panx1, Panx2 and Panx3), with Panx1 being the
most ubiquitously expressed throughout the vasculature [121]. There are organ-specific circulations
where it appears that other Panx isoforms have been described, but their function has not yet
been described [121]. In general, Panx1 is expressed in endothelium throughout conduit and
microcirculation, whereas Panx1 is restricted to smooth muscle of resistance arteries, and is not
found in conduit smooth muscle [56,121]. Overall, much less is known about the Panxs (compared
with Cxs) in the microcirculation, likely due to their more recent discovery, the inherent problems
associated with the global Panx1 knockout mouse (e.g., compensation with up regulation of Panx3
throughout the vasculature [122], as well as other cell types [123]), and specific inhibitors for Panx1
that do not also block connexin-built gap junctions (e.g., [124]). However, there are exciting pieces of
data emerging using inducible cell type specific Panx1 knockout mice that have revealed phenotypes
that are fundamental to the microcirculation.
For example, multiple groups have now demonstrated that Panx1 and the α1-adrenergic
receptor (AR) are uniquely coupled in a signaling axis that can regulate vasoconstriction [125–129].
Either SMC-specific Panx1 deletion, or use of multiple Panx inhibitors, blunts noradrenaline and
PE mediated vasoconstriction of resistance arteries, but leaves other vasoconstriction pathways
intact [125,127–129]. This translates to a hypotensive blood pressure response by the mouse at periods
of highest sympathetic nerve activity (evening) [130]. Importantly, the Panx1-α1-AR signaling axis is
not observed in large conduit arteries (e.g., aorta or carotid), which is likely because Panx1 is absent
from conduit vessel smooth muscle [56,121], and sympathetic nerve innervation is very low.
The Panx1-α1-AR signaling axis also highlights a potent link between sympathetic nerves and
vasoconstriction that may be directly druggable for treatment of hypertension in humans (e.g., [127,129]).
Indeed, this was recently highlighted by the discovery of trovafloxacin and spironolactone being able to
work directly on Panx1 channels [127,131], as evidenced by electrophysiology, inhibiting ATP release,
and blunting of vasoconstriction. Spironolactone in particular has been used for decades as a potent
anti-hypertensive whose primary effect had been thought to be due to mineralcorticoid antagonism.
Other more specific mineralcorticoid antagonists failed to block the Panx1 channel, indicating that the
potent effect of spironolactone may be due to blocking both mineralcorticoids and Panx1.
The mechanism of α1-AR activation of Panx1 is still under investigation, although based on
previous work it is thought that Panx1 may be selectively regulated by receptor stimulation at the
intracellular loop [130]. The use of both peptides and amino acid mutagenesis have confirmed
the importance of this region [130]. However, there are likely other regions where Panx1 can be
regulated that are especially important in the vasculature. For example, NO potently inhibits Panx1
channels by S-nitrosylating amino acids cysteine 40 and cysteine 346 to prevent channel opening
and ATP release [132]. This could be an important mechanism for feedback on sympathetic nerve
vasoconstriction. How the cross-talk of several different post-translational modifications fit together to
regulate Panx1 channel gating properties will be important moving forward.
There are other more specific regions where Panx1 may play a role in the microcirculation. There is
no identified role yet for Panx1 in regulation of endothelial-mediated dilation, except in large conduit
vessels, which do have augmented responses to endothelial-induced vasodilation in global Panx1
knockout animals [133]. However, this effect is not seen in resistance arteries, and endothelial specific
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deletion of Panx1 has no effect on blood pressure [134]. Thus, it is not clear what exactly the augmented
endothelial mediated dilation in conduit arteries may mean physiologically at this point.
Panx1 utilization could also be considered vascular bed specific. For example, it has recently
been demonstrated that myogenic tone is attenuated in the cerebral circulation of EC-specific Panx1
knockout animals, but is not altered in the mesenteric circulation of the same animals [134]. The EC-
specific Panx1 knockout mice also had resistance to middle cerebral artery occlusion (stroke model).
SMC-specific Panx1 knockout animals did not have an attenuation of myogenic tone in the cerebral
or mesenteric circulation, and were not resistant to induction of stroke [134]. Thus, different vascular
beds may utilize Panx1 differently. It also highlights the importance of using cell type-specific Panx1
knockouts in order to properly identify phenotypes.
Besides regulation of blood pressure, among other important aspects of the microcirculation, it is
an important regulator of the acute inflammatory response. It was recently demonstrated that TNFα
stimulation activates Panx1 in the venous, but not the arterial microcirculation [135]. Interestingly,
TNFα (but not IL-1β) induced ATP release via Panx1, as demonstrated in cultured venous ECs,
as well as isolated murine veins, but not in any arterial EC or isolated arteries [135]. The effect of
the increased ATP release caused an increase in leukocytes that was Panx1 dependent as shown
by genetic deletion [135]. The effect of EC deletion of Panx1 has also recently been shown in
ischemia, with deletion of Panx1 inducing a significant decrease in leukocytes after occlusion of
the middle cerebral artery, lessening the overall impact of the ischemic response [136]. Recently,
this work was even further expanded to include ischemic models in the lung and kidney [137,138].
These exciting observations point to a central role for Panx1 in ECs regulating ischemia and the acute
inflammatory response.
Also, in the microcirculation, there has been significant attention paid to the possible role of
purinergic signaling from red blood cells (RBCs) to endothelium to induce vasodilation, especially
during hypoxia. It had been hypothesized that Panx1 on RBCs was the mechanism by which ATP
(or other purinergic signals) could leave the RBC, bind to purinergic receptors on endothelium,
and induce vasodilation. However, although Panx1 can be localized to RBCs [136], the role for ATP
coming from RBCs has recently been called into question, especially via activation of the channel by
cAMP/PKA [136,139]. Indeed, the mechanism for increased ATP may be lysis of the RBCs [136,139].
This highlights the need to be careful with measurement of ATP, which is an inconsistent and difficult
methodological technique. However, further questions that arise based on this potential heterocellular
communication between RBCs and endothelium include what the possible role of Panx1 on RBCs
would be if it was present, or if other signaling mechanisms besides cAMP could induce Panx1 channel
opening on RBCs.
6. Role of Connexins and Pannexins in Venous and Lymphatic Function
Apart from their role in inflammatory cell recruitment at the level of venules (see Section 5),
the function of Panxs and Cxs in larger veins is much less studied. Venous valves play a crucial role in
the systemic circulation, promoting the one-way movement of blood from peripheral veins towards
the heart and augmenting venous return. In humans, valvular dysfunction or (congenital) absence of
valves in large veins typically result in common venous disorders such a varicose veins and edema in
the legs. Three gap junction proteins, i.e., Cx37, Cx43, and Cx47, are expressed in ECs, covering venous
valves in a highly polarized fashion, with Cx43 on the upstream side of the valve leaflet and Cx37 on
the downstream side. Cx47 seems more restricted to a small subset of ECs in the venous valves [140].
Similar to earlier observations in the lymphatic vasculature [141,142] veins from Cx37-deficient mice
lack valves [140]. As Cx37 seems a crucial regulator of valve development in both veins and lymphatic
vessels, there may be common molecular pathways controlling valve development in these distinct
vessel types. Mechanistically, it has been shown in lymphatic valves that the transcription factors
Prox1, Foxc2, as well as lymphatic flow, coordinately control the expression of Cx37 and activation
of calcineurin/NFAT signaling. Indeed, Cx37 and calcineurin are required for the assembly and
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delimitation of lymphatic valve territory during development and for its postnatal maintenance [142].
Interestingly, the development of venous valves, but not the formation of lymphatic valves, is affected
in Cx47-deficient mice [143,144]. Accordingly, Cx47 null mice also display normal lymphatic vascular
function [145]. Mutations in the Cx47 gene are associated with reduced venous valve number and
length, a crucial finding for understanding how some Cx47 mutations cause inherited (lymph) edema
in humans [144]. Recently, both Cx47 and Cx43 have been added to the limited repertoire of primary
lymphedema-associated genes (such as Foxc2, Vegfr3 and Sox18) [146–149]. Furthermore, Cx47 and
Cx37 mutations have been associated with increased risk for secondary lymphedema following breast
cancer treatment [150,151].
The lymphatic system regulates tissue fluid homeostasis, trafficking of immune cells to draining
lymph nodes and absorption of dietary fat. To investigate whether Panx1 affects lymphatic flow,
drainage of interstitial fluids following injection of Evans Blue in the footpad was recently compared
between Panx1−/−Apoe−/− and Apoe−/− mice. The dye progressively spread throughout the lymphatic
system to successive draining lymph nodes and finally the systemic circulation. The dye transport
was considerably smaller in Panx1−/−Apoe−/− mice than in control Apoe−/− mice. Moreover, tails
of Panx1−/−Apoe−/− mice showed increased diameters and increased interstitial fluid content than
control Apoe−/− mice, suggesting that lymphatic flow is impaired in mice with ubiquitous deletion
of Panx1. Finally, Panx1−/−Apoe−/− mice had reduced dietary fat absorption with control animals.
Collectively, these findings suggest a pivotal role for Panx1 in lymphatic function [56], and it will be
exciting to learn more on the cell type and molecular mechanism involved in this regulation.
7. Connexins and Pannexins in the Control of Platelet Function, Haemostasis and Thrombosis
Cx hemichannels and gap junctions have been studied widely in various cell types where
sustained cell interactions occur. Some reports, however, indicate the presence of Cxs on the surface of
some circulating cells, such as monocytes and T-cells, where gap junction and hemichannel functions
control cellular functions [152–154]. In recent studies, fundamental roles for these proteins in platelets
have emerged.
7.1. Platelets: Mediators of Haemostasis and Thrombosis
Platelets provide a front line of defense in response to injury, triggering haemostasis at sites of
injury, and are increasingly recognized for their involvement in a range of other (patho)physiological
processes, including inflammation, atherogenesis, and cancer cell metastasis. Platelets adhere to
collagens that are exposed at sites of arterial damage, initially via an indirect interaction with plasma
von Willebrand factor (VWF), which through binding to the platelet glycoprotein (GP) Ib-V-IX receptor
complex, a short-lived interaction that therefore serves to slow platelets, allows subsequent direct
binding to platelet collagen receptors GPVI and integrin α2β1 (Figure 2A) [155,156]. Integrin α2β1
functions principally as an adhesive receptor for collagen [157], while collagen binding to GPVI
stimulates platelet activation.
Collagen binding to GPVI causes receptor clustering and the tyrosine phosphorylation of the
Fc receptor γ-chain [158,159] by Src-family kinases [160]. The tyrosine kinase Syk is then recruited
and initiates the first step in a complex and branching signaling pathways incorporating, among
others, the linker for activation of T cells, phosphatidylinositol 3-kinase, protein kinase B, Bruton’s
tyrosine kinase, phospholipase Cγ2, integrin-linked kinase, and the mobilization of intracellular
calcium stores [161,162]. This culminates, via the GTP binding protein Rap1b, in an increase in affinity
of integrins that enhance adhesion to collagen (α2β1), and causes aggregation through the binding of
plasma fibrinogen to integrin αIIbβ3 [161,163].
A rapid and full platelet response is ensured through the autocrine and paracrine actions of factors
that are released by activated platelets such as ADP and thromboxane A2. Following the binding
of fibrinogen to integrin αIIbβ3 and collagen to integrin α2β1, outside-in signaling through these
integrins also contributes to sustained platelet activation and irreversible thrombus formation [164,165].
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Thrombin, which is generated on the surface of activated platelets within a thrombus, is also a potent
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Figure 2. Gap junction intercellular communication between platelets: a working model. (A) Blood
vessel injury leads to the exposure of subendothelial collagens. Through interaction with von Willebrand
factor, which also binds to collagens, platelets roll along the surface, slowing their movement and
allowing direct binding of collagen to the cell surface receptors integrin, α2β1, and GPVI, initiating
platelet intracellular signaling. This results in the secretion or release of prothrombotic factors such as
ADP and TXA2 that further propagate platelet activation. This culminates in an increase in affinity
of integrin αIIbβ3 which then binds fibrinogen that supports platelet-platelet adhesion and thrombus
formation. Close contact between platelets allows the formation of gap junctions that permit intercellular
signaling during thrombus formation and stabilization; (B) Intercellular signaling controls thrombus
contraction by enabling the formation of a core of platelets that are highlight activated and tightly
packed. A more loosely packed shell of platelets develops, although this is inhibited in the presence of
ADP receptor antagonists or aspirin (to prevent TXA2 formation). Whether gap junctional intercellular
communication controls platelet thrombus core and shell assembly has yet to be formally established.
A reactive system such as this, which incorporates many positive feedback mechanisms, requires
precise control to prevent un-needed platelet activation. The healthy endothelium produces molecular
signals, NO and prostaglandin I2, short-lived molecules that exert powerful inhibitory effects on
platelets through the stimulation of cyclic nucleotide-dependent intracellular signaling [166].
Inappropriate platelet activation, for example, at the site of atherosclerotic plaque formation or
rupture, results in the exposure of platelets to activatory substances, including collagens, resulting
in thrombosis and the occlusion of blood flow. As the principle cause of myocardial infarction and
ischemic stroke, platelets represent an important therapeutic target [163].
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In the last 20 years, substantial progress has been made in understanding the molecular
mechanisms that control platelets, and this is beginning to impact in the development of new
therapeutic approaches. These advances have largely involved study of traditional intra-cellular
signaling, the identification of key activatory or inhibitory signals, cell surface receptors required
to respond to these signals and the intracellular signaling pathways or networks that these
control. While platelets are singular circulating cells, activation and thrombus formation bring
them into close proximity for prolonged periods, and increasing evidence supports the importance
of sustained inter-platelet communications within the thrombus derived largely through integrin
outside-in signaling, with additional contributions from, for example, Eph family kinases and ephrin
counter-ligands [167–169]. Sustained signaling within the thrombus enables platelets to cooperate to
regulate thrombus compaction, structure and stability and subsequently clot retraction, a step believed
to be important for wound repair [170]. The ability of platelets to coordinate their functions within
a developing thrombus, particularly in the control of calcium signaling, led to early experimental
evidence that this may be mediated by intercellular communication (Figure 2B), although this was not
initially attributed to gap junctions [171].
7.2. Platelets Possess Connexins
Messenger RNA profiling of megakaryocytes, the precursor bone marrow cells from which
platelets form, revealed that these cells likely possess notable levels of Cx37, with additional expression
of Cx40 and Cx62. Indeed, Cx37 mRNA and protein were first reported to be expressed in human
and mouse platelets, and were found to be present at the cell surface [172,173]. Scanning electron
microscopy of sections of human platelet thrombi revealed regions of apposite membrane structures
with a typical appearance of gap-junction-like structures [173].
7.3. Platelet Gap Junction Formation—Orchestration of Intercellular Signaling within Arterial Thrombi
The transport of dye between platelets was first demonstrated following micro-injection of
neurobiotin, and transfer into surrounding platelets [172]. Gap junctional intercellular coupling
between platelets was confirmed by fluorescence recovery after photo-bleaching (FRAP) analysis
of thrombi preformed under arterial flow conditions using blood reconstituted with platelet that
were labelled preloaded with cytosolic calcein [173]. Transfer of dye was inhibited by selective or
non-selective inhibition of Cx37 (37,43Gap27). Clot retraction responses were also inhibited in the
presence of inhibitor, or the absence of Cx37 (using blood from Cx37-deficient mice) suggesting that
gap junctional coupling mediates physiological responses within platelets.
There currently exists a difference of experimental conclusions drawn from the study of
Angelillo-Scherrer, who reported modestly elevated platelet aggregation responses on Cx37-deficient
mouse platelets and following the use of inhibitory peptides with human platelets [172], while Vaiyapuri
reported substantially diminished responses [173]. Vaiyapuri also reported similar outcomes following
the inhibition or deletion of Cx40 [173]. These differences are likely to be explained by differences in
experimental conditions, although both studies indicate the potential importance of Cxs in the control
of platelet function.
The use of flow cytometry gated to examine the function of individual platelets revealed
that platelet activation, prior to platelet-platelet contact is inhibited in the absence of functional
Cx37, which is suggestive of important roles for Cx hemichannels in the initiation of platelet
responses [173,174]. Whether this is due to channel function or through interaction with other cell
surface proteins has yet to be established, although inhibition of Cx37 or Cx40 is associated with
diminished intracellular mobilization of calcium from stores, indicating a fundamental role in the
propagation of platelet cell signaling [173,174]. Consistent with this, inhibition of Cx37 in whole blood
results in diminished thrombus formation on a collagen-coated micro-fluidic flow cells under arterial
flow conditions. Infusion of 37,43Gap27 [173] or 40Gap27 (unpublished observation) into mice prior
analysis of laser induced thrombosis in cremaster muscle arterioles was found to result in diminished
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thrombotic responses. Diminished thrombus formation appears to be at the expense of haemostatic
control, since bleeding times were extended modestly. It is interesting to note the Cx37-deficient mice
were found to exhibit reduced survival time using a thrombo-embolism model, induced by intravenous
injection of collagen and adrenalin [172], which may be a consequence of reduced thrombus stability
that results in increased thrombus fragmentation and lung occlusion.
7.4. Panx1 Contributes to Platelet Function at Low Agonist Concentrations
Recent analysis of the megakaryocyte (and therefore the platelet) channelome revealed that
among a range of cell surface channel proteins, Panx1 is also likely to be expressed. A series of
pharmacological approaches using selective mimetic peptide inhibitor [175], subsequently confirmed
using Panx1-deficient mouse platelets [176], demonstrated this protein to contribute to calcium
responses to low concentrations of various platelet agonists. The ability of Panxs to facilitate the
release of ATP from cells is a property that has also been observed in platelets. Panx1 mediated
ATP release results in subsequent stimulation of the ATP-gated calcium channel P2X1, which causes
enhanced calcium influx and therefore propagation of platelet functional responses [175,176]. At higher
concentrations of collagen or other platelets agonists P2X1 makes little contribution to cell responses,
and therefore the effects of Panx1 are restricted to conditions where agonist concentrations are limited.
7.5. Cx37 and Panx1 Polymorphisms
It is fair to ask, are the effects of platelet Cxs likely to be physiologically important, or do they
contribute to cardiovascular disease risk? The clearest indication that gap junction and hemichannel
function may be important stem from studies that have explored the effects of common gene SNPs
in the human population. As discussed before (Section 3), a SNP in the coding sequence of Cx37
(P319S) influences the gating of Cx37 channels [46,48]. When transfected into HeLa cells, the 319P
polymorphism is associated with reduced diffusion of dye between cells [172]. 96 Caucasian men were
genotyped to explore the relationship between this polymorphism and platelet function. A relationship
was observed between the number of 1019C alleles of the Cx gene possessed by volunteers, with the
CC genotype associated with modestly increased platelet function [172]. These data suggest that
platelet reactivity levels may be determined by connexin-mediated platelet function.
Three variants exist in the human Panx1 coding sequence. These result in a Q5H variant at the
N-terminus, a I272V variant within the 4th transmembrane domain and deletion of amino acids 401 to
404 at the CT due a splice variant. In a population of 96 male Caucasian volunteers the splice variant
was not detected [176]. Two thirds of subjects possessed the allele coding for the histidine variant at
position 5 in the protein sequence, and the associated with a small increase in platelet aggregation in
response to collagen, although responses to other agonists were unaltered. Comparison between the
Panx1 alleles responsible for variability at position 272 showed no relationship with platelet reactivity.
The numbers of subjects included in these studies were relatively small, and more detailed
analysis of the relationship between platelet Cx and Panx polymorphisms and variability in platelet
responsiveness would be required to confirm these observations. Current data are, however, consistent
with a role of Cxs and Panxs in the regulation of haemostasis and potentially thrombosis, allowing the
potential development of new strategies for the prevention of thrombosis, or other conditions in which
these cells are implicated.
8. Conclusions and Perspectives
It is now well established that Cxs have an important function in the control of blood flow
distribution and tissue homeostasis, as well as in pathologies that involve a tight regulation and
coordination between cells in the blood vessel wall and circulating blood cells such as atherosclerosis
and hypertension. Strong evidence now also supports an important role for gap junctions and Cx
hemichannels in the control of haemostasis and thrombosis, although many questions remain to
be addressed in this field. More insight into the nature of molecular signals that are transported
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through gap junctions and hemichannels will be required in order to tease apart the basis of their
ability to modulate diverse aspects of vascular function. Systems biology approaches have revealed
exquisite detail regarding the architecture of platelet thrombi, which are organized into a densely
packed core, surrounded by a less densely packed shell, which is sensitive to the actions of anti-platelet
drugs [177]. It is possible that gap junctional intercellular communication mediates the organization
of thrombus architecture, function and sensitivity to anti-thrombotic medication. The ability of gap
junctions to support interactions between different cell types that are implicated in the stimulation
of localized inflammatory responses and atherogenesis [44,178,179], further supports the notion that
gap junctional coupling between different vascular cell types may impact on a wide(r) range of
(patho)physiological processes.
The release of ATP or Ca2+ are generally assumed to be the most relevant signaling mechanisms
mediated by both Cx hemichannels and Panx1 channels in vascular (patho)physiology. While recent
years have shown great progress in the knowledge on Cx43 protein domains involved in gap junction
channel vs. hemichannel gating [180], one of the inherit problems with Panxs is that the biophysical
properties of the channels are still being worked out, and thus technically there remains a significant
number of unknowns. For example, does ATP always come out of a channel? There is no reason that
this needs to be the case, as Panxs in general are large pore channels. Also, being able to distinguish
between receptor-mediated and caspase cleavage of the channel has become an important technical
differential. The physiological effects described in Section 5 would be considered receptor-mediated
Panx1 channel opening, which is uniquely different than caspase cleavage-mediated Panx1 opening
that occurs during apoptosis. Key physiological parameters such as electrophysiology and ATP
release can be observed in both receptor- and caspase cleavage-mediated Panx1 channel opening.
The difference being that receptor mediated Panx1-channel opening is transient, and caspase cleavage
produces a permanently “open” channel [126]. Perhaps differential dye uptake could help differentiate
these two events? Whatever the case, there is still a significant amount to learn about the relatively
recently discovered Panx1 channel and how it may affect vascular and platelet function.
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Abstract: Atrial fibrillation (AF) appears in the presence or absence of structural heart
disease. The majority of foci causing AF are located near the ostia of pulmonary veins (PVs),
where cardiomyocytes and vascular smooth muscle cells interdigitate. Connexins (Cx) form gap
junction channels and participate in action potential propagation. Genetic variants in genes encoding
Cx40 and Cx37 affect their expression or function and may contribute to PV arrhythmogenicity.
DNA was obtained from 196 patients with drug-resistant, symptomatic AF with and without
structural heart disease, who were referred for percutaneous catheter ablation. Eighty-nine
controls were matched for age, gender, hypertension, and BMI. Genotyping of the Cx40 −44G > A,
Cx40 +71A > G, Cx40 −26A > G, and Cx37 1019C > T polymorphisms was performed. The promoter
A Cx40 polymorphisms (−44G > A and +71A > G) showed no association with non-structural
or structural AF. Distribution of the Cx40 promoter B polymorphism (−26A > G) was different
in structural AF when compared to controls (p = 0.03). There was no significant difference with
non-structural AF (p = 0.50). The distribution of the Cx37 1019C > T polymorphism was different in
non-structural AF (p = 0.03) but not in structural AF (p = 0.08) when compared to controls. Our study
describes for the first time an association of drug-resistant non-structural heart disease AF with the
Cx37 1019C > T gene polymorphism. We also confirmed the association of the Cx40 − 26G > A
polymorphism in patients with AF and structural disease.
Keywords: atrial fibrillation; connexin; polymorphism; genetic variant
1. Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, its incidence increasing
with age to reach up to 35 new cases per 1000 population in the elderly [1,2]. In the general population,
its prevalence is estimated at 1.5–2%. AF is associated with increased risk of stroke, incidence of
heart failure, and an overall higher mortality [3,4]. Diagnosis of AF is based on electrocardiographic
characteristics such as rapid, irregular, fibrillatory waves, varying in size, shape, and timing [1].
Five clinical types of AF are recognized, mainly based on duration [2–5]: paroxysmal AF, persistent AF,
long-standing persistent AF, and permanent AF. Whilst controversial, the term idiopathic or lone AF is
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used in reference to AF appearing in the absence of structural disease such as atrial left enlargement
or valvular heart disease [6]. This historical concept and term should probably and progressively be
avoided as understanding of the multiple complex etiologies of AF is improved [7].
When underlying structural heart disease is present, such as in patients with hypertensive heart
disease, valvulopathy, or ischemic heart disease, this may trigger progressive remodeling of both
the ventricles and atria [3,4]. Structural abnormalities will induce remodeling of the myocardium by
affecting the extracellular matrix and cardiomyocytes through inflammatory processes and increased
fibrosis [3,4]. Electrophysiological alterations and remodeling are instrumental in maintaining AF after
its onset [8]. Initiation of AF is thought to depend on a combination of abnormal impulse formation,
conduction and a propensity for reentry at the ostia of pulmonary veins (PVs), where sheets of
cardiomyocytes and vascular smooth muscle cells (VSMCs) interdigitate [9,10]. However, the molecular
mechanism underlying this regional specificity remains to be discovered.
Variants in genes encoding for membrane channels have been associated with both familial and
other forms of AF, including genes encoding potassium channels such as KCNQ1 and KCNA5 [11–13].
Interestingly, atrial vulnerability to AF has been associated with polymorphisms in the Connexin40
(Cx40) gene, GJA5 [14–17]. In addition, specific somatic mutations in the same gene have been
discovered in idiopathic AF [18]. Other clinical AF presentations have been described with mosaicism
in another connexin gene, GJA1 encoding for Cx43 [19].
Connexins are gap junction proteins playing an essential role in direct cell–cell communication
in the vast majority of tissues in the body, including in electrical propagation in the heart [20].
There are 20 different connexins in humans, each forming channels with distinct properties and
with specific expression patterns [21]. Cx40, encoded by GJA5, is expressed by endothelial
cells (ECs), by coronary VSMCs, by atrial cardiomyocytes, and in the cardiac conduction system.
Cx37, encoded by GJA4, is found in ECs, pulmonary vein VSMCs, monocyte/macrophages,
and platelets. Cx43, encoded by GJA1, is expressed by ventricular and atrial cardiomyocytes, VSMCs,
ECs, and monocyte/macrophages [22]. Several polymorphisms have been described in GJA4 and
GJA5, which affect either their connexin expression level or gap junction channel function, some of
which may contribute to the arrhythmogenicity of the PVs [15]. In animal studies, downregulation of
either Cx40 or Cx43 expression increases susceptibility to AF [23,24].
Variants in the Cx37 (GJA4) gene have been associated with atherosclerosis and coronary heart
disease, most likely through their influence on monocyte adhesion, thereby regulating the extent of
local inflammation [25]. Both systemic and local inflammation appear to influence the development of
AF in various situations, in patients having undergone cardiac surgery as well as non-post-operative
patients [26].
Here, we investigated the relation between polymorphisms in GJA5 and GJA4 in defined AF
populations. Within the AF population, a distinction was made between patients with no underlying
structural cardiomyopathy, for the purpose of clarity referred to as non-structural AF, and those with
clearly documented structural disease, referred to as structural AF. All AF patients that were included
had undergone a trial of anti-arrhythmic drugs and were referred for catheter ablation because of
poor response.
2. Results
A total of 285 individuals were included in this study; 92 patients in the non-structural AF
group, 104 patients with structural AF, and 89 controls. Characteristics of the study population are
summarized in Table 1.
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Table 1. Characteristics and cardiovascular risk factors in the three cohorts.





Age, years (SD) 61.79 (7.81) 64.09 (8.87) 60.04 (9.96)
Males (%) 74.2 84.8 76.9
Smokers (%) 66.3 56.5 32.7 *
Diabetes (%) 10.1 3.3 13.4
Dyslipidemia (%) 17.0 26.1 42.3 *
Hypertension (%) 42.5 30.4 42.3
BMI (Kg/m2) (SD) 27.54 (4.48) 27.15 (5.70) 27.65 (5.77)
Controls were matched against the atrial fibrillation groups for age, gender, hypertension, and BMI. SD: standard
deviation; BMI: body mass index. Qualitative values compared with Fisher’s exact test. Quantitative values
compared with the Student’s t-test. * p < 0.05.
The type of cardiomyopathy present in the structural AF group is detailed in Table 2.
Valvular disease and dilated atria were the main structural abnormalities.
Table 2. Characteristics of heart disease in the structural AF group. (More than one type of
cardiomyopathy was possible in each patient).
Characteristics Numbers
Type of Heart Disease Total n (%) (n = 104)
Valvular heart disease
- Mitral regurgitation 71 (68.3)
- Mitral stenosis 2 (1.9)
- Aortic regurgitation 29 (27.9)
- Aortic stenosis 4 (3.8)
Ischemic heart disease 9 (8.6)
Other (HCM, interatrial communication, etc.) 34 (32.7)
Dilated left atrium (>20 cm2) 61 (58.7)
Echocardiography values
Average LVEF (%) 56
Average left atrial surface, cm2 (SD) 23 (6.9)
Average left ventricular ejection fraction, % (SD) 56.2 (10.1)
HCM: hypertrophic cardiomyopathy, LVEF: Left Ventricular Ejection Fraction, SD: standard deviation.
2.1. Cx40 − 44G > A/+71A > G Polymorphisms
Analysis of the two promoter A Cx40 polymorphisms (−44G > A and +71A > G) showed
an almost complete linkage disequilibrium of the −44G/+71A and −44A/+71G alleles. The overall
genotype distribution in the control group was −44GG/+71AA = 67.4%, −44AG/+71AG = 28.1% and
−44AA/+71GG = 4.5%. This genotype distribution was not significantly different in either of the AF
groups (non-structural AF: p = 0.846; structural AF: p = 0.132) (Table 3). There was also no significant
difference in between the two AF groups (p = 0.275).
2.2. Cx40 − 26G > A Polymorphism
The specific genotype distribution of the Cx40 − 26G > A polymorphism in the control group was
−26GG = 25.8%, −26AG = 47.2%, and −26AA = 27.0%. This distribution was significantly different in
the structural AF group: −26GG = 26.0%, −26AG = 61.5%, and −26AA = 12.5% (p = 0.029). There was
no significant difference between the control and the non-structural AF group (p = 0.511) (Table 3) or
between the two AF groups (p = 0.3).
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2.3. Cx37 1019C > T Polymorphism
The specific genotype distribution of the Cx37 1019C > T polymorphism in the control group was
1019CC = 42.7%, 1019CT = 34.8%, and 1019TT = 22.5%. This distribution was significantly different
in the non-structural AF group: 1019CC = 46.7%, 1019CT = 44.6%, and 1019TT = 8.7% (p = 0.034).
There was no significant difference between the control and the structural AF group (p = 0.080) (Table 3)
or between the two AF groups (p = 0.85).
Table 3. Allele distributions of the Cx40 (GJA5) and Cx37 (GJA4) polymorphisms in the control,
non-structural AF, and structural AF groups. Proportions were compared with Fisher’s exact test.
Genotype Gene p Value vs. Control Group
Cx40 −44G > A GG (n, %) AG (n, %) AA (n, %) Total
Control 60 (67.4) 25 (28.1) 4 (4.5) 89
Non-Structural AF 59 (64.1) 27 (29.3) 6 (6.5) 92 p = 0.846
Structural AF 55 (52.9) 41 (39.5) 8 (7.7) 104 p = 0.132
Cx40 +71A > G AA (n, %) AG (n, %) GG (n, %) Total
Control 60 (67.4) 25 (28.1) 4 (4.5) 89
Non-Structural AF 61 (66.3) 26 (28.3) 5 (5.4) 92 p = 1.000
Structural AF 55 (52.9) 41 (39.4) 8 (7.7) 104 p = 0.133
Cx40 − 26G > A GG (n, %) AG (n, %) AA (n, %) Total
Control 23 (25.8) 42 (47.2) 24 (27.0) 89
Non-Structural AF 26 (28.3) 48 (52.2) 18 (19.6) 92 p = 0.511
Structural AF 27 (26.0) 64 (61.5) 13 (12.5) 104 p = 0.029
Cx37 1019C > T CC (n, %) CT (n, %) TT (n, %) Total
Control 38 (42.7) 31 (34.8) 20 (22.5) 89
Non-Structural AF 43 (46.7) 41 (44.6) 8 (8.7) 92 p = 0.034
Structural AF 50 (48.1) 43 (41.3) 11 (10.6) 104 p = 0.080
In bold the genes and genotypes.
3. Discussion
Our study describes for the first time an association of the Cx37 1019C > T gene polymorphism
with drug-resistant non-structural AF, but not with structural AF. The potential differences in gene
susceptibility between non-structural and structural AF were further underlined by the fact that
we found an association of the Cx40 − 26G > A polymorphism with structural AF and not with
non-structural AF.
These results suggest that there are potential differences in the genetic susceptibility to AF in
given populations. Patients who develop AF in whom there is no underlying structural cardiac disease
appear to have an increased frequency of Cx37 1019C alleles than patients who do not develop AF.
This genetic polymorphism has previously been described in populations with coronary heart disease
and myocardial infarction [27,28]. The GJA4 genotype may predict survival after an acute coronary
syndrome [29]. Cx37 is principally expressed in endothelial cells, VSMCs, monocyte/macrophages,
and platelets. The 1019C > T polymorphism in GJA4 causes a Proline-to-Serine substitution at amino
acid 319 (P319S) in the cytoplasmic tail of Cx37, which in turn alters channel conductance and
permeability [25,30]. The Cx37 polymorphism has been shown to affect monocyte adhesion as well as
platelet aggregation [25,31]. Both mechanisms are thought to underlie the development of CAD [25].
Inflammation and its associated immune response are increasingly recognized to be involved in the
initiation and maintenance of atrial fibrillation [32]. Thus, the Cx37 1019C > T polymorphism might
affect the susceptibility to non-structural AF by virtue of its effect on monocyte adhesion. Alternatively,
initiation of non-structural AF is thought to depend on a combination of abnormal impulse formation
and conduction [9]. As Cx37 is also expressed in VSMCs at the ostia of pulmonary veins (PVs),
where sheets of cardiomyocytes and VSMCs interdigitate, the differences in gap junction channel
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electrophysiological properties associated with the Cx37 1019C > T polymorphism may accentuate the
latter mechanism [33].
Our results also show an association of the Cx40 − 26G > A polymorphism in patients with
AF with underlying cardiomyopathy, with the −26G allele being more frequent than in control
patients. This single nucleotide polymorphism (SNP) in the promoter B region of GJA5, the Cx40 gene,
which alters the TATA box sequence and modulates mRNA expression levels of Cx40, has previously
been associated with AF [34]. Of note, our study did not show any association of AF (either structural
or non-structural) with the promoter A polymorphisms, Cx40 − 44/+71; these polymorphisms were
also shown to reduce GJA5 expression in vitro by about 50%; however, Wirka et al. showed no effect
on GJA5 expression in atrial tissue, suggesting that promoter A is not necessary to Cx40 expression in
atrial myocytes [34]. In patients with structural AF, atrial remodeling is often present at a structural,
electrophysiological, and molecular level with changes in the refractory period and cardiomyocyte
contractility [8,10]. Some of these atrial cardiomyocyte characteristics can be explained by changes in
potassium channel properties and important changes to calcium handling [8]. Inconsistent observations
have been made with respect to Cx40 expression levels in patients with AF, with both higher and lower
levels being reported [35–37]. However, only few patients were included in these studies—10 and 12,
respectively—and almost exclusively with mitral valve disease. Complete deletion of Cx40 in murine
models leads to decreased atrial conduction velocity and increased atrial stability [8,38]. Somatic
mutations in GJA5 have been shown to predispose patients to idiopathic AF by either impairing the
assembly of Cx40 into gap junctions or by affecting the electrical coupling itself [14,18]. Importantly,
a recent study revealed that one of the reported Cx40 mutations (A96S) caused decreased atrial
conduction velocities and sustained episodes of induced atrial fibrillation in mice and rat [39,40].
The strength of our study is the distinction between patients with or without underlying
cardiomyopathy. This enables a more precise association study and a dissection of possible different
pathophysiological mechanism leading to AF. We chose to include patients in whom anti-arrhythmic
treatment was not successful in order to have long-standing or permanent AF. It may be interesting
in the future to include all AF. The main limitation of our study is nevertheless the relatively small
sample size, which increases the risk of falsely positive results. Furthermore, we acknowledge that
non-structural AF is a misnomer and an exhaustive search of underlying etiology reduces the number
of instances when there is truly no explanation for AF [7]. We also acknowledge that the link between
the severity of valvular disease, in particular mitral valve disease, and AF may be complex. This may
be an important aspect to further investigate. Associations between smoking or serum lipid levels and
Cx40 have never been reported; it is, however, quite unlikely that one of these confounding factors
would induce a significant association of the Cx40 − 26G > A polymorphism with structural AF.
4. Materials and Methods
4.1. Patients
Three patient cohorts were studied, namely patients with AF and no underlying structural
cardiac disease (non-structural AF), patients with AF and documented structural cardiac disease
(structural AF), and a control population with no AF or underlying cardiac disease. This study
protocol conforms to the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in prior
approval by the institution’s human research committee, namely the Internal Medicine Departmental
Ethics Committee, Geneva University Hospital (Protocol 03-167, 3 April 2010). Informed consent was
obtained from all patients.
The non-structural AF group consisted of patients undergoing catheter ablation of AF by
radiofrequency ablation through pulmonary vein isolation (RFAPVI). Inclusion criteria were
an age > 18 years, documented paroxysmal or persistent AF (for <2 years) with or without typical flutter
(ECG or Holter) after failure of at least one anti-arrhythmic treatment of Class I or III, with planned and
clinically indicated RFAPVI. Exclusion criteria were reversible AF, clinical heart failure, increased left
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atrial size (>20 cm2 four chamber view), decreased left ventricular ejection fraction, any valvulopathy,
or a history of prior AF or flutter ablation. The structural AF group consisted of patients undergoing
RFAPVI but in whom there was underlying cardiomyopathy, be it structural or valvular disease,
or documented ischemic heart disease (history of acute or chronic coronary disease, angiographically
proven disease). Inclusion criteria were an age > 18 years, documented paroxysmal or persistent AF
(for <2 years) with or without typical flutter (ECG or Holter) and with planned and clinically indicated
RFAPVI. Inclusion and exclusion criteria for these groups are detailed in Table 4. Demographics
and characteristics of each group are detailed in Table 1. The type of cardiomyopathy present in the
structural AF group is detailed in Table 1. The control group was considered as a whole and variables
were matched to the AF groups with priority given to age, gender, hypertension, and BMI, these being
major risk factors associated with AF development. These individuals were from the same population
basin as AF patients, seen in the same clinic, and were undergoing elective coronary angiography at
the Geneva University Hospital due to symptoms of suspected CAD or unrelated conditions requiring
angiographic evaluation [41]. Participants gave written informed consent for a blood draw at the time
of angiography for use in confidential studies approved by the hospital’s institutional review board.
Exclusion criteria for this control group were AF or a history of AF, or arrhythmia on 12 lead ECG,
a history of coronary heart disease, any significant angiographic lesions on coronary angiography,
or any known heart disease including valvulopathy.
Table 4. Inclusion and exclusion criteria for the non-structural and structural atrial fibrillation and
control groups.
Criteria Non-Structural AF Structural AF Control Group
Inclusion
criteria
Age > 18 years
Paroxysmal or persistent AF
Failure of at least 1 anti-arrhythmic
drug of class I or III
Age > 18 years
Any valvulopathy
Left ventricular or atrial dilatation
Documented ischemic heart disease
Hypertrophic cardiomyopathy
Any structural disease





Decrease left ejection fraction
Any valvulopathy
History or documented AF
Any heart disease including coronary
heart disease or significant coronary
lesion on angiography
Any valvulopathy
AF: atrial fibrillation; NYHA: New York Heart Association heart failure classification.
4.2. Echocardiography
Echocardiography was performed on a HP/Philips 5500, Philips Electronics North American
Corporation, Andover, MA, USA, with digitalization of images and analyzed according to
a standardized protocol in a core lab.
4.3. DNA Extraction and Genotyping
DNA was extracted from the peripheral blood and genotyping of the Cx40 − 44G > A,
Cx40 + 71A > G, Cx40 − 26A > G, and Cx37 1019C > T polymorphisms was performed by polymerase
chain reaction (PCR) and restriction fragment length polymorphism (RFLP) assays using previously
established methods [34,42,43].
4.4. Statistical Analysis
Clinical, biological, and echocardiographic characteristics are presented using descriptive statistics
and a number of cases with a percentage in parentheses for categorical variables. In view of
skewed allele distribution and small numbers of certain genotypes, we used non-parametric tests.
Proportions/categorical data were compared with the Fisher’s exact test.
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5. Conclusions
Our study suggests that there may be a different genetic predisposition to non-structural AF as
compared to AF appearing in the context of underlying heart disease. We report here for the first
time that the Cx37 1019C > T variant is associated with non-structural AF. Mechanistically, this might
involve effects of altered Cx37 channel function on the inflammatory response (monocyte adhesion)
or on abnormal impulse conduction (communication between VSMCs and atrial cardiomyocytes).
In addition, we confirmed that the Cx40 − 26G > A polymorphism affecting the expression level of
this protein in atrial cardiomyocytes is associated with structural AF.
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Abstract: Atrial fibrillation (AF) is the most common form of cardiac arrhythmia. Recently, four novel
heterozygous Cx40 mutations—K107R, L223M, Q236H, and I257L—were identified in 4 of 310 unrelated
AF patients and a followup genetic analysis of themutant carriers’ families showed that themutantswere
present in all the affected members. To study possible alterations associated with these Cx40 mutants,
including their cellular localization and gap junction (GJ) function, we expressed GFP-tagged and
untaggedmutants in connexin-deficientmodel cells. All four Cx40mutants showed clustered localization
at cell–cell junctions similar to that observed of wildtype Cx40. However, cell pairs expressing Cx40
Q236H, but not the other individual mutants, displayed a significantly lower GJ coupling conductance
(Gj) than wildtype Cx40. Similarly, co-expression of Cx40 Q236H with Cx43 resulted in a significantly
lower Gj. Transjunctional voltage-dependent gating (Vj gating) properties were also altered in the GJs
formed by Q236H. Reduced GJ function and altered Vj gating may play a role in promoting the Q236H
carriers to AF.
Keywords: atrial fibrillation; gap junction channel; connexin40; Vj gating; patch clamp
1. Introduction
Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia affecting millions of
people worldwide [1,2]. With an overall prevalence of 1%, AF increases with age, starting from 0.1%
in individuals younger than 55 years and reaching 9% in those over 80 years [3]. AF prevalence is
expected to increase substantially due to an aging population [3]. AF is characterized by a fast sporadic
beating of the atria, which causes substantial morbidity including a much higher risk of stroke [2,4].
Often, AF exists as a secondary disease to a wide range of other diseases, such as hypertension,
diabetes, and coronary artery disease [5]. However, AF is the primary disease in about 30% of AF
patients who are categorized as AF with genetic predisposition [1,6,7]. This group of AF patients has
been linked to multiple genetic mutations including genes encoding ion channels, such as potassium
channels, sodium channels, and gap junction (GJ) channels [8–14].
GJ channels are composed of connexins. In humans, there are 21 different connexins and all of
them share a similar topological structure of four transmembrane domains (M1–M4), two extracellular
domains (E1 and E2), one cytoplasmic loop (CL), and both the amino terminus (NT) and carboxyl
terminus (CT) lie within the cytoplasm [15,16]. Six connexins oligomerize to form a hemichannel (also
known as connexon) that could function as a channel on the plasma membrane [17]. Two hemichannels
from adjacent cells could dock head-to-head at their extracellular domains to form a GJ channel [18].
Human heart expresses three different types of connexins—Cx40, Cx43, and Cx45 [19,20]—allowing
for the possible formation of homomeric or heteromeric hemichannels and homotypic or heterotypic
GJ channels. Cx45 is dominantly expressed in the sinoatrial (SA) and atrioventricular (AV) nodes while
Cx43 and Cx40 are both expressed in the atrial myocardium and are often found to be co-localized at
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the intercalated discs between atrial myocytes [21,22]. Cx43 is the main connexin in the ventricles [23].
A much lower level of Cx45 is expressed in the atria and ventricles [24]. These connexins form GJ
channels between cardiomyocytes to mediate rapid propagation of action potentials (APs) in the
heart [24,25].
The importance of Cx40 and Cx43 in the heart has been highlighted in animal models and genetic
mutation studies. Mice with an ablation of Cx43 in the heart develop ventricular arrhythmias leading to
sudden cardiac death [26]. An in vitro study using cultured atrial synthetic strands from Cx43-deficient
mice showed a decrease in conduction velocity [27]. Moreover, an early onset of AF is associated with a
somatic Cx43 mutant, which exhibits GJ impairment [28]. Interestingly, viral expression of the exogenous
wildtype Cx43 in the atria was found to prevent AF in pig models [29,30]. For Cx40, earlier studies
reported that mice lacking the Cx40 gene exhibit a slower action potential propagation [31,32] and are
more susceptible to inducible atrial arrhythmias [32,33]. Recent studies reported an increased conduction
velocity and a decrease in the conduction heterogeneity in Cx40 knockout mice or cells derived from
these mice [27,34,35]. Furthermore, Cx40 promoter polymorphisms result in lower levels of Cx40 mRNA
and have been linked to an early onset of AF [36]. Somatic and germline mutations within the coding
regions of human Cx40 gene (GJA5) have been linked to AF patients and families [11–14]. A recent genetic
study identified four novel germline mutants in GJA5 in four of 310 unrelated AF patients, resulting in
heterozygous missense mutants in Cx40 protein: K107R, L223M, Q236H, and I257L [37]. Further testing
on available relatives of the mutant carriers revealed that these mutants presented in all affected family
members and were absent in 400 reference alleles [37]. Functional consequences of these AF-linked Cx40
mutants have not been studied. We hypothesize that these AF-linked Cx40 mutants impair GJ and/or
hemichannel function, which may predispose the mutant carriers to AF.
2. Results
2.1. AF-Linked Cx40 Mutants Formed GJ Plaque-Like Structures at the Cell–Cell Interface
Expression of AF-linked Cx40 mutants (K107R, L223M, Q236H, and I257L, all tagged with YFP at
the carboxyl terminus) was used to study their localization in live HeLa cells. As shown in Figure 1A,
each of the mutants was localized in intracellular compartments and displayed GJ plaque-like clusters
at the cell–cell interfaces similar to that of Cx40–YFP. The percentage of successful mutant-expressing
cell pairs displaying GJ plaque-like structures at cell–cell interfaces was calculated and was found to
be similar to that of cells expressing wildtype Cx40 (Figure 1B).
Figure 1. Cont.
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Figure 1. Localization of atrial fibrillation (AF)-linked Cx40 mutants. (A) Fluorescent images of HeLa
cell clusters or pairs expressing YFP-tagged Cx40, K107R, L223M, Q236H, or I257L superimposed on
their respective differential interference contrast (DIC) images. Cells expressing each of the AF-linked
Cx40 mutants were able to form GJ plaque-like structures at the cell–cell interface similar to that of
wildtype Cx40 (white arrows). Scale bars = 10 μm; (B) the bar graph summarizes the percentage of
cell pairs showing GJ plaque-like structures at the cell–cell interface for each mutant. No statistical
difference was observed between any of the mutants and wildtype Cx40. Approximately 100
positively-transfected cell pairs were examined for each transfection. The total number of transfections
is indicated on each bar.
2.2. Coupling Conductance of GJs Formed by AF-Linked Mutants
Dual whole-cell patch clamp was used to study the functionality of untagged AF-linked Cx40
mutants in N2A cell pairs. Representative junctional currents (Ijs) of cell pairs expressing each of the
Cx40 mutants and wildtype Cx40 are presented (Figure 2A). The averaged coupling percentage of each
Cx40 mutant in several transfections, plotted as a bar graph, was not different from that of wildtype Cx40
(Figure 2B, p > 0.05 for each of the mutants). The coupling conductance (Gj) of cell pairs expressing K107R,
L223M, or I257L was also not different from that of wildtype Cx40 (Figure 2C). However, a significant
reduction in Gj was observed in cell pairs expressing Q236H (Figure 2C, p < 0.05).
Figure 2. Coupling percentage and Gj of AF-linked mutants. (A) Dual whole-cell patch clamp technique
was used to measure junctional current (Ij) from N2A cell pairs expressing untagged Cx40, K107R, L223M,
Q236H, or I257L at 20 mV Vj; (B) bar graph summarizes the coupling percentages of cell pairs expressing
the AF-linked Cx40 mutants. No statistical difference was observed between each of the mutants and the
wildtype Cx40. The number of transfections is indicated on each bar; (C) bar graph illustrates the coupling
conductance (Gj) of coupled cell pairs expressing Cx40, K107R, L223M, Q236H, or I257L. Cell pairs
expressing Q236H showed a significantly lower Gj than those of wildtype Cx40 (* p < 0.05). The number
of cell pairs is indicated on each bar.
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2.3. Homotypic Cx40 Q236H GJs Showed an Altered Vj Gating
To investigate the transjunctional voltage-dependent gating (Vj gating) of AF-linked Cx40 mutants,
we measured Ijs in cell pairs in response to a series of Vj pulses (±20 to ±100 mV, Figure 3A). The Ijs
from cell pairs expressing untagged Cx40 mutant K107R, L233M, Q236H, or I257L showed similar
symmetrical Vj-dependent deactivation (sometimes also called inactivation) when Vjs ≥ 40 mV
(Figure 3). The normalized steady state conductance (Gj,ss) of each mutant (filled circles) or wildtype
Cx40 (open grey circles) was plotted at different Vjs (Figure 3B). The smooth black lines are Boltzmann
fitting curves for each of the mutants (Figure 3B). Boltzmann fittings of wildtype Cx40 (smooth grey
dashed lines) are plotted and superimposed onto each mutant Gj,ss–Vj plot for comparison (Figure 3B).
Compared to the wildtype Cx40, GJ channels formed by these mutants showed nearly identical
Boltzmann fitting curves, except Q236H, which showed a significant reduction in V0 for both Vj
polarities (Figure 3B, Table 1).
Figure 3. Vj gating of AF-linked mutant GJs. (A) Dual whole-cell patch clamp was used to measure
Ijs in N2A cell pairs expressing Cx40, K107R, L223M, Q236H, or I257L in response to a series of Vj
pulses as indicated. Superimposed Ijs for each mutant is shown; (B) normalized steady state junctional
conductance, Gj,ss, of the Cx40 mutants (black filled circles) and wildtype Cx40 (grey open circles)
were plotted at different Vjs. The Gj,ss–Vj plot of each mutant was fitted with a two-state Boltzmann
equation at each Vj polarity (smooth black lines). Boltzmann fittings of Gj,ss–Vj plot of wildtype Cx40
(smooth grey dashed lines) were obtained and superimposed on each plot for comparison. The number
of cell pairs is indicated.
Table 1. Boltzmann fitting parameters for Vj gating of AF-linked mutants.
Cells Expressing Vj Polarity Gmin V0 (mV) A
Cx40
(n = 7)
+ 0.25 ± 0.02 40.2 ± 1.4 0.15 ± 0.05
− 0.27 ± 0.02 42.9 ± 1.4 0.19 ± 0.07
K107R
(n = 5)
+ 0.21 ± 0.03 38.6 ± 1.6 0.15 ± 0.05
− 0.23 ± 0.03 41.1 ± 1.9 0.15 ± 0.05
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Table 1. Cont.
Cells Expressing Vj Polarity Gmin V0 (mV) A
L223M
(n = 5)
+ 0.24 ± 0.02 40.2± 1.0 0.20 ± 0.10
− 0.31 ± 0.03 43.2 ± 1.8 0.17 ± 0.06
Q236H
(n = 6)
+ 0.20 ± 0.02 33.3 ± 1.7 *,1 0.19 ± 0.04
− 0.24 ± 0.02 35.2 ± 2.0 * 0.15 ± 0.04
I257L
(n = 5)
+ 0.24 ± 0.03 40.9 ± 2.2 0.12 ± 0.03
− 0.24 ± 0.03 43.4 ± 2.2 0.17 ± 0.08
1 One-way ANOVA followed by Tukey post-hoc test was used to compare the Boltzmann fitting parameters of each
mutant and wildtype Cx40 at the corresponding Vj polarity. GJ channels formed by the mutant Q236H showed a
significantly lower V0 for both Vj polarities than those of wildtype Cx40 (* p < 0.05).
To analyze Vj-gating kinetics, we fitted the Ij deactivation by a single exponential process at Vjs
of ±60 to ±100 mV. As shown in Figure 4A, Ij deactivation of wildtype Cx40 GJs fitted well with a
single exponential process (with a time constant, τ) at each of the tested Vjs (Figure 4A). The averaged
time constants (τs) showed a decrease with the increase of Vjs (Figure 4B, open grey circles). The Ij
deactivations of the GJs formed by AF-linked mutants could be fitted by a single exponential process
and the τ–Vj plots were not statistically different from those of wildtype Cx40 GJs (filled black circles),
except Q236H GJ that showed consistently lower τs at all tested Vjs (Figure 4B, p < 0.05).
Figure 4. Vj-gating kinetics of AF-linked Cx40 mutants. (A) Ijs induced at different Vjs (60 mV light grey,
80 mV medium grey, 100 mV dark grey) were normalized and superimposed for each of the mutant or
Cx40 GJs. Ij deactivations under different Vjs were all fitted well with a single exponential process (smooth
black lines); (B) The time constants (τs) were plotted on a semi logarithmic scale against different Vjs.
When the Vjs increased, the averaged τs of the mutant GJs (black filled circles) decreased similar to those
observed for the wildtype Cx40 (grey open circles). No consistent statistical difference was found between
most of the mutant τs and the τs of wildtype Cx40, except the τs of Q236H was consistently lower than
those of wildtype Cx40 (two-way ANOVA). The number of cell pairs are indicated.
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2.4. Co-Expression of AF-Linked Mutants with Cx43
To investigate if AF-linked Cx40 mutants had a trans-dominant negative effect on wildtype Cx43,
each of the mutants was co-expressed with Cx43 (with an untagged DsRed). Cell pairs successfully
expressing both connexins were selected for dual whole-cell patch clamp. Cell pairs successfully
co-expressing K107R:Cx43, L223M:Cx43, or I257L:Cx43 showed coupling percentages and Gjs that
were not statistically different from those of wildtype Cx40:Cx43 (Figure 5B,C). The coupling percentage
of Q236H:Cx43 was also not statistically different from that of wildtype Cx40:Cx43. However, the Gj
of cell pairs co-expressing Q236H:Cx43 was significantly lower than that of wildtype Cx40:Cx43
(Figure 5C, p < 0.05).
Figure 5. Coupling percentage and Gj of co-expressing AF-linked mutants with wildtype Cx43.
(A) Representative Ijs are shown from N2A cell pairs co-expressing Cx40, K107R, L223M, Q236H,
or I257L (with an untagged reporter GFP) with wildtype Cx43 (with an untagged reporter DsRed);
(B) bar graph illustrates coupling percentages of N2A cell pairs expressing each combination.
The number of transfections is indicated; (C) bar graph illustrates the Gj of cell pairs co-expressing one
of the Cx40 mutants (K107R, L223M, Q236H, or I257L) with Cx43. The Gj of cell pairs co-expressing
Q236H:Cx43 was significantly lower than that of wildtype Cx40:Cx43 (* p < 0.05). The number of cell
pairs is indicated.
2.5. Function of Heterotypic Mutant/Cx40 GJ Channels
The above results showed that Cx40 Q236H had a significantly lower Gjs than wildtype Cx40
when expressed alone or co-expressed with Cx43. To further test whether Q236H could affect the
function of heterotypic Q236H/Cx40 GJs, we mixed cells expressing Q236H (with untagged GFP)
with cells expressing Cx40 (with untagged DsRed) and performed dual patch clamp on heterotypic
cell pairs (one GFP+ and the other DsRed+, Figure 6A). The coupling percentages and Gjs of
heterotypic Q236H/Cx40 cell pairs were not statistically different from those of the control (Cx40/Cx40,
Figure 6B,C). Similar results were also obtained for L223M (Figure 6).
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Figure 6. Functional test on heterotypic mutant/Cx40 GJs. (A) Ijs were obtained from heterotypic
Q236H/Cx40, L223M/Cx40, or Cx40/Cx40 (in all cases with untagged GFP or DsRed, respectively)
N2A cell pairs; (B) Bar graph summarizes the coupling percentages of heterotypic cell pairs. No
statistical difference was found between the coupling percentage of any of the mutant heterotypic GJs
and that of Cx40/Cx40 GJs. The number of transfections is indicated; (C) Gjs of cell pairs expressing
L223M/Cx40 or Q236H/Cx40 were not statistically different from those of Cx40/Cx40. The number of
cell pairs is indicated.
2.6. Propidium Iodide Uptake by AF-Linked Cx40 Mutant-Expressing Cells
Propidium iodide (PI) uptake assay was used to investigate the hemichannel function of AF-linked
Cx40 mutants as elevated PI uptake was observed in AF-linked Cx40 mutants, including L221I [38,39].
Figure 7A shows the fluorescent images of individual HeLa cells expressing GFP alone, Cx40, or one of
the mutants (L221I, K107R, L223M, Q236H, or I257L) in divalent cation-free solution. The percentage
of individual cells showing PI uptake in cells expressing K107R, L223M, Q236H or I257L was not
significantly different from either the wildtype Cx40 or the negative control (expressing GFP alone) but
was statistically lower than the positive control L221I (69%, p < 0.001) (Figure 7B). These results suggest
that the Cx40 mutants and the wildtype Cx40 failed to show PI uptake in divalent cation-free solution.
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Figure 7. Propidium iodide uptake of AF-linked Cx40 mutants. (A) HeLa cells transfected with Cx40
mutants, empty vector GFP, or Cx40 are shown: column 1 (under DIC), column 2 (GFP fluorescence
to show successful expression of respective vector), column 3 (propidium iodide [PI] uptake in red),
column 4 (an overlay of images of column2 and 3). Only cells expressing L221I showed PI uptake.
The scale bar = 50 μm; (B) bar graph summarizes PI uptake percentage of isolated individual cells
expressing Cx40 mutants, Cx40, or GFP. PI uptake percentage for each of the AF-linked mutants was not
statistically different from that of wildtype Cx40 or the empty vector (GFP), except L221I (*** p < 0.001).
The number transfection is indicated with observations of over 60 isolated cells for each transfection.
3. Discussion
In this study, we examined morphological and functional characteristics of four recently identified
AF-linked Cx40 mutations (K107R, L223M, Q236H and I257L) in vitro. Our localization experiments
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showed that YFP-tagged K107R, L223M, Q236H, and I257L were able to form GJ plaque-like structures
at the cell–cell interface in HeLa cells, similar to that of wildtype Cx40. PI uptake by each of these
mutant (untagged)-expressing cells showed no significant increase from that of Cx40, indicating no
increase in hemichannel activity in any of the mutant-expressing cells. Dual patch clamp experiments
revealed that the Cx40 mutants (K107R, L223M, and I257L) showed no apparent change in coupling
conductance (Gj) when expressed alone or together with Cx43. The GJs formed by each of these
mutants also failed to show any obvious change in the Vj gating properties. In contrast, Q236H GJs
exhibited a significantly reduced Gj when expressed alone or together with Cx43. In addition, Q236H
GJs also showed altered Vj gating, specifically a reduction in the Vj required to close the channel (V0)
and an increase in Vj-gating kinetics. These defects associated with Q236H might play a role in the
pathogenesis of AF in the mutant carriers.
3.1. AF-Linked Cx40 Mutants Showed Multiple Defects in GJ or Hemichannel Function
So far, a total of ten germlines and three somatic mutations in the coding region of the GJA5
gene (encoding Cx40) have been identified in AF patients with genetic predisposition [11–14,37,40].
In vitro studies on these AF-linked Cx40 mutants have revealed that these mutants display either
a loss of GJ function or a gain of hemichannel function. The detailed molecular and cellular
mechanisms leading to GJ or hemichannel functional changes appear to be quite different. (1) A Cx40
missense mutation P88S failed to localize to cell–cell interfaces to form GJ plaque-like structures [11].
Similarly, a nonsense Cx40 mutation (Q49X) was found to be retained in the endoplasmic reticulum
and unable to reach cell–cell junctions [41]. Functional impairment of GJs in these two mutants were
anticipated and confirmed experimentally, but interestingly both mutants showed dominant negative
and transdominant negative actions on GJ function when co-expressed with wildtype Cx40 or Cx43,
respectively [11,41]. (2) Other AF-linked Cx40 missense mutants (G38D, I75F, V85I, A96S, M163V,
L221I, L229M) and those in the present study (K107R, L223M, Q236H, and I257L) showed GJ plaques
at the cell–cell interfaces [11,14,38,39]. However, eliminated or significantly reduced macroscopic
coupling conductance (Gj) was observed in G38D, I75F, A96S, and Q236H GJs, probably due to
impairment at the GJ channel [11,42]. Some of the mutants in this category were also found to show
dominant negative action on Cx40 (I75F and A96S) and/or transdominant negative action on Cx43
(I75F, A96S, L229M, and Q236H) [11,42]. Although some isolated disagreements on the Gj levels of
G38D and A96S GJs have been reported [39,43], the majority of these studies agree on the GJ functional
impairments in most of the AF-linked Cx40 mutants [11,14,39,41,43]. (3) Detailed characterizations
of mutant-containing GJ channels revealed additional defects, including reduced Gj of heterotypic
mutant/wildtype GJs, altered Vj gating properties of homotypic (G38D, A96S, M163V, Q236H) or
heterotypic (I75F/Cx40, A96S/Cx40) Vj gating properties, a substantially reduced open probability
without changing unitary channel conductance (I75F), or elevated unitary channel conductance (G38D
and M163V) [14,39,42,43]. (4) Only a limited number of AF-linked mutants (G38D, M163V, and A96S)
have been studied for GJ permeability changes but significant permeability change to anionic dye
(Lucifer yellow) or cationic dye (ethidium bromide) was observed [43]. (5) The PI uptake assay was
used to study hemichannel function in isolated cells expressing AF-linked mutants. Among the tested
Cx40 mutants, only V85I- and L221I-expressing cells showed an elevated PI uptake compared to that
of wildtype Cx40, indicating a gain of hemichannel function in these mutants [38]. Patch clamp on
cells expressing Cx40 G38D showed unitary hemichannel currents [39]. Similar elevated hemichannel
function was also observed in a few other disease-linked mutants in Cx26, Cx43, and Cx50 [44–47].
3.2. AF-Linked Cx40 Mutants and Their Possible Role in AF Pathogenesis
As discussed above, there is a variety of molecular/cellular changes associated with AF-linked
Cx40 mutants. Whether these molecular/cellular changes play a role in the pathogenesis of AF is not
clear. Several theoretical possibilities exist. First, a reduced macroscopic coupling conductance (Gj) of
AF-linked Cx40 mutants due to either an impaired localization or GJ channel function is known to
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reduce the action potential conduction velocity [48,49], which could be an important contributing factor
in promoting re-entrant atrial arrhythmias [50]. Consistent with this model, about half of AF-linked
Cx40 mutants identified so far have shown Gj reduction not only in the mutant GJs but also when they
are co-expressed with wildtype Cx40 and/or Cx43 [51]. Our present study showed that Cx40 Q236H
also reduced Gj when expressed alone and together with Cx43. We did not perform co-expression
of this mutant with wildtype Cx40 because our untagged Cx40 construct (Cx40-IRES-DsRed) had a
very low transfection efficiency. Second, enhanced Vj gating by lower Vjs and faster gating kinetics by
Cx40 mutants could also dynamically down-regulate Gj when sufficient junctional delays exist [52,53].
Cx40 showed a pronounced Vj gating with a minimum conductance level reaching a quarter of the
maximum Gj [54,55]. A reduction in the Boltzmann fitting parameter, V0, and faster Vj-dependent
deactivation kinetics of Q236H mutant GJs predict an increased Vj gating when sufficient junctional
delay exists. It is not clear whether Vj gating of Cx40 or Q236H GJs could dynamically down-regulate
Gj as observed for Cx45 GJs [56]. Third, AF-linked Cx40 mutants have been shown to alter their GJ
permeability [43], which could alter intercellular exchanges of small signaling molecules, including
second messengers. This altered permeability of GJs could restrict/enhance signaling molecules
necessary for intercellular communication between atrial myocytes, which might be important for
atrial function. Fourth, three of the AF-linked mutants showed elevated PI uptake and/or hemichannel
current, indicating enhanced hemichannel activity under reduced divalent cations in the extracellular
medium [38,39]. Physiological and/or pathological stresses, such as large repetitive membrane
depolarizations, mechanical stretch, reduced extracellular divalent cations, reduced oxygen/glucose
during ischemia, have all been shown to enhance several other connexin hemichannels. Whether these
stress factors also promote the opening of Cx40 hemichannel remains to be determined. In summary,
it is not clear how these defects in Cx40 mutants in model cells link to the pathogenesis of AF in the
mutant carriers. Among the changes associated with AF-linked Cx40 mutants, the most consistent is
a reduced or eliminated GJ coupling (Gj) in different possible atrial GJs. At present, we cannot rule
out other changes, such as biosynthesis, and turnover of the mutant Cx40 protein may also change
the abundance and function of Cx40 at the intercalated discs, which may need genetically modified
animal models to assess fully.
3.3. AF-Linked Cx40 Mutants without Apparent Defects In Vitro
In our present study, we did not detect any obvious defects in GJ distribution, function,
or hemichannel activities in three out of four AF-linked Cx40 mutants (K107R, L223M, and I257L).
It is not clear how these mutants relate to AF. Here are some possibilities. (1) These mutants are
located in the CL (K107R), M4 (L223M), and CT (I257L) domains of Cx40. The CL and CT domains
of Cx40 show a lot more residue variation in different vertebrate species than the E1, E2, and M1–4
domains. Following this general trend, the conservation percentage at these residue positions in Cx40
are L223 (in M4 domain) 85%, K107 (in CL domain) 74%, and I257 (in CT domain) 28% across 47
different species (accessible online: https://omabrowser.org/oma/home/ OMA Group 752281). It is
possible that one or more of these mutants are benign mutants that do not necessarily play a role in
promoting AF, especially at the least conserved position, I257. (2) Both of our model cells, HeLa and
N2A cells, are convenient model systems to study localization, function of GJs, and hemichannels.
They are GJ deficient, easily transfected with connexin mutant constructs, and easily accessible
for morphological, dual patch clamp, or dye-uptake experiments. However, these cells are not
cardiomyocytes and may not recapitulate all aspects of GJs at the intercalated discs of cardiomyocytes
and, therefore, some defects might go undetected. Future studies on cell models that are closer to
atrial myocytes will likely help to resolve the role of these Cx40 mutants linking to AF. (3) We have
good rationales to focus our study on the morphology and functional changes in GJs and hemichannel
activities. However, there are other unconventional functions of connexins, including but not limited
to aggregation of protein complexes at the cell–cell junctions, adhesion, cell growth control, and
differentiation, etc., that require specific biological assays to evaluate.
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3.4. Other AF-Linked Genetic Factors
It is well known that genetic factors play a role in AF. A lot of research is focused on genes
responsible for inherited AF cases as these genes are putative independent AF risk factors [7,57].
The first genetic mutation linked to familial AF was identified in the KCNQ1 gene, which encodes
a potassium channel subunit [9]. Since then, more AF-linked mutations in different potassium
channel subunits have been identified and are now extended into genes encoding sodium channels,
transcription factors, Ca2+ handling proteins, nucleoporins, and atrial natriuretic peptide [8,58].
Our present study is consistent with several previous studies showing that atrial GJ impairments
represent an independent risk factor for AF [11,14,28,38,40,41,51].
4. Materials and Methods
4.1. Plasmid Construction
The C-terminal fusion fluorescent protein tagged human Cx40-YFP and the untagged constructs
(Cx40-IRES-GFP, Cx43-IRES-DsRed, Cx40-IRES-DsRed) were created as previously described [14,59].
The novel AF-linked tagged and untagged Cx40 mutants were generated by site-directed mutagenesis
on the corresponding tagged/untagged Cx40 as templates with the following primers.
K107R Forward: 5′ CAGGAGAAGCGCAGGCTACGGGAGGCC 3′
Reverse: 5′ GGCCTCCCGTAGCCTGCGCTTCTCCTG 3′
L223M Forward: 5′ CTCCTCCTTAGCATGGCTGAACTCT 3′
Reverse: 5′ AGAGTTCAGCCATGCTAAGGAGG 3′
I257L Forward: 5′ CCCTCTGTGGGCCTAGTCCAGAGCTGC3′
Reverse: 5′ GCAGCTCTGGACTAGGCCCACAGAGGG3′
Q236H Forward: 5′ GGAAGAAGATCAGACACCGATTTGTCAAACC3′
Reverse: 5′ GGTTTGACAAATCGGTGTCTGATCTTCTTCC3′
All these Cx40 mutant constructs were sequenced to confirm the accuracy of the nucleotide sequence.
4.2. Cell Culture and Transfection
Connexin-deficient mouse neuroblastoma (N2A) and human cervical carcinoma (HeLa) cells
(American Type Culture Collection, Manassas, VA, USA) were cultured at 37 ◦C with 5% CO2.
Cells were grown in Dulbecco’s modified Eagle’s medium (DMEM) (Cat# 10313-021, Thermo Fisher
Scientific, Waltham, MA, USA) containing 10% fetal bovine serum, 1% penicillin, 1% streptomycin,
4.5 g/L D-(+)-glucose, 584 mg/L L-glutamine, and 110 mg/L sodium pyruvate. Twenty-four hours
before cell transfection, N2A or HeLa cells were replated into a 35-mm dish at 60% confluency.
Transfection was performed the next day by adding 0.8–1 μg of DNA with 2 μL of the transfection
reagent X-tremeGENE HP DNA (Roche Applied Sciences, Indianapolis, IN, USA). To assess the effect
of Cx40 mutants on wildtype Cx43, N2A cells were transfected in a 1:1 ratio of Cx40 mutants-IRES-GFP
and Cx43-IRES-DsRed. Cell pairs successfully co-expressing both GFP and DsRed were selected for
measuring coupling conductance with dual whole-cell patch clamp (see below).
4.3. Localization
HeLa cells were transiently transfected with YFP-tagged Cx40 mutants. One day after transfection,
cells were replated on 10 mm glass coverslips and incubated overnight. The number of successfully
transfected cell pairs forming GJ plaque-like structures at the cell–cell interface were counted.
A confocal microscope (Zeiss LSM800 with Airyscan) (Zeiss, Oberkochen, Germany) was used to
observe mutant-YFP and wildtype Cx40-YFP localizations as described earlier [59].
4.4. Electrophysiology
On the experimental day, transfected N2A cells were replated onto glass coverslips and incubated
for 1.5 to 3 h. Coverslips with cells were transferred into a recording chamber and bathed in
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extracellular solution (ECS) containing 135 mM NaCl, 5 mM KCl, 10 mM Hepes, 1 mM MgCl2, 2 mM
CaCl2, 1 mM BaCl2, 2 mM CsCl, 2 mM Na Pyruvate, and 5 mM D-glucose with pH and osmolarity of
7.4 and 310–320 mOsm, respectively. The recording chamber was placed on an upright fluorescent
microscope (BX51WI, Olympus, Center Valley, PA, USA) to visualize reporter (GFP)-positive cell pairs.
Patch pipette was filled with intracellular solution (ICS) containing 130 mM CsCl, 10 mM EGTA,
0.5 mM CaCl2, 4 mM Na2ATP, and 10 mM Hepes with pH 7.2 and osmolarity of 290–300 mOsm.
Dual whole-cell patch clamp technique was performed on isolated cell pairs expressing the Cx40
mutant. Initially, cell pairs were both voltage clamped at 0 mV. Then, a 20 mV voltage pulse was
applied to one of the cell pairs (pulsing cell) while keeping the other clamped at 0 mV (the recording
cell). If functional GJ channels exist between the cell pairs then a transjunctional current (Ij) can
be measured at the recording cell via MultiClamp 700A (Molecular Devices, Sunnyvale, CA, USA)
and stored in a PC via an AD/DA interface (Digidata 1322A) and pClamp9.2 software (Molecular
Devices, Sunnyvale, CA, USA). Gj was calculated (Gj = Ij/Vj). Vj gating properties were studied by
applying a series of voltage pulses (±20 to ±100 mV in 20 mV increment) as described in our previous
studies [14,56].
4.5. Dye Uptake Assay
AF-linked Cx40 mutants hemichannel function were assessed using propidium iodide (PI) uptake
assay. HeLa cells were transiently transfected with each of the Cx40 mutants in an IRES-GFP vector [38].
We used a previously characterized AF-linked Cx40 mutant L221I-IRES-GFP as the positive control and
empty IRES-GFP vector as the negative control for these experiments [38]. Divalent cation containing
extracellular solution (DCC-ECS) was composed of 142 mM NaCl, 5.4 mM KCl, 1.4 mM MgCl2, 2 mM
CaCl2, 10 mM HEPES, and 25 mM D-(+)-glucose adjusted to pH 7.35 and osmolarity of ~298 mOsm.
HeLa cells were incubated in a divalent cation-free extracellular solution (DCF-ECS) containing PI
(150 μM). Removal of both Ca2+ and Mg2+ ions, as well as including EGTA (2 mM) in the DCF-ECS,
were used to facilitate PI uptake via GJ hemichannels. After incubation at 37 ◦C for 15 min, cells
were washed three times with DCC-ECS at room temperature prior to observation with a fluorescent
microscope (DMIRE2, Leica, Cridersville, OH, USA). The number of transfected HeLa cells with or
without PI uptake was counted and the percentage of cells with PI uptake was calculated. Only isolated
individual HeLa cells were counted to prevent errors caused by GJ channels in cell clusters.
4.6. Data Analysis
Mann–Whitney U test was used to compare each of the mutants against wildtype Cx40 for the
percentage of cell pairs with morphological GJ plaques, the coupling percentage and conductance
(Gj) using dual patch clamp, and the percentage of cells displaying PI uptake for the hemichannel
study. One-way ANOVA followed by Tukey post-hoc test was used to compare the Boltzmann fitting
parameters of each mutant and wildtype Cx40 at the corresponding Vj polarity. Statistical significance
is denoted with different levels of significance (* p < 0.05; ** p < 0.01; or *** p < 0.001).
5. Conclusions
In summary, our results indicate that the AF-linked Cx40 Q236H mutation exhibited GJ function
impairment by reducing the overall Gj when expressed alone or with the wildtype Cx43, and altered
Vj-gating kinetics and the V0, which might play a role in AF pathogenesis. The other mutants—K107R,
L223M, and I257L—did not exhibit any apparent GJ or hemichannel functional impairments in our
cell models.
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Abstract: Radiation of the chest during cancer therapy is deleterious to the heart, mostly due to
oxidative stress and inflammation related injury. A single sub-lethal dose of irradiation has been
shown to result in compensatory up-regulation of the myocardial connexin-43 (Cx43), activation
of the protein kinase C (PKC) signaling along with the decline of microRNA (miR)-1 and an
increase of miR-21 levels in the left ventricle (LV). We investigated whether drugs with antioxidant,
anti-inflammatory or vasodilating properties, such as aspirin, atorvastatin, and sildenafil, may affect
myocardial response in the LV and right ventricle (RV) following chest irradiation. Adult, male
Wistar rats were subjected to a single sub-lethal dose of chest radiation at 25 Gy and treated with
aspirin (3 mg/day), atorvastatin (0.25 mg/day), and sildenafil (0.3 mg/day) for six weeks. Cx43,
PKCε and PKCδ proteins expression and levels of miR-1 as well as miR-21 were determined in
the LV and RV. Results showed that the suppression of miR-1 was associated with an increase of
total and phosphorylated forms of Cx43 as well as PKCε expression in the LV while having no
effect in the RV post-irradiation as compared to the non-irradiated rats. Treatment with aspirin and
atorvastatin prevented an increase in the expression of Cx43 and PKCε without change in the miR-1
levels. Furthermore, treatment with aspirin, atorvastatin, and sildenafil completely prevented an
increase of miR-21 in the LV while having partial effect in the RV post irradiation. The increase
in pro-apoptotic PKCδ was not affected by any of the used treatment. In conclusion, irradiation
and drug-induced changes were less pronounced in the RV as compared to the LV. Treatment with
aspirin and atorvastatin interfered with irradiation-induced compensatory changes in myocardial
Cx43 protein and miR-21 by preventing their elevation, possibly via amelioration of oxidative stress
and inflammation.
Keywords: irradiation; heart; connexin-43; miR-1; miR-21; atorvastatin; aspirin
1. Introduction
Cardiovascular injury due to radiation is the most common cause of adverse events among cancer
survivors [1,2]. Key factors responsible for the establishment of cardiovascular injury, i.e., oxidative
stress, inflammation, and epigenetic modifications, have been linked to potential treatments and
been recently described [1,2]. Ionizing radiation induces oxidative stress and causes changes in the
expression of several microRNAs (miRNA)s, including miR-1 and miR-21. An increase of miR-21
is involved in myocardial hypertrophy [3,4] and fibrosis [5]. An increase in miR-21 has also been
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associated with the up-regulation of the protein kinase C (PKC) δ [6], which is also implicated in
tissue remodeling. Fibrosis and necrosis were reduced by the treatment with a free radical-scavenging
component such as melatonin [7]. However, molecular mechanisms of the irradiation induced injury
are unknown and there is currently a lack of treatment strategies.
Cardiac connexin-43 (Cx43) channels are essential for coordinated heart function because they
ensure electrical coupling and direct intercellular communication. We and others [6,8] have shown
that a single sub-lethal dose of irradiation results in up-regulation of Cx43, which has been associated
with the protection of the heart against malignant arrhythmias [9] and infarction [10]. An increase in
myocardial Cx43 expression and its active phosphorylated forms has been shown to be associated with
the suppression of miR-1 (which regulates GJA1 gene transcription for Cx43) and the enhancement of
PKCε (which phosphorylates Cx43) [6]. It appears that these early post-irradiation related myocardial
alterations, including up-regulation of Cx43, are most likely compensatory responses of the heart
to maintain its normal function [10–12]. Since irradiation induces inflammation and oxidative
stress [12], we hypothesized that compounds exerting anti-inflammatory and antioxidant actionswould
interfere with irradiation-induced compensatory responses. To this context, we considered several
drugs, which included acetylsalicylic acid (aspirin), a non-selective inhibitor of cyclooxygenase-1 and
cyclooxygenase-2, which prevents formation of pro-inflammatory prostaglandins and thromboxanes.
Antioxidant properties of acetylsalicylic acid are attributed to its ability of inhibiting lipid peroxidation
and DNA damage [13]. Atorvastatin is widely used for treatment of human dislipidemia due to
inhibition of the 3-hydroxy-3-methylglutaryl coenzyme A reductase. In addition, its pleiotropic
effects are associated with anti-inflammatory and antioxidative actions [14] as well as promoting the
availability of vascular nitric oxide [15]. Sildenafil, the inhibitor of phosphodiestherase 5, is used for
its vasodilatation and activation of nitric oxide [16].
Our goal was to demonstrate whether treatment with the drugs targeting oxidative stress and
inflammation might result in attenuation of irradiation induced myocardial compensatory responses
previously reported [6,10]. In particular, we examined myocardial changes in Cx43, PKC, miR-1 and
miR-21 in rats exposed to single chest irradiation.
2. Results
2.1. Main Characteristics of Experimental Rats
Comparing to non-irradiated rats, the body, heart, and left ventricular weight were significantly
decreased in irradiated animals after six weeks. On the other hand, irradiation did not alter the right
ventricular weight. Treatment with selected drugs also had no effect on these biometric parameters
in any treated group, except for the heart weight in post-irradiated + sildenafil group. Data are
summarized in the Table 1.
Table 1. Biometric parameters registered in control and irradiated Wistar rats.
GROUP BW (g) HW (g) LVW (g) RVW (g)
C 344.22 ± 28.40 0.89 ± 0.11 0.36 ± 0.07 0.09 ± 0.02
C-A 382.61 ± 32.19 0.92 ± 0.09 0.39 ± 0.04 0.12 ± 0.01
C-AT 371.01 ± 20.45 0.87 ± 0.07 0.37 ± 0.04 0.10 ± 0.02
C-S 363.63 ± 23.93 0.90 ± 0.10 0.39 ± 0.04 0.11 ± 0.02
I 252.24 ± 14.31 a 0.83 ± 0.05 0.25 ± 0.04 a 0.10 ± 0.04
I-A 227.41 ± 26.47 c 0.73 ± 0.09 c 0.24 ± 0.02 c 0.11 ± 0.03
I-AT 253.23 ± 31.82 c 0.77 ± 0.08 0.27 ± 0.03 c 0.13 ± 0.03
I-S 233.62 ± 14.50 c 0.67 ± 0.05 b,c 0.23 ± 0.02 c 0.12 ± 0.03
BW—body weight; HW—heart weight; LVW—left ventricular weight; RVW—right ventricular weight; C—control
non-irradiated; C-A—control + aspirin; C-AT—control + atorvastatin; C-S—control + sildenafil; I—irradiated rats;
I-A—irradiated + aspirin; I-AT—irradiated + atorvastatin; I-S—irradiated + sildenafil. Results are the mean ± SD of
6 hearts. a p < 0.05 vs. C (C vs. C-A, C-AT, C-S, I); b p < 0.05 vs. I (I vs. I-A, I-AT, I-S); c p < 0.05 treated C vs. treated I
(C-A vs. I-A; C-AT vs. I-AT; C-S vs. I-S).
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2.2. Protein Expression of Myocardial Cx43 in Control and Irradiated Wistar Rats
Western blot analysis showed that total Cx43 protein was increased in the LV (p < 0.05) and
to a lesser extent in RV post-irradiation as compared to the non-irradiated group (Figure 1A,B,D,E).
In parallel, the active phosphorylated forms of Cx43 were significantly increased in the LV and RV
of irradiated rats versus the non-irradiated controls (Figure 1A,C,D,F). Treatment with aspirin and
atorvastatin for six weeks (starting one day before irradiation) suppressed the elevation of the total
as well as the phosphorylated forms of Cx43, significantly in the LV (Figure 1A–C) while having
no effect in RV (Figure 1D–F) of post-irradiated animals. The administration of sildenafil had no
significant effect on the irradiation-induced increase in myocardial Cx43, i.e., either on total levels or
its phosphorylated forms after six weeks (Figure 1).
Figure 1. Representative immunoblots showing three forms of Cx43 (A,D) and densitometric
quantification of total Cx43 expression (B,E), and its phosphorylated forms (C,F) normalized to GAPDH
in the LV (left panel) and RV (right panel) of non-irradiated and post-irradiated Wistar rats with and
without treatment. Abbreviations—P0: unphosphorylated form of Cx43; P1 and P2: phosphorylated
forms of Cx43; GAPDH: housekeeper; C: control non-irradiated rats; C-A: control + aspirin; C-AT:
control + atorvastatin; C-S: control + sildenafil; I: post-irradiated rats; I-A: post-irradiated + aspirin;
I-AT: post-irradiated + atorvastatin; I-S: post-irradiated + sildenafil. Data are means ± SD of 6 hearts.
a p < 0.05 vs. C (C vs. C-A, C-AT, C-S, I); b p < 0.05 vs. I (I vs. I-A, I-AT, I-S); c p < 0.05 treated C vs.
treated I (C-A vs. I-A; C-AT vs. I-AT; C-S vs. I-S).
2.3. Expression of Protein Kinase Cε in Control and Irradiated Wistar Rats
PKCε was significantly increased in the LV (Figure 2A,B) but not in the RV (Figure 2C,D) of rats
following irradiation when compared to the non-irradiated controls. Six weeks of treatment with
aspirin and atorvastatin following irradiation normalized PKCε in the LV (Figure 2A,B) while having
no effect in the RV (Figure 2C,D). Treatment with sildenafil had no effect on the PKCε expression of
the irradiated rats. There was no change in the expression of PKCε in non-irradiated rats following
treatment with drugs (Figure 2).
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Figure 2. Representative immunoblots of PKCε expression (A,C) and its quantitative evaluation
normalized to GAPDH in the LV ((B), left panel) and RV ((D), right panel) of non-irradiated and
post-irradiated Wistar rats with and without treatment. Abbreviations—PKCε: protein kinase C
epsilon; GAPDH: housekeeping protein; C: control non-irradiated rats; C-A: control + aspirin; C-AT:
control + atorvastatin; C-S: control + sildenafil; I: post-irradiated rats; I-A: post-irradiated + aspirin;
I-AT: post-irradiated + atorvastatin; I-S: post-irradiated + sildenafil. Data are means ± SD of 6 hearts.
a p < 0.05 vs. C (C vs. C-A, C-AT, C-S, I); b p < 0.05 vs. I (I vs. I-A, I-AT, I-S).
2.4. Expression of Protein Kinase C δ in Control and Irradiated Wistar Rats
Similar to PKCε, the myocardial expression of PKCδ (Figure 3) was increased in response to
irradiation. The increase was significant in the LV (Figure 3A,B) while no change was observed in the
RV (Figure 3C,D) when compared to the to non-irradiated controls. Treatment with drugs had no effect
on the expression of PKCδ in the LV or RV in the irradiated and non-irradiated groups (Figure 3).
Figure 3. Representative immunoblots of PKCδ expression (A,C) and quantitative evaluation
normalized to GAPDH in the LV ((B), left panel) and RV ((D), right panel) of non-irradiated and
post-irradiated Wistar rats. Abbreviations—PKCδ: protein kinase C delta; GAPDH: housekeeping
protein; C: control non-irradiated rats; C-A: control + aspirin; C-AT: control + atorvastatin; C-S: control
+ sildenafil; I: post-irradiated rats; I-A: post-irradiated + aspirin; I-AT: post-irradiated + atorvastatin;
I-S: post-irradiated + sildenafil. Data are means ± SD of 6 hearts. a p < 0.05 vs. C (C vs. C-A, C-AT, C-S,
I); c p < 0.05 treated C vs. treated I (C-A vs. I-A; C-AT vs. I-AT; C-S vs. I-S).
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2.5. Myocardial Expression of miR-1 in Control and Irradiated Wistar Rats
miR-1 level decreased following six weeks after irradiation (Figure 4), which was signficant in the
LV (Figure 4A) but not in the RV (Figure 4B). Treatment with the drugs had no significant effect on
miR-1 level in post-irradiated as well as in non-irradiated groups (Figure 4).
Figure 4. Myocardial expression of miR-1 in the LV ((A), left panel) and RV ((B), right panel) of
non-irradiated and post-irradiated Wistar rats with and without treatment. Endogenous U6 small
nuclear RNA (U6snRNA) was used to normalize miR-1. Abbreviations—C: control non-irradiated rats;
C-A: control + aspirin; C-AT: control + atorvastatin; C-S: control + sildenafil; I: post-irradiated rats; I-A:
post-irradiated + aspirin; I-AT: post-irradiated + atorvastatin; I-S: post-irradiated + sildenafil. Data are
means ± SD of 5 hearts. a p < 0.05 vs. C (C vs. C-A, C-AT, C-S, I); c p < 0.05 treated C vs. treated I (C-A
vs. I-A; C-AT vs. I-AT; C-S vs. I-S).
2.6. Expression of miR-21 in Control and Irradiated Wistar Rats
The expression of myocardial miR-21 was significantly increased in both the LV and RV of the
post-irradiated rats compared to the non-irradiated controls (Figure 5). Six weeks of treatment with
the selected drugs significantly suppressed miR-21 expression in the left (Figure 5A), although to a
lesser extent in the RV (Figure 5B) following irradiation. There was no effect of drugs on miR-21 levels
in the non-irradiated control groups (Figure 5).
Figure 5. Myocardial expression of miR-21 in the LV (A) and RV (B) of non-irradiated and
post-irradiated Wistar rats with and without treatment. Endogenous U6 small nuclear RNA
(U6snRNA) was used to normalize miR-21. Abbreviations—C: control non-irradiated rats; C-A:
control + aspirin; C-AT: control + atorvastatin; C-S: control + sildenafil; I: post-irradiated rats; I-A:
post-irradiated + aspirin; I-AT: post-irradiated + atorvastatin; I-S: post-irradiated + sildenafil. Data are
means ± SD of 5 hearts. a p < 0.05 vs. C (C vs. C-A, C-AT, C-S, I); b p < 0.05 vs. I (I vs. I-A, I-AT, I-S);
c p < 0.05 treated C vs. treated I (C-A vs. I-A; C-AT vs. I-AT; C-S vs. I-S).
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3. Discussion
In the present study, we showed that exposure of rats to a single dose of chest irradiation at
25 Gy caused up-regulation in the expression of Cx43, PKCε, and PKCδ in the LV following six
weeks. In parallel, miR-1, which is known to repress GJA1 for Cx43 [3,6] was decreased. While
miR-21, which is involved in myocardial remodeling and apoptosis [3,6], was increased following
irradiation. These results are in accordance with our previous findings [6,10] and in line with the
reported enhancement of myocardial Cx43 protein and mRNA expression found in the rabbit heart in
response to heavy ion radiation [8,9]. Importantly, these alterations were associated with protection of
the heart against arrhythmia and infarction [8,10].
In the present study, we have also demonstrated that irradiation did not induce significant
changes in the expression of total Cx43 in the RV, although there was a trend towards an increase.
This may be in part due to the miR-1, which was not changed in the RV in contrast to its significant
suppression associated with the enhancement of Cx43 in the LV. Furthermore, neither PKCε nor
PKCδ expression was altered in the RV unlike its significant elevation in LV following irradiation.
Whether such distinct responses to irradiation in the LV and RV have any relationship with functional,
metabolic, structural, and other differences of the heart chambers [17,18] needs to be investigated.
Chamber related differences in Cx43 and PKC expression in response to altered thyroid status have
been previously suggested [19]. A higher metabolic rate and mechanical load of the LV seems to be
more prone to oxidative stress and injury. Nevertheless, our results suggest that cardiac response
to chest irradiation is associated with the up-regulation of myocardial Cx43 connected with the
suppression of miR-1 and enhanced PKCε and PKCδ signaling in the LV but not in the RV. On the
other hand, the expression of miR-21 was significantly increased in both the LV and RV following
irradiation. It is possible that the anti-apoptotic [20] and proliferation promoting effects of miR-21 [5]
may be pro-survival to cardiac tissue during the early period in response to radiation-induced injury.
Our results also show that treatment of the irradiated rats with aspirin and atorvastatin prevented
up-regulation of Cx43, i.e., its total and phosphorylated forms in the LV. Interestingly, none of the drugs
reduced the level of miR-1 in the LV following irradiation. These data suggest that apart from the
miR-1, other post-translational factors may modulate Cx43 levels in response to irradiation. Neither
atorvastatin nor aspirin had any effect on the basal myocardial expression of Cx43 in the non-irradiated
control rats.
The question arises, how aspirin or atorvastatin may affect changes in myocardial Cx43 protein
levels induced by single chest irradiation? Considering that both compounds exert protection
from oxidative stress and inflammation—the important culprits in irradiation-induced cardiac
injury [1,2]—it is reasonable to speculate that these drugs may suppress these processes. If so,
then cardiac stress would be attenuated and a subsequent compensatory response (most likely
mediated by free radicals and pro-inflammatory molecules signaling) will be reduced. Indeed, the
administration of antioxidants and/or scavengers of free radicals, such as hesperidin [21], melatonin [7]
or selenium [22] prior to irradiation attenuated oxidative stress, inflammation, and cardiomyocyte
necrosis. The potential use of statins as radioprotective agents has been recently reviewed, where
signaling pathways targeting pro-inflammatory NF-κB might be implicated [1]. In support of this
concept, it should be noted that unlike aspirin and atorvastatin, treatment with sildenafil (dominant
vasculo-protective drug) did not affect the myocardial Cx43 levels in irradiated rats. Moreover, aspirin
and atorvastatin but not sildenafil reduced expression of TNF-α in irradiated rats in our model, as
reported previously [23].
In general, oxidative stress and/or inflammation contribute to the impairment of intercellular
communication due to the acceleration of Cx43 and Cx43 interacting proteins that are in degradation
and/or dysfunction [24]. Consequently, down-regulation of Cx43 due to chronic redox disorders
and subclinical inflammation often accompanies cardiovascular disease [25,26]. On the other
hand, acute heart injury (e.g., intermittent ischemia) triggers endogenous pro-survival molecular
pathways, including up-regulation of Cx43, to protect heart function [27]. It appears that the
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heart may respond to stressors by compensatory/adaptive (such as up-regulation of Cx43) and
by maladaptive/decompensatory changes (down-regulation of Cx43). Accordingly, enhanced Cx43
level observed in the compensatory hypertrophy was induced by pressure overload, while reduced
Cx43 occurred in the decompensatory state [25].
Our results also show that the treatment of irradiated rats with aspirin and atorvastatin normalized
the myocardial expression of PKCε, which is associated with the expression of phosphorylated forms
of Cx43. These results suggest that oxidative stress and inflammation may modulate myocardial
PKCε, signaling and its cardioprotective role as shown in various conditions [28]. Interestingly,
treatment did not affect elevated myocardial PKCδ expression, i.e., its pro-hypertrophic signaling in
irradiated rat heart. However, the expression of pro-fibrotic miR-21 was significantly decreased in
the left heart ventricle by all tested drugs. Of note, miR-21 has been shown up-regulated in human
fibroblast cells due to various stress-inducing conditions, including radiation [3,29]. Thus, more
attention should be paid to elucidate the possible anti-fibrotic effects of atorvastatin, aspirin, and
perhaps sildenafil. Importantly, microRNA-21 has been reported as a novel promising target in cancer
radiation therapy [20] and atorvastatin was shown to suppress expansive remodeling by inhibition of
macrophage infiltration [30].
Taken together, we assume that protection of the heart from oxidative stress and inflammation
by appropriate drugs, including aspirin and atorvastatin or nonpharmacological compounds like
melatonin [7], omega-PUFA [31] may counteract compensatory responses and attenuate adverse
consequences of chest irradiation.
4. Materials and Methods
Animal experiments were approved by the Animal Research and Care Committee of the Institute
for Heart Research, Slovak Academy of Sciences—Project 1873/11-221/3, approved on 30 September
2011 and in accordance with the rules issued by the State Veterinary Administration of the Slovak
Republic, legislation No 289/2003. Rats were maintained on a 12:12 h’s light/dark cycle with access to
standard pellet and water ad libitum.
4.1. Experimental Model of Irradiation Induced Cardiac Injury
Three-month-old male Wistar rats were randomly divided into irradiated (n = 24) and
non-irradiated (n = 24) groups. Rats were anesthetized with Narketan (115 mg/kg body weight)
followed by myorelaxant Xylan (1 mg/kg body weight) and exposed to a single dose of 25 Gy of
ionizing radiation given locally on mediastinum at the area of the heart using the electron linear
accelerator UELR 5-1S (Producer NIIEFA St. Petersburg, RF, Russia), as described previously [6].
Control animals were shielded with lead plates. Non-irradiated controls (C) and irradiated (I) rats were
treated one day before, the day of irradiation, and for the next six weeks with aspirin (A; 3 mg/day),
atorvastatin (AT; 0.25 mg/day) or sildenafil (S; 0.3 mg/day) via a gastric tube. Doses of the drugs were
calculated from the maximal therapeutic dose for humans in relation to the rat body weight.
At the end of the experiment, hearts were excised from the anesthetized animals (thiopental,
65 mg/kg body weight) followed by the registration of the whole heart as well as left (LV) and right
ventricle (RV) weight. Frozen tissues from the heart ventricles were stored at −80 ◦C in freezer box
and used for the analysis of Cx43, PKCε and PKCδ expression by the Western blot method and for
miR-1 and miR-21 expression analysis by qRT-PCR.
4.2. Determination of Myocardial Cx43, PKCε and PKCδ Protein Expression
The western blot analysis was performed as previously described [6]. Briefly, the ventricular
samples (n = 6 per group) were powdered and solubilized in SB20 (20% SDS, 10 mmol/L EDTA,
0.1 mol/L tris(hydroxymethyl) aminomethane (TRIS), pH 6.8 by sonicator UP 100H (Hielscher, Teltow,
Germany). Total proteins (10–30 μg) from each sample were separated in 10% sodium dodecyl sulfate
polyacrylamide gels, transferred onto a nitrocellulose membrane, and blocked with 5% non-fat dry milk
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in Tris-buffered saline. For the determination of Cx43, the membrane was incubated with a primary
rabbit polyclonal antibody (diluted 1:4000; Anti-Connexin 43 C 6219; Sigma-Aldrich, St. Louis, MO,
USA). For PKCε and PKCδ determination, the nitrocellulose membrane was incubated with primary
rabbit polyclonal antibodies (PKCε Antibody, C-15: sc-214, Santa Cruz Biotechnology, Inc., PKCδ
Antibody, C-17: sc-213, Santa Cruz Biotechnology, Inc., Santa Cruz, CA, USA) diluted 1:1000, overnight
at 4 ◦C, followed by further incubation for 1 h at room temperature with a secondary donkey antibody
(peroxidase-labeled anti-rabbit, 1:2000, Amersham Biosciences, Piscataway, NJ, USA). After ECL
visualization, the densitometric analysis by Carestream Molecular Imaging Software (version 5.0,
Carestream Health, New Haven, CT, USA.) was done using a KODAK In-Vivo Multispectral System
FX. The measured values were normalized to the expression of GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) serving as a control [6].
4.3. Estimation of Myocardial miR-1 and miR-21 Levels
miR reverse transcription and TaqMan-based qRT-PCR analysis were performed as previously
reported [6]. Total RNA including small RNA was isolated from the frozen ventricular tissue
of the non-irradiated (n = 5 per group) and irradiated (n = 5 per group) Wistar rats using a
miRNA mini kit according to the manufacturer’s protocol (QIAGEN Sciences, Germantown, MD,
USA). The concentration and purity of the isolated RNA was checked using a Nanodrop ND-1000
spectrophotometer (Agilent Technologies, Santa Clara, CA, USA). Briefly, 10 ng of total RNA were
subjected for reverse transcription reaction with miRNA specific RT primers using microRNA reverse
transcription kit (Applied Biosystems, Foster City, CA, USA) in accordance to the manufacturer’s
instructions. Real time PCR was performed using a Roche Light cycler 480 II (Roche Applied Science,
Indianapolis, IN, USA). TaqMan miRNA assay probe (Applied Biosystems, Foster City, CA, USA) was
applied to determine the expression level of miR-1 and miR-21. Endogenous U6 small nuclear RNA
was used to normalize RNA content. Reverse transcription was performed using stem loop specific
microRT primers under the following conditions: 16 ◦C for 30 min, 42 ◦C for 30 min, and 85 ◦C for
5 min. The obtained cDNA was diluted in 1:3 ratios and subjected to real-time PCR using a TaqMan
amplicon specific assay probe under the following PCR cycle conditions: 95 ◦C for 10 min, 95 ◦C for
15 s, and 60 ◦C for 60 s [6].
4.4. Statistical Analysis
Data are expressed as means ± SD. One way two-tailed ANOVA and Tukey post hoc tests were
used for statistical analysis. p < 0.05 was considered as statistically significant.
5. Conclusions
In conclusion, we have demonstrated that irradiation related changes are less pronounced in the
RV as compared to the LV. Our results also suggest that treatment with aspirin and atorvastatin
attenuate irradiation-induced up-regulation of myocardial Cx43 and PKCε signaling as well as
miR-21 expression. Whether treatment related prevention or attenuation of irradiation-induced
myocardial alterations at the early responsive period might help to prevent adverse late effects needs
further investigations.
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Abstract: The molecular mechanisms governing the formation of lymphatic vasculature are not
yet well understood. Pannexins are transmembrane proteins that form channels which allow for
diffusion of ions and small molecules (<1 kDa) between the extracellular space and the cytosol.
The expression and function of pannexins in blood vessels have been studied in the last few decades.
Meanwhile, no studies have been conducted to evaluate the role of pannexins during human
lymphatic vessel formation. Here we show, using primary human dermal lymphatic endothelial cells
(HDLECs), pharmacological tools (probenecid, Brilliant Blue FCF, mimetic peptides [10Panx]) and
siRNA-mediated knockdown that Pannexin-1 is necessary for capillary tube formation on Matrigel
and for VEGF-C-induced invasion. These results newly identify Pannexin-1 as a protein highly
expressed in HDLECs and its requirement during in vitro lymphangiogenesis.
Keywords: lymphatic endothelial cells; pannexins; Panx1; lymphangiogenesis; cell invasion; Vascular
Endothelial Growth Factor-C (VEGF-C)
1. Introduction
Pannexin-1 (PANX1) is one of the three members of the Pannexin family with PANX2 and
PANX3 discovered through homology to the invertebrate gap-junction forming proteins, innexins [1,2].
Pannexins (PANXs) and Connexins (CXs) share similar protein structure while they lack amino
acid sequence homology [3]. By hexameric oligomerization PANX1 forms unopposed large-pore
channels [4,5] which allow the release of molecules up to 1 kDa into the extracellular space such as
ions, adenosine triphosphate (ATP) and other nucleotides [6,7]. PANX1 is ubiquitously expressed in
several organs and tissues [2,8–12] and is the best characterized isoform of the PANX family. For a
long time, PANX2 expression has been restricted to the central nervous system [13], but it is now well
described that PANX2 is also ubiquitously distributed throughout the body [14]. Similarly, PANX3
has been mainly described in cartilage, bone and skin [2,11,15–21] but accumulating evidences show
PANX3 expression in other tissues such as skeletal muscle, heart, cochlea, and arteries [2,15,18,22,23].
In line with the large PANX1 tissue distribution, this ATP release channel is directly or indirectly
involved in numerous physiological functions or pathologies such as inflammatory diseases [24] or
cancer [25,26]. However, little is currently known regarding the role of PANX1 in the vasculature.
PANX1 has been found to be expressed in vivowithin the vascular wall in arteries, arterioles, capillaries,
veinules and smooth muscle cells (SMCs) but not in veins [12,27] and in vitro in isolated blood
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endothelial cells (ECs) [28–30]. Panx1-deficient mice showed significantly impaired endothelial
function [31]. ATP release via PANX1 channels by either ECs or SMCs has been involved in the
regulation of vascular tone, inflammation, and cerebral ischemic stroke [30,32,33]. While many data are
available in blood vascular system, studies regarding roles of Panxs in regulating lymphatic vascular
development are currently missing [34]. The main role of the lymphatic system is to transport in
a unidirectional way extravasated fluids and macromolecules from tissues, through lymph nodes,
back to the blood circulation to maintain homeostasis [35]. Lymphangiogenesis, the formation of new
lymphatic vessels from preexisting ones [36,37], is associated with several diseases such as chronic
inflammation, graft rejection and metastatic dissemination [38]. Since the identification of the Vascular
Endothelial Growth Factor-C (VEGF-C) as the major lymphangiogenic factor [39], several other key
genes and proteins involved in lymphatic development have been identified. Among them, it has
recently been shown that at least three CX isoforms (CX37, CX43 and CX47) are expressed in developing
and mature lymphatic vessels [40–42]. These studies showed that these CXs are necessary for the
proper lymphatic valve development in collecting vessels and contribute to morphogenesis of the
jugular lymph sac and thoracic duct. Moreover, CX mutations or deficiency in mouse and humans
have been found to lead to lymphedema [40,43,44]. Regarding PANXs, no in vitro nor in vivo data
were available onto their expression and/or function in human lymphatic vasculature and only one
recent study has shown the expression of Panx1 in mouse LECs by qPCR [45]. This study aims to
investigate the expression of PANXs in human lymphatic endothelial cells and more particularly the
role of PANX1 during lymphangiogenesis.
2. Results
2.1. Human Lymphatic Endothelial Cells Express Pannexins
PANX1, -2 and -3 mRNA expression was examined by quantitative RT-PCR in human lymphatic
endothelial cells. As shown in Figure 1A, the expression of PANX1 was highest among the 3 PANX
gene family while PANX2 and PANX3 were barely expressed.
Interestingly, Western blot analysis demonstrated that all three PANX isoforms were expressed in
the HDLECs (Figure 1B). All PANXs were detected at the expected molecular weight. As previously
described, a specific banding pattern of three bands was revealed for PANX1 indicating three different
glycosylation states: Gly0, non-glycosylated core protein; Gly1, high-mannose species and Gly2,
complex glycosylated species [4,46].
Confocal imaging of HDLECs showed a clear localization of PANX1 to the plasma membrane and
in the perinuclear compartment (Figure 1C). Importantly, we found that VEGF-C, the main regulator
of lymphangiogenesis, increased PANX1 expression in HDLECs after 6 and 24 h treatment by 78 ± 5%
and 70 ± 5%, respectively (Figure 1D,E) whereas PANX2 and PANX3 expressions remained unaffected
(Figure S1). Taken together, these results show that PANXs are expressed in HDLECs. Since PANX1 is
the prevalent isoform and its expression is specifically modulated by VEGF-C, PANX1 is likely to be
involved in lymphatic function.
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Figure 1. Pannexin isoforms expression in human dermal lymphatic endothelial cells (HDLECs).
(A) PANXs mRNA expression in isolated HDLECs quantified by RT-PCR and normalized by GAPDH.
The data represent mean ± SD from three independent experiments; (B) Western blot analysis of total
protein extracts (20 μg/lane) from four independent HDLEC cultures demonstrating PANXs expression
in HDLECs. Unglycosylated (Gly0) and glycosylated isoforms (Gly1 and Gly2) of PANX1 are indicated;
(C) PANX1 immunofluorescence in HDLECs (red), F-actin was FITC-phalloidin stained (green) and
nuclei were DAPI-stained (blue). CTRL: control immunofluorescence after omission of the primary
antibody, Scale bar: 50 μm; Enlarged image marked by the white box shows higher magnification
of PANX1 staining, scale bar 7 μm; (D) Representative Western blot analysis and (E) densitometric
quantification of PANX1 expression normalized to GAPDH following 100 ng/mL VEGF-C treatment
for the indicated times in HDLECs. Values are expressed as mean ± SD from three independent
experiments. * p < 0.05 and ** p < 0.01.
2.2. Pharmacological Inhibitors of Pannexin-1 Modulate In Vitro Lymphangiogenesis
To investigate whether PANX1 might be involved in lymphangiogenesis we used the in vitro
tube-formation assay which is a well-established test based on the ability of LECs to form
three-dimensional capillary-like network when seeded on basement membrane extracts (Figure 2A,
untreated). Treatment of HDLECs with Probenecid or Brilliant Blue FCF resulted in a disorganized
tubular network (Figure 2A). Tube length complexes were significantly inhibited by 28 ± 4% and
20 ± 3% with probenecid at 0.1 and 1 mM respectively and inhibited by 21 ± 3% and 29 ± 4% with
Brilliant Blue FCF at 1 and 5 μM respectively (Figure 2B). Number of junctions were also significantly
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inhibited by 28 ± 4% and 22 ± 3% with probenecid at 0.1 and 1 mM respectively and inhibited by
25 ± 4% and 33 ± 6% with Brilliant Blue FCF at 1 and 5 μM, respectively (Figure 2B).
Figure 2. Inhibition of capillary-like formation in HDLECs by pharmacological inhibitors of Pannexin-1.
(A) Representative images of capillary network formation by HDLECs seeded on Matrigel and treated
with Probenecid, Brilliant Blue FCF or mimetic peptide 10Panx; (B) Quantitative analysis for total
length of tubule complexes and for total number of junctions in control and treated HDLECs. Data
represent the mean ± SD from three independent experiments conducted in triplicate. * p < 0.05 and
** p < 0.01.
The implication of PANX1 in this process was confirmed by a second set of experiments using the
mimetic inhibitory peptide 10Panx instead. Results showed that the lengths of the capillary-like
complexes and number of junctions in the HDLECs treated with 10Panx at 50 or 100 μM were
respectively 22 ± 2% or 34 ± 3% shorter and 25 ± 2% or 40 ± 4% lower than those observed in
the control group (Figure 2B).
2.3. Pannexin-1 Silencing Inhibits In Vitro Lymphangiogenesis
To confirm the role of PANX1, we decided to inhibit its expression in HDLECs by siRNA silencing.
Figure 3A shows that the siRNA significantly inhibited by 80 ± 11% the expression of PANX1 24 h after
transfection compared to scramble. We observed no compensation by PANX2 nor PANX3 expression
after PANX1 silencing (Figure 3B). Using the tube formation assay, PANX1 siRNA-transfected HDLECs
showed less extensive capillary formation compared to control (Figure 3C). Once again, quantitative
analyses showed that the total length of tubule complexes and the number of junctions formed by
HDLECs were significantly inhibited by 24 ± 4% and 34 ± 3% respectively when PANX1 was silenced
as compared with control (Figure 3D).
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Figure 3. Silencing Pannexin-1 expression affects capillary-like formation by HDLECs. (A) Representative
immunoblots of HDLECs extracts prepared 48 h after transfection with either the control or the
PANX1-specific siRNAs. GAPDH blot served as the loading control; Bar graph shows the quantification
of PANX1 expression loss 48 h after siRNA transfection. Data represent the mean ± SD from
four independent experiments; (B) Representative immunoblots and densitometric quantification
of PANX1, PANX2 and PANX3 expression from HDLECs extracts prepared 48 h after transfection
with either the control or the PANX1-specific siRNAs. GAPDH blot served as the loading control;
(C) Representative images of tube structure formation in HDLECs on Matrigel after transfection. Cells
transfected with PANX1 siRNAs showed defects in capillary network formation; (D) Quantitative
analysis for total length of tubule complexes and total number of junctions per field in control and
PANX1 siRNA-transfected HDLECs. Data represent the mean ± SD from six independent experiments
conducted in duplicate. * p < 0.05, ** p < 0.01 and *** p < 0.001.
2.4. Pannexin-1 Silencing Inhibits In Vitro HDLECs Invasion but Not Cell Proliferation
To investigate if PANX1 deficiency in HDLECs affected lymphangiogenesis by modulating cell
proliferation, we used the BrdU incorporation assay. The results showed that knockdown of PANX1
had no effect on HDLECs proliferation when LECs were grown in EGM-V2 media (Figure 4A).
Finally, we tested the hypothesis that PANX1 is important for HDLECs invasion and we
examined whether invasion of HDLECs induced by VEGF-C is affected by loss of PANX1 using
a modified Boyden chamber assay. Figure 4B shows the results of a typical invasion experiment.
The quantification revealed a significant inhibition of HDLECs invasion by 59 ± 6% after PANX1
expression silencing compared to scramble (Figure 4C) that can explain the disorganized capillary
network we observed previously.
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Figure 4. Loss of Pannexin-1 inhibits VEGF-C-mediated invasion of HDLECs. (A) HDLECs proliferation
measurement 48 h after transfection with either control of PANX1 siRNAs in EGM-V2 media.
Data represent the mean from three independent experiments conducted in triplicate (B) HDLECs
were transfected with either control or PANX1 siRNAs and subjected to Boyden chamber assays in
the presence or absence of VEGF-C (100 ng/mL). Representative images of HDLECs that invaded and
migrated through the membrane pores after 18 h are shown; (C) Bar graph represents the mean number
of invading cells. Results are expressed as the mean ± SD of three independent experiments conducted
in triplicate. ** p < 0.01.
3. Discussion
In this present work, we tested the hypothesis that Pannexin-1 is important for human
lymphatic endothelial cells to form capillary-like structures for extracellular matrix (ECM)-induced
morphogenesis.
We expected PANX1 to be present in human LECs because it is ubiquitously expressed in vivo [2],
in several cell lines [47], in human venous ECs [29,30,48] which share a common origin with
LECs [36,37] and in murine LECs [45]. Indeed, by quantitative RT-PCR, we found that PANX1 was
the most expressed member of the pannexin family in HDLECs. We also observed weak mRNA
expression of PANX2 and PANX3 which could confirm their wider expressions in the human body
as demonstrated by previous studies [14,15,18,22,23]. Additional work will be required to define the
possible role of PANX2 and PANX3 in lymphatic development especially in pathological situations,
since no major lymphatic phenotypic abnormalities are observed in adult mice deficient for these
PANXs [19,20,32].
Our study reveals that PANX1 exhibited diverse localization patterns in HDLECs. As expected,
based on its channel-forming ability, PANX1 localized at the plasma membrane [49,50]. PANX1 has also
been found in the perinuclear compartment which has already been observed with endogenous PANX1
in other primary cell cultures or cell lines such as osteoblasts [49] or astrocytes and neurons [51–53].
Interestingly, when PANX1 was transfected into human bone marrow ECs, PANX1 localized in the
endoplasmic reticulum (ER) and Golgi apparatus [8] and this pattern was observed in vivo in blood
ECs of the lens [9]. It is well documented that this pattern reflects the intracellular PANX1 trafficking
during which PANX1, as an unglycosylated core (Gly0), is glycosylated in the ER to a high-mannose
form (Gly1), and then, in the Golgi to a complex glycosylated form (Gly2), before reaching the plasma
membrane [4,46,54]. Our Western blot analysis obtained from HDLECs lysates revealed these multiple
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species of PANX1 which correlate with PANX1 distribution observed in HDLECs. Another possibility
to explain this intracellular localization is that PANX1 may form Ca2+-permeable channels in the
endoplasmic reticulum as observed in prostate cancer cells [55].
There is then no clear evidence that PANX1 might be essential for proper lymphatic vasculature
development. Indeed, neither the Panx1-deficient mice [56,57] nor the only first patient with a
PANX1 homozygous germline variant [58] display obvious phenotypes such as lymphedema that
would suggest alteration in lymphatic vasculature function. Recently, Molica et al. showed, using
double knock-out mice for Panx1 and Apoliprotein E (Apoe) to evaluate Panx1 role in atherosclerosis,
that Panx1 in this context is necessary for lymphatic function by contributing to the drainage of
interstitial fluid and to the uptake of dietary fat from the gut [47]. Nevertheless, in this study, there
was no detail regarding density and morphology of the lymphatic vasculature in this Panx1-/-ApoE-/-
mice as for the other Panx1-deficient models. In this present study, using three different strategies
to inhibit PANX1, we find that this pannexin is required for in vitro lymphangiogenesis. In addition,
we did not observe compensation by PANX2 or PANX3, in PANX1 siRNA-treated HDLECs that
failed to form in vitro a well-organized capillaries network. Given the apparent normal lymphatic
development in Panx1-deficient mice, it is possible that compensation by Panx2 or/and Panx3 arises
in vivo in LECs. This has been observed in muscle [23] and arteries [59] where Panx1 deletion caused
an increase in Panx3 expression which can also act as an ATP-release channel [60]. Additional work
using Panx1-deficent mice to study the expression of all the members of the pannexin family in the
lymphatic vasculature and in isolated LECs will be required to answer this question.
Lymphangiogenesis is a multistep process in which the proliferation and invasion abilities of
LECs play a fundamental role. Depending on the cell types, PANX1 may promote [61], decrease [11,62]
or have no effect on proliferation [23]. Our work shows that PANX1 knockdown did not change the
proliferative rate of HDLECs, which suggests that the inhibition of the in vitro lymphangiogenesis
that we observed is not due to an inhibitory effect on the cell cycle. Finally, we focused our work
on the role of PANX1 in invasion which is a process that combines both ECM degradation and cell
migration. We found out that PANX1, which was up-regulated in HDLECs by VEGF-C, is necessary
for the VEGF-C-mediated invasion of HDLECs. Since PANX1 was found at the plasma membrane of
HDLECs, it is reasonable to speculate that PANX1 acts as an ATP-release channel to explain its role
during this step. We hypothesize that the release of ATP modulates LECs function such as migration
through the activation of purinergic receptors as shown for other cell types [63,64]. Once bound to
these receptors, ATP might induce Ca2+ release from intracellular Ca2+ stores, a signaling pathway
that has been implicated in LECs migration and lymphangiogenesis [65,66]. LECs are known to
express four P2 purinergic receptors (P2RX4, P2RX7, P2RY1 and P2RY11) with high expression of
P2RX4 and P2RY1, and interestingly, inhibition of P2RY1 in presence of a specific antagonist impaired
ATP-induced migration of HDLECs [67].
Meanwhile, we cannot exclude the hypothesis that PANX1 has channel-independent roles in
regulating in vitro lymphangiogenesis. PANX1 directly interacts with the cytoskeleton through
its association with actin and Arp2/3 and this association has been shown to modulate cell
behavior [50,68,69]. Detailed molecular mechanism of PANX1-driven lymphangiogenesis is still
unclear. Future studies using mouse model with lymphatic-specific deletion of PANX1, PANX2 or
PANX3 will clarify their relative roles during developmental and pathological lymphangiogenesis.
4. Materials and Methods
4.1. Antibodies and Reagents
Rabbit polyclonal antibody against PANX1 was purchased from Sigma (HPA016930, St. Louis,
MO, USA). Rabbit polyclonal anti-PANX2 was purchased from Santa Cruz Biotechnology (sc-133880,
Santa Cruz, CA, USA). Mouse monoclonal anti-PANX3 was from R&D Systems (MAB8169,
Minneapolis, MN, USA). Mouse monoclonal anti-GAPDH antibody (5G4) was supplied by HyTest
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(Turku, Finland). Goat polyclonal HRP-conjugated secondary antibodies anti-Mouse and anti-Rabbit
were from Agilent Dako (P044701-2, Santa Clara, CA, USA) and Sigma (A0545), respectively.
Goat polyclonal Alexa Fluor 568-conjugated antibodies (anti-Mouse) were purchased from Molecular
Probes, Thermo Fisher Scientific (A-11011, Waltham, MA, USA). FITC-Phalloidin (F432) and DAPI
(D3571) were from Molecular Probes, Thermo Fisher Scientific. Calcein-AM was purchased from Sigma
(C1359). Silencer Pre-designed siRNA against PANX1 (134470) and Silencer Select negative control
siRNA (4390843) were obtained from Ambion, Thermo Fisher Scientific. Matrigel® matrix was obtained
from Corning (354234, Corning, NY, USA). Recombinant Human Vascular Endothelial Growth Factor-C
(VEGF-C) was obtained from Immunotools (11344692, Friesoythe, Germany) and reconstituted as a
100 μg/mL solution in sterile water. Probenecid (P8761) and Brilliant Blue FCF (80717) were purchased
from Sigma and reconstituted as 50 mg/mL solution in 1M NaOH and as 30 mg/mL solution
in sterile water, respectively. 10Panx mimetic peptide (Trp-Arg-Gln-Ala-Ala-Phe-Val-Asp-Ser-Tyr)
and Scrambled 10Panx control peptide (Phe-Ser-Val-Tyr-Trp-Ala-Gln-Ala-Asp-Arg) were from Tocris
Bioscience (Bristol, UK) and reconstituted as 0.5 mg/mL solution in PBS or water, respectively.
4.2. Cell Culture
Primary human dermal lymphatic endothelial cells (HDLECs) were obtained from Promocell
(Heidelberg, Germany) and grown in EGM-V2 media which consists of EBM-2 basal media
supplemented with 5% FCS and defined supplements such as epidermal growth factor (EGF), basic
fibroblast growth factor (bFGF), insulin-like growth factor 1 (long R3 IGF-1), vascular endothelial
growth factor A (VEGF-A), ascorbic acid and hydrocortisone. When HDLECs reached 80% confluency,
cells were trypsinized following the procedure recommended by Promocell and then plated at
1 × 103 cells/cm2. HDLECs were used up to passages 6–8 for all experiments.
4.3. Quantitative Real-Time PCR Analysis
1 × 105 HDLECs in 2 mL EGM-V2 medium were seeded in six-well plates and 24 h after, total
RNA was extracted using the NucleoSpin RNA XS kit (Macherey-Nagel, Düren, Germany). Reverse
transcription was performed with SuperScript II (Invitrogen, Thermo Fisher Scientific, Waltham,
MA, USA) from 2 μg of total RNA according to the manufacturer’s instructions. Gene expression was
assessed relative to GAPDH by quantitative PCR with the GeneAmp 7000 Sequence Detection System
and SYBR Green chemistry (Applied Biosystems, Thermo Fisher Scientific). Human GAPDH, PANX1,
PANX2 and PANX3 primer sequences are listed in Table S1. Sensitivity and specificity of each primer
couple were checked. For each primers, qPCR was also performed with plasmids containing the cDNA
of PANX1, PANX2 and PANX3, serving as positive controls.
4.4. Western Blot
1 × 105 HDLECs in 2 mL EGM-V2 medium were seeded in six-well plates. 24 h after, cells
were lysed with 30 μL extraction buffer (150 mM NaCl, 10 mM Tris-HCl, pH 8.0, 1 mM EDTA,
1 mM EGTA, 1% Triton X-100, 0.5% NP-40, 100 mM sodium orthovanadate) completed with 1×
protease inhibitors cocktail (Roche Applied Science, Penzberg, Germany). Protein concentration was
measured using DC protein assay kit (Bio-Rad Laboratories, Hercules, CA, USA). Afterwards 20 μg
total proteins samples were mixed with an equal volume of 5X SDS gel-loading buffer (150 mM
Tris-HCl, pH 6.8, 5% SDS, 12.5% 2-mercaptoethanol, 25% glycerol and 0.025% bromophenol blue).
Proteins were resolved using 10% SDS-PAGE gels and transferred to PVDF membranes (Merck
Millipore, Darmstadt, Germany). Membranes were blocked with 5% non-fat powdered milk in
Tris-buffered saline-Tween (TBS-T; 25 mM Tris-HCl, pH 8.0, 15 mM NaCl, 0.01% Tween 20) for 3 h
and incubated overnight at 4 ◦C with primary antibodies (anti-PANX1, 1:800; anti-PANX2, 1:350;
anti-PANX3, 1:1000). Membranes were then washed with TBS-T and incubated with corresponding
secondary horseradish peroxidase-conjugated antibodies (1:10,000) for 1 h. The anti-GAPDH antibodies
are used as the loading control (1:10,000). Immunodetection was performed using chemiluminescent
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substrate Luminata Forte (Merck Millipore) and LAS-3000 imaging system (Fujifilm, Tokyo, Japan).
Densitometric analysis of signals was carried out using ImageJ software (version 1.39o, National
Institutes of Health, Bethesda, MD, USA). Preliminarily to expression experiments, positive controls
samples were used to further validate the banding pattern of each antibody (Figure S2).
4.5. Immunofluorescence
HDLECs were plated on 0.1% gelatin-coated sterile glass coverslips in removable 12 well chambers
(Ibidi GmbH, Martinsried, Germany) at 2 × 104 cells/well in EGM-V2. After 48 h, HDLECs were
washed with 1X PBS and fixed in 4% PFA in 1X PBS at room temperature (RT) for 10 min. HDLECs
were then washed with 1X PBS and coverslips were blocked with 1% BSA, 1% Triton X100 in 1X
PBS at RT for 1 h. HDLECs were incubated overnight at 4 ◦C with anti-PANX1 primary antibodies
prepared in blocking buffer at 1:100 dilution. A negative control was performed by omitting the primary
antibody. The following day, HDLECswere incubatedwith Alexa Fluor 555 donkey anti-goat secondary
antibodies (1:500) in blocking buffer for 2 h at RT. F-actin filaments and cell nuclei were stained with
1 nM FITC-phalloidin (Life Technologies, Thermo Fisher Scientific, Waltham, MA, USA) and 100 nM
DAPI (Molecular Probes, Thermo Fisher Scientific) in 1X PBS for 30 min at RT. After extensive washing
with 1X PBS, cover slips were mounted with Mowiol fluorescent mounting medium and Images were
captured using a confocal microscope (Olympus FV1000, Tokyo, Japan). Control experiment omitting
primary antibody was also performed.
4.6. siRNA Interference
The siRNA sequence used for small-interfering RNA-mediated inhibition of PANX1 was the
following: PANX1 siRNA: 5′-AGGAUCCCUGAUUUGAUGCTG-3′. The siRNA sequence for the
non-targeting control siRNA was undisclosed by the manufacturer. Transfections were performed
using siPORT reagent according to the manufacturer’s instructions. 2 × 105 HDLECs in 2.3 mL
EGM-V2 medium were seeded in six-well plates. For each well, 5 μL siPORT Amine agent were
diluted into 100 μL Opti-MEM medium and incubated for 10 min at RT. 7.5 μL and 12.5 μL of PANX1
or scramble siRNA at 10 and 1 μM respectively were diluted into Opti-MEM. Diluted siRNA and
diluted siPORT Amine agent were mixed, incubated for 10 min at RT and finally dispensed onto
HDLECs. Medium was finally removed 24 h after transfection prior experiments. The efficiency of the
siRNA knockdown was determined by Western blot analysis 24 and 48 h post-transfection. XTT assay
confirmed non-cytotoxic effects of both siPORT and oligos after 24 h treatment on HDLECs (Figure S3).
4.7. Cell Proliferation
BrdU incorporation assay was used to monitor the mitogenic effects of the siRNA silencing of
PANX1. siRNA-transfected HDLECs were plated in 96-well plates at a density of 6 × 103 cells/well in
100 μL EGM-V2 and after 24 h bromodeoxyuridine (BrdU) was added into wells at a final concentration
of 100 μM and incubated overnight at 37 ◦C. BrdU incorporation rate was measured using “Cell
Proliferation ELISA, BrdU colorimetric kit” (Roche Applied Science, Penzberg, Germany) according
to the manufacturer’s instructions. Absorbance was measured at 450 nm with a 96-well microplate
reader after adding sulfuric acid to stop colorimetric reaction.
4.8. Tube Formation
96-well plates were coated with 50 μL/well of cold Matrigel and allowed to solidify for 1 h at
37 ◦C. HDLECs were trypsinized and 15 × 103 cells in 200 μL of EGM-V2 medium were loaded on the
solidified Matrigel in the presence or absence of PANX1 chemical inhibitors, Probenecid (at 1 or 2 mM
final) or BBFCF (at 1 or 5 μM final). In a second set of experiments, HDLECs were mixed and loaded
on Matrigel with the specific PANX1 mimetic peptide channel blocker, 10Panx or the control peptide at
50 or 100 μM. Finally, PANX1 or control siRNA-transfected HDLECs were used in the same conditions
than the native HDLECs in this assay. After 20 h, HDLECs were stained with 25 μM calcein-AM
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and then fixed with 2% PFA in 1X PBS. The 3-dimensional cell organization was photographed using
Olympus MVX10 macroscope (objective 1×/1; 22 ◦C; medium: PBS; Camera: Hamamatsu ORCA-03G;
cellSens Dimension Version 1.4 software Olympus, Tokyo, Japan). Capillary-like structures (length of
tubule complexes and number of junctions) were quantified by automatic counting in duplicate using
the AngioQuant Version 1.33 software. Previously to these experiments we have determined that the
concentrations of inhibitors used in this assay on the HDLECs were not cytotoxic (Figure S3).
4.9. Endothelial Cells Invasion
HDLECs migration was evaluated using 24-well cell culture inserts with 8-μm pores (BD
Biosciences, Franklin Lakes, NJ, USA). 24 h after siRNA transfection, HDLECs were rinsed with EBM-2
media, detached with trypsin and seeded at 5× 104 cells/100 μL 0.5% FCS EBM-2 onto Matrigel-coated
(25 μL of 1 mg/mL) inserts. The inserts were then placed in the 24-well plates containing 500 μL of
EBM-2 medium with or without 100 ng/mL recombinant human VEGF-C. The filters were removed
following incubation for 17 h at 37 ◦C and 5% CO2 and the Matrigel was wiped with a cotton swab.
The invasive HDLECs were fixed in 4% PFA for 10 min prior to staining with DAPI. Filters were
mounted with Mowiol fluorescent mounting medium and cells were photographed using an Olympus
MVX10 macroscope (objective 2X, Tokyo, Japan). Cells were counted using ImageJ software after
binarizing images.
4.10. Statistical Analysis
Statistical analyses were carried out on GraphPad Prism 5 software. All reported data are
expressed as mean ± SD. ANOVA followed by Bonferroni post-tests was performed for analysis of 3 or
more groups. Unpaired Student’s t-test (Mann-Whitney) was used when only 2 experimental groups
were analyzed.
5. Conclusions
In this study, we provide evidences that Pannexin-1 is expressed in human lymphatic endothelial
cells and is involved in in vitro lymphangiogenesis.
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Abstract: Pulmonary arterial hypertension (PAH) is a chronic condition characterized by vascular
remodeling and increased vaso-reactivity. PAH is more common in females than in males (~3:1).
Connexin (Cx)43 has been shown to be involved in cellular communication within the pulmonary
vasculature. Therefore, we investigated the role of Cx43 in pulmonary vascular reactivity using
Cx43 heterozygous (Cx43+/−) mice and 37,43Gap27, which is a pharmacological inhibitor of Cx37 and
Cx43. Contraction and relaxation responses were studied in intra-lobar pulmonary arteries (IPAs)
derived from normoxic mice and hypoxic mice using wire myography. IPAs from male Cx43+/−
mice displayed a small but significant increase in the contractile response to endothelin-1 (but not
5-hydroxytryptamine) under both normoxic and hypoxic conditions. There was no difference in
the contractile response to endothelin-1 (ET-1) or 5-hydroxytryptamine (5-HT) in IPAs derived from
female Cx43+/− mice compared to wildtype mice. Relaxation responses to methacholine (MCh)
were attenuated in IPAs from male and female Cx43+/− mice or by pre-incubation of IPAs with
37,43Gap27. Nω-Nitro-L-arginine methyl ester (L-NAME) fully inhibited MCh-induced relaxation.
In conclusion, Cx43 is involved in nitric oxide (NO)-induced pulmonary vascular relaxation and plays
a gender-specific and agonist-specific role in pulmonary vascular contractility. Therefore, reduced
Cx43 signaling may contribute to pulmonary vascular dysfunction.
Keywords: pulmonary arterial hypertension (PAH); connexin43 (Cx43); gap junction; vascular
reactivity; nitric oxide; serotonin; endothelin-1; isoprenaline
1. Introduction
Pulmonary arterial hypertension (PAH) is a progressive disease in which the mean resting
pulmonary artery pressure rises above 25 mmHg with a mean resting capillary wedge pressure lower
than 15 mmHg [1]. This increase in pressure is associated with both constriction and remodeling
of the distal pulmonary vasculature and eventually leads to right-sided heart failure. Prognosis is
poor and survival has been reported to only 68% after three years on therapy [2]. PAH is far more
common in females than in males (~3:1) [3]. Dysregulation of cell-to-cell communication particularly
between pulmonary artery endothelial cells (PAECs) and pulmonary artery smooth muscle cells
(PASMCs) is thought to play an important role in both constriction and remodeling of the pulmonary
vasculature in PAH [4]. For example, PAECs from patients with PAH have increased gene and protein
expression of tryptophan hydroxylase 1 (Tph1), which is the rate-limiting enzyme in the synthesis
of 5-hydroxytryptamine (5-HT) [5]. 5-HT causes contraction of pulmonary arteries and proliferation
of PASMCs [6]. In addition, PAECs from PAH patients produce decreased amounts of nitric oxide,
which is a potent vasodilator that suppresses proliferation of PASMCs [7].
Connexins are transmembrane proteins that can oligomerize to form a pore in the cell
membrane known as a hemi-channel with small regulatory molecules such as 3′,5′-cyclic
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adenosine monophosphate (cAMP), adenosine 5′ triphosphate (ATP), calcium (Ca2+), and inositol
1,4,5-triphosphate (IP3), which can pass directly through the cell membrane. Hemi-channels on
adjacent cells can align to form gap junctions that allow these mediators to pass directly from the
cytoplasm of one cell to that of another. Connexins 37 (Cx37), 40 (Cx40), 43 (Cx43), and 45 (Cx45)
are expressed in diverse networks throughout the vasculature [8–10]. In the systemic vasculature,
connexins have established roles in regulating vascular tone, vascular cell growth, angiogenesis, cell
differentiation, and development [11]. Pannexins belong to the same super-family as connexins and
also form membrane-associated channels that can mediate the release of small signaling molecules [12].
Pannexin-1 (Panx1) is expressed throughout the vasculature in the endothelium and also in the
medial layer of small resistance arteries [13] and has been shown to play an important role in the
α-adrenoceptor mediated contractile response [14].
Recent evidence suggests that dysregulated connexin signaling is involved in the pathophysiology
of PAH. For example, blood outgrowth endothelial cells from patients with PAH show abnormal
gap junctional communication. In addition, the nitric oxide synthase (NOS) inhibitor asymmetric
dimethyl arginine (ADMA), is upregulated in PAH patients and inhibits gap junctional communication
in human PAECs. The effects of ADMA are prevented by over-expression of Cx43 or by treatment
with rotigaptide, which enhances connexin coupling [15]. In line with this, Cx37 and Cx40 are
down-regulated in PAECs from PAH patients. Restoration of the transcription factor myocyte
enhancer factor 2 leads to increased expression of various transcriptional targets including Cx37
and Cx40. It also rescues pulmonary hypertension in experimental models [16]. Mice genetically
deficient in Cx40 are protected against hypoxic-induced pulmonary hypertension. Both genetic
knockdown and pharmacological inhibition of Cx40 attenuates hypoxic pulmonary vasoconstriction in
the mouse isolated perfused lung [17]. Moreover, contraction to phenylephrine (an α-1 adrenoceptor
agonist) in pulmonary arteries taken from chronic hypoxic and monocrotaline (MCT) treated rats
is inhibited by both 37,43Gap27 and 40Gap27 (connexin mimetic peptide blockers of Cxs37/ 43 and
Cx40, respectively) [18].
Furthermore, Cx43 has been shown to play a role in 5-HT mediated signaling in the pulmonary
vasculature. 5-HT can be synthesized in human PAECs by Tph1 and then released to act on neighboring
PASMCs to mediate both proliferation and contraction [6,19–21]. Studies have shown in experiments
using co-cultures of rat PAECs and rat PASMCs that 5-HT can pass through myoendothelial gap
junctions formed principally by Cx43 [22,23]. In line with this, 5-HT-induced contraction of isolated
rat pulmonary arteries was attenuated by 37,43Gap27 [18].
In the current study, we have assessed the role of Cx43 in pulmonary vascular reactivity using
pulmonary arteries from Cx43 heterozygous mice (Cx43+/− mice). Heterozygous mice were used
as a complete genetic knockdown of Cx43, which is lethal in mice [24]. In addition to assessing
vasoreactivity in Cx43+/− mice, we have also assessed vasoreactivity in the presence of 37,43Gap27.
Since PAH is more common in females than males [3], the role of Cx43 in vascular reactivity
was assessed in both male and female mice under normoxic conditions. Paradoxically, male mice
have previously been shown to develop more pronounced hypoxic-induced PAH than females [25]
and, therefore, our hypoxic experiments were conducted in male mice. Gene expression of Cx37
(encoded by GJA4), Cx40 (encoded by GJA5), Cx45 (encoded by GJC1), and Panx1 was assessed in
pulmonary arteries from Cx43+/− mice along with gene expression of various mediators known to play
a role in the development of PAH: Tph1, endothelial nitric oxide synthase (eNOS, encoded by NOS3),
and bone morphogenetic receptor type II (BMPRII, encoded by BMPR2). BMPRII mutations have been
found in patients with various forms of PAH [26]. Dysregulated bone morphogenetic protein (BMP)
signaling is thought to be pivotal to the pathophysiology of PAH [27].
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2. Results
2.1. Gene Expression of Connexins in Pulmonary Arteries from Cx43 heterozygous Mice
First, quantitative real time PCR (qPCR) was performed to confirm reduced gene expression
of Cx43 in pulmonary arteries of male and female Cx43+/− mice. Cx43 expression was higher in
females than in males in both WT and Cx43+/− mice (Figure 1A). Afterward, pulmonary arterial gene
expression levels of Cx43 with Cx37, Cx40, and Cx45 in wildtype mice were compared. Cx43 was the
predominant vascular connexin in female mice. In male mice, there was a trend towards Cx43 being
expressed at greater levels than Cx37 and Cx40, but this was not significant. Cx45 was expressed at
lower levels in both male and female mice (Figure 1B).
Figure 1. Connexin gene expression in pulmonary arteries from male and female mice. Cx43 gene
expression is reduced in pulmonary arteries from Cx43 heterozygous (Cx43+/−) mice (A). Female mice
have increased levels of Cx43 compared to males (A). Cx43 is the predominant vascular connexin in
female mice while male mice show similar levels of Cx43, Cx40, and Cx37. Cx45 is expressed in lower
levels than Cxs 43, 40, and 37 in both male and female mice (B). Data are presented as mean ± S.E.M.
and were analyzed by two-way ANOVA. n = 6 with each sample run in triplicate. A: * p < 0.05,
B: ** p < 0.01, **** p < 0.0001 compared to Cx43.
We explored the effects of genetic knockdown of Cx43 on gene expression of Cx37, Cx40, Cx45,
and Panx1, which are all expressed in the vasculature. Male Cx43+/− mice displayed reduced gene
expression of Cx37, Cx40, Cx45, and Panx1 mRNA (Figure 2A–D) when compared to WT littermates.
Female Cx43+/− mice, however, displayed no changes in gene expression of Cx37, Cx40, Cx45, or Panx1
compared to WT littermates (Figure 2A–D). The housekeeping gene β2-microglobulin was expressed
at similar levels in all four groups of mice studied (Ct values: male WT 24.9 ± 0.2, male Cx43+/−
24.4 ± 0.2, female WT 25.0 ± 0.2, female Cx43+/− 24.6 ± 0.3, p = 0.86).
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Figure 2. Gene expression of Cx37 (A), Cx40 (B), Cx45 (C), and Panx1 (D) in pulmonary arteries
from male and female wildtype (WT) and Cx43 heterozygous (Cx43+/−) mice. Data are presented as
mean ± S.E.M. and were analyzed by two-way ANOVA. * p < 0.05, ** p < 0.01, n = 6 per group with
each sample analyzed in triplicate.
2.2. Pulmonary Arterial Contractile Responses
In the intra-lobar pulmonary arteries (IPAs) of male mice, endothelin-1 (ET-1) was more potent
(had a lower median effective concentration or EC50 value) in Cx43+/− mice compared to WT mice
(Figure 3A; Table 1). Maximal response to ET-1 (Emax) was, however, unchanged between WT and
Cx43+/− mice. There was no global shift in the concentration response curve (Figure 3A; Table 1).
IPAs from male Cx43+/− mice showed similar contractile responses to 5-hydroxytryptamine (5-HT) as
those from WT mice (Figure 3B; Table 1). Contractile responses to both ET-1 and 5-HT were similar in
IPAs from female Cx43+/− mice compared to female WT mice (Figure 3C,D; Table 1).
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Figure 3. Pulmonary vascular contractility to ET-1 and 5-HT in intralobar pulmonary arteries (IPAs)
from male and female wildtype (WT) and Cx43 heterozygous (Cx43+/−) mice. ET-1 was more potent in
IPAs from male Cx43+/− mice than WT mice (A). There was no difference in contractile response to 5-HT
in IPAs from male WT and Cx43+/− mice (B). There was no difference in ET-1 (C) or 5-HT (D) induced
contractile response in IPAs from female WT or Cx43+/− mice. Data are shown as mean ± S.E.M.
Global differences in concentration response curves were compared by two-way ANOVA. Changes
in logarithm of median effective concentration (Log EC50) and maximal contractile responses (Emax)
between two different groups were analyzed by using the Student’s t-test. * EC50 is significantly
(p < 0.05) reduced in male Cx43+/− mice, n = 5–7 per group.
Table 1. The contractile effects of ET-1 and 5-HT in IPAs of male and female wildtype (WT) and Cx43
heterozygous (Cx43+/−) mice.




Male WT −8.46 ± 0.08 131.8 ± 2.5
NS
6
Male Cx43+/− −8.77 ± 0.12 * 127.4 ± 2.8 5
ET-1
Female WT −8.31 ± 0.06 126 ± 2.2
NS
5
Female Cx43+/− −8.48 ± 0.04 130.3 ± 4.5 7
5-HT
Male WT −6.67 ± 0.05 112.7 ± 2.8
NS
6
Male Cx43+/− −6.64 ± 0.07 118.9 ± 4.8 5
5-HT
Female WT −6.82 ± 0.05 119.6 ± 3.5
NS
5
Female Cx43+/− −6.83 ± 0.1 116.6 ± 6.7 5
Log EC50 indicates logarithm of median effective concentration. Emax maximal contractile effect. Global differences
in concentration response curves were compared by two-way ANOVA. Changes in logarithm of median effective
concentration (Log EC50) and maximal contractile responses (Emax) between two different groups were analyzed by
the Student’s t-test. NS: not significant. * p < 0.05 compared to male WT mice. Data are shown as mean ± S.E.M.
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2.3. Pulmonary Arterial Relaxation Responses
The relaxation response produced by methacholine (MCh) was significantly reduced in IPAs
of both male and female Cx43+/− mice when compared to WT mice (Figure 4A,B; Table 2).
Pharmacological inhibition of Cx43 with 37,43Gap27 also significantly attenuated the relaxation
responses produced by MCh in IPAs of both male and female mice (Figure 4C,D; Table 2).
We then confirmed that MCh-induced relaxation responses were dependent upon nitric oxide
(NO) since the L-NAME completely inhibited MCh-induced relaxation (Figure 4E; Table 2). Then we
assessed the role of Cx43 in isoprenaline-induced relaxation. Isoprenaline is classically thought to
induce relaxation via the cAMP pathway. In these experiments, the relaxation induced by isoprenaline
was partially inhibited by 37,43Gap27 (Figure 4F; Table 2). Furthermore, we showed nitric oxide plays
a role in isoprenaline-induced relaxation since the L-NAME partially attenuated isoprenaline-induced
relaxation (Figure 4G; Table 2).
Figure 4. Cont.
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Figure 4. Effects of genetic reduction or pharmacological inhibition of Cx43 on pulmonary vascular
relaxation responses. Male (A) and female (B) Cx43 heterozygous (Cx43+/−) mice show reduced
relaxation in response to MCh. Pre-incubation with 37,43Gap27 also reduced the relaxation response
in male (C) and female (D) mice. MCh-induced relaxation was ablated in the presence of L-NAME
(E). 37,43Gap27 partially inhibited isoprenaline-induced relaxation in IPAs from male mice (F) as did
L-NAME (G). Global differences in concentration response curves were compared by two-way ANOVA.
Changes in logarithm of median effective concentration (Log EC50) and maximal relaxation responses
(Rmax) between two different groups were analyzed by using the Student’s t-test. Data are shown as
mean ± S.E.M. * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001, n = 5–6 per group. Statistical symbols
shown on the right hand side of graphs indicate global shifts in the concentration response curves.
Statistical symbols underneath curves indicate changes in maximal relaxation (Rmax) values.
Table 2. Log EC50 (logarithm of median effective concentration) and Rmax (maximal relaxation) values
for MCh-induced or isoprenaline-induced relaxation.
Agonists Groups Log EC50 (M) Rmax (%)
Global Shift in Concentration
Response Curve n
MCh
Male WT −6.93 ± 0.08 55.6 ± 6.8
****
5
Male Cx43+/− −7.14 ± 0.21 ** 28 ± 4.1 ** 5
MCh
Female WT −6.52 ± 0.14 55.3 ± 8.5
****
6
Female Cx43+/− −6.48 ± 0.24 26.8 ± 7.8 * 6
MCh
Male WT −6.39 ± 0.2 42.1 ± 4.6
****
6
Plus 37,43Gap27 −6.08 ± 0.1 **** 22.9 ± 5.6 * 6
MCh
Female WT −6.8 ± 0.08 63.1 ± 4.8
****
6
Plus 37,43Gap27 −6.36 ± 0.1 ** 42.2 ± 5.2 * 6
MCh
Male WT −6.27 ± 0.11 32.8 ± 4.6
****
6
Plus L-NAME not applicable 2.2 ± 3.4 *** 6
Isoprenaline Male WT −7.77 ± 0.17 92.1 ± 1.19 **** 5Plus 37,43Gap27 −7.41 ± 0.16 80.8 ± 4.2 * 5
Isoprenaline Male WT −7.84 ± 0.2 86.7 ± 3.2 **** 6Plus L-NAME −7.5 ± 0.13 60.4 ± 4.3 *** 6
Global differences in concentration response curves were compared by two-way ANOVA. Changes in logarithm of
median effective concentration (Log EC50) and maximal relaxation responses (Rmax) between two different groups
were analyzed by using the Student’s t-test. Data are shown as mean ± S.E.M. * p < 0.05, ** p < 0.01, *** p < 0.001
and **** p < 0.0001.
2.4. Gene Expression of Bone Morphogenetic Protein Receptor Type II, Tryptophan Hydroxylase 1,
and Endothelial Nitric Oxide Synthase in Pulmonary Arteries from Cx43 Heterozygous Mice
Since Cx43+/− mice displayed dysregulated pulmonary vascular reactivity, gene expression of
BMPRII (encoded by BMPR2), eNOS (encoded by NOS3), and Tph-1, mediatorsimportant for regulating
pulmonary vascular function, were assessed. Expression of BMPR2, NOS3 , and Tph-1 were not
significantly altered in either male or female Cx43+/− mice compared to WT littermates (Figure 5A–C).
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The expression of NOS3 and BMPR2 were significantly lower in female WT mice when compared to
male WT mice (Figure 5A,B).
Figure 5. Gene expression of BMPRII (encoded by BMPR2) (A), eNOS (encoded by NOS3) (B), and Tph1
(C) in pulmonary arteries of male and female WT and Cx43+/− mice. No differences were observed in
expression of BMPR2, NOS3, or Tph1 between WT and Cx43+/− mice (either male or female). BMPR2
and NOS3 were significantly downregulated in female WT mice compared to male WTs. Data are
presented as mean ± S.E.M. and were analysed by using two-way ANOVA. * p < 0.05, n = 6 per group
with each sample run in triplicate.
2.5. Effects of Hypoxia on Pulmonary Vascular Contractility in Male Cx43 Heterozugous Mice
The effects of chronic hypoxia on pulmonary vascular reactivity in Cx43+/− mice were investigated.
The hypoxic experiments were carried out in male mice since it has been previously shown that male
mice are more susceptible to hypoxic-induced PH than female mice [25]. Both WT and Cx43+/−
mice developed the right ventricular hypertrophy after two weeks of chronic hypoxic exposure,
which verifies the mouse hypoxic model (Figure 6A). IPAs derived from chronic hypoxic Cx43+/− mice
showed an increased sensitivity to ET-1, which was assessed by a reduced EC50 value and a global
leftward shift in the contractile response. In addition, the maximal contractile effect produced by ET-1
was significantly greater in IPAs from hypoxic Cx43+/− mice than from hypoxic WT mice (Figure 6B;
Table 3). There was no difference in a contractile response to 5-HT in IPAs from hypoxic Cx43+/− mice
(Figure 6C; Table 3).
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Figure 6. Assessment of the development of right ventricular hypertrophy by right ventricular weight
ratio left ventricle plus septal weight (RV/LV+Septum) (A). Concentration response curves (CRCs)
to ET-1 (B) and 5-HT (C) in intra-lobar pulmonary arteries derived from hypoxic wildtype (WT) and
hypoxic Cx43 heterozygous (Cx43+/−) mice. Data are shown as mean ± S.E.M. Data in panel A were
analyzed by two-way ANOVA. In panels B and C, global differences in CRCs were compared by
two-way ANOVA. Changes in the logarithm of median effective concentration (Log EC50) and maximal
contractile responses (Emax) between two different groups were analyzed by using the Student’s t-test
* p < 0.05, ** p < 0.01, *** p < 0.001, n = 5–7 per group. The statistical symbol shown on the right hand
side of graph B indicates a global shift in the CRC. The symbol underneath the curve indicates changes
in the median effective concentration (EC50) while the symbol above the curve indicates changes in the
maximal response (Emax).
Table 3. The contractile effects of ET-1 and 5-HT in intra-lobar pulmonary arteries of hypoxic wildtype
and Cx43 heterozygous mice.
Agonists Genotypes Log EC50 (M) Emax (%)
Global Shift in Concentration
Response Curve n
ET-1
Hypoxic WT −7.95 ± 0.06 91.7 ± 8.1
**
6
Hypoxic Cx43+/− −8.07 ± 0.09*** 112.7 ± 5.6 * 7
5-HT
Hypoxic WT −6.56 ± 0.04 126 ± 2.2
NS
7
Hypoxic Cx43+/− −6.5 ± 0.03 130.3 ± 4.5 7
Log EC50 indicates the logarithm of median effective concentration, Emax maximal contractile effect.
Global differences in concentration response curves were compared by using two-way ANOVA. Changes in
logarithm of median effective concentration (Log EC50) and maximal contractile responses (Emax) between two
different groups were analyzed by using the Student’s t-test. NS: not significant * p < 0.05, ** p < 0.01, *** p < 0.001.
Data are shown as mean ± S.E.M.
235
Int. J. Mol. Sci. 2018, 19, 1891
2.6. Effects of Hypoxia on Expression of Cx43 in Mouse Lung and Pulmonary Artery
Afterward, the effects of chronic hypoxia on Cx43 gene and protein expression were assessed.
Using qPCR, it was shown that hypoxia significantly down-regulated Cx43 gene expression in
both WT and Cx43+/− male mice (Figure 7A). We then used immunofluorescence to visualize the
effects of hypoxia on Cx43 protein expression. Lung expression of Cx43 (green fluorescence) was
reduced in hypoxic WT mice when compared to normoxic WT mice (Figure 7B). Furthermore,
Cx43 immunoreactivity was further reduced in lungs of hypoxic Cx43+/− mice when compared
to normoxic Cx43+/− mice (Figure 7B).
 
Figure 7. Cx43 expression in pulmonary arteries of wildtype (WT) and Cx43 heterozygous (Cx43+/−)
mice under normoxic and chronic hypoxic conditions. Cx43 gene expression is reduced by hypoxia in
both WT and Cx43+/− mice (A). Confocal images of Cx43 immunofluorescence staining in normoxic
and hypoxic WT and Cx43+/− mouse lung tissue sections are shown in (B). Green fluorescence punctate
findings represent Cx43 immunoreactivity and blue staining represents nuclei. Scale bars represent
10 μm. For panel A, data is presented as mean ± S.E.M. and was analyzed by two-way ANOVA,
* p < 0.05, n = 6 with each sample run in triplicate.
236
Int. J. Mol. Sci. 2018, 19, 1891
2.7. Effects of Hypoxia on Gene Expression in Pulmonary Arteries Derived from WT and Cx43+/− Mice
As chronic hypoxia mediated increased vascular reactivity to ET-1 and decreased Cx43 expression,
the effects of chronic hypoxia on the expression of other vascular connexins and Panx1 were assessed
(Figure 8 A–D). Hypoxia mediated a downregulation of Cx40 gene expression in WT mice (Figure 8B)
while gene expression of Cx45 was up-regulated by hypoxia in Cx43+/− mice (Figure 8C). Hypoxia had
no effect on the expression of Cx37 or Panx1 in WT or Cx43+/− mice (Figure 8A,D).
Gene expression of BMPR2, Tph1, and NOS3 in response to hypoxia in Cx43+/− mice was also
assessed. BMPR2 was downregulated by hypoxia in WT mice and Tph1 was up-regulated by hypoxia
in Cx43+/− mice. There were no differences in BMPR2, NOS3, or Tph1 expression between hypoxic WT
and hypoxic Cx43+/− mice (Figure 8E–G).
Figure 8. Gene expression of Cx37 (A), Cx40 (B), Cx45 (C), Panx1 (D), BMPRII (E), eNOS (F) and Tph1
(G) in pulmonary arteries of wildtype (WT) and Cx43 heterozygous (Cx43+/−) mice under normoxic
and chronic hypoxic conditions. All data are presented as mean ± S.E.M. and were analyzed by
two-way ANOVA. * p < 0.05, ** p < 0.01, n = 6 per group with each sample run in triplicate.
3. Discussion
To our knowledge, this is the first study to show that mice genetically deficient in Cx43 develop
pulmonary vascular dysfunction. It is also the first study to show that Cx43 plays a role in NO-induced
pulmonary vascular relaxation. These findings add to the growing body of evidence that suggests that
Cx43 is involved in regulation of the pulmonary vasculature. Since PAH is associated with altered
pulmonary vascular reactivity, these data suggest Cx43 is worthy of further investigation as a novel
therapeutic target for PAH.
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Relaxation responses to MCh were reduced in IPAs from both male and female Cx43+/−
mice. Subsequently, we found that pharmacological inhibition of Cx43 using 37,43Gap27 also
attenuated MCh-induced relaxation. 37,43Gap 27 inhibits both Cx37 and Cx43 and both Cx37 and
Cx43 are down-regulated in male Cx43+/− mice. However, the vascular connexins of only Cx43
are downregulated in female Cx43+/− mice. Therefore, reduction of MCh-induced relaxation in
female Cx43+/− mice suggests an important role for Cx43 in this effect. Our studies confirmed that
MCh-induced relaxation was NO-dependent since the MCh mediated relaxation responses were
completely abolished in the presence of L-NAME. It is widely considered that NO can diffuse
through the endothelial and smooth muscle cell membranes to activate guanylate cyclase within
the smooth muscle cell and mediate vasodilation. It has been shown, however, that diffusion of
NO across the vascular cell membrane requires specific connexin channels [28]. NO opened and
permeated hemichannels expressed in HeLa cells transfected and selected to express Cx43, Cx40,
or Cx37. In addition, the blockade of connexin channels abolished myoendothelial NO transfer
and NO-dependent vasodilation induced by acetylcholine in rat mesenteric arteries [28]. There is
also mounting evidence that NO can interact with gap junctions in a complex and inter-dependent
fashion [29]. Cx43 is constitutively S-nitrosylated at cysteine 271 by NO at the myoendothelial gap
junctions. This nitrosylation keeps the myoendothelial gap junction open and denitrosylation closes
the gap junction channel [30]. Additionally, NO has been shown to enhance gap junction coupling and
increase trafficking of Cx40 to the membrane in endothelial cells via the protein kinase A activation [31].
Cx40 has been shown to co-localize with eNOS in the mouse aorta and is involved in conducting
vasodilation [32]. Cx40 knock out (Cx40−/−) mice showed reduced basal and acetycholine induced
NO release and reduced eNOS expression in aortas [32]. However, NO can act as a negative regulator
of Cx37, which reduces Cx37-mediated dye transfer and electrical coupling in human umbilical
vascular endothelial cells (HUVEC) and mouse microvascular endothelial cells [33,34]. Therefore,
it is possible that Cx43 and NO interact in such a fashion that when Cx43 is genetically downregulated
or pharmacologically inhibited, it leads to a reduction in NO-mediated vasorelaxation. In the present
study, pulmonary arterial gene expression of eNOS was unchanged in male and female Cx43+/− mice
when compared to WT controls. It would, however, be of interest to investigate eNOS protein levels
and also MCh-induced NO release in pulmonary arteries from WT and Cx43+/− mice. It would also be
of interest to investigate potential interactions between eNOS and Cx43 using co-immunoprecipitation.
37,43Gap27 also mediated a small but significant inhibition of isoprenaline-induced relaxation.
Isoprenaline is classically thought to act through the cAMP pathway. In the present study,
isoprenaline-induced relaxation was, however, partially inhibited by L-NAME, which suggests
that NO plays a role in isoprenaline-induced relaxation. A previous study has also shown β2
adrenoceptor induced relaxation in mouse pulmonary arteries are attenuated by the L-NAME,
endothelial denudation, or deletion of eNOS [35]. β2 adrenoceptors have been detected in the mouse
pulmonary endothelial layer by immunostaining [35]. The inhibitions of isoprenaline relaxation
mediated by 37,43Gap27 and L-NAME were of a similar magnitude. It is, therefore, possible that
inhibition of connexin mediated communication via 37,43Gap27 inhibits the NO component of
isoprenaline relaxation. In future studies, it would be of interest to analyze whether smooth muscle
responses to NO are affected by downregulation of Cx43. This could be achieved using an NO donor
such as sodium nitroprusside.
Enhanced ET-1 mediated contraction was observed in IPAs derived from both normoxic and
hypoxic male Cx43+/− mice compared to their WT counterparts. Normoxic female Cx43+/− mice
did not show an increased contractile response to ET-1. However, male Cx43+/− mice showed
downregulation of Cx37, Cx40, Cx45, and Panx1. These effects were not observed in female Cx43+/−
mice. Downregulation of Cx37, Cx40, Cx45, or Panx1 may, therefore, play a role in the increased
contractile response to ET-1 observed in the male Cx43+/− mice. The reduced Cx43 expression
observed in the pulmonary arteries of male mice compared to female mice observed in this study
may also contribute to the increased effects of ET-1 in male Cx43+/− mice. Gender differences in the
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endothelin system may also contribute to contractile differences between male and female Cx43+/−
mice [36]. Studies have shown that plasma endothelin levels were higher in men when compared
to women [37,38]. At the receptor level, the ratio of ETA and ETB receptors in the endothelium of
saphenous vein was greater in male subjects (3:1) than in female subjects (1:1) [39]. Haemodynamically,
a rat model showed pressor responses induced by intravenous administration of ET-1 were greater
in male rats than in female rats [40]. In vitro cell culture studies have also confirmed that 17-β
oestradiol (E2) inhibited ET-1 gene expression through the extracellular signal regulated kinase
(ERK) pathway [41].
5-HT mediated contractile responses in the IPAs were not affected by the partial loss of Cx43
in either male or female mice under either normoxic or hypoxic conditions. Therefore, the effects of
reduced Cx43 gene expression varied according to the agonist used. These results agree with previously
published data showing that the effects of pharmacological inhibition by 37,43Gap27 on contractile
responses in IPAs were dependent on the agonist used [18]. In line with the current results, Billaud et al.
showed that 37,43Gap27 had no effect on 5-HT induced contraction in IPAs derived from hypoxic rats.
However, they did report that 37,43Gap27 could inhibit 5-HT induced contraction in IPAs from normoxic
rats. In contrast with the results reported here showing that downregulation of Cx43 enhanced ET-1
mediated contraction in IPAs form both normoxic and hypoxic Cx43+/− mice, Billaud et al. found
that 37,43Gap27 had no effect on ET-1 induced contraction in IPAs derived from normoxic or hypoxic
rats [18]. 5-HT and ET-1 have different mechanisms of contraction. Since connexins are modulated
by PKA, PKC, and calcium [42], the role of connexin mediated communication in the contractile
response differs according to the agonist used. A possible reason for the disparity between the
Billaud study and our own could be due to the ratiometric changes in the balance of Cx43:Cx40:Cx37
expression between rats and mice. A number of studies have reported tissue and species specific
variation in connexin expression profiles and 37,43Gap27 is defined as being specific to the SRPTEKTIFII
sequence—conserved between Cx43 and Cx37 but different in Cx40 [43–46]. In addition, Cx43+/−
mice will have compensatory changes in other genes, which may affect the contractile response while
37,43Gap27 inhibits Cx37 as well as Cx43. This also potentially affects the contractile response.
In the gene expression studies, Cx43 expression was higher in female mice than in male mice.
This is in keeping with a report which showed that Cx43 expression was higher in rat cardiomyocytes
derived from females than males [47]. Furthermore, treatment with oestradiol increased Cx43
expression in human myometrium [48]. In addition to this, there is direct evidence that estrogen
can regulate Cx43 gene expression since the promotor region of Cx43 gene contains an estrogen
response element [49].
Chronic hypoxic rodents are a commonly used model for PAH. In the current study, the chronic
hypoxia suppressed Cx43 gene and protein expression are located in the pulmonary arteries of both WT
and Cx43+/− mice. Hypoxia can regulate Cx43 expression post-translationally by phosphorylation [50].
For example, one study showed exposure to hypoxia is associated with an increase in phosphorylation
of Cx43- serine 368 (Ser368) in human microvascular endothelial cells and this phosphorylation
was associated with downregulation Cx43 protein expression [51]. As hypoxia downregulates Cx43
expression, it would be of interest in future studies to assess the effects of hypoxia on MCh-induced
relaxation in Cx43+/− mice. The current study showed Cx40 expression was also downregulated in
hypoxic WT mice. Previous studies have shown that Cx40 expression was reduced during PAH in rats
and treatment with sildenafil increased Cx40 expression via BMP signaling [52,53]. We found Cx45
expression to be upregulated in the Cx43+/− mice under chronic hypoxic conditions. The function of
Cx45 in the vasculature remains unknown even though it has long been known to be expressed in
vascular smooth muscle cells [54].
It is interesting to note that Cx43+/− mice did not develop increased right ventricular hypertrophy
(RVH) in response to hypoxia compared to their wildtype counterparts. It has previously been
shown by ourselves and others that changes in pulmonary vascular pressures and pulmonary
vascular remodeling do not always lead to the development of RVH in mice. For example, increased
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pulmonary pressures and remodeling have been observed in the absence of RVH in mice that
over-express the serotonin transporter, mice that over-express Mts 1, and mice that are dosed with
dexfenfluramine [55–57]. In addition, Cx43 is highly expressed in cardiac myocytes and is thought
to play an important role in hypertrophy of these cells. Expression and localization of Cx43 in
cardiac myocytes has been shown to be dynamically regulated in various animal models of cardiac
hypertrophy [58]. Therefore, it is possible that cardiac myocytes from Cx43+/− mice are functionally
abnormal and, therefore, have an atypical hypertrophic response to hypoxia.
Female Cx43+/− mice did not exhibit the compensatory reduction in gene expression of Cx37,
Cx40, Cx45, or Panx1 that was observed in male Cx43+/− mice. Multiple lines of evidence show
that Cx43, Cx40, and Cx37 are interdependent on each other and compensatory changes occur upon
connexin deletion. For instance, in Cx40 knock out (Cx40−/−) mice both total and smooth muscle Cx43
protein expression was reduced in the mouse aortas [59]. In addition, in Cx40−/− mice, the pericellular
component of Cx43 staining was lost and there was increased redistribution of Cx43 in the perinuclear
region [59]. This suggests deletion of Cx40 not only leads to Cx43 downregulation but also affects
its trafficking. Conversely, another group found that Cx40−/− mice showed upregulation of Cx37
and Cx43 in the aortic endothelium [60]. In Cx40−/− neonatal mice, Cx37 protein expression was
downregulated in the endothelium and there was an increased Cx37 and Cx43 in the medial layer [61].
Genetic deletion of Cx37 in mice showed reduction in endothelial Cx40 [61]. In the present study,
we have assessed changes in gene expression in the whole pulmonary artery. It would be of interest to
assess cell type specific changes in future studies.
Gene expression of eNOS, BMPRII, or Tph1 were not affected by the loss of Cx43 under normoxic
or hypoxic conditions. Among the normoxic WT mice, eNOS and BMPRII expression was reduced
in the females compared to male WT mice. The literature on eNOS expression in PAH patients is
contradictory. eNOS was initially reported to be decreased in lungs of PAH patients [62], but evidence
later found eNOS expression was unchanged or even increased in PAH patients [63,64]. Furthermore,
NO levels have been shown to be reduced in PAH patients [65] and it has been reported that the
activity of eNOS rather than its expression was altered in a murine model of PAH [63]. Our findings
show that BMPRII expression is reduced in pulmonary arteries from female mice, which is in line
with proof that activation of the estrogen response element in the promoter region of BMPRII can
downregulate BMPRII expression [66].
In conclusion, this study has shown that Cx43 plays a role in NO-dependent vasodilation in the
pulmonary vasculature. Cx43 is also involved in pulmonary vascular contractility. However, effects
on contractility are gender-dependent and agonist-dependent. Hypoxia has been shown to decrease
Cx43 expression in mouse pulmonary arteries, which is an effect that may contribute to the increased
vasoreactivity observed under hypoxic conditions.
4. Materials and Methods
4.1. Ethical Statement
All experimental procedures were carried out in accordance with the United Kingdom Animal
Procedures Act (1986) and with the “Guide for the Care and Use of Laboratory Animals” published
by the US National Institutes of Health (NIH publication no.85, eighth edition). Ethical approval was
granted by the Glasgow Caledonian University Animal Welfare and Ethics Committee (PPL70/7875,
16 September 2013).
4.2. Animals
Male and female wild-type (WT) and Cx43 heterozygous (Cx43+/−) mice (C57BL6, 5 to 9 months
old) were used in this study. The generation of Cx43+/− mice was originally carried out by replacing
exon 2 of the Cx43 gene with the neomycin resistance gene, which was previously described [24].
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Mice were grouped under standard laboratory conditions. All mice had access to a commercial diet
and water ad libitum.
4.3. Genotyping
DNA was extracted from ear notch tissues derived from WT and Cx43+/− mice. Tissues
were suspended in 300 μL TNES buffer [10 mM tris(hydroxymethyl)aminomethane (Tris), 0.4 M
sodium chloride (NaCl), 100 mM ethylenediaminetetraacetic acid (EDTA), and 0.6% sodium dodecyl
sulphate (SDS)] to which 1.5 μL proteinase K (Fisher Scientific, Loughborough, UK) was added.
Samples were then incubated overnight at 55 ◦C. The next day, 84 μL of 5 M NaCl was added
to each sample and samples were centrifuged for 10 min. The supernatant was collected and
transferred to fresh tubes. DNA was precipitated by adding 200 μL ice cold 100% ethanol
to each tube and vortexing. Samples were then centrifuged for 10 min, the supernatant was
discarded, and the pellet was retained. Excess salt was removed by adding 200 μL ice cold 75%
ethanol and samples were centrifuged again for 10 min. The supernatant was decanted gently
and the pellet was allowed to air dry. The pellet was then re-suspended in 15 μL nuclease-free
water and stored at −20 ◦C until use. A polymerase chain reaction (PCR) was then carried out
to amplify the Cx43 (GJA1) and neomycin resistance (neor) genes. The primers used were as
follows: neor forward 5′-GATCGGCCATTGAACAAGATG, melting temperature (Tm) = 56.4 ◦C,
molecular weight (MW) = 6808.5, neor reverse: 5′-CCTGATGCTCTTCGTCCAGAT Tm = 57.2 ◦C,
MW = 6637.3, Cx43 forward: 5′-CAGTCTGCCTTTCGCTGT, Tm = 56 ◦C, MW = 5433; Cx43 reverse:
5′-GTAGACCGCACTCAGGCT, Tm = 58 ◦C, MW = 5485. All primers were purchased from Integrated
DNA technologies, Belgium. PCR reactions were performed in a thermal cycler (MJ Research PTC-100
Thermal Cycler, Watertown, MA, USA) and comprised an initial denaturation at 95 ◦C for 3 min
followed by 40 cycles of: denaturation at 95 ◦C for 30 s, annealing at 55 ◦C for 30 s, and extension at
72 ◦C for 1 min. A final extension step was carried out at 72 ◦C for 15 min. Samples were then run in
2% agarose gel (v/v) for 45 min at 100 V.
4.4. Induction of Hypoxia
For induction of hypoxia, male WT and Cx43+/− mice were placed in a hypobaric chamber for
14 days, which is previously described [19]. The pressure was adjusted to 550 mbar (equivalent to 10%
v/v O2) slowly over two days to allow mice to acclimate. The temperature was maintained at 20–22 ◦C.
Control littermates were kept in a normoxic environment.
4.5. Tissue Preparation
Mice were euthanized by injection of phenobarbitone (60 mg/kg i.p.). After death was
confirmed, the chest walls were opened using the mediastinal approach and the hearts and lungs were
dissected freely.
4.6. Wire Myography Studies
Pharmacological experiments were carried out in third generation intra-lobar pulmonary arteries
(IPAs; ~300 μm internal diameter), which was previously described [67,68]. IPAs were mounted on
a wire myograph (Danish Myo Technology, DMT) in freshly prepared Krebs-Henseleit Solution
(composition (mmol/L) NaCl 119, KCl 4.7, CaCl2 2.5, MgSO4 1.2, NaHCO3 25, KH2PO4 1.2,
and D-glucose 5.5) at (37 ◦C) and gassed with 95%O2 / 5% CO2. All chemicals required for
Krebs-Henseleit solution were purchased from Fisher Scientific except CaCl2 which was purchased
from VWR International Ltd. (Lutterworth, Leicestershire, UK). Following equilibration for one
hour, IPAs from normoxic mice were placed under pressures of 12–15 mmHg and IPAs from hypoxic
mice that were placed under pressures of 30–35 mmHg to mimic the in vivo environment described
previously [67]. Arteries were initially constricted with potassium chloride (KCl, 60 mM), which were
then washed out. These processes were repeated two times before contractile or relaxation experiments
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were carried out. For contractile experiments, cumulative concentration response curves (CCRCs) to
5-HT (1 nM–300 μM) or ET-1 (0.1 nM–0.1 μM) were constructed. For relaxation experiments, vessels
were pre-constricted with phenylephrine (PE; 3 μM) and CRCs to MCh (0.1 nM–30 μM) or isoprenaline
(1 nM–30 μM) were constructed. In a subset of relaxation experiments, vessels were incubated with
37,43Gap27 (100 μM) for 30 min prior to MCh or isoprenaline-induced relaxation responses. 37,43Gap27
has previously been shown to have an IC50 of 31.5 ± 4.1 μM and to produce a maximum effect
at 100 μM [69]. We previously used 37,43Gap27 at 100 μM [70–72]. In another subset of relaxation
experiments, the L-NAME (100 μM) was used to inhibit eNOS. In these experiments the L-NAME was
applied for 30 min prior to pre-constriction with PE and the concentration of PE was reduced to 30 nM.
It should be noted that 30 nM PE in the presence of L-NAME produced a similar contractile response to
3 μM PE alone. Changes in isometric tension were recorded on LabChart 7 software (AD Instruments
Pty Ltd., Bella Vista, New South Wales, Australia). PE, L-NAME, MCh, ET and 5-HT were purchased
from Sigma-Aldrich Company Ltd. (Gillingham, Dorset, UK).
4.7. Quantitative Real Time PCR (qPCR)
Main and branch pulmonary arteries (1st and 2nd order) were homogenized and RNA was
extracted using the Nucleospin RNA kit (MACHEREY-NAGEL GmbH & Co. KG, Düren, Germany)
as per the manufacturer instructions. RNA was then reverse transcribed to cDNA using the Precision
nanoScriptTM 2 Reverse Transcription Kit (Primerdesign Ltd., Chandler’s Ford, UK), according to
the manufacturer’s protocols. qPCR was performed using Precision PLUS 2x qPCR master mix
(Primerdesign Ltd.) II with taqman primers described in Table 4. β2-microglobulin (B2M) (assay ID:
HK-DD-mo-300, Primerdesign Ltd.) was used as the endogenous control and the sequences for the
B2M were kept confidential by Primerdesign Ltd.
qPCR reactions were run in a real time PCR thermo-cycler machine (ViiaTM 7 Real Time PCR
System, ThermoFisher Scientific, Loughborough, UK) using the following conditions: 50 ◦C for 2 min
and 95 ◦C for 10 min followed by 40 cycles of 95 ◦C for 15 s and 60 ◦C for 1 min. Gene expression was
analyzed by the 2ΔΔCt method. Samples from at least six mice were used for each group and reactions
for each sample were run in triplicate.
Table 4. TaqMan probe primers and their sequences for qPCR reactions.












































Sagittal sections (7 μM) were cut from lung embedded at an optimal cutting temperature (OCT)
compound using a cryostat (CryostarTM NX70 Cryostat from, Thermofisher Scientific). Sections were
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fixed in ice cold (−20 ◦C) methanol for 20 min and rehydrated in phosphate buffer saline (PBS, pH = 7.4).
Sections were permeablised in PBS containing 0.1% (v/v) Triton-X100 before being blocked in 5% (w/v)
skimmed milk in PBS solution for 30 min at room temperature. Sections were stained with primary
antibody (rabbit polyclonal anti-Cx43, 1:100; Sigma-Aldrich Company Ltd., Gillingham, Dorset, UK)
and incubated at 4 ◦C overnight. The next day, sections were washed in PBS for 30 min at room
temperature and incubated with secondary antibody (goat anti-rabbit conjugated to Alexa flour 488,
1:500; Fisher Scientific) at 4 ◦C for 2 h. Nuclei were counter-stained with DAPI (1:1000; Thermofisher.
Loughborough, UK). Mounting medium was applied on tissue sections and cover slides were applied.
Slides were then examined under the LSM 800 Carl ZEISS confocal microscope, (Königsallee, Germany)
for immunoreactivity.
4.9. Statistical Analysis
All data were shown as mean ± S.E.M. Data for cumulative concentration response curves
(CRCs) were analyzed using GraphPad Prism 6 software (La Jolla, CA, USA). Data were fitted to
a logistic equation, CRCs were generated, and EC50 values were derived. Global differences in CRCs
were compared by two-way ANOVA with the Bonferroni’s post hoc test. Changes in the logarithm
of median effective concentration (Log EC50), maximal contractile responses (Emax), and maximal
relaxation responses (Rmax) between two different groups were analyzed by using the Student’s t-test.
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Abstract: Since their characterization more than five decades ago, gap junctions and their structural
proteins—the connexins—have been associated with cancer cell growth. During that period,
the accumulation of data and molecular knowledge about this association revealed an apparent
contradictory relationship between them and cancer. It appeared that if gap junctions or connexins
can down regulate cancer cell growth they can be also implied in the migration, invasion and
metastatic dissemination of cancer cells. Interestingly, in all these situations, connexins seem to be
involved through various mechanisms in which they can act either as gap-junctional intercellular
communication mediators, modulators of signalling pathways through their interactome, or as
hemichannels, which mediate autocrine/paracrine communication. This complex involvement of
connexins in cancer progression is even more complicated by the fact that their hemichannel function
may overlap with other gap junction-related proteins, the pannexins. Despite this complexity, the
possible involvements of connexins and pannexins in cancer progression and the elucidation of the
mechanisms they control may lead to use them as new targets to control cancer progression. In this
review, the involvements of connexins and pannexins in these different topics (cancer cell growth,
invasion/metastasis process, possible cancer therapeutic targets) are discussed.
Keywords: cancer; connexin; growth control; invasion; metastasis; pannexin; therapeutics
1. Introduction
The majority of cancers in adults are solid tumours [1]. Whatever their tissue origin, those tumours
are characterized by two fundamental properties, which are, first, an uncontrolled cell proliferation
forming the tumour itself and then an acquired invasion capacity leading to the dissemination of
cancer cells in the organism. Fifty years of investigation have shown involvement of gap junctions
(GJs) or their molecular components, the connexins (Cxs), in these two fundamental characteristics of
cancer progression [2–4]. More recently, it appeared that the involvement of Cxs could be complicated
by the fact that they can act independently from the establishment of gap-junctional intercellular
communication (GJIC). For instance, Cxs may be involved in these mechanisms through their
interactome to modulate signalling pathways [5] or by acting as hemichannels (Hcs) mediating
autocrine/paracrine communication [6]. This last activity may overlap with pannexins (Panxs) which
are Cx-related proteins (Figure 1) [7].
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Figure 1. Connexin and pannexin molecules and channels formed by these molecules. As molecules,
connexins (Cx) and pannexins (Panx) have similar topology with four transmembrane and intracellular
(Intra.) NH2 and COOH domains. In the left panels, both kinds of molecules are shown in a “spread”
way to distinguish their topology (1) and in a “condensed” way (2) to better represent as transmembrane
subunits of channels (centre panels) and gap junctions (right panel). In humans, 21 subtypes of
connexins have been characterized, which are differentially expressed in tissues [8]. They are named
according to their expected molecular weight (kDa) from the smallest connexin (Cx23: 23 kDa) to the
largest one (Cx62: 62 kDa). The best-known member of the connexin family is the connexin43 (Cx43)
which is the most common in the organism. Only 3 pannexin subtypes are known in human (PANX1,
PANX2, PANX3) [9,10]. Except for Cx26, connexins can be phosphorylated mostly at their intracellular
COOH tail (red spots) [11]. The level of phosphorylation potentiallymodifies channel gating, interaction
with intracellular or other membrane proteins (connexin interactome) and thus their function and life
cycle [11,12]. So far, pannexins do not appear to be regulated by phosphorylation as connexins are but
they are more characterized as potentially N-glycosylated (green spots) molecules at their extracellular
(Extra.) domain. Both connexins and pannexins can aggregate to form hexameric transmembrane
channels permitting the passive passage of ions (e.g., Ca2+) and small (<1–1.5 kDa) hydrophilic
molecules such as nutrients (e.g., glucose: Glu), amino acids (e.g., glutamate: Glut), nucleotides
(e.g., ATP) and second messengers (e.g., cAMP and IP3). Theoretically, connexin-made channels
(connexons also called hemichannels) and pannexin-made channels (pannexons) are permeable to
the same type of ions and molecules even if pannexons permeability has been mostly studied for
ATP, Ca2+ and glutamate (Glut). Moreover, connexons from one cell can dock with connexons of
juxtaposed cells forming intercellular channels aggregated in gap junctions which permit the direct
intercellular transfer from cytosol to cytosol (gap-junctional intercellular communication, GJIC) of
same ions and molecules as isolated connexons. So far, no pannexon-made gap junctions have been
described in physiological/pathological conditions. The term connexon is mostly used to define the
transmembrane unit of gap junctions. When isolated in the plasma membrane, connexons are usually
called hemichannels and can open with various stimuli such as, for example, hypoxia. For clarity in
the figure, putative phosphorylation sites (red spots) and N-glycosylated sites (green spots) are not
shown in channels and gap junctions.
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Possible involvements of Cxs and Panxs in cancer progression and the elucidation of the
mechanisms they control lead to their use as new possible targets to control cancer progression [13,14].
Here, we will review the involvement of Cxs and Panxs in these different topics, which are cancer cell
proliferation, invasion/metastasis process and as possible targets for cancer control.
2. Connexins and Pannexins Involvement in Tumour Cell Growth
2.1. Connexins Involvement in Tumour Cell Growth
Shortly after their characterization, GJs were thought to be involved in growth regulation [15].
This assumption was the consequence of the possibility to estimate GJ functions through electrical
coupling or diffusion of small hydrophilic fluorescent tracers [16,17]. By using such approaches, it
rapidly appeared that cells derived from solid tumours (hepatoma, thyroid tumours, etc.) were not
able to communicate through GJs [18,19]. These seminal studies introduced the notion that lack of
GJ coupling could be a fundamental process in cancer leading to the formation of solid tumours by
uncontrolled cell growth [15]. In other terms, growth regulation was the very first physiological role
attributed to GJs and their mediation of a direct intercellular communication.
During the following decades, the involvement of GJIC in cancer cell growth regulation has been
supported by a wide range of data. An early observation was about tumour promoter agents acting as
inhibitors of GJIC [20,21]. This was observed in several models and reinforced the parallel between
decreased GJIC and increased cell growth [22,23]. This parallel was extended to all kinds of phenomena
able to inhibit GJIC such as cancer-causing viruses [24]. And such a phenomenon was so widely
observed that it has been proposed that any GJIC inhibitor could be a potential tumour promoter [25].
If the tumour promoting effects of these chemicals were mostly known from in vitro studies, in some
cases, GJIC inhibition effect could also be observed in vivo with transgenic mice exhibiting higher
tumour susceptibility when defective for specific Cxs [26,27]. One of these best examples is liver
since Cx32 gene knockout (KO) mice were shown to be more susceptible than wild-type mice to liver
carcinogenesis after chemical treatments or even spontaneously [26]. This example was relevant to
rodent and human situations for which liver tumours were correlated with lack of GJIC either by loss
of expression or aberrant cytoplasmic localization of Cx32, respectively [28,29].
Conversely, strategies permitting the recovery of GJIC, by increasing Cx expression from
non-communicating cancer cells, were expected to decrease cell growth. And indeed, globally this was
the case as shown by approaches using chemical treatments or cDNA transfection. Chemicals known
to be putative chemopreventing agents (flavonoids, carotenoids, retinoic acids, etc.) appeared to act
on transformed cell lines by inducing GJIC and decreasing cell growth [30,31]. Cx cDNA transfection
in GJIC-defective cancer cell lines brought similar conclusions that Cx expression is accompanied
by decreased cell growth. This was observed in a variety of cancer cells (hepatoma, glioma, breast,
etc.) in vitro and in vivo [32]. However, the type of transfected Cx was important since such an effect
was mostly observed when the Cx of the normal tissue (before transformation or cancer progression)
was re-expressed [33,34]. These results suggested that a recovery of GJIC is not sufficient by itself to
have tumour suppressive effects but should be specifically controlled by the Cx subtype depending
probably on the permeability capacity of the GJ it forms.
Thus, significant data accumulated over 50 years supported a similar conclusion. Whatever the
models or the approaches (in situ detection of Cxs in tumours, cancer cell lines, chemical treatments,
transgenic mice, cDNA transfection, etc.), the global conclusion is that Cx expression/GJIC is inversely
correlated to cell growth. All these data have been analysed and synthesized in many reviews during
past decades [2–4,32]. By considering all these observations, two kinds of molecular mechanisms can
explain the involvement of Cxs in tumour cell growth regulation. The first one is to describe how Cxs,
when present, can control cell growth. The second kind of molecular mechanisms, which are also
needed for explaining the link between Cxs and cell growth, has to elucidate the origin of the lack of
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Cx expression or function which is observed in tumour cells. These are the two kinds of mechanisms
that will be reviewed below.
2.1.1. How Can the Presence of Connexins Regulate Cell Growth?
Most data attempting to elucidate how Cxs control cell growth came from Cx cDNA transfection
in cancer cell lines. And from such approaches, whatever the cell types which were used (osteosarcoma,
liver or lung carcinoma cells, etc.), a constant observation was that the increased expression of the
original Cxs was followed by a longer G1 cell cycle phase slowing down the cell proliferation rate
(Figure 2). A global analysis of these results suggests that this effect was the consequence of p27
accumulation [35,36]. From this common fact, diverse observations were made such as inhibition of
enzymatic activity of Cyclin-dependent kinases (CDK) [36] and decreased amount of Cyclin D1 [37]
and S-phase kinase-associated protein 2 (Skp2) [36,38,39]. To our knowledge, so far, no direct molecular
link between Cx presence and the regulation of cell cycle has been demonstrated. Besides such an
effect of Cxs on nuclear regulation of the cell cycle, it has been shown that Cxs can also act on the level
of expression of growth factors. For instance, Cx43 re-expression but not Cx32, in C6 glioma cells is
related to a decreased amount of milk fat globule-EGF factor 8 (MFG-E8) mRNA through an unknown
mechanism (Figure 2) [40]. Therefore, Cx expression is mostly related to change of expression of
growth factors or/and cell cycle regulators (p27, Cyclin D1, etc.). The most obvious scenarios for
explaining how Cxs, when localized at the plasma membrane, can control gene expression might
be through two major pathways. A first one would be through the Cx interactome by controlling
growth transduction signalling and the second would be by diffusing growth regulators through GJs.
Interestingly, as reported in the literature, both mechanisms have been observed and can explain the
specificity of cell growth control induced by Cxs.
Figure 2. Connexin-mediated negative control of cell proliferation. Cx43 negatively regulates cell
growth by acting differently on activators (red) and inhibitors (blue) of cell proliferation. This regulation
is mediated through various mechanisms in which Cx43 acts by itself (1), as a sequestrator (2) of growth
regulators (e.g., CCN3, PTEN, Csk, c-Src), as a mediator of GJIC (3), through hemichannel activity (4)
or its 20 kDa carboxyl tail (CT)-domain (5). These various mechanisms act on the nucleus (thick black
arrows) to decrease cell proliferation. Some of these mechanisms are mediated by hemichannel or
gap-junction permeability (thick blue arrows). Positive (+)/negative (−) effects of Cx43 on cell cycle
regulators (p27, Cyclin D1, etc.) and c-Src effect on Cx43 are also shown (thin blue arrows).
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Gap-Junctional Intercellular Communication and Cell Growth Control
As mentioned above, the effect of Cx43 and Cx32 on cell growth has been extensively studied
through various experimental models (cDNA transfection, transgenic mice, etc.) and appears to be
specific. This specificity can be explained by their differential permeability which is illustrated
by adenosine whose permeability is shifted from Cx32 to Cx43 channels by adding phosphate
residues [41]. From such an observation, Cx channels appear as putative filters of intercellular
signals that can be the consequence of the channel itself (diameter, amino-acid composition) or
the configuration of the carboxyl tail (CT) which is sensitive to phosphorylation such as Cx43
channels closed by Src activation [42]. To our knowledge, a direct link between GJIC and growth
regulation can be found in three situations. The first one is about the osteoblastic model in which
extracellular growth stimulation induces the synthesis of second messengers that transit through
GJs to activate extracellular signal-regulated kinase (ERK) and phosphatidylinositol-4,5-bisphosphate
3-kinase (PI3)/Akt serine/threonine kinase 1 (Akt) pathways. The translocation of ERK into the
nucleus activates transcription factors that recognize a Cx-response element (CxRE) and induce
osteocalcin and collagen I-1 expression [43]. Another example finally could explain the specific tumour
suppressor effect of Cx26 on HeLa cells that was described two decades ago [33]. This effect seems to
be the consequence of the maintenance of Cx26-mediated GJIC during the G2/M phase which permits
intercellular cyclic 3′,5′-adenosine monophosphate (cAMP) redistribution able to delay the cell cycle
progression (Figure 2) [44]. And more recently, it was shown that not only metabolites like cAMP
could act as growth regulators passing through GJIC but also microRNAs (miRNAs) (Figure 2). As an
example, the transmission of anti-proliferative effects from miR-124-3p-transfected to non-transfected
glioma cells was mediated by GJIC [45]. Similarly, GJIC was shown to inhibit cancer cell growth
by transferring miRNAs from endothelial cells in vitro [46]. And interestingly, it was observed that
miRNA transfer can occur also by delivering from exosomes in which Cx43 facilitates the release of
content into target cells [47].
Cell Growth Control Independent from Gap-Junctional Intercellular Communication
The specific effect of Cxs in cell growth control can come also from their cytoplasmic domains
(internal loop and CT domain) which are unique in length and amino-acid sequences [8]. It has been
known for a long time that these parts and in particular the CT domain, can interact directly with
cytosolic/membrane proteins. Such interactomes have been mostly described for Cx43 for which
about 40 different proteins have been identified as interacting ones [12,48]. From such observations, it
became clear that the interactome may participate both to cell growth regulation by controlling channel
permeability (i.e., channel closure due to Src-induced tyrosine phosphorylation of the Cx43 CT domain)
or by modulating signalling pathways from the plasma membrane to the nucleus. For this last case, it
has been postulated that the CT domain of Cxs could control, through sequestration, the translocation
of putative transcription factors from the cytosol to the nucleus (Figure 2). Such a behaviour has been
described for Cx32 with Discs large homolog 1 (hDlg1) in hepatocytes [49] and for Cx43 with CCN3 in
rat C6 glioma cells [50,51]. In this last case, down regulation of Cx43 permits the translocation of CCN3
to the nucleus which activates cell growth (Figure 2) [50]. Such a situation can explain why glioma
cell growth is higher when Cx43 expression is repressed and vice-versa. A similar situation has been
shown for the transcription factor ZO-1–associated nucleic acid–binding protein (ZONAB) [52]. More
recently, the tumour suppressive effect of Cx43 expression could be explained by the region 266–283 in
the CT domain of Cx43 which is able to recruit PTEN and C-Terminal src kinase (Csk) to inhibit the
oncogenic activity of c-Src (Figure 2) [53]. It is also possible that such a phenomenon could still happen
when Cx43 is localized in the cytoplasm. Even if it has not been described yet, it would explain the
down regulation of growth which was observed in human glioblastoma cells after transfection of Cx43
which was mainly localized in the cytoplasm [54].
In this last example, Cx43 signal was also detected in the nucleus of the cells [54].
The anti-proliferative effect associated with a nuclear signal of Cx43 is more intriguing. This effect
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could be due to the Cx43 CT domain since the transfection of that part only was followed by decreased
growth in several cell types (HeLa, Neuro2a and HEK293 cells) [55–57]. It has been suggested that
the Cx43 CT domain would then act as a transcription factor but this hypothesis has not been proven
yet (Figure 2). However, a 20 kDa isoform which corresponds to the Cx43 CT domain is known to be
translated in some cell types under certain conditions activated in cancer cells and hypoxia [58]. Its
function is not known yet even if it has been shown to act as a chaperone protein for trafficking of
Cx43 to the cell membrane [59] and for microtubule dependent mitochondrial transport [60].
Finally, to be complete, Cxs are known to form Hcs in the plasma membrane (Figure 1) [61].
Study of those Hcs has been growing this last decade, especially for Cx43 but their link with cell
proliferation is still not obvious even if adenosine triphosphate (ATP) release and modulation of Ca2+
concentrations were correlated with decreased cell proliferation in several cell types [62]. In osteocytes,
they have been found to be involved in suppression of breast cancer cell growth and bone metastasis
using transgenic mouse models expressing dominant-negative mutants inhibiting either GJIC and/or
Hcs [63]. With recent development of new research tools, such as Cx-interacting peptides, antibodies
and dominant-negative mutants, the distinctive mechanisms of GJs versus Hcs, although still limited
start to be elucidated. However, the action of Cx Hcs can still be confounded with Panx channels
(Figure 1).
2.1.2. What Does Prevent Connexin Expression or Function during Tumour Progression?
The expression of Cxs is often decreased in tumours whatever their origin [32]. Such a decreased
expression may then participate to increase tumour growth by preventing the molecular mechanisms
controlled by the presence of Cxs that were reviewed in the previous section. The molecular events
leading to the disappearance of Cxs are not known precisely but could come from two mechanisms
acting either at the transcriptional or at the post-transcriptional levels of Cx expression.
At the transcriptional level, similar to other genes which are shut down during tumour
progression, Cx genes could be the target of epigenetic control. However, data about such a
transcriptional control of Cx expression are not abundant in the cancer context even if it was suggested
two decades ago [64]. In HeLa cells, silencing of the Cx43 gene was thought to be controlled by DNA
methylation [65]. Loss of Cx32 function through hypermethylation is necessary for the development
of renal cell carcinoma at the early carcinogenic process [66,67]. The CpG island hypermethylation
level was associated with heavy smoking, poorly-differentiated tumour and low expression of Cx43 in
non-small cell lung cancer [68]. More recently, hypermethylation of the Cx45 gene has been linked to
its reduced expression in colon cancer [69]. This field of research is probably under investigated and
would reveal if pursued that epigenetic phenomena are more involved than expected in the control of
Cx expression.
At the post transcriptional level, Cx function can be regulated by ubiquitination, glycosylation,
S-nitrosylation and in particular, phosphorylation of the CT domain. This has been mostly studied
for Cx43 whose phosphorylation regulates GJIC through different mechanisms such as Cx trafficking,
connexon assembly, channel gating and GJ degradation [11]. And indeed, in the cancer context, many
oncogenes encode for kinases (i.e., c-Src) or proteins activating kinases (growth factor receptors) that are
known to phosphorylate Cx43 and modulate its function [70]. As an example among others, epidermal
growth factor (EGF) inhibits GJIC by inducing mitogen-activated protein kinase (MAPK)-mediated
phosphorylation of Cx43 [71,72]. A similar effect has been observed for platelet-derived growth factor
(PDGF) which activates MAPK and protein kinase C (PKC) pathways [73]. Interestingly, such a
phosphorylation of the Cx43 CT domain establishes a direct link between growth stimulation and GJIC
inhibition, which appears to be either the consequence of channel gating or Cx degradation [74].
Still at the post transcriptional level, an emerging field is about repression of Cx expression by
miRNAs. For instance, mi-R-221/222 complex and miR-125b have been shown to downregulate Cx43
expression in glioma [75,76] or miR-20a in prostate cancer [77]. This field is still emerging and no
doubt that it will be more involved in Cx gene regulation in future years.
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Finally, the lack of expression or function of Cxs could be also theoretically the consequence of
mutations affecting either the coding region of the Cx genes or their promoters. However, contrary
to classical tumour suppressors (p53, Rb, etc.), such mutations have been rarely reported in the
cancer context [32]. The most convincing result revealed a mutation affecting the Cx43 CT domain
in human colon adenocarcinomas, which resulted in a restricted expression in invasive parts of the
tumours [78]. To our knowledge, such an observation has not been confirmed. The fact that Cx
mutations are not involved in human cancer is intriguing when considering their involvement in
several human hereditary diseases [79]. So far, none of these diseases are known to be associated
with a particular cancer susceptibility except for Cx26 mutations in the case of keratitis ichthyosis
deafness (KID) syndrome which are associated with squamous cell carcinomas in 15% of patients [79].
The apparent general lack of association with cancer is probably the consequence of a lack of follow up
of such patients.
2.2. Pannexins Involvement in Tumour Cell Growth
Originally, Panxs (3 members in mammals: Panxs1, 2 and 3) were identified as GJ proteins
exhibiting homology with the invertebrate GJ proteins, the innexins [9]. Present in chordates, contrary
to Cxs and despite a similar topology, they are not able to form functional GJs but form single
membrane channels releasing autocrine and paracrine signals similar to Cx Hcs [10].
Data about a possible relationship between Panx expression and cancer progression or cancer cell
growth are not so developed as they are for Cxs. In general, it seems that Panxs exhibit a so-called
tumour suppressive effect similar to what is observed with Cxs. Such an analogy started during
the last decade with the analysis of the brain cancer gene expression database REMBRANDT which
revealed that the expression level of PANX2 and also PANX1 is positively correlated to post diagnosis
survival of glioma patients [80]. To some extent, these observations were confirmed by the tumour
suppressive effect induced both by Panx1 and Panx2 overexpression in rat C6 glioma cells in vitro and
in vivo conditions [81,82]. In those cells, Panx1 expression had a wide range of anti-tumour activity by
reducing in vitro cell proliferation, cell motility, anchorage-independent growth and tumour growth
in nude mice. Interestingly, these effects, which are globally similar (except cell motility) with those
observed after Cx43 transfection, were accompanied by an increased GJIC [81].
Similar observations have been obtained from skin where PANX1 and PANX3 levels are reduced
both in human keratinocyte-derived basal cell carcinomas and squamous cell carcinomas [83].
This is in line with studies showing that those Panxs reduce growth of rat epidermal keratinocytes
when overexpressed [84]. Such a growth inhibition was also observed for Panx3 in chondrocytes
and osteoprogenitor cells by inhibiting the WNT pathway and via calcium-mediated regulation
of p21 [85,86]. Recently, Panx3 was shown to inhibit the odontoblast proliferation through
AMP-activated protein kinase (AMPK)/p21 signalling pathway and promote cell differentiation
by bone morphogenetic protein (BMP)/Smad signalling pathway [87].
However, the situation is not so clear and probably depends on the cell type by considering
melanocytes in which Panx1 expression is low whereas increased expression is correlated with
melanoma aggressiveness [88]. More data are necessary before understanding the real involvement of
Panxs in cancer cell growth control.
3. Connexins and Pannexins: Involvement in Tumour Metastasis and Microenvironment
3.1. The Process of Metastasis
In order to become metastatic, a clone of cancer cells must acquire aggressive growth properties
and/or stem cell-like properties and the tumour microenvironment can drive acquisition of migratory
and invasive properties through epithelial to mesenchymal transition (EMT). In the majority of
tumours, which are epithelial in origin, cells must be able to breach the basement membrane, invade
into the stroma and into blood vessels (intravasation) that infiltrate the tumour site. In the vasculature,
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they will adhere to blood vessel walls and be transported to distant sites where they emerge from
the circulation (extravasation) to initiated new tumours. Finally, establishment of metastatic tumours
requires survival and growth in the new tissue microenvironment. During all of these processes
metastatic cells must evade the anti-tumoral immune response (Figure 3).
 
Figure 3. Gap-junctional intercellular communication in the tumour microenvironment and upon
metastasis. (A) The tumour microenvironment consists of tumour cells (blue cells), non-tumour cells
(light grey cells), immune cells including dendritic cells (dark grey cell) and CD8+ T-cells (pink cell),
the basement membrane (brown dotted line) and the stroma (green cells). Tumour cells often display
reduced gap junctions (transparent black lines) but can form heterotypic gap junctions with dendritic
cells. Once they invade through to the stroma they can also form junctions with stromal cells. Upon
intravasation into blood vessels tumour cells create gap junctions with endothelial cells lining the
blood vessels; (B) Upon extravasation into a metastatic site, metastatic cells (orange cells) initiate
gap-junctional intercellular communication with stromal cells and with other cells in the metastatic
tumour microenvironment (light grey cells) and this may facilitate establishment of metastases.
Depending on the site of metastasis, tumour cells may interact with cells of the immune system.
3.2. Connexin Involvement in Tumour Metastasis and Microenvironment
3.2.1. The Role of Connexins in Cancer Progression
Cxs can change expression levels, be re-localized [89–92] and/or exhibit altered phosphorylation
upon progression to invasive tumour (Table 1) [93]. The resulting loss of functional GJs could alter
tumour cell interaction with its microenvironment and promote EMT and migration from the primary
tumour. Conversely, Cx expression can facilitate intravasation and adhesion to endothelial cells,
enabling increased survival in the circulation. There is also evidence that Cx expression promotes exit
from blood vessels into the metastatic site, where GJIC may be reinitiated [94] (Figure 3). However,
Cxs may both promote tumour cell dormancy and cell survival, at metastatic sites. These effects
may be reliant on tumour/stromal interactions and cooperation between invasive/metastatic cells
and GJ formation in the tumour microenvironment and are likely to be Cx type, tumour type
and cancer-stage-specific.
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Table 1. Selected representative examples of changes in connexins during tumour progression and metastasis.
TISSUE ORGANISM CONNEXIN REGULATION REFERENCE







CERVICAL CANCER Human Cx26, Cx30, Cx43 Loss of connexinexpression [95–97]
BREAST CANCER Human Cx26, Cx43 Loss of Cx43 gapjunctions [98–101]
PROSTATE CANCER Human Cx32, Cx43 Decreased expression [102]
COLON CANCER Human Cx32, Cx43 Gradual loss ofexpression [92]
MELANOMA Human Cx26, Cx30 Increased expression [103]
PRIMARY TUMOUR TO METASTASIS


















MELANOMA HumanHuman cell lines Cx26 Increased expression
[103,115]
[116]
3.2.2. Invasion and the Local Microenvironment
E-cadherin is required for invasion in EMT and its loss is a marker of tumour progression. During
invasion, cells display decreased GJIC, modification of cell-matrix interactions and acquisition of
proteolytic properties to degrade the basal laminal proteins. Following this, altered stromal cells
and microenvironment facilitate the motility of invasive cells through the extracellular matrix. All of
these processes could be potentially altered by changes in Cx expression. For example, transfection of
poorly coupled mouse epidermal cells with an E-cadherin expression construct increased GJIC [117].
Conversely, in prostate cancer cells, Cx43 levels correlated with levels of the transcription factor Snail-1
that inhibits expression of E-cadherin to promote EMT [118]. High levels of Cx43 and Snail-1 resulted
in increased tumour cell invasion and Cx43 was downregulated upon Snail-1 silencing and vice
versa. In keeping with these findings of a Cx43-Snail-1 axis controlling tumour cell behaviour, Cx43
expression could reverse A549 lung tumour cell resistance to the chemotherapeutic drug cisplatin by
downregulating E-cadherin and EMT, while siRNA depletion of Cx43 initiated EMT [119]. Melanoma,
breast, prostate and gastric cancers all display upregulated Cx43 and Cx26 in invasive lesions and
metastases (Table 1) [101,103,104,112,115].
3.2.3. Promoting Metastasis: Connexins and Cell Motility
Early studies revealed that HeLa cervical cancer cells overexpressing Cx43 gained invasive
properties in a chicken heart spheroid assay [120]. In a mouse melanoma model of metastasis
following subcutaneous injection, clone F10 was less metastatic than the high Cx26-expressing clone
BL6 but became as metastatic as BL6 upon Cx26 overexpression and BL6 cells expressing dominant
negative Cx26 showed reduced metastatic potential [116]. γ-irradiation of C6 glioma cells induced
Cx43 expression and increased ERK signalling and cell migration and a high Cx43 expressing clone
displayed increased motility and invasion [121]. Conversely, knocking down Cx43 abrogated p38
MAPK activation and radiation-induced C6 cell migration [122]. Although GJIC was decreased upon
Cx43 small interfering RNA (siRNA) depletion in the high Cx43 expressing C6 cells, GJ inhibitors
did not alter motility indicating that Cx43 itself was responsible for the pro-metastatic effects [121].
Similarly, in a six-cell model of hepatocellular carcinoma, following injection into the tail vein of
mice, only those lines with high metastatic potential formed foci in the lungs of the animals and this
256
Int. J. Mol. Sci. 2018, 19, 1645
was reversible by depletion of Cx43 expression [113]. Another study found that blocking GJIC in
GL15 glioblastoma cells increased motility in an in vitro 3D culture model [123]. However, blocking
heterologous GJIC in ex vivo brain tissue by carbenoxolone reduced cell migration [123].
Cxs can facilitate adhesion of migrating cells to the endothelial layer of blood vessels and/or to
specific distal sites (Figure 3). For instance, metastatic lung cancer cells could adhere to endothelial
cells through GJs [124] as could metastasis-enabled melanoma cells ectopically expressing Cx26 in
in vitro cultured vein segments [116]. In the case of colon cancer cells, conditioned medium from
primary tumour cells enhanced phosphorylation of Cx43 and GJ formation between tumour and
endothelial cells via the molecular chaperone heat shock protein 27 (HSP27), while metastatic colon
cancer cells induced expression of Cx32 through action of the chemokine receptor CXCR2 [125]. Breast
cancer cells that formed functional Cx43 GJs with endothelial cells facilitated migration out of the
endothelial layer in in vitro culture [126] implicating Cx43 in the extravasation phase of metastasis.
In zebrafish and chick embryo models, breast cancer and melanoma cell metastasis was dependent
upon Cx43 and Cx26 to initiate brain metastatic lesions in association with the vasculature. Inhibition
of Cx43-mediated GJIC inhibited extravasation, as did knock down of the EMT transcription factor
twist [127].
3.2.4. Involvement of Gap Junctions and Hemichannels in Metastasis
Apparently contradictory effects of Cx43 in metastasis have been observed in different studies.
When a functional null mutant Cx43 mouse line (G60S: that also has dominant negative effects on
endogenous Cx43 activity) was crossed with erythroblastic leukemia viral oncogene homologue (ErbB)
overexpressing mice [128], there was delayed onset and fewer and smaller primary breast tumours
than in wild type mice but increased metastases to the lung [128]. In contrast, Cx43 overexpression in
highly metastatic lung cancer cells reversed the metastatic tumour phenotype [129] but decreased Cx43
gene expression yielded breast cancer cells with increased metastatic potential [130,131]. In a two-cell
model of prostate cancer, overexpressed Cx43 was present only in the cytoplasm and repressed
proliferation, adhesion and invasion of normally invasive PC-3 cells. In contrast, overexpression
of Cx43 in poorly metastatic LNCaP cells, re-established GJIC and increased bone metastasis in
mice [132]. Stable overexpression of Cx43 in the MDA-MB-435 breast cancer cell line did not alter
GJIC, invasion or migration in vitro. However, when injected into mice, the cells exhibited a reduced
growth rate and fewer lung metastases [106]. This phenomenon was found to be GJIC-independent
and it was suggested that it could be related to reduced N-cadherin expression, which would inhibit
EMT. In another study, GJIC was restored in the same metastatic breast cancer cell line upon ectopic
expression of the breast cancer metastasis suppressor gene BRMS1 [130]. The BRMS1-expressing
cells showed increased levels of Cx43 but reduced Cx32, leading to loss of GJIC between breast
cancer cells and between them and breast epithelial cells [130]. An in vivo murine study revealed
that metastatic breast cancer cells in the bone formed more active GJs with osteoblasts than with
themselves and BRMS1 expression increased homotypic GJIC. The breast cancer cells with increased
heterotypic, relative to homotypic, GJ channels with osteoblasts were more metastatic than those
that did not [105]. This suggests that the relative percentage of homo- and heterotypic GJ channels
in tumour cells can influence metastasis. Moreover, it suggests that heterotypic GJs could be an
important survival mechanism of tumour cells in the metastatic tumour microenvironment. It can be
concluded that the precise timing of elevated or reduced Cx expression could be key to any effects
during tumour progression.
Compared to GJs changes in Hc activity can produce different effects in metastasizing tumour
cells. In a bone metastatic clone of MDA-MB-231 breast cancer cells, decreased Cx26 and Cx43 levels
correlated with metastatic potential partly through alterations in Hc activity [107]. Similarly, a recent
study reported suppression of breast cancer cell metastasis to the bone through osteocytic Cx43
Hcs [63]. Drug or mechanically-induced opening of Cx43 Hcs to release ATP from osteocytes led
to inhibition of invasion and migration of the cancer cells. Analysis of a dominant negative Cx43
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mutant that blocks GJs but not Hcs, revealed that Cx43 Hcs protected against tumour progression
and metastasis [63]. The precise role of Cxs in tumour progression and metastasis might depend
on the nature of the tumour, the properties of the cancer cell itself, the site of metastasis and the
possibility of forming functional GJs at that site. It is clear that the tumour microenvironment drives
cancer metastasis and Cx43 seems to stimulate growth of brain metastases after extravasation and
tumour vasculature remodelling [133]. Protocadherin 7, a brain-specific cadherin, promoted Cx43-GJ
assembly between breast and lung tumour cells and astrocytes. These GJs allowed cyclic guanosine
monophosphate (cGAMP) to activate the stimulator of interferon genes (STING) pathway in astrocytes
to induce an interferon response. The resulting changes in cell signalling could enhance growth of
metastatic cells [133].
3.2.5. The Tumour Microenvironment
The tumour microenvironment, whether at the primary or secondary sites, is key to tumour
cell survival and tumour progression [134]. In agreement with the hypothesis that Cxs control the
microenvironment, Cx43-transfected glioma cells, which formed GJs with astrocytes in the striata of
rats, were able to disseminate throughout the brain parenchyma. Cx43 itself, unlinked to GJIC, was
shown to induce adhesive properties in the malignant glioma cells, which formed aggregates and were
more invasive [135]. Also in rats, formation of GJIC with fibroblasts in co-culture stimulated prostate
cancer cell migration [136,137]. However, Cx32 expression in metastatic renal cancer cells caused
abrogation of invasive capacity via inactivation of c-Src signalling [138]. Tumour-associated immune
cells are components of the tumour microenvironment. Heterotypic Cx43-GJs between tumour cells
and dendritic cells can transmit melanoma antigenic peptides leading to activation of cytotoxic T-cells
in vitro [139]. In vivo demonstration of Cx43-GJ transmission of antigenic peptides between antigen
presenting cells has also been demonstrated [140]. GJ transmission of miRNAs between immune
cells in the microenvironment and tumour cells is also expected to be a major regulator of metastasis
because of the key role of many miRNAs in tumour suppression, while others can promote tumour
progression [141].
3.3. Pannexins and Metastasis
The potential role of Panxs in metastasis is relatively unexplored. However, high levels
of PANX1 mRNA were associated with metastatic spread in a two-cell model of hepatocellular
carcinoma [142]. A key advance in understanding the role of Panxs in metastasis came from a
study of the isogenic melanoma cell lines, F10 and BL6, mentioned previously. PANX1 levels were
greatest in the most metastatic BL6 line [88]. PANX1 knock down reverted BL6 cells to a more
normal melanocyte phenotype and these cells had reduced levels of vimentin and β-catenin, both
markers of melanoma progression [88]. Importantly, in vivo data in a chick embryo xenograft model
showed that reducing PANX1 expression reduced tumour growth and metastasis to the liver. A recent
RNASeq analysis of breast cancer cells with different metastatic capacities revealed that cell lines
with high metastatic potential had significantly enriched mutant mRNA encoding a N-terminal
truncated PANX1 channel [143]. Truncated PANX-1, in association with wild type PANX1, seemed
to confer a gain-of-function to channel activity and was found to promote metastatic cell survival.
This appeared to be due to protection of tumour cells exiting the microvasculature via restrictive spaces
between endothelial cells by enhancing ATP release from the Panx channels stimulated by mechanical
deformation and abrogation of cell death [143]. In melanomas, P2X7/PANX1 channel activity has been
linked to regulation of the NLRP3 inflammasome, which can result in release of pro-inflammatory,
tumour promoting cytokines. Downstream effects on the tumour microenvironment could stimulate
tumour growth and invasion. Of course, like Cxs, Panxs might also be found in future to repress
tumour progression and metastasis.
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4. Connexin and Pannexin Channels in Potential Cancer Therapeutics
4.1. Connexin Channels in Potential Cancer Therapeutics
The usefulness of Cxs and GJs as potential therapeutic targets for treating cancer has been studied
for over four decades [4,144,145]. In recent years, several approaches have been developed in animal
models to determine treatment modality by manipulating Cx channels. Although preclinical studies
targeting connexin channels are still in their infancy, they hold great promise as de novo targets for
cancer treatment.
4.1.1. Chemical Compounds in Modulating Connexins and Potential Cancer Therapy
Major attempts have focused on enhancement of GJIC function due to its impairment in primary
cancer cells. Multiple chemical compounds have been used (e.g., retinoids, vitamin D, carotenoids,
cAMP and lovastatin), which can fully or partially reverse the deficiency of GJIC in tumorigenic
cells [146]. Lypopene, a carotenoid stimulates GJIC and Cx43 expression and inhibits the growth
of the breast cancer MCF-7 cell line [147]. Extracts from the zooxanthellate jellyfish that show
antioxidant activity exhibit higher levels of GJIC and cytotoxicity in MCF-7 cells than human epidermal
keratinocytes [148].
An experimental approach was developed that killed tumorigenic cells based on GJIC selectively
formed between them. In this study, tumorigenic BALB/c 3T3 and rat liver cells were loaded with
Lucifer yellow (LY) and co-cultured with non-tumorigenic cells. By irradiation with blue light,
only tumorigenic cells containing LY died but not the surrounding non-tumorigenic cells without
LY [149]. This study further showed that when dibutyryl cAMP, retinoic acid, fluocinolone acetonide
or dexamethasone were used during cell transformation, there was a reduction of transformed
BALB/c 3T3 cell foci. These chemicals also increased and established GJIC between tumour cells and
surrounding non-tumour cells, suggesting that the effects of chemicals on reversing the phenotypes of
transformed cells rely on the establishment or enhancement of GJIC between tumour and normal cells.
Several cholesterol-lowering statin drugs (lovastatin, simvastatin, etc.) are suggested as anticancer
reagents and high levels of mevalonate production are documented in various types of malignancies.
Therefore, inhibition of the mevalonate producer, β-Hydroxy β-methylglutaryl-CoA (HMG-CoA)
reductase, by statins offers a great potential for cancer treatment [150]. An earlier study shows that
lovastatin increases GJIC in transformed E9 mouse lung carcinoma cells through the inhibition of PKC,
although Cx43 expression and phosphorylation are not affected [151]. Moreover, apigenin, a flavonoid
and lovastatin that is known to increase GJIC enhances bystander effect of the herpes simplex virus
thymidine kinase/ganciclovir with reduction of cancer cell recovery on MCA38 adenocarcinoma cells,
while neither chemical alone has such effect [152]. In vivo injection of both chemicals achieves 60–70%
complete remission of tumour implanted in mice [152]. Simvastatin induced up-regulation of GJIC in
Leydig tumour cells and this upregulation sensitized tumour cells to etoposide, a chemotherapeutic
drug [153]. Simvastatin inhibited Cx43 phosphorylation by PKC and enhanced Cx43 membrane
localization to promote formation of GJs (Ser368 phosphorylation promotes Cx43 internalization).
However, a follow up study by the same group reported a protective function of simvastatin against
toxicity by cisplatin on normal Sertoli cells [154]. This effect occurs at high cell density where GJIC
forms and decreased GJIC by inhibitors or knocking down Cx43 by siRNA attenuates cell protective
role of simvastatin. These two studies elucidate differential roles of GJIC by statins in chemotherapy
by sensitizing drug effect on cancer cells and ameliorating toxicity in normal cells.
For Cx43 Hcs in cancer development, carbon monoxide (CO), a promising molecule to treat
several diseases including cancer has been shown to inhibit their function [155]. CO donors inhibit
Hc uptake in tumour cell lines (MCF-7 and HeLa cells) expressing exogenous Cx43 or Cx46 [156].
However, in general, scarce information is currently available describing the involvement of Cx Hcs in
cancer cells.
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Cxs can directly mediate the effect of chemotherapeutic drugs on cytotoxicity and apoptosis
of cancer cells. Upregulation of Cx43 by cisplatin improves its resistance in a mesothelioma cell
line (H28) [157]. GJIC inhibition fails to abrogate this effect but it is Cx43-dependent through the
suppression of c-Src activation. Cx43 is increased in H28 cells by sunitinib treatment, which promotes
apoptosis via the inhibition of receptor tyrosine kinase (RTK) signalling. This effect is likely to be
mediated through direct interaction of Cx43 with an apoptotic related protein, Bax [158]. The Cx43
enhanced apoptotic effect of sunitinib was via enhancement of activation of Bax localized at the
mitochondrial membrane and the phosphorylation of c-Jun N-terminal kinase (JNK) [159]. Several
studies focus on the strategy of enhancing Cx expression in cancer cells. Ganoderma lucidum, an
herbal mushroom known to inhibit tumour growth can increase Cx43 expression as well as vascular
endothelial growth factor (VEGF) and inhibit growth of human ovarian cancer cells [160]. Such
effect was abrogated by knocking down Cx43 expression. The bioactive substance sulforaphane
inhibits cancer stem cells in aggressive pancreatic ductal adenocarcinoma through increased Cx43
and E-cadherin expression [161]. This treatment also inhibits the cancer stem cell markers c-Met and
CD133, alters activation of several kinases and substrates, Glycogen synthase kinase 3 (GSK3), JNK
and PKC and enhances GJ channels. Therefore, chemicals that can enhance GJs and Cx expression
exhibit a high potency in suppressing cancer cell proliferation and tumour growth.
4.1.2. Connexin-Targeting Strategies in Potential Cancer Therapy
In recent years, several Cx mimetic peptides that reproduced portions of Cx sequences have been
widely used in basic research as well as preclinical and therapeutic development [145]. Cx43-GJIC is
decreased in breast cancer cells and efforts have been made to restore GJIC in these cells. αCT1,
a mimetic peptide that targets CT domain of Cx43 can sustain and enhance GJIC function and
has shown a great promise in promoting wound healing in skin by reducing scar formation [162].
A recent study shows that this peptide enhances Cx43 GJIC and reduces proliferation or survival
of MCF7 and MDA-MB231 breast cancer cells but has no effect on MCF10A non-transformed
cells [163]. A combination of αCT1 with tamoxifen or lapatinib augmented their effects on oestrogen
receptor-positive MCF7 or Her2-positive BT474 breast cancer cells. Furthermore, treatment with
αCT1 peptide sensitized human O-6-methylguanine-DNA methyltransferase (MGMT)-deficient and
chemotherapeutic agent temozolomide (TMZ)-resistant glioblastoma (GBM) cells and combined
treatment with the peptide and TMZ further incur autophagy and apoptosis of TMZ-resistance GMB
cells [164]. A recent study shows that a cell-penetrating Cx mimetic peptide, TAT-Cx43(266-283) inhibits
c-Src and focal adhesion kinase (FAK), upregulates phosphatase and tensin homology and reduces
the growth, migration and survival of glioma stem cells (GSCs) from patients [165]. A Cx43 mimetic
peptide juxtamembrane 2 (JM2) that is based on the Cx43 microtubule-binding domain inhibits Cx43
trafficking to the cell surface by promoting microtubule polymerization and reduces Hc numbers in the
membrane for proinflammatory function. The authors imply that this peptide may have therapeutic
value in treating proliferative diseases and cancer [166]. However, it is important to note that the
recovery of GJIC does not consistently entail normalization of the tumour cells.
There are several reports concerning use of antibodies against Cxs. When a labelled monoclonal
antibody against the second Cx43 extracellular loop domain was intravenously injected into rats
with intracranial C6 glioma, antibody signals were detected in reactive, glial fibrillar acidic protein
(GFAP)-positive astrocytes [167]. PEGylated immunoliposomes carrying monoclonal antibodies
against GFAP and the above-described Cx43 monoclonal antibody were detected at the periphery
of the glioma using either fluorescent or a paramagnetic probe [168]. These studies imply that
these antibodies could potentially be used for targeted delivery of drugs to the zone of high-grade
gliomas. Furthermore, magnetic resonance imaging data show that weekly administration of this
Cx43 antibody at a dose of 5 mg/kg significantly reduces low-differentiated glioma volume and
increases lifespan with a full recovery without delayed relapses in 19% animals [169]. Both Cx43 and
brain-specific anion transporter (BSAT1) are preferably expressed in the brain tumour and peritumoral
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areas. Cisplatin-loaded nanogel conjugated with monoclonal Cx43 antibody [170] and BSAT1 was
used to treat rats bearing tumours and the median survival was greater than control groups [171].
Vector nanogels seemed to reduce systemic toxicity of cisplatin [170]. Intriguingly, a combination
of this Cx43 antibody with TMZ completely abolishes the antitumor effect of this antibody while
combination treatment with γ-irradiation greatly inhibits tumour development and prolongs survival
median to 60 days versus 38 days [172]. Recently, a magnetic resonance imaging (MRI) study further
shows that uptake of Gd-based contrast agent with the same monoclonal Cx43 antibody is more than 4
times higher than nonspecific IgG-contrast agent and this Cx43 antibody conjugated agent markedly
enhances visualization of glioma in vivo [173]. Although the specific molecular mechanism of this
antibody is unknown, this Cx43-targeting monoclonal antibody could be developed as a potential
drug and/or diagnostic agent for glioma therapies.
Finally, recombinant lentiviruses carrying siRNA were used to knockdown Cx37 expression
in subcutaneous gastric tumours in mice [174]. Reduced levels of Cx37 are associated with higher
apoptotic index of tumour cells in vivo. Cx46 is also detected in GBM cancer stem cells, while Cx43
is predominantly expressed in non-stem cells [175]. Besides Cx43, Cx46 is shown to express in
GBM cancer stem cells (CSCs) that forms GJIC, while Cx43 is present in non-CSCs. During cancer
differentiation, Cx46 is reduced associated with an increase of Cx43 and knocking down Cx46 by short
hairpin RNA (shRNA) reduces stem cell maintenance.
Drug resistance is a major challenge for cancer treatment. Cisplatin is a commonly used
chemotherapeutic agent for advanced non-small cell lung cancer but prolonged treatment leads
to resistance due to development of EMT [119]. Overexpression of Cx43 reverses EMT and cisplatin
resistance while Cx43 deletion initiates EMT and drug resistance in human lung cancer cell line A549.
Patients with GBM, an aggressive adult primary brain tumour with poor prognosis, develop resistance
to TMZ chemotherapy. In contrast to the situation in lung cancer, Cx43 is increased with the formation
of GJIC in the resistant tumour cells and this increase is induced by epidermal growth factor receptor
(EGFR) activated JNK-ERK1/2-AP-1 signalling [176]. Moreover, Cx43 expression in human glioma cells
enhances resistance to TMZ via a mitochondrial apoptosis pathway by the reduction in Bax/Bcl-2 ratio
and the release of cytochrome C [177]. Consistently, a recent study [178] showed that TMZ-resistant
subline of U251 human GBM cells exhibited elevated Cx43 level compared to parental U251 cells,
which was companied with increased EMT markers including vimentin, N-cadherin and β-catenin and
decreased cell migration, monocyte adhesion and levels of vascular cell adhesion molecule (VCAM)-1.
These studies suggest that depending upon cancer types, Cx43 expression and GJIC could be involved
in either promoting or inhibiting sensitization of resistant cells to the chemotherapy. However, the
underlying mechanisms remain elusive.
Recently, a new paradigm was proposed based on the data obtained in chronic inflammatory
disorders and trauma in the eye that protecting cancer vasculature leads to reduced tumour hypoxia
and promote survival of normal cells [179]. Given that Cx43 Hcs are involved in vascular leakage
and endothelial cell death [180], modulation of these channels may provide an alternative for cancer
treatment. Together, with advanced understanding of the mechanism of Cx channels in various types
and stages of cancer development and metastasis, new lines of drugs that target them in cancer therapy
are moving closer to reality.
4.2. Pannexin Channels in Potential Cancer Therapeutics
A great progress has been made in recent years for our understanding of Panx biology and
physiology. However, compared to that of Cxs, the potential therapeutic application of Panxs in cancer
is still limited.
4.2.1. Pannexin Channel Activation and Potential Cancer Therapy
Panx channels mediate ATP release and anti-tumour immune responses are associated with such
a release from apoptotic cancer cells to engage P2 purinergic receptor signalling in leukocytes. A study
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shows that apoptotic reagents activate Panx1 channels via caspase-3 cleavage, which leads to ATP
release in Jurkat T cell acute lymphocytes in chemotherapeutic drug-induced apoptosis [181,182]. Panx1
level is much higher in leukemic T lymphocytes than untransformed T lymphoblasts. Interestingly,
chemotherapeutic drugs also cause ATP release with inhibition of caspase activation, which implies
a Panx-independent mechanism. This study suggests that Panx1 channels and ATP release may
mediate paracrine interaction between dying tumour cells and leukocytes in anti-tumour responses.
A follow up study by the same group shows that activation of Panx1 channels by ATP is determined
by expression level of particular ectonnucleotidases in tumour cell variants in Jurkat cell lines with
and without the Fas-associated death domain (FADD) or receptor-interacting protein kinase 1 (RIP1)
cell death regulatory proteins [183]. They noticed that robust levels of extracellular ATP/AMP were
accumulated in apoptosis-deficient cells, not in apoptotic cells with the activation of Panx1 channels
in response to chemotherapeutic drugs. Panx1 channel assists in accumulating immune-stimulatory
ATP versus immunosuppressive adenosine within the tumour microenvironment. In support of the
role of ATP and Panx1 channels in mediating immune response, a very recent study shows that ATP
increases migration of dendritic cells through the activation of Panx1 channel and P2X7 receptor
(P2X7R) [183]. In this study, they show that ATP actives P2X7R, which leads to opening of Panx1
channels and consequently results in more ATP release, re-organization of the actin cytoskeleton and
faster migration of dendritic cells. Additionally, in vivo data show that Panx1 channels are required
for the homing of dendritic cells to lymph nodes but not for maturation. Therefore, given that ATP acts
as danger signal that recruits phagocytes including dendritic cells to cancer sites, activation of Panx
channels through therapeutic drugs could hinder tumour growth and metastasis. Moreover, an US
Food and Drug Administration (FDA)-approved anti-parasitic drug, Ivermectin allosterically regulates
P2X4 receptors in breast cancer cells through opening of the P2X4/P2X7-gated Panx1 channels, which is
associated with ATP release and consequently, cancer cell death [184]. Additionally, Ivermectin induces
activation of autophagy and enrichment of inflammation mediators, ATP and high-mobility-group B
(HMGB), suggesting that modulation of purinergic receptor signalling could be used as a platform for
cancer immunotherapy [185].
4.2.2. Pannexin in Potential Cancer Diagnosis
A clinical report shows high relative expression of Panx3 in a patient with primary cutaneous
sweat gland carcinomas with histologic features of a high-grade osteosarcoma [186]. By using
quantitative trait loci (QTL) analysis, sequence comparison between strains and gene network analysis,
this report links both body mass index (BMI) and tumorigenesis with Panx3 as a candidate gene in
a genetically heterogeneous mouse model with carcinogen-induced cancer. A mutation encoding a
truncated Panx1 (1–89) was identified which was enriched in highly metastatic breast cancer cells [143].
This truncated form of Panx1 further enhanced ATP release. In contrast to general belief of Panx
channels in promoting cancer cell death, this paper suggests that ATP release by Panx1 suppresses
deformation-induced apoptosis through P2Y receptor signalling and inhibition of Panx1 channels
could reduce the efficiency of breast cancer metastasis. This could be partially explained by excess
release of ATP by mutated Panx1 channels. Panx1 is present in skin melanocytes and is upregulated
during melanoma tumour progression and tumorigenesis [88]. Knockdown of Panx1 in tumour cells
decreases tumour cell growth, which indicates Panx1 as a potential target for treating melanoma.
More studies are required to assess the expression levels of Panx subtypes in various types and stages
of cancer.
4.2.3. Pannexin Channels in Pain Management Related to Cancer Treatment
Repeated treatment with the chemotherapeutic drug oxaliplatin is limited due to the development
of a neuropathic pain in cancer patients. Functional recruitment of Panx1 mediates the increase of
P2X7Rs in cerebrocortical nerve terminal in oxaliplatin-treated rats. Moreover, P2X7R antagonists and
Panx1 inhibitors, Erioglaucine and 10Panx peptide reverts neuropathic pain caused by oxaliplatin,
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while Panx1 inhibitors do not interfere the cytotoxic effect of oxaliplatin on human colon cancer cells
HT-29 [187]. Consistently, a recent study shows that Panx1 expressed in immune cells plays a critical
role for pain-like effects after nerve injury and this response is abrogated in Panx1 gene deficient
mice [188]. These studies suggest that therapeutic modulation of Panx1 could be useful for treating
neuropathic pain associated with cancer and cancer treatment.
5. Discussion and Conclusions
The involvement in cancer of GJs and their structural proteins, the Cxs, is a long story [4]. It rose
just after the discovery of these particular intercellular junctions, which appeared to be absent in cancer
cells. These very first observations suggested that the lack of GJIC could contribute to the lack of cell
growth control which characterizes tumorigenesis [18]. Therefore, cell growth control was assumed to
be one of the fundamental roles played by GJs. However, if this implication was assumed fifty years
ago, the precise molecular mechanisms controlling cell growth came very late and are still unclear.
There is a kind of paradox between the amount of observations accumulated for decades confirming
a possible role of GJs as guardians of cellular homeostasis and replication and the lack of sufficient
evidence explaining such a phenomenon.
Indeed, despite few exceptions, all kinds of observations were suggesting that the lack of GJs
or Cxs is correlated to the lack of cell growth control and vice versa This consensus was supported
by observations collected from a tremendous variety of models (cancer cell lines, primary cultures
of tumour cells, in situ from biopsies, Cx-cDNA transfected cells, Cx-KO mice, chemical treatments
decreasing or upregulating GJIC, etc.) whatever the species origins [32]. However, despite this
consensus of observations, the assumption that GJs and Cxs were so-called tumour suppressors
was not fully supported by several facts. First, GJs and Cxs did not behave as classical tumour
suppressors since Cx gene mutations never appeared in tumours as commonly shown as for p53,
Rb and so forth [32]. Second, no clear molecular mechanisms underlying the growth control that
GJs and Cxs could exert has been established contrary to what was observed with classical tumour
suppressors. These two aspects probably restricted GJs and Cxs to be considered as a real hallmark of
cancer despite all the consensus studies we mentioned above [189]. The few molecular mechanisms
that could explain the cell growth control exerted by GJs and Cxs seems to be “diffuse” and not so
straightforward as growth signalling pathways described for oncogenes and tumour suppressors.
Indeed, the involvement of Cxs in cell growth control is not clear at the molecular level and appears to
be either GJIC-dependent or not. When this involvement was found to depend on GJIC, Cxs permit the
intercellular diffusion of metabolites acting on cell growth control (i.e., Cx26 and the diffusion of cAMP,
all along the cell cycle phases in HeLa cells) [44]. When this growth control is GJIC-independent, Cxs
seem to act through their CT domain as a sequestrator preventing the nuclear translocation of cell
growth regulators [53]. By comparing to our knowledge about cell growth control, Cxs seems to be a
“helper” instead of a master regulator of cell growth control. Hopefully, future studies will bring more
clear-cut information about the real involvement of GJs and Cxs in cancer cell growth [190].
In addition, we have also to consider that exceptions were observed in the consensus supporting
the parallel between GJIC and cell growth control. These exceptions, supported by experimental
observations, led to the hypothesis that Cxs could be protumoral actors when expressed at late stage of
cancer progression. Indeed, from about twenty years ago, it appeared that Cxs could favour migration
and invasion of cancer cells and participate to their dissemination [2,94]. A new wave of data then
confirmed this new assumption that Cxs are actively involved in the late stages of carcinogenesis and
participate to the aggressiveness of solid tumours. Very interestingly, from this more recent domain of
investigation, Cxs were shown to play a role not only on migration and invasion of cancer cells but also
on metastasis development by acting on intravasation, extravasation and dormancy of the metastatic
cells. Within a few years, the Cx cancer statute has been changed then from tumour suppressor to
tumour enhancer. Contrary to what appears at a first glance, this is not contradictory since an inverted
correlation is often observed between cell proliferation and invasion capacity [191].
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As for cell growth control, the molecular mechanisms underlying the involvement of Cxs
in cell migration are not very clear. Once again, Cxs seem to control cell migration either
through channel-dependent or –independent mechanisms. In the first case, the establishment of
heterologous GJIC between cancer cells and cells of the tumour microenvironment may increase
motility (such as glioma cells communicating with astrocytes) and further, helps to intravasation
and extravasation [124–127,192]. When isolated in extracellular matrix, Cxs act on motility through
GJIC-independent mechanisms by its CT domain. This has been particularly studied for Cx43 and
even if the precise molecular events are not elucidated yet, it seems that the CT domain is involved
by interacting with the actin cytoskeleton and helps to manage directional migration of the cancer
cells [193]. Interestingly, such a phenomenon would not be pathological by itself since this process
is present in migrations occurring in normal situations such as embryogenesis (neuron precursors
migrating to the cortex) and leucocyte migration [194–196]. Other data also suggest that Cxs could
be involved in formation of invadopodia and secretion of proteases during invasion process and also
in metastasis targeting [132]. The molecular processes of all these phenomena are far from being to
be elucidated. More data are needed to explain at the molecular level how Cxs can control cancer
cell invasion and metastasis. These data are necessary for targeting Cxs to prevent eventually cancer
invasion. This is of fundamental importance when considering that the majority of cancer deaths are
the consequence of metastasis [1].
To conclude, there are globally sufficient data showing that Cxs are involved in carcinogenesis,
especially in the progression of solid tumours. However, despite these data, the molecular mechanisms
of the Cx involvement in carcinogenesis are not sufficiently elucidated yet. This lack of knowledge
limits to use them as general therapeutical targets for cancer control. Moreover, the multifunctional
sides of Cxs able to act as mediator of GJIC, through their interactome or even as Hcs make difficult to
define their real implication in cancer. In addition, the similarity of Panxs with Cx Hcs adds another
complexity to this area of research since this family of proteins seems to share functions with Cxs
both in cell proliferation control and invasion. Facing this complexity, the only way to decipher the
real impact of Cxs or Panxs in the cancer cell behaviour is to consider their involvement specifically
in particular types of tumours but not globally [190]. One strategy could be by increasing in situ
observations in order to localize precisely Cx/Panx expressions in the complex heterogeneity of specific
human tumours and reveal the possible links of Cx/Panx localizations with the tumour behaviour. In
particular, it could prove definitively the apparently opposed roles of Cxs in cell growth control and
in cancer cell invasion through their differential expression either in the core of the tumour or in its
invasive edges [111]. Therefore, due to uniqueness of the action of subtypes of Cxs and Cx channels on
various types and stages of cancers, therapeutic approaches ought to be developed based on precise
mechanism elucidated with more targeting approaches. This aligns with the current trend of drug
development in treating cancer with precision medicine.
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Abstract: Gap junction transmembrane channels allow the transfer of small molecules between the
cytoplasm of adjacent cells. They are formed by proteins named connexins (Cxs) that have long
been considered as a tumor suppressor. This widespread view has been challenged by recent studies
suggesting that the role of Connexin 43 (Cx43) in cancer is tissue- and stage-specific and can even
promote tumor progression. High throughput profiling of invasive breast cancer has allowed for
the construction of subtyping schemes that partition patients into at least four distinct intrinsic
subtypes. This study characterizes Cx43 expression during cancer progression with each of the tumor
subtypes using a compendium of publicly available gene expression data. In particular, we show
that Cx43 expression depends greatly on intrinsic subtype. Tumor grade also co-varies with patient
subtype, resulting in Cx43 co-expression with grade in a subtype-dependent manner. Better survival
was associated with a high expression of Cx43 in unstratified and luminal tumors but with a low
expression in Her2e subtype. A better understanding of Cx43 regulation in a subtype-dependent
manner is needed to clarify the context in which Cx43 is associated with tumor suppression or
cancer progression.
Keywords: gap junctions; Connexin 43 (Cx43); breast cancer; survival analysis; intrinsic subtype
1. Introduction
Connexin 43 (Cx43), a protein encoded by the Gap Junction protein alpha 1 gene (GJA1), forms gap
junction transmembrane channels facilitating communication between the cytoplasm of two adjacent
cells. Small molecules, including metabolites, second messengers and electrical signals pass through
these channels in a process called Gap Junction Intercellular Communication (GJIC). Cx43 transcription
is thought to be regulated both by transcription factors and by epigenetic mechanisms [1], but is also
regulated at the protein level by post-transcriptional modifications, trafficking to and from the plasma
membrane and gating of the channels [2].
The breast epithelium is composed of two layers of cells: an inner layer of luminal cells surrounded
by an outer layer of basal cells, composed mainly of myoepithelial cells but also comprising stem and
progenitor cell populations [3]. It is well established that Cx43 is expressed mainly in the basal layer;
however, a few studies showed Cx43 expression in luminal cells [4–6]. A study using transmission
electron microscopy reported gap junctions to be present between the basal and the luminal layers in
normal breast tissues, although the exact connexin involved was not determined [7]. A few studies
have also demonstrated the expression of Cx43 in fibroblasts surrounding the breast epithelium and in
endothelial cells [8–10].
The role of Cx43 in breast cancer is controversial. On the one hand, Cx43 has long been considered
a tumor suppressor [11] with studies demonstrating it was under-expressed at the mRNA and the
protein level in cancer cell lines [12,13] or aberrant localization and phosphorylation in tumors [12–16].
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Cx43 has also been linked to the control of processes associated with breast cancer progression and
metastasis such as proliferation, invasion, migration and apoptosis [17]. Moreover, it was shown in
vivo and in vitro that metastatic capacity was increased in tumors cells showing a weak GJIC capacity
and a lower number of gap junction plaques [18,19]. Re-expression of Cx43 in tumor cells led to
reduced growth of tumors in nude mice and fewer metastases to the lungs [20,21]. Mice expressing a
mutant form of Cx43 (G60S) also showed increased breast tumor metastasis to the lung [3].
On the other hand, much evidence suggested that Cx43 is involved in later stages of breast cancer
progression. For instance, it has been suggested that Cx43 mediates the interaction between tumor and
endothelial cells to facilitate adhesion and extravasation at secondary sites [22–24]. Cx43 has also been
found to be expressed at higher levels in lymph node metastasis than in the corresponding primary
tumor [25]. The context of expression that allows Cx43 to act as a tumor suppressor or promoter has
not been elucidated and therefore precludes its targeting in breast cancer therapies [11].
Breast cancer is highly heterogeneous, with both intra- and inter-tumoral molecular variability.
During the last decade, high throughput techniques have generated a body of new data in many
diseases including breast cancer. Genome-wide gene expression profiling has produced classification
schemes including the intrinsic subtypes consisting of luminal A (LumA), luminal B (LumB), basal-like
and HER2-enriched (Her2e) tumors. Luminal tumors are generally characterized by the expression of
the estrogen receptor alpha (ERα) and the progesterone receptors (PR). Most Her2e tumors harbor a
genomic amplification of chromosome 17q12 that contains the erb-b2 receptor tyrosine kinase 2 gene
(ERBB2/HER2). Approximately half of Her2e tumors express ERα. Basal-like tumors are often negative
for ERα or PR receptors as well as for HER2 and also express basal cytokeratins [26,27].
This study aims to investigate Cx43’s ambiguous role during cancer progression with each of the
breast tumor intrinsic subtypes using a compendium of publicly available gene expression data with
large samples. Here, we report that Cx43 expression depends greatly on intrinsic subtype. Tumor grade
also co-varies with patient subtype, resulting in Cx43 co-expression with grade in a subtype-dependent
manner. Better survival was associated with a high expression of Cx43 in unstratified and luminal
tumors but with a low expression in the Her2e subtype.
2. Results
2.1. GJA1 Expression and Localization in the Breast
We first investigated the tissue localization and level of expression of Cx43 protein in human
samples of both morphologically normal breast tissue and tumors using the Human Protein Atlas.
This is a public database containing a large collection of normal and cancer tissue slides which have
been probed with various antibodies followed by a hematoxylin counterstain [28]. Cx43 is a membrane
channel and is usually considered to be expressed in the myoepithelial cell. A typical punctate staining
of junctional plaques formed by Cx43 channels was observed for normal tissues. The staining could be
observed in the myoepithelial layer, as expected, but also in some luminal cells (Figure 1a). Although
an under-expression of Cx43 protein is observed in some of the 21 cancer samples available (Figure 1a),
others show a clear over-expression, mostly in well differentiated luminal-like neoplastic cells, which
did not appeared to be associated with a basal layer (Figure 1c). In other samples, Cx43 could also
be seen in a layer of cells separating neoplastic tissue from stroma, although this layer sometimes
adhered poorly to both adjacent compartments (Figure 1d,e). Cx43 was also observed in samples with
poorly differentiated cell and tissue morphology (Figure 1f,g). Interestingly, Cx43 protein could also
be found in spindle-shaped cells in the stroma (Figure 1h). Overall, some normal punctate patterns
could be observed in some tumors (Figure 1d) while the majority of the samples showed either a
downregulation or an aberrant cytoplasmic localization of Cx43 in tumor cells.
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Figure 1. (a–h) TheHuman ProteinAtlas normal and breast cancer tissue staining by immunohistochemistry
for Connexin 43 (Cx43) (CAB010753 antibody). (a) Normal breast. Insert: Arrow head: myoepithelial cell’s
staining; arrow: luminal cell’s staining. (b–h) Breast cancer tissue, (h) arrow: staining of spindle shaped
stromal cells. Scale bar = 100 μm. (i) GJA1 mRNA expression in breast tumor vs. adjacent normal breast
tissue in the The Cancer Genome Atlas (TCGA) dataset. p value: * <0.05; ** <0.01; *** <0.001. (j) Scatter plot
showing Cx43 protein and GJA1 mRNA level in tumors. In the legend, “Breast” indicates adjacent normal
breast tissue. Pearson’s correlation coefficient is given (r).
We next compared transcript levels of GJA1 in breast tumor samples and in the non-cancerous
adjacent tissues using microarray-based data of The Cancer Genome Atlas project (TCGA) breast
invasive carcinoma cohort (BRCA) of clinical samples. We observed a far greater variance in mRNA
expression in tumor samples compared to tumor adjacent morphologically normal breast tissue
(Figure 1i, the Fligner–Killeen test of homogeneity of variances, p value < 10−12). We also used whole
sample Cx43 protein levels obtained for 105 TCGA samples by mass spectrometry. GJA1 mRNA and
protein level are significantly correlated (Figure 1j, (Pearson correlation rho = 0.6515, p value < e−13).
Our results confirm that, in breast cancer, GJA1 is concurrently dysregulated at both the protein and
the mRNA level.
2.2. GJA1 Expression Varies with Breast Cancer Subtype
We then speculated that GJA1 variability could be linked to the molecular heterogeneity of breast
cancer. When we compared GJA1 mRNA expression after stratifying patient samples by their intrinsic
subtype (Pam50 by genefu [29]) (Figure 2a), the increase in variance in gene expression of tumor
samples relative to normal tissue was observed in every subtype. The LumA had a mean expression
level statistically indistinguishable from morphologically normal samples, but a small significant
progressive decrease in expression is observed from LumB to basal and Her2e subtypes (Figure 2a).
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Figure 2. The GJA1 expression level is more variable in breast tumor than in normal tissue and varies
with subtype. (a) The GJA1 mRNA level in normal breast tissue and in each tumor intrinsic subtype.
(b) The Cx43 protein level in each intrinsic subtype. In the legend, “Breast” indicates adjacent normal
breast tissue. All data are from the TCGA dataset. p value: * <0.05; ** <0.01; *** <0.001; NS Not
statistically significant.
A similar pattern was observed in the four other datasets, although normal breast tissues were
only used in TCGA and Curtis datasets (Figure A1). A similar pattern was also observed at the protein
level in the TCGA dataset (Figure 2b). Together, these results suggest that the expression of GJA1
is strongly associated with tumor subtype and is more variable in each subtype in comparison to
morphologically normal tissue.
2.3. Somatic DNA-Level Events of GJA1 Do Not Drive Expression Changes of GJA1 in Breast Cancer
We next asked if underlying DNA-level somatic copy number changes in the genomic loci
harboringGJA1 influence gene expression levels. For the TCGA dataset, a few tumors had amplification
or deletion of GJA1, compared to genes known to be amplified in breast cancer (Figure 3a).
Moreover, tumors with GJA1 amplification did not show an increase in expression while only
deep deletions reduced expression (−2 in called copy number, as shown in Figure 3c). Most luminal
tumors with the highest expression of GJA1 were found to have either a normal copy number or
single deletion (Figure 3b–d). Moreover, in tumors with a GJA1 gain or amplification, a slight but
significant decrease in expression, rather than an increase, could be observed compared to normal
tissues (Figure 3c). GJA1 mRNA also weakly negatively correlated with DNA copy number (Figure 3c),
suggesting that Cx43 over-expression in breast cancer is not driven by DNA amplification. To validate
our procedure, we used the HSF2 gene, a close neighbor of GJA1 on chr6q22 which shares similar
copy number in 99% of TCGA’s breast cancer cases. In contrast to what was observed for GJA1, HSF2
mRNA was positively correlated with the copy number of its own gene (Figure 3c). Moreover, somatic
point mutation data showed that, in the TCGA cohort, only three breast cancer patients out of 977
harbored at least one GJA1 mutation, accounting for 0.31% of the tumors (Figure 3e). Only one tumor
with an extremely high number of total mutations (TCGA-AN-A046) was found to have both a GJA1
mutation and a slightly higher expression of the gene (2.76) compared to normal range (−1.01 to 2.20)
(Figure 3c,e). Together, these results argue that loss or amplification of the GJA1 gene likely does not
dictate mRNA and protein dysregulation in breast cancer.
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Figure 3. Somatic DNA-level events of GJA1 do not drive expression changes of GJA1 in breast
cancer. (a) Percentage of tumors with a relative linear copy number >1 (amplification, in red) and <−1
(hemi- or homozygous deletion, in blue) for GJA1 compared to other genes known to be altered in
breast cancer. (b) Relative linear copy number value for each breast cancer subtype. (c) Somatic copy
number alteration and putative copy number calls against mRNA expression for GJA1 and HSF2. Copy
number calls were computed by TCGA using GISTIC 2.0 (−2, Homozygous deletion; −1, Hemizygous
deletion; 0, Neutral/no change; 1, Gain; 2, High level amplification). Pearson’s correlation coefficient
between relative linear copy number value and mRNA expression is given GJA1 and HSF2. In the
legend, “Breast” indicates adjacent normal breast tissue. (d) Contingency table and barplot showing
the distribution of copy number alteration (CNA) by subtype. Due to the small number of samples
in −2 and 2 CNA, Fisher’s exact test was applied on −1, 0 and 1 CNA. (e) Total number and GJA1
mutations observed in the 3 cases out of 988 patients. All data from the TCGA dataset. p value: * <0.05;
** <0.01; *** <0.001; NS Not statistically significant.
2.4. GJA1 Level Is Dependent on Hormonal Receptor Status
Because Cx43 level varies through the mammary gland development and the reproductive cycle,
it has been suggested that it could be regulated by hormones, similar to what has been observed in
other tissues [4,30–32]. We thus next investigated whether the GJA1 mRNA level was directly linked
with hormonal receptors status.
Consistent with the subtype-specific expression of Cx43, ERα- or PR-positive breast tumors
had a significantly higher expression of GJA1 mRNA compared to ERα- or PR-negative tumors
(Figures 4a and A1–A3). Results were similar for all five datasets, except for PR in the NKI dataset
where the low number of samples did not allow statistical significance to be reached (Figures 4a,
A2a and A3a). However, there were no strong correlations between GJA1 expression and ESR1
mRNA, with total protein level (ERα), or with the activated form of ERα phosphorylated on serine
118 (ERα_pS118) (Figures 4b–e and A1b,c). While only weak correlations were observed in most
individual subtypes, a stronger correlation between GJA1 and ESR1 mRNA and protein was observed
when the tumors were pooled (Figure 4b–d). As expected, ESR1 mRNA was better correlated with
total ERα (Pearson’s rho = 0.9011, Spearman’s rho = 0.8969) than with ERα_pS118 proteins (Pearson’s
rho = 0.5459, Spearman’s rho = 0.6407).
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Figure 4. Depending on the receptor status, GJA1 is associated with different mRNA levels in clinical
samples. (a) Expression of GJA1 mRNA stratified by estrogen receptor alpha (ERα), progesterone
receptor (PR) and erb-b2 receptor tyrosine kinase 2 (ERBB2/Her2) status in the TCGA dataset. p value:
* <0.05; ** <0.01; *** <0.001; NS Not statistically significant. (b) Plot of GJA1 vs. ESR1, PGR and ERBB2
mRNA (microarray) level in each subtype and in normal breast tissue. In the legend, “Breast” indicates
adjacent normal breast tissue. (c) Bootstrapped correlations between ESR1, PGR or ERBB2 and GJA1
mRNA level either in pooled breast cancer tumors or in individual breast cancer intrinsic subtypes and
in normal breast tissue. (d) Plot of GJA1 mRNA vs. ER-alpha, ER-alpha pS118, PR or HER2 protein
level assessed by reverse phase protein assay (RPPA). (e) Bootstrapped correlations between GJA1
mRNA and ER-alpha, ER-alpha pS118, PR or HER2 protein level (RPPA). All data are from TCGA’s
BRCA dataset.
Stronger correlations between PGR mRNA and protein levels and GJA1 mRNA levels were
observed, not only in unstratified (pooled) analysis, but also in individual subtypes within most
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datasets (Figures 4b–e and A1b,c). This association was stronger in cancer samples than in normal
breast tissues in all datasets for which normal tissues were available. Similar to ERα, total PR protein
was well correlated with PGR mRNA (Pearson’ rho = 0.8593 and Spearman’s rho = 0.8723).
Tumors positive for the HER2 receptor by histochemistry (TCGA dataset) did not express
significantly different levels of Cx43 mRNA. However, when HER2 status was given by HER2
amplicon probes or HER2 mRNA expression (Vanvliet, NKI and Curtis datasets), HER2+ tumors had
a significantly lower level of GJA1. No direct correlation was observed between GJA1 and the HER2
(ERBB2) mRNA (Figures 4a–e and A4a–d). A good correlation was observed between HER2 mRNA
and total HER2 protein level (Pearson’s rho = 0.8344, Spearman’s rho 0.68634). The correlation between
HER2 protein (HER2 and HER2_pY1248 activated form) and GJA1 mRNA was not stronger than that
observed for HER2 mRNA (Figures 4b–e and A3d).
Together, the significant differences observed in GJA1 mRNA level in individual subtypes and
with receptor status suggest that GJA1 level is dependent on the molecular context provided by such
subtypes. In addition, GJA1 does not vary directly with ESR1 and HER2 mRNA and protein levels but
shows a stronger correlation with PGR mRNA and PR protein in tumor samples.
2.5. GJA1 mRNA Is Dysregulated at the Early Stages of Breast Cancer and Is Reduced with Grade When
Tumors Are Pooled
To reconcile evidence supporting both tumor-suppressive and -promoting roles, it has been
suggested that Cx43 function could depend on tissue type or evolve with tumor stage [11]. We therefore
investigated whether GJA1 expression in primary breast tumor changed with stage and grade at the
mRNA level in breast cancer. Since grade/stage are strongly associated with subtype, we first stratified
our cohorts by intrinsic subtype. We used the Curtis dataset, as GJA1 expression was available for
invasive tumors (stages 0 to IV) and “normal” adjacent tissue for numerous samples. A significant
dysregulation of GJA1 expression occurred at the early stages in all breast cancer subtypes, although
both over-expression and downregulation could be observed (Figures 5 and A5). Most of the GJA1
over-expressing luminal tumors were found to be of low stage (0–II). However, a reduction was
observed in early stage basal-like and Her2e tumors (Figures 5 and A5). A significant increase in GJA1
was also observed in the invasive stage I compared with stage 0 in all subtypes (Figure 5).



































































LumAPooled LumB Basal Her2e






Figure 5. GJA1 mRNA level is dysregulated in clinical samples at the early stages of breast cancer.
GJA1 mRNA level for each tumor stage and for normal breast in the Curtis Discovery dataset, either
in pooled breast tumors or stratified by intrinsic subtype. In the legend, “Breast” indicates adjacent
normal breast tissue. p value: * <0.05; ** <0.01; *** <0.001.
We then investigated whether or not the expression of GJA1 could be linked to tumors’ grade.
Our analysis revealed that GJA1 mRNA expression was significantly decreased with grade when
all tumors were pooled, but not when they were stratified by intrinsic subtype (Figures 6 and A6).
A significant decrease in GJA1 with grades in LumB tumors could be observed only in the Vanvliet’s
dataset but not in other datasets analyzed (Figures 6 and A6).
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Figure 6. GJA1 mRNA level is downregulated with grade in clinical samples only in pooled tumors
but not in individual subtypes. GJA1 mRNA level for each tumor grade in the Curtis Discovery dataset,
either in pooled breast tumors or stratified by intrinsic subtype. In the legend, “Breast” indicates
adjacent normal breast tissue. p value: * <0.05; ** <0.01; *** <0.001.
Interestingly, basal and Her2e tumors, which express a low level of GJA1 (Figure 2), account for
an important proportion of grade 3 tumors, thus reducing the mean GJA1 expression for this grade
(Figure 6). Moreover, grade 1 tumors are mostly luminal A and B, with a subset of GJA1 over-expressing
tumors, introducing an upward bias in this grade. Grade 2 tumors consist of a more balanced mix of
all the subtypes (Figures 2 and 6). These results suggest that an observed reduction in GJA1 with grade
in pooled tumors is likely a bias induced by the pooling of the tumors’ subtypes.
2.6. In Her2e Breast Tumors, a Low Expression of GJA1 Is Associated with a Better Prognosis
To gain further insight into the role of Cx43 in breast cancer, we analyzed how the level of
GJA1 mRNA expression in each subtype was associated with outcome. Observations that Cx43
expression was associated with a worse prognostic in ER-negative [33] and Her2e [34] tumors have
been previously reported using the web-based platform KMPlotter [35] while ER-positive tumors had
a better prognosis [33]. Investigating further the results of BreastMark and KMPlotter Web platforms,
survival analysis showed that pooled and luminal tumors with high levels of GJA1 mRNA were
associated with a better prognostic (hazard ratio < 1), although results were not always statistically
significant (Figures 7 and A7a,b). Conversely, basal-like and Her2e tumors followed an opposite trend
(hazard ratio > 1), with high expression of GJA1 strongly associated with a worse prognosis in the
Her2e subtype (Figures 7 and A7a,b).


















































































































































Figure 7. GJA1 is associated with a diverging outcome depending on breast cancer subtype.
The Kaplan–Meyer plots show survival curves for patients with breast tumors expressing either
high (blue) or low (red) levels of GJA1 mRNA in pooled tumors or in individual intrinsic subtypes.
TCGA, NKI, Vanvliet and both Curtis datasets were aggregated for the analysis. The best cutoff was
determined as the percentile lending the lowest log rank test p value (Figure A12) and was 53 in Pooled
tumors, 35 in luminal A (LumA) tumors, 68 in luminal B (LumB), 13 in Basal and 18 in Her2e tumors.
Since the aggregation of several datasets in BreastMark and KMPlotter platforms could lead to
artifacts in survival analysis, we went further by performing our own survival analysis for each subtypes
for either aggregated (Figure 7) or individual datasets (Figures A9 and A12) following the determination
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of the best cutoff either by the receiver operating characteristic (ROC) curve (Figure A8a–c) or by the
smallest p value of the log rank test for different thresholds (10–90) (Figure A10).
ROC curves have shown that the highest area Under the curve (AUC) for GJA1 was obtained when
tumors were pooled (Figure A8a) and GJA1 was then ranked, at worst, in the eleven first percentiles
when compared to all the probes present in the five datasets (Figure A8c). The log rank test was highly
significant for all the analyses (Figures 7, A9 and A12) and for a vast range of cutoffs (Figure A10c),
suggesting that GJA1 has the greatest discriminating power when cohorts are unstratified. This is
in line with a differential expression of GJA1 in luminal vs. basal and Her2e tumors that also have
diverging prognostics (Figure 2a).
When analyzing individual subtypes, a high expression was also significantly associated with a better
prognosis in all analyses for LumA and for most analyses for LumB tumors (Figures 7, A9 and A12).
However, survival curves in most analyses as well as the hazard ratio for a wide range of cutoffs
(Figure A11) showed that this tendency is reversed in Basal and Her2e tumors where GJA1 is mostly
associated with a worse prognosis. This result was most significant in Her2e tumors, especially with
smaller cutoffs while significance was rarely reached for Basal tumors.
However, GJA1 ROC curves showed that GJA1 did not consistently identify bad prognosis tumors
with a high specificity and sensitivity (Figure A8a). These results suggest that although stratifying
tumors revealed that the role of GJA1 possibly differs in different breast cancer subtypes, GJA1 should
not be used as a clinical marker. These results also highlight once again how analyses using pooled
tumor subtypes might induce biases and hide diverging results that are subtype-specific.
3. Discussion
Traditionally, Cx43 was considered as a tumor suppressor in the breast, with many studies
reporting decreased Cx43 expression in tumor compared to normal breast tissue via both in vivo and
in vitro studies [3,12,13,18–21]. However, other studies contradict these findings [8,22–25]. This recent
evidence has cast doubt on Cxs tumor’s suppressive role, suggesting that the Cxs function in cancer
was tissue- and tumor stage-dependent [11,17]. At least four different subtypes of breast cancer
have been identified, each having unique molecular profiles, responses to treatment and prognostics.
Our evidence suggests that the role of Cx43 is dependent on subtype.
3.1. Cx43 Expression Is Dysregulated in Breast Cancer
Early studies first showed a dramatic downregulation of GJA1 at the mRNA and the protein level
in breast cancer cell lines as well as in rat and human breast tumors [12,13]. Conversely, other studies
showed an increase in a subset of tumors [15]. Most of these studies analyzed a limited number of
samples and were conducted either prior to the intrinsic subtype classification of breast cancer or did
not use such classification. Our results, with several large cohorts of breast cancer clinical samples,
reconcile these contradictory data by demonstrating that the observed dysregulation can involve
both he increased and decreased expression of the Cx43 protein and mRNA. These observations are
consistent with more recent reports at the protein level [15,16,25,36].
3.2. Dysregulation of Cx43 Is Linked to Hormonal Receptor Status and Tumor Subtype
Our results showed that the expression of Cx43 in breast tumors was lower in basal and Her2e than
in normal tissues and that Cx43 levels vary greatly within luminal subtypes. This subtype-dependent
expression was also shown by more recent studies, the result of which also support a higher expression
of Cx43 mRNA and protein in luminal tumors than in basal-like and Her2e subtypes [36,37]. Because
the intrinsic subtypes are characterized by, among others, hormonal receptor status, we wanted to
evaluate whether a functional link could be captured in whole-tumor expression profiles between Cx43
and ERα, PR or HER2. Whole-tumor expression has been used by others, both to assess the content
of specific cell types in samples and to decipher functional links between genes [38,39]. Using this
method, we showed that GJA1 mRNA increases in a subset of ERα- and PR-positive tumors and in the
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luminal subtypes, which are largely ERα- and PR-positive. These results were not surprising as much
evidence supports a link between Cx43 and hormones in breast tissue [32] and in other tissues [40–43].
GJA1 is also expressed at lower levels when HER2 status is positive and within the Her2e breast cancer
subtype, except in the TCGA dataset. In an early study, it was reported that Cx43 gap junctions were
dramatically reduced in breast tumors, and that this reduction was considered to occur regardless
of ERα, PR or HER2 status [12]. More recent studies have reported that Cx43 protein expression
correlated positively with PR and ERα status [44,45] and negatively with HER2 protein expression [45].
However, Conklin et al. reported that no correlation was observed between Cx43 and HER2 protein in
tissue microarrays [44].
Our results suggest a direct relationship between GJA1 and PR expression in breast cancer
samples. Our analysis shows that GJA1 level correlates with PR mRNA and protein in several subtypes.
These results suggest that either PR or GJA1 levels are dependent on the relative amount of some cell
types co-expressing both genes, or that a functional link exists in the regulation of these genes in the
same cell type or via paracrine signaling. Accumulating evidence has shown that ERα and PR are
expressed in cell populations that do not totally overlap. GJA1 is usually associated with basal cells
while PR is thought to be expressed mainly in hormone-responsive luminal cell [1]. However, PR has
been detected in some human breast basal cells, especially within immature lobules [1], suggesting
an expression in primitive basal progenitor cells. PR has been suggested to coordinate basal cell
proliferation, either via paracrine or autocrine stimulation [1]. It was also reported that the unliganded
progesterone receptor isoform A (PRA) could activate Cx43 transcription by interacting with AP-1
heterodimers composed of FRA2 and JUND [42]. More studies are needed to better understand Cx43
localization and regulation, as well as its potential link with hormones. This knowledge is essential to
further understand mammary gland morphogenesis and how Cx43 and hormones are involved in
breast cancer.
Several other questions remain unanswered regarding the link between GJA1 and ERα, PR and
HER2. While the receptor’s protein and mRNA levels were well correlated in our study, their functional
status in the samples is unknown. Protein expression data for some phosphorylated forms of ER
(ERα_pS118) and HER2 (HER2_pY1248) receptor were available. Beyond single phosphorylation, the
activation of these receptors is mostly dependent on complex post-transcriptional processing which
affects receptors’ specific functions and gene transcription. As a result, prognostic significance of ERα
has been shown to be phosphorylation site-specific [46]. Therefore, it cannot be excluded that GJA1
mRNA expression can be regulated by ERα or HER2 and that these links could not be captured by
expression profiles from breast cancer samples. Regardless of the precise nature of the link between
GJA1 and hormone receptors, our results suggest that GJA1 level is dependent on the overall molecular
context provided by each breast cancer subtype and that this might relate to PGR level, at least in
some subtypes.
3.3. Upregulation of Cx43 mRNA Is Not Driven by DNA Amplification in Breast Cancer
Somatic DNA-level chromosomal aberrations are a defining characteristic of cancer and are
common in breast carcinoma. Genomic loss and amplification cause decreases and increases in
the transcription of genes in the region and often with concomitant effects of protein expression.
We found that GJA1 is rarely the target of such somatic events, and when it occurred it was often in
Her2e and basal subtypes, consistent with the observation that these two subtypes generally have
an increased amount of genomic instability in comparison to the luminal subtypes. Our results are
also in accordance with previous studies that have shown that the region of human chromosome 6
where GJA1 is located (6q22.31) has a relatively low level of amplification and deletions [47]. Cx43 was
rarely mutated in breast cancer samples. Together, these results suggest that GJA1 dysregulation at
the mRNA and protein levels involves a dysregulation of other factors impacting the transcription
(epigenetics, transcription factors) or mRNA stability.
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3.4. Cx43 mRNA Level Is Dysregulated at the Early Stages of Breast Cancer
It was previously reported that, in primary tumors, Cx43 protein expression correlated with
clinical stages [45]. Our analysis of microarray data from large cohorts of primary tumors suggested
that Cx43 is decreased in a subset of tumors during early carcinogenesis (stage 0) and is re-expressed at
higher levels in stage I tumors. While stage 0 of the luminal subtypes showed an increased variance of
expression, those of basal-like and Her2e tumors had a significantly reduced expression compared to
normal tissues. However, we could not observe a robust mRNA reduction, or increase, in later stages
compared either to early tumor stages or to normal tissues.
A previous study investigated immunohistochemistry for Cx43 protein expression in ductal
carcinoma in situ (DCIS), DCIS with microinvasion, DCIS with invasive ductal carcinoma (IDC) and
IDC alone. In pooled tumors as well as in most subtypes, the lowest expression of Cx43 protein
occurred neither in DCIS nor IDC alone but precisely in DCIS with microinvasion where only three out
of thirty-seven cases (8%) were positive [36]. On the other side, out of 193 invasive lesions, sixty-three
(33%) expressed Cx43. When looking specifically at the Her2e subtype, Cx43 was not expressed in
a lower number of DCIS with microinvasion as in other subtypes since Cx43 was rarely expressed.
Cx43 was present in only one of twenty IDC samples while the remaining twenty-six samples of other
groups (DCIS, DCIS with microinvasion and DCIS with IDC) were all negatives. Whether or not the
stromal compartment was included in the analysis was not specified. These results are consistent with
our observation that, in all subtypes, DCIS (typically stage 0) had a lower expression than invasive
stage I tumors. Together, these result point to Cx43 dysregulation as an early event in tumorigenesis,
similar to what has been observed in the early stages of cervix, endometrial and thyroid cancers [48].
Moreover, it should be noted that while breast cancer stages are based on the size and the
spreading of the disease in the tissue or to distant sites, the mRNA expression profiles we used
only account for gene expression in whole primary tumors. Important morphologic information is
therefore lost. During cancer progression, localized neoplastic cells acquire the capacity to invade
surrounding tissues, and eventually reach the blood or lymphatic vasculature, allowing them to spread
to other organs [49]. Depending on the stage and their location within the tumor or the tissue, these
tumor cell populations face different challenges depending on the processes accomplished and on
the microenvironment surrounding them [49]. Microarray data do not make it possible to either
finely assess the expression of specific cells according to their specific localization in the tumor or to
distinguish tumor gene expression from the stroma. A comprehensive study of events occurring early
in carcinogenesis and accounting for the geographical localization within the tumors at primary or
distant sites, and for the different cell populations in a subtype-dependent manner, is therefore the
next logical step in further understanding Cx43’s role in tumor progression.
3.5. The Apparent Grade-Dependent Decrease in Cx43 Is Linked to Its Low Expression in More
Aggressive Subtypes
Tumor grade is a measure of the degree of abnormality of tumor cells and of dedifferentiation of
cancer tissues compared to normal breast tissue. Our results showed that, when all tumors are pooled,
the GJA1 mRNA level seems to increase in grade 1 tumors compared to normal tissues and gradually
decrease with increasing grade. However, stratifying the tumors by subtype showed that within
an intrinsic subtype, the distribution of the tumors within each grade varies considerably. Indeed,
luminal A and B tumors are more frequently of grade 1 or 2 and some of them over-express GJA1
(Figure 2), while most basal and Her2e tumors, that express a low level of Cx43, are mostly of grade 3.
As a result, GJA1 mRNA is not lost with grade in individual subtypes. These results suggest that
the observed correlation in pooled tumors is, in fact, a bias attributable to the pooling of the tumors,
and reflects the high grade of basal and Her2e tumors. These results also highlight how pooling the
different intrinsic subtypes, expressing varying degrees of GJA1, can introduce important biases in
cohort analysis and will likely yield different results depending on the composition, in terms of the
subtypes, of the cohorts studied.
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3.6. High Expression of Cx43 Is Associated with a Good Prognostic in Luminal Subtypes, but with a Worse
Prognostic in Her2e Tumors
Our results showed that, consistent with its ascribed role as a tumor suppressor in breast cancer,
Cx43 was expressed at lower levels in more aggressive basal and Her2e subtypes than in luminal
subtypes. Survival analysis of pooled tumors therefore showed a better survival of tumors highly
expressing Cx43. However, as with grade, pooling breast cancer subtypes to analyze the effect of
GJA1 on the outcome introduces biases. Tumors expressing low levels of GJA1 are overrepresented in
aggressive basal and Her2e tumors, likely dragging down the survival of the group expressing a low
level of GJA1. Therefore, performing survival analysis on pooled tumors, a good prognosis patient is
automatically segregated into the curve of tumors highly expressing GJA1, and vice versa.
Paradoxically, the prognostic associated with Cx43 expression diverged depending on the
intrinsic subtype, with a good prognosis in luminal tumors and an opposite trend in Her2e tumors.
A previous study using immunohistochemistry found no correlation between Cx43 protein level
and patient outcome [44]. However, similar to our results, more recent studies using expression
array-based survival curves found that a highGJA1 expressionwas associatedwith a better prognosis in
ERα-positive breast cancer tumors, while an opposite trend was observed in ERα-negative tumors [33]
and Her2e tumors [34]. The worse prognosis associated with GJA1 in Her2e tumors suggests that GJA1
function in breast cancer might not just be tissue- and stage-dependent, as suggested by others [11,17],
but might also be subtype-dependent.
Cx43 has been reported to be expressed both in epithelial and stromal cells types. The molecular
landscape provided by different cell types and/or by different breast cancer subtypes might provide
different context, possibly allowing Cx43 to assume different functions and leading to different
outcomes. It could be hypothesized that such context may provide different sets of interacting partners
for GJA1, and its expression might even be driven by a different set of transcriptional or epigenetic
regulators. In addition, an important determinant of the capacity of Cx43 to assume its channel
function is unarguably its proper membrane localization. From array based mRNA expression data,
it is until now impossible to assess neither the cellular localization nor the functional status of Cx43.
It is very likely that these important and relevant information would contribute to a more complete
understanding of the functions of Cx43 in breast cancer. For instance, a recent study demonstrated that
over-expressing Cx43 in two different HER2-positive breast cancer cell lines lead to a diverging ability
to proliferate, migrate, form mammospheres and form tumors in mice. Tumorigenic characteristics
of the cancer cells were enhanced when functional gap junction channels could not be formed upon
Cx43 over-expression, but were reduced when membrane gap junctions plaques allowed cells to
communicate [34]. These aspects of Cx43 biology might explain its different roles according to
subtypes but also possibly within subtypes and should therefore be addressed. Additional researches
are required to better understand the context that allows Cx43 to suppress or promote carcinogenesis
in different intrinsic subtypes.
4. Materials and Methods
4.1. Gene Expression
We used 4K samples over different expression platforms. Vanvliet used Affymetrix Human Genome
U133A (data processed with Robust Multi-Array Average (RMA)) [50]. Curtis discovery and Curtis
validation used the Illumina HT-12 v3 platform (expression given as a Log2 intensity level) [47]. The
Cancer Genome Atlas (TCGA) used a custom Agilent G4502A 244K array (expression given as Log2
Lowess normalized ratio) [51]. NKI used a Hu25K Agilent platform (samples were hybridized against
a pool of equal amount of RNA from each patient and gene expression is given as a log10 of intensity
ratio) [52]. Normalized signal per probe or probe set mRNA expression was downloaded for tumor
samples for all five datasets. Breast cancer intrinsic subtype was assigned to each sample with the Pam50
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molecular subtyping algorithm using the R genefu package [29]. Survival for each case was determined
as in [27].
ERα, PR and HER2 status provided in the original publication of the dataset was used. For TCGA,
ER, PR and HER2 status was obtained by immunohistochemistry (IHC). For NKI, ER and PR status
was determined by IHC and the sample was considered positive if at least 10% of the cells were
positive. For Vanvliet, ER and PR status was determined with the Bioconductor package ROCR based
on the expression of the probe 205225_at and validated with IHC when available. NKI and Vanvliet
HER2 status was determined using the probes of the HER2 amplicon genes. For Curtis datasets, ER, PR
and HER2 status was based on mRNA expression. In the TCGA dataset, the level of some proteins has
been investigated with reverse phase protein assay (RPPA). Data were available for total ERα, PR and
HER2 as well as for the phosphorylated forms of ERα (pS118) and HER2 (pY1248) that are at least
partially indicative of the activation status [46,53]. GJA1 protein level obtained by mass spectrometry
for 105 TCGA samples was retrieved from the protein report found at the Clinical Proteomic Tumor
Analysis Consortium (CPTAC) data portal [54]. Levels are given as the log2 of the ratio of each sample
with respect to a pooled reporter sample.
4.2. DNA Alteration
Copy number alterations (CNAs) were measured in the TCGA dataset with Affymetrix 6.0
single nucleotide polymorphism (SNP) arrays and segmented using Circular Binary Segmentation
(labeled here as Relative linear copy number values) [51]. Data were further processed by TCGA
using GISTIC 2.0 to assign the Putative copy number calls per gene (−2: Homozygous deletion,
−1: Hemizygous deletion, 0: Neutral/no change, 1: Gain, 2: High level amplification) [51]. Mutations
were detected using whole-exome sequencing after controlling for germline and normal adjacent tissue
mutations [51]. Linear and called CNA data as well as mutation data for the TCGA dataset were
retrieved using R via cBioportal [55,56]. A total of 977 patients had data for mutations [51].
4.3. Survival Analysis
Survival data was available for all five datasets. The log-rank test was used to estimate significance
and hazard ratios (95% CI) were computed via Cox regression using survival package [57]. ROC curves
were computed using the pROC package [58]. Kaplan–Meier plots were used to visualize the data.
The best cutoff to determine tumors expressing high or low levels of Cx43 was selected using either
the ROC curves or based on the smallest p value of the log rank test computed for each threshold
between 10 and 90. For aggregated datasets analysis, each cohort was first split into groups based on
the selected threshold and datasets were pooled only after splitting.
In addition, survival analyses were computed using the BreastMark and KMPlotter web platforms
that use several well-known dataset [35,59]. BreastMark allows thresholds of 25, 50 and 75 percentile to
be selected to split the different cohorts used before aggregating them. For each analysis, we selected
the threshold giving the best results. Since less samples were available in KMPlotter for statistical
computation, we only included analyses for which there were at least 100 samples to draw both high
and low expression curves for each subtype.
4.4. Statistical Analysis
All statistical analyses were carried out with R version 3.4.3 [60]. For two class comparisons,
(cancer vs. normal tissues; positive vs. negative hormonal status) the Wilcoxon-Mann-Witney test
was used. When more than two classes were compared, the Kruskall-Wallis test was used followed
by the Dunn post-hoc test to assess the statistical significance for each pair of samples (to compare
subtypes). For stages and grades, differential gene expression was assessed using Limma package [61].
A Benjamini-Hochberg correction was applied to adjust the p values for multiple testing. Because
each subtype had a different number of patients, when correlation tests were performed between the
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expression of GJA1 and the expression of other genes, a non-parametric bootstrap procedure was used
for each subtype to derive the mean correlation coefficient and a percent confidence interval.
5. Conclusions
Our study has clarified the expression pattern of GJA1 mRNA in breast cancer and showed that
GJA1 expression, as well as its prognostic significance, is dependent on breast cancer subtype. We also
highlighted important biases that are introduced in analyzing pooled tumors. These biases need to be
taken into consideration when studying GJA1, but also numerous other genes that are known to be
linked, for instance, to ERα expression. Breast cancers are heterogeneous and genetically diverse and
the lack of recognition of this molecular heterogeneity might explain the conflicting results from the
literature, not only for GJA1, but potentially for other tumor suppressors or oncogenes. Overall, these
results clearly showed that the molecular context where Cx43 is expressed in general, and the tumor
subtypes of breast cancer in particular, should be taken into account when investigating Cx43’s role
in carcinogenesis.
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CNA Copy number alterations
Cx43 Connexin 43
DCIS Ductal carcinoma in situ
ERα Estrogen receptor alpha
ERBB2 erb-b2 receptor tyrosine kinase 2
GJIC Gap Junction Intercellular Communication
GJA1 Gap Junction protein alpha 1, the gene encoding Connexin 43
Her2e HER2-enriched




RPPA Reverse phase protein assay
TCGA The Cancer Genome Atlas
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Figure A1. GJA1 mRNA level in breast cancer clinical samples is dependent on breast cancer subtype
in four datasets. GJA1 mRNA level in tumors stratified by subtype in Vanvliet, NKI, Curtis Discovery
and Curtis Validation datasets. In the legend, “Breast” indicates adjacent normal breast tissue. p value:
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Figure A2. GJA1 mRNA level in breast cancer clinical samples is higher in ER-positive tumors in four
datasets. (a) GJA1 mRNA level in breast tumors stratified by estrogen receptor status determined as
described in Material and Methods. p value: * <0.05; ** <0.01; *** <0.001. (b) Expression of GJA1 vs.
estrogen receptor alpha (ESR1) mRNA in each subtype and in normal breast tissue. (c) Bootstrapped
correlations between ESR1 and GJA1 mRNA level either in pooled breast cancer tumors or in individual
intrinsic subtypes and in normal breast tissue. Data from Vanvliet, NKI, Curtis Discovery and Curtis
Validation datasets.
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Figure A3. GJA1 mRNA level in breast cancer clinical samples increases with PGR expression in four
datasets. (a) GJA1 mRNA level in breast tumors stratified by PR status determined as described in
Material and Methods. In the legend, ”“Breast” indicates adjacent normal breast tissue. p value: * <0.05;
** <0.01; *** <0.001; NS Not statistically significant. (b) Expression of GJA1 vs. progesterone receptor
(PGR) mRNA in each subtype and in normal breast tissue. (c) Bootstrapped correlations between PGR
and GJA1 mRNA level either in pooled breast tumors or in individual breast cancer intrinsic subtypes.
Data from Vanvliet, NKI, Curtis Discovery and Curtis Validation datasets.
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Figure A4. GJA1 mRNA level in breast cancer clinical samples is lower in HER2-positive breast
tumors in four datasets. (a) GJA1 mRNA level in breast tumors stratified by HER2 status determined
as described in Material and Methods. In the legend, “Breast” indicates adjacent normal breast
tissue. p value: * <0.05; ** <0.01; *** <0.001. (b) Expression of GJA1 vs. ESR1 mRNA in each
subtype and in normal breast tissue. (c) Bootstrapped correlations between ERBB2 and GJA1 mRNA
level either in pooled breast cancer tumors or in individual intrinsic subtypes and in normal breast
tissue. Data from Vanvliet, NKI, Curtis Discovery and Curtis validation datasets. (d) GJA1 mRNA vs.
pY1248 phosphorylated form of HER2 protein level determined by RPPA in breast tumors from the
TCGA dataset.
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Figure A5. GJA1 mRNA level is dysregulated in the early stages of breast cancer in clinical samples.
GJA1 mRNA level for each tumor stage either in pooled breast tumors or stratified by intrinsic subtype.
Data from TCGA and Curtis Validation datasets. In the legend, “Breast” indicates adjacent normal
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Figure A6. GJA1 mRNA level is reduced with grade in breast cancer clinical samples but only in pooled
tumors. GJA1 mRNA level for each tumor grade, in Vanvliet, NKI and Curtis Validation datasets, either
in pooled breast tumors or stratified by intrinsic subtype. In the legend, “Breast” indicates adjacent
normal breast tissue. p value: * <0.05; ** <0.01; *** <0.001.
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Figure A7. GJA1 is associated with different outcomes depending on the breast cancer subtype.
(a) BreastMark’s; and (b) KMPlotter’s web interface were used to complete the survival analysis for
GJA1 expression. Disease-Free Survival (DFS), Distant Disease-Free survival (DDFS), Overall Survival
(OS) and Combined Survival (Combined) are given either for pooled tumors or for individual breast
cancer subtypes in Breast Mark (a). Relapse-Free Survival (RFS) and Distant Metastasis-Free survival
are given for GJA1 probe 201667_at in KMPlotter (b). The best cutoff was determined manually for
BreastMark (25, 50 or 75 percentile) based on p value and logrank score and automatically for KMPlotter.
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Figure A8. (a) Determination of the best cutoff for GJA1 using ROC curves in individual subtypes of
breast cancer. ROC curves evaluating the sensitivity vs. the specificity of GJA1 as a marker of prognostic
(occurrence of events in five years after tumor removal) in pooled tumors and each individual subtype
of breast cancer of five datasets (TCGA, NKI, Vanvliet and Curtis discovery and Curtis validation).
AUC, Area under the curve. The best cutoff is given in blue and is used in a subsequent survival
analysis in Figure A9. (b) Expression of GJA1 in pooled tumors and individual subtypes in five datasets.
The red lines indicate the cutoff as determined by the ROC curves. In the legend, “Breast” indicates
adjacent normal breast tissue. X indicates tumors with subsequent recurrence events. (c) Rank of the
GJA1 probe in pooled tumors and each individual subtype for five datasets. Rank given in percentile of
the area under the ROC curve compared to all the other probes.
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Figure A9. Survival analysis of GJA1 in individual subtypes of breast cancer with cutoff selected
according to the ROC curve. Kaplan–Meyer plots show survival curves for patients with breast tumors
expressing either high (blue) or low (red) levels of GJA1 mRNA in pooled tumors or in individual
intrinsic subtypes. TCGA, NKI, Vanvliet and both Curtis datasets were used for the analysis. The best
cutoff was determined from ROC curves as in Figure A8.
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Figure A10. Determination of the best cutoff for GJA1 using the log rank test p value in individual
subtypes of breast cancer. Graph of the p value of the log rank test to compare the survival of patients
with Cx43 expressed at high or low levels according to varying thresholds (10–90 percentile). Horizontal
red lines indicate 0.05 p value. Vertical red lines indicate the threshold with the lowest p value for the
log rank test, used for subsequent survival analysis in Figures 7 and A12. Results given for pooled
tumors or individual breast cancer subtypes in our five datasets (TCGA, NKI, Vanvliet and Curtis
discovery and Curtis validation) as well as in aggregated datasets (Pooled datasets).
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Figure A11. Cox regression hazard ratio associated with GJA1 for different thresholds. Graph of the
Cox regression hazard ratio to compare the survival of patients with Cx43 expressed at high or low
levels according to varying thresholds (10–90 percentile). Horizontal red lines indicate a neutral hazard
ratio of 1. Vertical red lines indicate the threshold with the lowest log rank test p value as determined
in Figure A10, used for subsequent survival analysis. Results given for pooled tumors or individual
breast cancer subtypes in our five datasets (TCGA, NKI, Vanvliet and Curtis discovery and Curtis
validation) as well as in aggregated datasets (Pooled datasets).
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Figure A12. Survival analysis of GJA1 in individual subtypes of breast cancer with the cutoff selected
according to the log rank test p value. The Kaplan–Meyer plot shows survival curves for patients with
breast tumors expressing either high (blue) or low (red) levels of GJA1 mRNA in pooled tumors or in
individual intrinsic subtypes. TCGA, NKI, Vanvliet and both Curtis datasets were used separately for
the analysis. The best cutoff was determined as the percentile lending the lowest log rank test p value
as in Figure A10.
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Abstract: It has long been known that the gap junction is down-regulated in many tumours. One of
the downregulation mechanisms is the translocation of connexin, a gap junction protein, from
cell membrane into cytoplasm, nucleus, or Golgi apparatus. Interestingly, as tumours progress
and reinforce their malignant phenotype, the amount of aberrantly-localised connexin increases
in different malignant tumours including oesophageal squamous cell carcinoma, thus suggesting
that such an aberrantly-localised connexin should be oncogenic, although gap junctional connexins
are often tumour-suppressive. To define the dual roles of connexin in head and neck squamous
cell carcinoma (HNSCC), we introduced the wild-type connexin26 (wtCx26) or the mutant Cx26
(icCx26) gene, the product of which carries the amino acid sequence AKKFF, an endoplasmic
reticulum-Golgi retention signal, at the C-terminus and is not sorted to cell membrane, into the
human FaDu hypopharyngeal cancer cell line that had severely impaired the expression of connexin
during carcinogenesis. wtCx26 protein was trafficked to the cell membrane and formed gap junction,
which successfully exerted cell-cell communication. On the other hand, the icCx26 protein was
co-localised with a Golgi marker, as revealed by immunofluorescence, and thus was retained
on the way to the cell membrane. While the forced expression of wtCx26 suppressed both cell
proliferation in vitro and tumorigenicity in mice in vivo, icCx26 significantly enhanced both cell
proliferation and tumorigenicity compared with the mock control clones, indicating that an excessive
accumulation of connexin protein in intracellular domains should be involved in cancer progression
and that restoration of proper subcellular sorting of connexin might be a therapeutic strategy to
control HNSCC.
Keywords: gap junction; cell-cell communication; connexin26; head and neck squamous cell
carcinoma; ER-Golgi retention signal; cancer progression
1. Introduction
Gap junction (GJ) is an intercellular channel directly connecting the cytoplasms of two adjacent
cells, which then exchange water-soluble small molecules (<1 kDa) through GJ [1]. Serving as a tool for
cell-cell communication, GJ plays essential roles in the homeostasis of cellular society. To the contrary,
it has been well known that failure in gap junctional intercellular communication (GJIC) is profoundly
involved in serious disorders and diseases of various organs, including arrhythmia [2], sensorineural
hearing loss [3], Charcot-Marie-Tooth disease [4], and even cancers [5]. A gap junctional channel
Int. J. Mol. Sci. 2018, 19, 2134; doi:10.3390/ijms19072134 www.mdpi.com/journal/ijms302
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comprises two membrane-integrated hemichannels provided by each of two adjacent cells, and each
hemichannel is composed of hexameric connexin molecules to become functional. In mammals, more
than 20 molecular species have so far been identified in a connexin protein family [6,7]. Usually, several
different connexin proteins are co-expressed in a single cell and the combination of the expressed
connexin proteins varies tissue to tissue, i.e., while the keratinocytes of the epidermis express many
connexin proteins such as connexin26, 30, 30.3, 31.1, 32, 43, and 45 [8], the cardiomyocytes express
connexin40, 43, and 45 [9].
A large number of reports from us and others have established that GJIC suppresses tumour
promotion in carcinogenesis by restraining the cancer-initiated cells in cellular society and that
downregulation of GJIC leads to cancer development, as proven by a considerable number of
experiments both in vitro and in vivo [10]. In this context, since the connexin protein localised in
cytoplasm cannot participate in GJ formation, translocation of connexin protein from cell membrane
to cytoplasm is considered to be loss-of-function of GJ in terms of tumour suppression. However,
there is a growing body of evidence indicating that an excessive accumulation of connexin protein in
cytoplasm and/or organelles enhances cancer progression such as invasion and metastasis [11–14].
Notably in squamous cell carcinoma of the head and neck and the oesophagus, the expression level
of connexin26 (Cx26) in various intracellular domains correlates to the grade of malignancy or the
extent of lymph node metastasis [15,16]. Furthermore, we have previously reported that accumulation
of connexin32 (Cx32) in Golgi apparatus increases cancer stem cells in number and enhances the
metastatic ability of the cell lines derived from human hepatocellular carcinoma [17].
In the present study, to define the roles of connexin protein localised in a Golgi area in the
malignant phenotype of human head and neck squamous cell carcinoma (HNSCC), we transduced
human FaDu hypopharyngeal cancer cells with the retrovirus vector carrying the mutant Cx26 cDNA
which encoded intracellular Cx26 (icCx26) protein and compared their cancerous behaviours with
those of the clones transduced with the wild-type Cx26 (wtCx26) or the empty vector. Our different
analyses finally indicated that while wtCx26 protein integrated into GJ at cell membrane functioned
tumour-suppressively, icCx26 protein rather reinforced malignant phenotype in FaDu cells.
2. Results
2.1. AKKFF Amino Acid Sequence Successfully Retains Cx26 Protein in a Golgi Area in FaDu Cells
As previously reported, an excessive accumulation of Cx32 protein in Golgi apparatus reinforces
the malignant phenotype of human hepatoma HuH7 cells, suggesting that connexin protein in Golgi
apparatus might have a distinct function from GJ [18]. Thus, to define the roles of intracellular
connexin protein in the malignant phenotype in the context of HNSCC, the mutant Cx26 protein in
which the amino acid sequence AKKFF, an endoplasmic reticulum (ER)-Golgi retention signal [19],
was added to the C-terminus was overexpressed in human FaDu hypopharyngeal HNSCC cells by
retroviral transduction. As shown in Figure 1a, the control mock-transduced FaDu cells express a
negligible amount of endogenous Cx26 protein. On the other hand, the clones transduced by either
wtCx26 or icCx26 construct overexpress respective corresponding proteins. Consistently with the
immunoblotting, wtCx26 protein successfully provides punctuate strong fluorescent signals at a
cell-cell contact area, indicating an efficient formation of GJ plaques (Figure 1b). In contrast, the icCx26
protein covalently-conjugated with the ER-Golgi retention signal fails to locate in cell membrane and
is co-localised with a Golgi marker GM130, indicating a dense accumulation of icCx26 protein in
a Golgi area. The amino acid sequence AKKFF we used as an ER-Golgi retention signal has been
reported to target connexin43 (Cx43) protein to the ER-Golgi intermediate compartment (ERGIC) [19].
As shown in Figure 1b, immunofluorescent signals given by icCx26 protein appear much larger than
ERGIC [20]. We thus interpret that icCx26 protein is localised not only in ERGIC but also inside or on
Golgi apparatus. It has been known that Cx26, unlike Cx32 and Cx43, takes an alternative pathway
instead of the secretory pathway as a membrane trafficking route [21]. However, as shown in Figure A1,
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GJ plaques composed of wtCx26 are disrupted in the presence of Brefeldin A, suggesting that wtCx26
could take the secretory pathway in our FaDu cells as observed in mouse keratinocytes [22].
Figure 1. Expression and subcellular localisation of wtCx26 or icCx26 protein in the FaDu clones
retrovirally-transduced by each construct examined. (a) Immunoblotting of Cx26 protein expressed in
the wtCx26, icCx26, and mock clones. The expression of glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was examined as a loading control. (b) Indirect immunofluorescence of Cx26, p120catenin
(p120ctn), and GM130 proteins in the FaDu clones. The fluorescent signals of p120ctn protein were
visualised by Alexa-568 (orange to red) and indicate a juxtamembrane area in the wtCx26 clone. Nuclei
were stained with diamidine phenylindole dihydrochloride (DAPI). Note that signals of both Cx26 and
GM130 proteins are co-localised in the icCx26 clone (overlay). Scale bar, 20 μm.
2.2. wtCx26 but Not icCx26 Protein Has the Ability to Exert GJIC
As mentioned above, wtCx26 protein is sorted to cell membrane and is capable of forming GJ
plaques in a cell-cell contact area of FaDu cells. To examine whether the wild type-mediated GJs are
indeed functional in FaDu cells, we performed a scrape loading dye-coupling assay. As shown
in Figure 2a, while the primarily-scraped cells are co-stained by rhodamine B isothiocyanate
(RITC)-dextran and Lucifer yellow in all the clones examined, the clone transduced with wtCx26
but neither icCx26 nor the mock construct is positive only for Lucifer yellow in a zone adjacent to
RITC-positive cells. Since, unlike RITC-dextran, Lucifer yellow can pass through GJ, the cells in
the Lucifer yellow-positive zone are considered to have received the dye through functional GJs.
As predicted, these results clearly indicate that icCx26 protein cannot contribute to GJ formation in cell
membrane and is thus non-functional as a GJ protein (Figure 2b).
2.3. wtCx26 and icCx26 Proteins Regulate Cell Proliferation and Invasion in a Reciprocal Manner
To examine the effects of intracellular accumulation of Cx26 protein on cell proliferation, each
clone transduced with wtCx26, icCx26, or the mock construct was plated in 60-mm dishes in triplicate
and the cell number was counted with hemocytometer. As shown by growth curve (Figure 3a), the
proliferation rate of FaDu cell clone overexpressing wtCx26 protein is significantly lower than that
of the mock clone. More interestingly, overexpression of icCx26 protein retained in a Golgi area has
remarkably elevated the proliferation rate compared with the mock clone. It has been known that
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GJ-mediated modulation of cell proliferation is often most obvious in the alteration of saturation
density [23,24]. It is also the case with our experiments, i.e., the saturation densities of wtCx26- and
icCx26-transduced clones are approximately 60% and 180% of that of the mock clone, respectively
(Figure 3a). Taken together, while cell proliferation is suppressed by Cx26 protein integrated into GJ,
GJ-independent Cx26 protein localised in a Golgi area enhances cell proliferation.
We further investigated whether overexpression of icCx26 protein could affect invasiveness
of FaDu cells by evaluating the ability of each clone to invade the basement membrane matrix.
Similarly to other malignant phenotypes, Figure 3b demonstrates that overexpression of icCx26 and
wtCx26 proteins enhances and declines the invasiveness of FaDu cells, respectively.
Figure 2. Scrape-loading dye-transfer assay to measure GJIC ability. The wtCx26, icCx26, and mock
clones were soaked in a cocktail of Lucifer yellow CH and RITC-dextran, scraped by a micropipette
tip, and observed under a fluorescence microscope after 5 min of incubation. (a) Representative
micrographs of 3 different clones. The same fields of each clone were captured. Note that dye-coupled
cells with Lucifer yellow CH were observed only in the wtCx26 clone. (b) Histogram showing the
mean GJIC capacity of each clone. Error bars represent the SD (n = 6).
Figure 3. Effects of wtCx26 and icCx26 proteins on cell proliferation and invasion capacity in vitro of
FaDu cells. (a) Growth curve of each clone of FaDu cells. The wtCx26, icCx26, and mock clones were
cultured for the indicated periods. The cells were counted every 2 or 3 days in triplicate dishes. Error
bars represent the SD (n = 3). No error bar is indicated when the SD is too small to show. * p < 0.001
(significantly different from the mock clone at the corresponding time point). (b) Invasion capacity of
each clone into the matrix basement membrane. The cells were seeded onto Matrigel, which had been
settled on cell culture inserts in advance. The cells that infiltrated into the Matrigel layer were counted
and their proportion to the total cell number is indicated. Error bars represent the SD (n = 6).
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2.4. icCx26 Protein Reinforces Tumorigenicity of FaDu Cells in Nude Mice
To assess the effect of intracellular accumulation of Cx26 protein on tumorigenicity in vivo,
1 × 106 cells each of the three clones transduced with wtCx26, icCx26, or the mock construct were
implanted subcutaneously into the backs of 6 male nude mice per clone. All of the 18 mice examined
developed xenograft-derived subcutaneous tumours (Figure 4a). The growth curves of tumours
show that the clone overexpressing icCx26 protein manifests a greatly higher growth rate of tumours
compared with the mock clone (Figure 4a,b). Consistent with many other papers, the growth rate of
tumours was significantly declined by overexpression of wtCx26 protein (Figure 4b), which forms GJ
plaques at a cell-cell contact area (Figure 1b).
Furthermore, the tumours derived from each clone were subjected to immunohistochemistry
to determine subcellular localisation of Cx26 protein in the tumours. Figure 4c shows that wtCx26
and icCx26 proteins are localised in cell membrane and cytoplasm, respectively, in the corresponding
tumours. Regardless of expressed types of Cx26 protein, the behaviours of the Cx26 proteins examined
are not different between in vitro and in vivo. These results clearly indicate that oncogenic roles of
icCx26 protein have been confirmed both in vitro and in vivo.
Figure 4. Xenografts of the wtCx26, icCx26, and mock clones into nude mice and tumorigenicity
assay in vivo. (a) Representative mice bearing tumours raised from 1 × 106 cells of each clone.
(b) Tumorigenicity in vivo of each clone. The size of each tumour was measured every 2 or 3 days.
Error bars represent the SD (n = 6). No error bar is indicated when the SD is too small to show. * p < 0.03,
** p < 0.001 (significantly different from the mock clone at the corresponding time point). (c) Expression
and subcellular localisation of Cx26 protein in the tumours raised from the xenografts. As revealed by
immnohistochemistry, wtCx26 was localised in a cell-cell boundary area. Scale bar, 20 μm.
3. Discussion
It has been established by many convincing evidences that GJ is, in general, a tumour-suppressive
cellular apparatus. As such, are connexin proteins, an exclusive component of GJ, considered
to be a tumour suppressor? When connexin proteins serve as GJ components, they are usually
tumour-suppressive. However, connexin proteins often translocate from cell membrane into an
intracellular site in different histological types of malignant tumours [14]. Although such an
aberrantly-localised connexin protein cannot function as GJs, their intracellular translocation might
generate an unexpected intrinsic function in connexin molecules and make some contribution to
tumour progression. To address such a question, we have previously demonstrated that Cx32 protein
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is not localised in plasma membrane but in the Golgi-apparatus in human HuH7 hepatoma cells and
that accumulation of Cx32 protein in the Golgi-apparatus reinforces different malignant phenotypes
of HuH7 cells, resulting in the induction of metastasis in the mice xenografted with HuH7 cells
overexpressing Cx32 protein in the Golgi-apparatus [17,18].
HuH7 cells are, by nature, incapable of forming GJs due to retention of Cx32 protein in the
Golgi-apparatus. In the present study, we employed FaDu HNSCC cells, which express almost no
connexin protein, but which can support membrane sorting of a normal connexin protein to generate
functional GJs (Figure 1). In other words, FaDu cells are quite normal in terms of the GJ system.
HNSCCs are raised from the basal cells, which express mainly Cx26 among different connexin proteins,
in the stratified squamous epithelium. Therefore, using FaDu cells and the mutant Cx26 construct
coding Cx26 protein conjugated with an ER-Golgi retention signal, we could successfully compare
functions between icCx26 and wtCx26 proteins in terms of GJIC, cell proliferation, invasion, and
tumorigenicity and find out that icCx26 protein had a GJ-independent intrinsic oncogenic function.
We have been unable to provide the mechanism of how our icCx26 protein behaves in a
pro-oncogenic manner. Since icCx26 protein is localised in a Golgi area, ER-stress response may
be involved in the mechanism. ER-stress induces two contradictory responses called “adaptive
response” and “destructive response” [25]. The adaptive response can be pro-oncogenic. While many
proteins related to ER-stress response function in a Golgi-independent manner, ER-resident ATF6
protein is translocated to Golgi apparatus, activated there, then imported into nucleus, and finally
induces ER-stress response [26]. icCx26 protein might be involved in such a pathway. More directly,
icCx26 protein might play a role in recently-unravelled Golgi stress [27].
It has long been proposed that connexin in tumour has dual or even multiple functions [28,29].
Although intracellular connexin proteins including intra-Golgi, cytoplasmic, and nuclear connexins are
rather common in tumours [30–33], there has been little examination thus far of their existence and roles
in a physiological condition [34]. Thus, this study has contributed to proving a pathological significance
of intracellular connexin proteins. Furthermore, membrane-sorting mechanism of connexin proteins
still remains controversial. From aspects of cancer control, mechanism of intrinsic function of connexin
proteins in a pathological condition and improvement of membrane sorting of connexin proteins
should become targets to be elucidated.
4. Materials and Methods
4.1. Vector Construct
To add the amino acid sequence AKKFF, an ER-Golgi retention signal [19], to C-terminus of Cx26,
the fragment containing the coding sequence of human Cx26 (GJB2) cDNA [35] was amplified by
polymerase chain reaction with the following set of primers: Forward, 5′-ACACAAGCATCTTCTTC-3′;
Reverse, 5′-GCGAATTCTTAGAAGAACTTCTTGGCAACTGGCTTTTTTGACTTCCCAGA-3′. It was
then digested by the restriction enzymes Bsp119I and EcoRI. The Bsp119I-EcoRI fragment was
exchanged with the corresponding fragment of the previously prepared human Cx26/pQCXIN
construct, resulting in the mutant Cx26 cDNA, coding icCx26 protein, cloned into pQCXIN retrovirus
vector (Clontech Laboratories, Mountain View, CA, USA).
4.2. Cell Culture and Retroviral Transduction
Human FaDu hypopharyngeal squamous cell carcinoma cell line was supplied by American Type
Culture Collection (ATCC, Manassas, VA, USA). It has been confirmed that our FaDu cells express no
detectable level of Cx43 protein as revealed by immunoblotting and immunofluorescence (Figure A2).
The cells and their established subclones were cultured in RPMI1640 medium (Nissui Pharmaceutical,
Tokyo, Japan) containing 10% foetal calf serum (FCS), 100 units/mL penicillin and 100 μg/mL
streptomycin. PT-67 packaging cells were grown in Dulbecco modified Eagle medium (Thermo
Fisher Scientific, Rockford, IL, USA), 10% FCS, 100 U/mL penicillin and 100 μg/mL streptomycin.
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All the cells were incubated at 37 ◦C in a humidified atmosphere containing 5% CO2 in air. To determine
cell proliferation, 5 × 104 cells were seeded into 60-mm dishes in triplicate in 4 mL of medium with
10% FCS. The cells were grown under the aforementioned conditions and counted every 2 or 3 days
with a haemocytometer. Dead cells, as determined by trypan blue staining, were left out of the count.
FaDu cells expressing wtCx26 or icCx26 protein were established as follows. wtCx26/pQCXIN,
icCx26/pQCXIN construct, or pQCXIN empty vector was transfected with FuGENE HD Transfection
Reagent (Promega, Madison, WI, USA) into the packaging cell PT-67, and stable transformants were
selected with 400 μg/mL G418. FaDu cells were then infected with virus-containing supernatant,
supplemented with 4 μg/mL of polybrene, from PT-67 cells transfected with each of the 3 constructs.
After 3 weeks of selection with 400 μg/mL G418, G418-resistant FaDu transductants were subcloned
by limiting the dilution method. Randomly-selected 8 clones each from wtCx26 and icCx26 stable
transductants as well as 5 clones from mock transductants were subjected to a preliminary cell
proliferation assay to measure population doubling time. Since all the mock clones showed similar
population doubling times without variation, native clonal variation of FaDu cells is considered to
be small (Figure A3). 2 and 1 clones of wtCx26 and icCx26 transductants, respectively, showed a
population doubling time indistinguishable from that of the mock clones (Figure A3). Omitting these
3 clones, we used a clone indicating a median value from each of three groups for later experiments.
It has been confirmed by immunoblotting that the omitted 3 clones express no exogenous Cx26 protein.
4.3. Immunoblotting
Immunoblotting analysis was performed mostly as previously described [23]. As primary
antibodies, anti-Cx26 polyclonal antibody (pAb) (Thermo Fisher Scientific) and anti-GAPDH
monoclonal antibody (mAb) clone 6C5 (HyTest, Turku, Finland) were applied after diluted at 1:500
and 1:10,000, respectively. Then as second antibodies, horseradish peroxidase (HRP)-conjugated
anti-rabbit and anti-mouse IgG antibodies (GE Healthcare Bio-Sciences, Piscataway, NJ, USA) were
applied at dilution ratios 1:2000 and 1:5000, respectively. Finally, the protein-antibody complex was
chemiluminated with a WEST-one Western Blot Detection System (iNtRON Biotechnology, Seoul,
Korea) following the manufacturer’s protocol.
4.4. Indirect Immunofluorescence
Indirect immunofluorescence was performed as described previously. Anti-Cx26 mAb clone
CX-12H10 (Thermo Fisher Scientific) and anti-p120 Catenin pAb (Sigma-Aldrich, St. Louis, MO, USA),
anti-GM130 pAb (Sigma-Aldrich) were diluted at 1:150, 1:200, and 1:3500, respectively. After fixation
with acetone, cells are incubated with the diluted primary antibodies. Specific signals were revealed
by anti-mouse IgG-Alexa 488 (Thermo Fisher Scientific) and anti-rabbit IgG-Alexa 568 (Thermo Fisher
Scientific). Nuclei were stained with DAPI (KPL, Gaithersburg, MD, USA) at a concentration of
0.5 μg/mL.
4.5. Scrape-Loading Dye-Transfer Assay
The assay was performed as described in el-Fouly et al. [36] with modification. The confluent
cells on 60-mm dishes were washed with PBS containing 1 mM CaCl2 and immersed in 3 mL of dye
cocktail composed of 0.1% Lucifer yellow CH (Sigma-Aldrich) and 0.1% RITC-dextran (Sigma-Aldrich).
Several parallel scrape lines were then made with a micropipette tip, and the cells were incubated for
5 min at 37 ◦C. After rinsed with PBS, the cells dye-coupled with Lucifer yellow were detected under a
fluorescence microscope. The cells positive for RITC-dextran were considered to be primarily-scraped
but not dye-coupled cells.
4.6. Invasion Assay
Invasion capacity was evaluated quantitatively with Falcon Permeable Support with 8-μm-pore
filter (Corning Inc. Life Sciences, Tewksbury, MA, USA). The filters of cell culture inserts were
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precoated with 500 μg Matrigel (Corning Inc. Life Sciences), dried for 24 h in an incubator and
rehydrated by RPMI1640 for 1 h before inoculation of cells. The cell culture inserts were set on 4 mL
of FCS-supplemented RPMI1640 poured for the lower compartments of 6-well plates. 5.0 × 105 cells
resuspended in 2 mL of serum-free RPMI1640 containing 0.01% bovine serum albumin were seeded
to each upper well. After 72 h of incubation, cells were trypsinised and collected separately from the
top of the membrane, the underside of the membrane, and the lower compartment. Invasion was
quantified as the percentage of cells recovered from the underside of the membrane and the lower
compartment over the total cell number.
4.7. Xenograft into Nude Mice
1 × 106 cells suspended in 200 μL of PBS were injected subcutaneously into the backs of 6 male
BALB/c-nu/nu mice of 6 weeks of age per clone. Two perpendicular diameters (d1 and d2) of each
tumour were measured every 2 or 3 days and converted to tumour volume (mm3) according to the
formula: V = (π/6)(d1 × d2)3/2 [37]. 40 days after injection, the mice were euthanized. A portion of each
tumour was frozen, and the rest was fixed in 10% buffered formalin for further analysis. The protocol
of the animal work was approved (No. 14016, 31/Jan/2014) by the Committee for Ethics of Animal
Experimentation and in accordance with the Guidelines of Animal Experiments of Akita University.
4.8. Immunohistochemistry
Formalin fixed paraffin-embedded sections on slide glass were deparaffinised, then immersed
in 3% hydrogen peroxide/methanol at room temperature for 15 min. The slides were incubated
with anti-Cx26 mAb clone CX-12H10 (Thermo Fisher Scientific) in a humidified chamber at 4 ◦C
overnight. Specific signals were visualised by employing HRP-labelled polymer method as follows,
the slides were reacted with EnVision+ system-HRP for mouse (Agilent, Santa Clara, CA, USA) at
room temperature for 30 min and finally 3,3′-diaminobenzidine was oxidized for signal detection.
4.9. Statistical Analysis
The student’s t-test was performed for the estimation of statistical significance. p values
are two-tailed. All experiments were independently repeated at least 3 times except for the
tumorigenicity assay of xenografts in mice, which was performed only once.
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GJ gap junction
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icCx26 intracellular conexin26
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Appendix A
Figure A1. Effect of Brefeldin A on wtCx26-mdiated GJ plaques. Indirect immunofluorescence of Cx26
protein in wtCx26 clone in the presence or absence of 5 μg/mL Brefeldin A/DMSO. The fluorescent
signals of Cx26 protein were visualised by Alexa-488. Nuclei were stained with DAPI. Scale bar, 20 μm.
Figure A2. Expression of Cx43 protein in FaDu cells. Immunoblotting was performed with two
different anti-Cx43 antibodies, mAb (Invitrogen; clone CX-1B1) and pAb (Sigma-Aldrich). As a positive
control, IAR20 cells were used. For indirect immunofluorescence, the fluorescent signals of Cx26
protein were visualised by Alexa-488. Nuclei were stained with DAPI. Note that no positive signals for
Cx26 protein are detected. Scale bar, 20 μm.
Figure A3. Population doubling time of randomly-selected clones of stable transductants.
Randomly-selected 8 clones each from wtCx26 and icCx26 stable transductants as well as 5 clones from
mock transductants were subjected to a preliminary cell proliferation assay to measure population
doubling time. Each plot corresponds to a single clone. Note that none of the mock clones show native
clonal variation. 2 and 1 clones of wtCx26 and icCx26 transductants, respectively, show a population
doubling time indistinguishable from that of the mock clones. It has been confirmed that these 3 clones
express Cx26 protein at a similar level to that of parental FaDu cells as revealed by immunoblotting.
Therefore, omitting the 3 clones, a clone (arrow) indicating a median value was chosen from each
of three groups for later experiments. Clonal variation between the clones is due to difference in
expression levels of the transgene products.
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Abstract: Epithelial tissues line the lumen of tracts and ducts connecting to the external environment.
They are critical in forming an interface between the internal and external environment and,
following assault from environmental factors and pathogens, they must rapidly repair to maintain
cellular homeostasis. These tissue networks, that range from a single cell layer, such as in airway
epithelium, to highly stratified and differentiated epithelial surfaces, such as the epidermis, are held
together by a junctional nexus of proteins including adherens, tight and gap junctions, often forming
unique and localised communication compartments activated for localised tissue repair. This review
focuses on the dynamic changes that occur in connexins, the constituent proteins of the intercellular
gap junction channel, during wound-healing processes and in localised inflammation, with an
emphasis on the lung and skin. Current developments in targeting connexins as corrective therapies
to improve wound closure and resolve localised inflammation are also discussed. Finally, we consider
the emergence of the zebrafish as a concerted whole-animal model to study, visualise and track the
events of wound repair and regeneration in real-time living model systems.
Keywords: epithelial tissue; connexin; pannexin; wound healing; inflammation; zebrafish models
1. Introduction
Connexins are a highly conserved group of transmembrane proteins, with 21 subtypes expressed
in a human, which form gap junctions with neighbouring cells to enable intercellular communication
and metabolite exchange. Connexin hemichannels in the plasma membrane are typically in a
default-closed position but can be induced to open under conditions of cell stress to release adenosine
triphosphate (ATP) and other small signalling molecules [1,2]. Pannexins, a family of three sister
proteins to the connexins, also form membrane channels and are increasingly associated with
inflammatory mediated events [3]. Connexins and pannexins share a common topology consisting of
four transmembrane domains that span the plasma membrane; two highly conserved extracellular
loops, and intracellular C- and N-terminal domains. Six connexin subunits oligomerise to form a
connexon that is trafficked to and inserted into the plasma membrane. Connexins laterally accrete
to dock with other hemichannels from neighbouring cells to form an intercellular gap junction [1].
Pannexins also oligomerise to form channels and trafficking to the plasma membrane is dependent
on interaction with the actin cytoskeleton [4,5]. Both connexins and pannexins play a key role in
coordinating processes that mediate the development and maintenance of tissues in multicellular
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organisms. Distinct connexin and pannexin expression profiles are observed in different tissues with
multiple connexins often expressed within the same cell. For example, in the cardiovascular system
connexins (Cxs) 37, 40, 43 and 45 are expressed. In epithelial tissue, such as the airway epithelium and
stratified epidermis, Cx43 is still the predominant connexin present with Cxs 26, 30 and 31 in particular
emerging to play important roles as discussed below. Each connexin forms transmembrane channels
that have unique permeability properties in terms of size, ionic permeability and selectivity [6,7].
Thus, the pattern in which these proteins are expressed is very important to cellular function, with each
combination of heteromeric channel conferring unique signalling properties. Heterotypic channels are
limited in function by connexin compatibility, predicted to prevent cells following different differential
pathways to ‘communicate’ [8]. Connexins have a short half-life, resulting in rapid turnover and,
together, these properties enable specialised tissue-specific, spatial and temporal communication
compartments. It is well established that connexins participate in liver regeneration after injury [9].
However, less is known about the mechanisms of airway epithelium repair in the adult respiratory
system. This review will focus on tissue-specific communication compartments during the dynamic
events that occur during the regeneration and repair of epithelial tissue networks including the
lung airway epithelium and the epidermis. Wound repair in the whole zebrafish model will also
be addressed.
2. Connexins in Normal and Repairing Airway Epithelium
2.1. Connexins in the Airway Epithelium
The airway epithelium is a fundamental component of the innate immune system by protecting the
lung against invading pathogens. The concerted action of ciliated and mucin-secreting cells maintain
efficient mucociliary clearance, and regulates the production of anti-inflammatory and antimicrobial
molecules [10]. Connexin- and pannexin (Panx)-channels provide a complex communication network
that maintains lung homeostasis and modulates host defences in both conductive and respiratory
(alveoli) airways [11,12]. The upper airway epithelium and submucosal glands express (identified at
the mRNA level and/or protein level) about 10 connexins (Cx26, Cx30, Cx30.3, Cx31, Cx31.1, Cx32,
Cx37, Cx43, Cx46). Cx32, Cx43 and Cx46 are found in the alveolar epithelium while Cx37, Cx40
and Cx43 are expressed in the alveolar endothelium. Panx1 is ubiquitously expressed, while little
information is yet available for Panx2 and Panx3.
In the conducting airways, the communication network plays key roles within the mucosa
barrier. For example, cell-to-cell transfer of ions and second messengers is thought to contribute to
mucociliary clearance by hydrating the luminal surface and controlling ciliary beat frequency [13,14].
The latter mechanisms are fine-tuned by Panx1-mediated release of ATP which, in an autocrine
manner, regulates mucin and water secretion as well as cilia activity [15–17]. Gap junctions are
also components of the innate immunity defence system by mediating the cell-to-cell spread of
pro-inflammatory and pro-apoptotic signals according to the pathogen recognition receptors (PRRs)
activated [18,19]. Hence, connexins and Panx1 are deregulated in terms of activity and/or expression
in several pathologies, including chronic rhinosinusitis [20] and cystic fibrosis [21,22].
In the respiratory alveoli, the intercellular network participates in the production of surfactant in
response to stretch on the epithelial side of the alveoli [23]. On the endothelial side, connexin and Panx1
channels mediate hypoxia-induced vasoconstriction, leukocyte adhesion and transmigration across
the endothelial-alveolar wall [24–26]. Finally, it has been proposed that alveolar macrophages attached
to the alveolar surface may communicate immunosuppressive signals to alveolar epithelial cells,
since leukocyte-specific knockdown of Cx43 enhanced endotoxin-induced lung inflammation [27].
Epithelial repair is a multi-step process initiated by migration of basal cells (BCs) at the leading
edge of the wound along with the induction of proliferation to repopulate the injured area [28].
This phase of newly proliferating cells, or blastema, is followed by cell differentiation and patterning
(Figure 1). Stem cells and BCs contribute to the regeneration of intact airway epithelium. The BC
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population is highly heterogeneous comprising morphologically indistinguishable multipotent stem
cells and committed precursors [28,29]. The mechanisms that underlie cell-fate specification in
repairing airway epithelia are poorly known but several transcription factors, including Yap/Sox
and Fox family members as well as Notch family receptors and specific microRNAs, has been
reported [28–34]. For example, Notch signalling is required for the transition of mature BCs to
early progenitor cells (EPs), and at later phases for differentiation into goblet/secretory cells (GCs) and
ciliated cells (CCs) (Figure 1).
Figure 1. The different phases of airway epithelium regeneration after wounding. The top left images
show the histology of the pseudostratified airway epithelium after culturing human airway epithelial
cells for 1.5 months on Transwell filter, and the capacity of the epithelium to repair after wounding.
BC: basal cell; CC: ciliated cell; GC: goblet cell. The scheme illustrates the steps involved in airway
epithelium repair after injury (blue arrows); wound closure is reached within 3–4 days. Orange triangle:
CK5-expressing quiescent basal cells; orange square: CK5 and CK14-activated basal cells; light green
square: early progenitor cells; dark green square: late progenitor cells. Early differentiation (passage
from proliferating cells to early progenitors) is dictated in part by Notch activation (green arrows).
Cell division arrest and later differentiation requires increased expression of miR-449. The relative
changes in connexin expression (Cx26, Cx30, Cx31) is illustrated for the different stages of the repair
process by the size of the fonts. PPARγ signalling also contributes to BC differentiation and decreases
connexin expression (red arrow). Bar: 50 μm.
2.2. Repair Research in the Adult Airway Epithelium
Re-establishment of the integrity of the airway epithelium is a prerequisite to restoration of the
tissue homeostasis and host-defence mechanisms [20]. The tracheobronchial airway epithelium is
composed of BCs, GCs and CCs.
2.3. Connexins in Wound Repair of the Airway Epithelium
The pattern of connexin expression by the human airway epithelium depends on cell phenotype
and the stage of differentiation. Several connexin isoforms are expressed in the undifferentiated
airway epithelium of which Cx26 and Cx43 rapidly disappear upon differentiation [35,36].
In the well-polarized epithelium, cell-specific localization of connexin expression is found.
Thus, Cx31 connects BCs while Cx30 connects CCs and perhaps BCs to CCs, suggesting distinct
compartments of intercellular communication within the airway epithelium. Remnants of Cx26 could
be detected, however, in a subset of BCs [36]. At least two populations of BCs can be distinguished
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by their expression of cytokeratins (CK5 and CK14) whereas CK8 is a marker of EPs and of fully
differentiated BCs and CCs. Interestingly, Cx26 expression is strongly induced in CK14-expressing BCs
undergoing proliferation in response to wounding [36]. The sustained increase of Cx26 is maintained
until wound closure, a point at which the protein progressively returns to its basal level of expression
with epithelium differentiation (Figure 1). It is proposed that induction of Cx26-mediated intercellular
communication by proliferative signals in activated BCs may represent a means to contain their
over-proliferation, which would make them permissive for further differentiation signals. Not only
Cx26 but also Cx30 and Cx31 are subjected to modulation during wound repair (Figure 1). At the
mRNA level, both Cx30 and Cx31 are upregulated during the proliferation phase to reach a plateau at
the time of wound closure. Cx30 detection coincided with the apparition of EPs. The expression of
both connexins decreased back to basal levels during the differentiation period (Figure 1). Although an
apparent relationship between connexin expression and proliferation can be proposed, the mechanisms
involved have not yet been elucidated.
Among the multitude intracellular signalling pathways that control cell-fate specification in
lung development and lung-related diseases, a role for the lipid-responsive transcription factor
peroxisome proliferator-activated receptor gamma (PPARγ) has been proposed [37,38]. PPARγ is
endogenously activated by 15-keto prostaglandin E2 (15kPGE2), which is generated from PGE2
by the activity of hydroxyprostaglandin dehydrogenase (HPGD). In a recent report, Bou Saab and
collaborators found that HPGD is involved in the PPARγ-dependent control of the BC population
during the repair process [39]. Interestingly, Cx26 expressed in activated BCs was found to be highly
sensitive to the differentiating signals mediated by PPARγ [40]. One hypothesis is that PPARγ-induced
downregulation of Cx26 may promote in a subpopulation of activated BCs their exit of the cell cycle
for further differentiation and/or trigger their return to their original state. Clearly, additional studies
are required to understand the regulatory mechanisms and the role fulfilled by the dynamic changes
in connexin expression during airway epithelium repair. Gene-silencing approaches using clustered
regularly interspaced short palindromic repeats-Cas9 (CRISPR-Cas9) in primary cultures of human
airway epithelial cells are anticipated to bring important information on the role of gap junctional
intercellular communication in cell fate during airway mucosal regeneration.
3. Connexins in the Epidermis
The epidermis is a highly specialised, stratified epithelial layer forming a tough barrier to the
external environment. It plays a vital protective role from environmental insult and is highly subject to
localised trauma and injury resulting in a need for rapid repair of the tissue [41]. The key components
of the epidermis are keratinocytes, a specialised subset of cells that attach firmly to the basement
membrane of the skin that provides an interface between the vascular dermal layers and the avascular
epidermis. A small subset of epidermal stem cells, resident in the hair follicle and interfollicular
regions are responsible for the continual renewal of the epidermis [42]. Cells on the basal membrane
are, under normal conditions, the only proliferative cells within the epidermis, although only about
15% of cells actively participate in this process, this increases when enhanced proliferation is needed
such as in wound healing. Stratification occurs as subsets of the basal layer keratinocytes undergo
asymmetrical cell division and enter a differentiation programme resulting in the stratified and
cornified epidermis and watertight epidermal barrier (Figure 2). These differentiated layers are
characterised by a complex differentiation process typified by changes in the expression profile of
keratins, key intermediate filaments of the epidermis. Keratins form pairs with basic and acidic partner
complexes; the CK5/CK14 complex is associated with basal keratinocytes and CK1/CK10 expression
with cells committed to terminal differentiation pathways [43]. Keratinocyte differentiation results
in the transformation of cellular morphology and protein expression, ultimately resulting in a loss of
nuclei and the production of keratinohyalin granules in the stratum corneum layer. Keratins interact
with a range of proteins including desmosomes, fillagrin, loricrin and keratolinin to give a highly
ordered and structured epidermis and the stratum corneum its flattened shape (Figure 2). There is a
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balance between the renewal and desquamation of the epidermis, a process that takes about 28 days in
a man with a normal epidermal profile of about 10 cell layers [43].
Figure 2. Connexin expression profile in the normal epidermis, at a chronic wound edge,
and representative state in a psoriatic epidermis.
Up to 10 different connexin isoforms are expressed with the profile characterised by the
differentiation status (Figure 2). Cx43 is the predominant connexin in the basal layers, associated with
proliferation, while Cx26 and Cx30 are associated with upper differentiated cell layers. Cx31 tends to
be expressed in similar layers to Cx43 while Cx31.1 is only found in the upper differentiated layers
and linked with apoptosis and cell shedding [44,45]. Due to the avascular nature of the epidermis,
it is generally accepted that gap junctional intercellular communication is central to ensuring correct
signalling between the inner and outer layers. Specialised communication compartments have been
suggested due to the predicted nature of the α and β connexin interactions and selective permeability
properties [6,46]. Recent evidence suggests that Cx43 (a member of the α connexin subgroup) and
Cx31 (a member of the β connexin subgroup) can form heteromeric channels, indicating that such
interactions could act as a bridging link between epidermal areas where the incompatible Cx43 and
β-connexins Cx26 and Cx30 are the predominant connexins expressed [47,48]. In the human epidermis,
the two main connexins are Cx26 and Cx43. Cx26 expression is also found in hair follicles and eccrine
sweat glands, whereas Cx43 is located in the interfollicular epidermis [44,49,50]. The importance of
connexins in the epidermis is further highlighted by the plethora of mutations that are associated with
both inflammatory and non-inflammatory hyperproliferative epidermal disorders (recently reviewed
by [51,52]). Pannexins 1 and 3 are also expressed in keratinocytes where knockout mouse models
revealed an important role for Panx1 in epidermal formation [53–55].
3.1. Connexins in Epidermal Wound Healing
Skin integrity is dependent on interactions between keratinocytes and the extracellular matrix
(ECM), and these are the first cell type to sense injury. The introduction of a wound to the epidermis
triggers an acute inflammatory response, keratinocyte migration and proliferation, and induces
changes in the cytoskeleton and keratinocyte adhesion [56,57]. In the context of connexins, a key
event in normal wound healing is the downregulation of Cx43 at the wound edge within 6 h of
injury [58]. This is associated with the activation of migration of keratinocytes into the gap. There is
also evidence of specialised spatial communication compartments behind the wound edge where
Cx43 is subject to phosphorylation, particularly at P-ser368 on the carboxyl terminal domain [59,60].
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The localised switch in phosphorylation probably changes the functional signalling parameters
of Cx43 channels, further enhancing migration of wound edge keratinocytes. This may include
the induction of signalling pathways, including Transforming Growth Factor-β TGF-β and ECM
deposition, all of which are key events in wound closure [61–63]. Upon re-stratification, levels of Cx43
are re-established [45,58,64,65]. In other studies, Panx1 was also shown to be elevated at the wound
edge during the early stages of wound healing and overall rates of wound closure were reduced in
Panx1 Knockout (KO) mice models [66].
3.2. Connexins and Inflammation in the Epidermis: Chronic Wounds and Psoriasis
Dysregulation of connexin expression in the epidermis is associated with a variety of conditions,
re-enforcing the importance of these proteins in maintaining epidermal integrity. This is most
evident for Cx43 and Cx26 where alteration in the fine balance of control of expression is associated
with pathological conditions including chronic non-healing wounds, psoriasis and a range of
connexin-channelopathies linked with mutations in β-connexins causing skin disease [8,51].
Chronic non-healing wounds are maintained in a high inflammatory state and are subject to
infection. These are increasingly associated with situations such as diabetic ulcers and lower limb
disease, but also with conditions such as pressure sores, prevalent in ageing societies, increased obesity
and diabetes rates [57,67]. Such events place enormous burdens on healthcare resources and
management. Although many novel therapies are under development, including hyperbaric oxygen
therapy, growth factors and stem-cell implantation, current treatments only manage the condition
by frequent debridement therapy and pressure off-loading [68]. In terms of connexin expression,
Cx43 is significantly upregulated at the wound edge of chronic non-healing wounds in both diabetic
and non-diabetic patients [58,69,70]. Such changes in expression significantly alter the dynamic
and subtle crosstalk between cells with the local area; it is proposed that it plays a vital role in the
sustainment of the non-healing wound state. Thus, Cx43 in particular has become a prime therapeutic
target to improve wound healing with both antisense Cx43 and Cx43 peptidomimetic strategies
exhibiting exciting opportunities [71] (see Section 5). In chronic non-healing wound margins, reports
have also determined that Cx26/Cx30 expression is significantly enhanced and associated with the
hyper-proliferative and inflammatory skin phenotype [70].
Psoriasis is another chronic inflammatory skin condition affecting 2–3% of the population.
The classic phenotype of psoriasis can be likened to that of a chronic wound with its persistent
inflammation and changes to the healing profile of the epidermis [72]. Persistent plaques that vary in
size and depth form the prototypic form of psoriasis, Psoriasis vulgaris, often described as the Koebner
phenomenon with well defined, silvery-white scaly skin areas of skin lesions. The leading hypothesis
on disease initiation in psoriasis is T-cell driven via the immune system (inside-out hypothesis);
however, recent data suggest that the environment may play a role (outside-in), including shifts in the
skin microbiome [73,74], epidemiological factors such as geographical location [75], and epidermal
barrier disruption [76,77]. Genetic factors also play a role, with several loci identified as psoriasis
susceptibility risk factors. The most prominent is PSOR1, a Major Histocompatibility Complex (MHC)
Class 1 region on the chromosome 6p21 [78], and a number of reports suggest that polymorphisms on
GJB2 represent suitable markers of susceptibility [79–82].
Enhanced Cx26 and Cx30 protein expression is highly evident in psoriatic plaques and a
transcriptome analysis revealed GJB2, to be among the top 100 genes upregulated in psoriasis, with its
expression levels increased up to 18-fold in psoriatic lesions compared to normal tissue [50,51,83–85].
Epidermal hyperplasia in the psoriatic epidermis drives an accelerated growth and altered
differentiation of the keratinocytes that results in a loss of the discrete epidermal layers. The highly
proliferative basal layer leads to an extended cell number in the spinous layer and a merging of
the granular and cornified layers. Nuclei are retained in the outer layers and there is an overall
defective terminal differentiation, which drives a change in keratin expression from the normal CK1
and CK10 to CK6 and CK16, characteristic markers for psoriasis [72,86]. In support of a role for the
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over-expression of Cx26 in driving some of these events, transgenic mice studies over-expressing
Cx26 in suprabasal keratinocytes exhibited pathological features similar to those seen in psoriasis,
with the suggestion that enhanced Cx26 hemichannel activity plays a central role [87]. Several further
lines of evidence suggest that susceptibility to psoriasis is linked to the epidermal differentiation
complex, including downregulation of E-cadherin and Cx43 and enhanced expression of Claudin13,
a key component of epidermal tight junctions [76,88–92].
4. Disruption of Cx43:Cx26 Balance in Epithelial Tissue: Connexins and the Environment
Maintaining homeostasis with the microbiome is a critical feature of all epithelial tissues [93,94].
Dysbiosis of the skin microflora has been associated with many dermatological conditions including
but not limited to psoriasis and chronic non-healing diabetic wounds. Bacterial colonisation of psoriatic
skin shows a shift from commensal organisms, such as Staphylococcus epidermidis, to more opportunistic
pathogens such as S. aureus [73,95] and shifts in skin flora of diabetic patients and non-healing wounds
are highly evident. The microbiome of the respiratory system is less well characterized but recent
reports showed its alteration in diseases such as Cystic Fibrosis CF. The lungs of CF patients are normal
in utero and in the newborn period, and are usually colonized by a variety of opportunistic bacterial,
viral and fungal pathogens in an age-dependent sequence [94]. The most frequently found organism
during colonization of CF airways is S. aureus, followed later by Pseudomonas aeruginosa, which remains
the critical determinant of pulmonary pathology in the late stages of the disease.
Accumulating evidence suggests that exposure of epithelial cells to components of opportunistic
pathogens, such as S. aureus, P. aeruginosa and Shigella flexneri, can alter connexin hemichannel activity
and connexin expression levels [77,96,97]. In the context of the epidermis, we previously determined
that exposure of keratinocytes to peptidoglycan isolated from the cell wall of the opportunistic
skin pathogen S. aureus induces Cx26 expression with associated links to inflammation, while that
isolated from the commensal S. epidermidis is without effect [77]. In parallel studies in other tissue
networks, bacterial colonisation has been shown to trigger connexin signalling including the glial,
intestine and lung epithelia [98]. Hence, controlling the level of Cx expression and/or function in
these specialised tissue niches and regulating the balance of Cx43 and Cx26 is a critical focus for
maintaining epithelial integrity. Further studies suggest that acute exposure to pro-inflammatory
mediators, such as peptidoglycan or lipopolysaccharide, is sufficient to trigger connexin hemichannel
activity and release of secondary messengers such as ATP, nicotinamide adenine dinucleotide (NAD+),
glutamate and prostaglandins [99,100]. Following the release of ATP, the activation of purinergic
signalling cascades occurs that plays a central role in differentiation and proliferation of the epidermis
as well as regulation of innate immune responses [101]. In conditions such as psoriasis or chronic
non-healing wounds where connexin expression levels are excessive, the localised release of ATP
could be in part responsible for exacerbated pro-inflammatory responses, altering intracellular calcium
dynamics leading to changes in the terminal differentiation programme and a hyperproliferative
state [102–105].
Similarly, the release of extracellular ATP is thought to amplify the inflammatory response evoked
by P. aeruginosa-dependent infection of the airway epithelium. Interestingly, both connexins and Panx1
were found to be involved in ATP release at the airway mucosa [106,107]. However, protective or
deleterious outcomes of ATP on inflammation may depend on the activated purinergic receptors.
For example, the release of ATP from airway epithelial cell via Panx1 channel and subsequent activation
of P2Y11 contributes to the resolution of inflammation and triggers wound repair [21].
5. Connexins as Therapeutic Targets in Epithelial Tissues
De-regulation of connexin expression is thus a key event in epithelial pathology. To enable the
dissection of the molecular mechanisms underpinning these events, a range of studies utilising
knockout and antisense technologies and connexin peptidomimetics have provided extensive
information and revealed exiting therapeutic strategies [108].
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In targeted epidermal ablation of Cx43 in mouse models, wound-healing rates were significantly
faster than in normal mice. The reduction of Cx43 showed that the keratinocyte layer was much thinner
with a wound closure rate that more than doubled, reaching or surpassing the rates of the untreated
controls [65,109]. Early studies by Becker and Green developed a topical application of an antisense
oligonucleotide targeted to Cx43, reducing Cx43 expression and improving wound closure rates in
both “normal” and diabetic rat wound-healing models. Day one observations of epidermal regrowth
determined that, after injury, diabetic skin showed no re-growth compared to the controls, but when
treated with the Cx43 antisense oligonucleotide the regrowth matched that of the controls [110–113].
This strategy was taken forward to clinical trials providing powerful evidence for the development
of Cx-therapeutic strategies. Significantly, these studies provided evidence that reduction of Cx43
reduced the inflammatory status, altered ECM deposition and reduced scarring [114–116].
Although an antisense approach is applicable, there is much controversy over channel versus
non-channel function. A peptide targeted to the carboxyl terminal domain of Cx43, thereby interfering
with ZO-1 interactions, was identified as a potent regulator of Cx43 channel function. Application of
this peptide, ACT-1, to wounds in animal models determined that it enhanced wound-closure rates
and reduced inflammation, ECM deposition and scarring, without altering Cx43 gene expression. It is
the first in its class of connexin peptidomimetics to be successfully applied in clinical trials showing
profound improvement in healing rates of venous leg ulcers [117–120]. Further mimetic peptides
that mimic the extracellular loops of connexins (Gap26 and Gap27) have been reported to enhance
wound-closure rates in in vitro 2D and 3D human and mouse epidermal models. Gap27 blocks
hemichannel and gap junctional communication without influence on Cx43 gene expression in
keratinocytes [64,121–123]. It enhances keratinocyte migration rates, without altering cell proliferation
supporting concepts that hemichannel activity is involved in keratinocyte galvanotaixis [61,124].
Less is known regarding the targeting of connexins and Panx1 in the airway epithelium.
In a murine bleomycin model of acute lung injury, intravenous administration of a Panx1
mimetic peptide reduced the presence of leukocytes in the bronchoalveolar lavage fluid [125].
Similarly, neutrophils’ recruitment to the airspace in response to lung lipopolysaccharide (LPS)
administration was reduced by intratracheal instillation of Gap26 during the course of
inflammation [26]. Whether this inhibition occurs at the epithelium, endothelium or leukocyte level is
not clear. Finally, the effects of peptidomimetics on airway epithelium repair have not yet been reported.
6. Zebrafish Connexins in Wound Repair and Regeneration
Zebrafish are an emergent model organism used to study development and regeneration because
of their unique advantages, including their small body length (2–3 cm), easy breeding, large number of
fertilised eggs (over 100) obtained from a single pair of zebrafish at one time, and short generation
time (3 months). The embryos usually hatch and start swimming at 3 days after fertilisation
and begin feeding about 5 days after fertilisation, indicating that the development of the nervous
system, motor function, and digestive organs is almost complete in this short period. Furthermore,
zebrafish have a transparent embryo body, facilitating the observation of development by live imaging.
In addition, genome information and genetic-modification methods, including Tol2-mediated gene
transfer and CRISPR gene knockout, have been utilised in zebrafish [126,127]. These tools have
enabled confirmation of these phenomena, as shown in other organisms, and have accelerated
biological research.
6.1. Wound-Repair Research in Zebrafish
In addition to skin and bone, which are common targets in wound-repair and regeneration
studies, nerves, heart, retina, tendon and muscles are actively evaluated in studies utilising the
high regeneration capacity of zebrafish [128,129]. Furthermore, by exploiting the transparency
characteristics of zebrafish embryos, live cell imaging of wound repair has been performed.
In a recent report, for example, the H2O2 concentration gradient occurring in skin wounds was
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successfully visualised, and macrophages accumulated at the wound point on the skin in an H2O2
concentration-dependent manner [130].
6.2. Zebrafish Connexins
With regard to gap junction genes, 38 connexin and four pannexin genes are predicted in the
zebrafish genome. The higher number of connexin genes in zebrafish compared with that in humans
is due to gene duplication events, which occurred in the teleost lineage during fish evolution [131].
Because expression analysis and functional analysis have not been performed for all of these genes,
it is unclear how many genes are actually functional. Cx43 is the most abundantly expressed connexin
in many organs and is being actively studied. Zebrafish (Zf) Cx43 and human Cx43 have a very high
identity of 80% at the amino acid level, and functional conservation between ZfCx43 and mammalian
Cx43 was analysed and confirmed [132,133]. As a connexin specific to the teleost lineage, ZfCx39.4 is
not present in the genome of amphibians or higher organisms. Interestingly, ZfCx39.4 is involved in
skin pattern formation in zebrafish, together with ZfCx41.8, which is an orthologue of mammalian
Cx40 [134,135].
6.3. Zebrafish Connexins in the Heart
Unlike epithelial tissues discussed above, mammalian hearts do not regenerate because cell
division ceases after birth; however, recent studies have confirmed that partial cell division ability is
retained [136]. On the other hand, amphibians and fish have higher regeneration ability than mammals,
and wounded hearts regenerate well in these organisms because differentiated cardiomyocytes can
undergo dedifferentiation and proliferation throughout the organisms’ lifetime [137].
The expression of ZfCx36.7 (an orthologue of human Cx31.9), ZfCx43 (an orthologue of Cx43),
ZfCx41.8 (an orthologue of Cx40), ZfCx45.6 (an orthologue of Cx45), and ZfCx48.5 (an orthologue of Cx
46) have been reported in zebrafish hearts [138–141]. Among these proteins, mutations in ZfCx36.7 and
ZfCx48.5 have been isolated from mutant zebrafish with heart defects, indicating that these connexins
are important for maintaining heart function. In contrast, no defects have been detected in the hearts
of ZfCx41.8 and ZfCx45.6 mutants, although knockout of Cx40 in mammals causes severe defects in
heart function. With regard to Cx43 in zebrafish, expression was detected in normal and regenerating
hearts; however, the role of Cx43 in regeneration is still unclear [142,143].
6.4. Zebrafish Connexins in the Fin
The fin of the zebrafish is composed of segmented hemirays of bone matrix that surround
mesenchymal cells. The amputation of the fin follows subsequent steps, wound healing,
blastema formation and regenerative outgrowth. During this process, osteoblasts function both in fin
bone elongation and joint formation, and the fin returns to its original form in about 10–14 days [137].
As a connexin involved in the development and regeneration of the fin, Cx43 has been isolated
from a zebrafish mutant, short-of-fin (sof ), which exhibits shorter fin segment length compared with
that of wild-type fish [133]. Four alleles of the sof mutant have been isolated. One is a mutant having
low expression of Cx43 mRNA but no amino acid substitution in the protein, and the other three have
amino acid substitutions in Cx43. Electrophysiological analysis has been performed for each of the
three mutants, indicating that the electrical properties of gap junctions are well linked to caudal fin
length in adult fish [144].
In a model of Cx43 function in fin regeneration, it was proposed that Cx43 controls the switch
for elongation of fin length or for initiation of joint formation [145]. Cx43 is expressed in regenerating
fin mesenchyme and cells surrounding the bone joint, and expression of cx43 was correlated with cell
proliferation during fin regeneration. In the cx43 mutant, decreased expression levels were detected
and the cell proliferation rate was also decreased, resulting in shortening of fin length [146]. Loss of
Cx43 function also causes premature joint formation, leading to shorter fin ray segments [145–147].
Several genes acting downstream of cx43 were identified. The evx1 gene is required for joint formation
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in the zebrafish fin [148]. Indeed, evx1 mutant fish do not form joints, although normal development
and regeneration in fin formation are observed [149]. Recent studies determined that Cx43 can regulate
evx1 expression [150]. Independent of evx1 function, Cx43 controls the switching of fin growth and
joint formation through Semapholin3d (Sema3d) function [148,151]. This process involves Cx43
activating Sema3d, which suppresses joint formation through the receptor, PlexinA3. At the same
time, Sema3d also induces cell proliferation by suppressing the Neuropilin2a receptor, which has
negative effects on cell proliferation. In contrast, when Cx43 function is suppressed, cell proliferation
is also suppressed because Neurpilin2a is activated, and joint formation is activated by negative
regulation of PlexinA3. Furthermore, with regard to cell proliferation, Hela1n1a protein is involved in
the stabilisation of Sema3d function [152,153].
As a zebrafish-specific phenomenon, Cx43 function may be influenced by ZfCx40.8, which is a
paralogue of Cx43. As described above, ZfCx43 has 80% identity at the amino acid level with human
Cx43, whereas ZfCx40.8 has only 63% identity with human Cx43. This lower identity is due to the
presence of a low homology region in the C-terminal domain of ZfCx40.8, suggesting that factors
causing functional diversification of ZfCx40.8 exist in this region. Moreover, ZfCx40.8 is thought to
be localised to and function in the cell membrane at the time of ontogeny, but remains in the Golgi
at the time of fin regeneration. In previous in vitro experiments, the C-terminal domain of ZfCx40.8,
which shows low homology to Cx43, was found to control the difference in membrane localisation
of ZfCx40.8 between generation and regeneration of fins. Differences in membrane localisation
of ZfCx40.8 may be involved in controlling the promoting function of ZfCx43 for cell division or
differentiation [154,155].
7. Concluding Remarks
Connexin expression profiles within epithelial tissue networks are dynamically regulated
following wounding and assault from external pathogens. These events are localised and result in
changes in spatial, tissue-specific, communication compartments that allow tissues to respond to repair
processes. We have reviewed recent understanding of the connexin communication compartments
within the airway epithelia and epidermal networks. Another stratified epithelium surface, continually
exposed to the external environment and renewed via a subset of specialised stem cells, is the
cornea [42]. Corneal wound healing is a complex process that has many similarities to epithelial,
stromal and endothelial cells. Wound healing of the corneal epithelium involves cell migration,
cellular proliferation, adhesion, differentiation and cell-layer stratification much like is observed in the
epidermis, and injury of the cornea again results in dysregulation of Cx43 expression. In addition to
the studies in the skin, accumulating evidence highlights connexins as advanced therapeutic targets for
corneal wound repair with both antisense Cx43 and peptidomimetic strategies proving advantageous,
accelerating wound healing and reducing inflammation [156–158]. Furthermore, Gap27 was recently
reported to promote migration during corneal repair, but had a limited effect on deeper vascular tissue
and inflammation, again illustrating the importance of these complementary strategies in determining
channel versus non-channel functions in specific subcellular compartments [159].
In conclusion, the molecular mechanisms that are driven by altered signalling caused by shifts
in connexin expression profiles are now beginning to be resolved. The use of 3D ex vivo model
systems, CRISPR-Cas9 technologies, and the emergence of the zebrafish and its genetic modification
capabilities, together with the panel of tools to modify connexin function, provide pivotal tools for
future studies. Although transfection of primary epithelial cells is challenging, lentiviral vectors can
be used to introduce large transgenes into dividing or quiescent cells; thus, knockdown of target genes
by delivery of CRIPR-Cas9 has already been achieved [160].
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Abstract: In the epidermis, remodelling of Connexin43 is a key event in wound closure. However,
controversy between the role of connexin channel and non-channel functions exist. We compared
the impact of SiRNA targeted to Connexin43 and the connexin mimetic peptide Gap27 on scrape
wound closure rates and hemichannel signalling in adult keratinocytes (AK) and fibroblasts sourced
from juvenile foreskin (JFF), human neonatal fibroblasts (HNDF) and adult dermal tissue (ADF).
The impact of these agents, following 24 h exposure, on GJA1 (encoding Connexin43), Ki67 and
TGF-β1 gene expression, and Connexin43 and pSmad3 protein expression levels, were examined by
qPCR and Western Blot respectively. In all cell types Gap27 (100 nM–100 μM) attenuated hemichannel
activity. In AK and JFF cells, Gap27 (100 nM–100 μM) enhanced scrape wound closure rates by ~50%
but did not influence movement in HNDF or ADF cells. In both JF and AK cells, exposure to Gap27
for 24 h reduced the level of Cx43 protein expression but did not affect the level in ADF and HNDF
cells. Connexin43-SiRNA enhanced scrape wound closure in all the cell types under investigation.
In HDNF and ADF, Connexin43-SiRNA enhanced cell proliferation rates, with enhanced proliferation
also observed following exposure of HDNF to Gap27. By contrast, in JFF and AK cells no changes
in proliferation occurred. In JFF cells, Connexin43-SiRNA enhanced TGF-β1 levels and in JFF
and ADF cells both Connexin43-SiRNA and Gap27 enhanced pSmad3 protein expression levels.
We conclude that Connexin43 signalling plays an important role in cell migration in keratinocytes
and foreskin derived fibroblasts, however, different pathways are evoked and in dermal derived
adult and neonatal fibroblasts, inhibition of Connexin43 signalling plays a more significant role in
regulating cell proliferation than cell migration.
Keywords: wound healing; connexin mimetic peptide; connexin hemichannel; cell migration; SiRNA
1. Introduction
Connexin43 (Cx43) is expressed in nearly every tissue in the body where it forms hemichannels
and intercellular gap junctions and plays diverse roles in coordinating cellular activities [1].
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The connexin mimetic peptide (CMP) Gap27, targeted to the SRPTEKTIFFI sequence (amino acids
204–214) on the second extracellular loop of Cx43 is a versatile inhibitor of connexin-mediated
communication (CMC) in tissue networks [2–4]. Early investigations with these peptides by Evans,
Griffiths and colleagues [5–8] led to advancement of understanding of the role of connexins in
the vasculature and identification of heterocellular communication at the myoendothelial gap
junction [9,10]. Other studies employing Gap27 in excitable tissue networks have identified the
role of connexins in the coordination of cardiomyocyte activities and calcium wave propagation [11,12],
at neuronal synapses and more recently in pathological processes such as epilepsy [13]. In non-excitable
tissues, Gap27 blocks the passive exchange of small gap junction permeable dyes such as calcein AM
and determined a role for intercellular communication during transendothelial migration [14,15].
Many of the ”acute” studies using CMPs have provided evidence for connexin channel signalling
in coordinating cellular activities [2]. However, connexins also have reported ”non-channel” functions
and controversy exists in longer term studies as to whether channel or non-channel activities play
key roles in events such as cell adhesion and migration [16]. This is no less evident in the skin
where dynamic changes in connexin expression occur during wound healing [17–19]. Antisense
oligonucleotides targeted to Cx43 provided the first evidence that connexin based therapies could
improve wound healing and resolve inflammation [18,20,21]. Gap27 and other connexin mimetic
peptides targeted to the carboxyl terminal domain of Cx43 (such as αCT-1) also improved cell migration
rates in 2D and 3D organotypic skin wound model systems [22–25]. In previous studies [22,23],
we determined that while Gap27 enhanced migration rates in keratinocytes and fibroblasts isolated
from juvenile foreskin discards it was less effective in fibroblasts isolated from adult dermal explants.
In the present work we compared the effect of Gap27 and SiRNA targeted to Cx43, on cell
migration in adult keratinocytes (AK) and adult dermal (ADF), juvenile foreskin (JFF) and neonatal
foreskin (HDNF) derived fibroblasts. Our findings provide new insights into the effects of Cx43
channel inhibition versus Cx43 gene expression on cell migration, and our results also show that the
response of such behaviour varies between cell types (keratinocyte versus fibroblast) and between
cells of the same type (skin fibroblasts) but of different tissue origins.
2. Results
2.1. The Impact of Gap27 on Cell Migration Rates in Juvenile Foreskin Fibroblasts
Previously we determined that Gap27 inhibits CMC and enhanced scrape wound closure in
fibroblasts and keratinocytes derived from juvenile foreskin explants [22,24]. To further explore the
effect of 100 μM Gap27 on cell motility, JFF cells were subject to time-lapse microscopy and images
captured every 15 min over a 48 h migration period. The speed of cell movement in non-treated
and Gap27 (100 μM) treated cells was analysed: Gap27 treated cells reached 50% scrape closure in
approximately half the time taken by non-treated cells (Figure 1A).
Image trajectory analysis was performed to elucidate if the differences observed in JFF scrape
closure ± Gap27 were due to variation in cell directionality or speed of movement. Graphical
representation of the XY co-ordinate data obtained from tracking the movement of 18 individual
cells for each set of JFF images (±100 μM Gap27) illustrated differences in cell migration between the
control and peptide treated cells, most noticeably an increase in distance travelled by the Gap27 treated
cells, compared to controls, into the scraped area. The data also suggest that the majority of peptide
treated cells migrate in straighter lines towards the scraped area compared to controls which had a
more lateral movement. Cell tracking data determined that Gap27 treatment in JFF cells significantly
increased the average cell velocity over 48 h by 2.5 μm/h compared to controls; the average velocity
was 0.23 ± 0.003 μm/min (13.8 μm/h) in control cells and 0.27 ± 0.004 μm/min (16.3 μm/h) in peptide
treated cells (Figure 1B). To further explore these differences, data sets of the rate of cell movement at
the leading edge (Figure 1C), 0–50 μm (Figure 1D) and 50–100 μm (Figure 1E) behind the wound edge
were analysed. At the leading wound edge, the migration of control and peptide treated cells were
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comparable (Figure 1C). However, in cells located 0–50 μm behind the wound edge cell migration
rates in Gap27 was faster, with the greatest difference in velocity occurring 50–100 μm behind the
wound edge, where the Gap27 treated cells migrated at a rate of 0.273 ± 0.006 μm/min compared to
the non-treated cells that migrated at rates of 0.214 ± 0.004 μm/min (Figure 1D,E). These data indicate
that during scrape wound closure in JFF cell monolayers, cell velocity is greater in wound edge cells
compared to cells behind the wound edge. However, Gap27 treatment enhances the scrape wound
closure in JFF cell monolayers in vitro by increasing cell velocity in cells behind the wound edge.
Figure 1. Gap27 (100 μM) influences the speed of Juvenile Foreskin Fibroblasts (JFF) cell migration.
(A) time-lapse migration data of JFF cells; (B) Average cell velocity of JFF cells; (C) Cell velocity of JFF
cells at the leading edge of the scrape wound; (D) Cell velocity of JFF cells 0–50 μm behind the wound
edge; (E) Cell velocity of JFF cells 50–100 μm behind the wound edge. n = 18 cells were tracked in total
with 6 cells from each specific area. *** p < 0.005.
2.2. Impact of Gap27 and SiRNA Targeted to Cx43 on Cell Migration in Skin Model Systems
While both CMPs and antisense Cx43 knockdown strategies are widely accepted to enhance
wound closure rates [20,22,26], a direct comparison of their effects on cell migration events has not
been reported. We thus explored the impact of Gap27 and SiRNA targeted to Cx43 on scrape wound
closure rates in keratinocytes and fibroblasts isolated from adult skin biopsies and compared this
to cells derived from juvenile foreskin and neonatal human fibroblasts. Initially a dose response of
Gap27 determined that the peptide effectively enhanced scrape wound closure rates in primary adult
keratinocytes at 100 nM–100 μM, but was without effect at lower doses (Figure 2A). In these AK
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cells, SiRNA targeted to Cx43 significantly enhanced the rate of scrape wound closure (Figure 2B).
In JFF cells, 100 nM Gap27 and SiRNA targeted to Cx43 significantly enhanced the rate of scrape
wound closure with 50% closure rates more than two times faster than non-treated samples (Figure 2C).
Multiple studies performed in adult fibroblasts demonstrated that 100 nM–100 μM Gap27 had limited
impact on cell migration responses (Figure 2D); by contrast, significant increase in 50% closure rates
occurred in adult fibroblasts transfected with SiRNA targeted to Cx43, compared with the SiRNA
control (Figure 2D).
To further compare the efficacy of Gap27 on fibroblast cell migration events, scrape wound assays
were also performed using commercially sourced human neonatal dermal fibroblasts. Treatment
with Gap27 was ineffective in enhancing migration responses at concentrations of 100 nM or 100 μM
(Figure 2E,F). By contrast, inhibition of Cx43 expression by transfecting the cells with SiRNA targeted to
Cx43 significantly improved cell migration rates suggesting a ”non-channel” role for Cx43 in migration
of these neonatal fibroblasts (Figure 2E). We also explored the migration responses of HNDF cells on
various extracellular matrix components in the presence and absence of 100 μM Gap27. Although the
cells migrated slightly faster on both fibronectin and collagen matrices, Gap27 still did not enhance
cell migration rates [27].
Figure 2. Gap27 and SiRNA targeted to Cx43 have differential effects on scrape wound closure rates in
skin cells. Dose response of Gap27 in AK cells (A); SiRNA targeted to Cx43 and 100 nM Gap27 enhance
scrape wound closure in AK (B) and JFF cells (C); Gap27 does not enhance cell migration rates in ADF
or HNDF cells (D–F). n = 3, ** p < 0.01; *** p < 0.005.
2.3. Gap27 Attenuates Hemichannel Signalling at Lower Doses than Gap Junction Coupling
In previous studies, microinjection analysis with Alexa 488 determined that Gap27 effectively
inhibits gap junction coupling at concentrations of 50 μM in keratinocytes and HeLa43 cells [23,24].
We also previously reported that Gap27 inhibits ATP release in both keratinocytes and fibroblasts
isolated from juvenile foreskin tissue discards at concentrations of 100 μM [22,23,28]. In view of
the stark contrast in the impact of Gap27 on cell migration rates between the different cell types,
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we further explored the ability of Gap27 to attenuate hemichannel activity. In all the cell types, Gap27
effectively inhibited ATP release in a dose responsive manner, effective at 10–100 μM concentrations
(Figure 3A–D). This data further suggests that in the ADF and HNDF, hemichannel signalling events
are unlikely to be involved in controlling cell migration.
Figure 3. Gap27 inhibits hemichannel signalling. JFF cells (A); Keratinocytes (B); ADF (C) and HNDF
(D) cells were exposed to a dose response of Gap27 and ATP release assays performed following
calcium deprivation. Data are presented at the Fold change in ATP release over control cells that were
not subject to calcium challenge. n = 3, *** p < 0.005, ** p < 0.01.
2.4. The Impact of Gap27 and SiRNA Targeted to Cx43 on Gene and Protein Expression Profiles in Skin
Model Systems
At the end point of the cell migration assays, RNA and protein were extracted and subject
to qPCR and Western blot analysis to determine any significant changes in gene and or protein
expression profiles.
SiRNA targeted to Cx43 reduced the level of Cx43 gene and protein expression by >50% in JFF,
AK, ADF and HNDF cells (Figure 4A–D). Exposure to 100 nM Gap27 for up to 24 h reduced Cx43 gene
expression levels in JFF cells but had limited impact on Cx43 gene expression levels in the other cell
types (Figure 4A–D (panel 1)). In ADF and HNDF cells, 100 nM Gap27 did not influence the level of
Cx43 protein expression (Figure 4C,D (panels 2 and 3)). However, in JFF cells exposure to 100 nM
Gap27 for 24 h caused a >2-fold reduction in the level of Cx43 protein expression and a similar trend,
although not as pronounced, was observed in AK cells (Figure 4A,B (panels 2 and 3)).
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Figure 4. The impact of Gap27 and SiRNA targeted to Cx43 on gene expression. At the end of scrape
wound closure assays, RNA and protein was harvested from cells and subject to real time PCR or
Western blot analysis to determine levels of Cx43 expression. JFF (A); AK (B); AF (C) and HNDF (D).
Panel 1 represents changes in gene expression, Panel 2 represents a typical Western blot, Panel 3
represents densitometric analysis of three Western blots. n = 3, *** p < 0.005, ** p < 0.01 a threshold of
two fold increase or decrease in expression was considered significant.
2.5. The Impact of Gap27 and SiRNA Targeted to Cx43 on Cell Proliferation, TGF-β1 and SMAD3
Signalling Pathways
To determine if the differences observed in cell migration responses between the various cell
groups were related to changes in cell proliferation, the level of Ki67 gene expression in each of the
cell types and treatment groups was determined. In JFF and AK cells, none of the treatments evoked
a greater than two-fold increase in the level of Ki67 gene expression (Figure 5A, AK and JFF panels).
By contrast, in ADF cells a 10-fold increase in Ki67 gene expression was observed in cells exposed to
SiRNA targeted to Cx43 but not in those exposed to Gap27 (Figure 5A, ADF panel). In HNDF cells,
proliferation was dramatically enhanced in all treatment groups (5-10 fold) compared to non-treated
cells (Figure 5A, HNDF panel).
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Transforming growth factor β1 (TGF-β1) is a major transcription factor regulating cell signalling
events involved in migration. The level of TGF-β1 gene expression was enhanced ~3–4 fold in JFF cells
following knockdown of Cx43 gene expression and following treatment with 100 nM Gap27 for 24 h
(Figure 5B, JFF panel). By contrast, in AK, AF and HNDF cells, Gap27 and SiRNA targeted to Cx43
had limited impact on the level of TGF-β1 gene expression levels (Figure 5B) at the 24 h time point.
?
Figure 5. The impact of Gap27 and SiRNA targeted to Cx43 on Ki67 and TGF-β1 gene expression.
At the end of scrape wound closure assays RNA was harvested from cells and subject to real time
PCR analysis to determine changes in gene expression of (A) Ki67 and (B) TGF-β1 n = 3, *** p < 0.005,
** p < 0.01 a threshold of two fold increase or decrease in gene expression was considered significant.
Finally, previous reports identified that phosphorylation of Smad3 is associated with exposure
of mucosal derived fibroblasts to Gap27 [29]. Probing the Western blots with an antibody targeting
pSmad3 identified that in JFF and ADF cells exposure to SiRNA targeted to Cx43 and 100 nM Gap27
for 24 h enhanced the level of pSmad3 expression (Figure 6A,C). By contrast, in HNDF and AK cells
the level remained constant (Figure 6B,D), further suggesting differential signalling pathways are
triggered in different compartments of the skin following remodelling of Cx43.
A summary of the combined data is presented in Table 1.
Table 1. Summary of the effect of 100 nM Gap27 (Gap27) and Cx43-SiRNA (SiRNA) on cellular events
related to wound closure in JFF, AK, ADF and HDNF cells. Hemichannel activity was monitored
following 90 min exposure to peptide and 15 min challenge with Calcium free media. All other assays
were recorded 24 h post scrape wounding in the presence or absence of 100 nM Gap27 or Cx43-SiRNA.
n = 3 in all cases. ND: not determined; NE: no effect; ↑ enhanced effect; ↓ inhibitory effect. For details
of experimental design and statistics see text and figures.
Cell Type Treatment HC Migration Cx43 Protein Proliferation TGF-β1 pSmad3
JFF
SiRNA ND ↑ ↓ NE ↑ ↑
Gap27 ↓ ↑ ↓ NE ↑ ↑
AK
SiRNA ND ↑ ↓ NE NE NE
Gap27 ↓ ↑ ↓ NE NE NE
ADF
SiRNA ND ↑ ↓ ↑ ↑ ↑
Gap27 ↓ NE NE NE NE ↑
HDNF
SiRNA ND ↑ ↓ ↑ NE NE
Gap27 ↓ NE NE ↑ NE NE
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Figure 6. The impact of Gap27 and SiRNA targeted to Cx43 on pSmad3 expression. At the end of scrape,
wound closure assays protein was harvested from cells and subject to Western blot analysis. Blots were
probed with an antibody targeted to pSmad3 and GAPDH. Representative blots are presented for each
cell type JFF (A); AK (B); AF (C) and HNDF (D) (panel 1). Panel 2 represents densitometric analysis of
triplicate blots and relative pSmad3 protein levels compared to GAPDH. n = 3, *** p < 0.005, ** p < 0.01;
* p < 0.5.
3. Discussion
In the present study we compared the effect of Gap27 and SiRNA targeted to Cx43 on scrape
wound closure rates in fibroblasts derived from neonatal, juvenile foreskin and adult dermal explants
and matched adult keratinocytes. Both of these reagents enhanced scrape wound closure in the JFF
cells and adult keratinocytes with Gap27 enhancing cell migration rates at concentrations of 100 nM,
reflecting the dose of peptide that inhibited hemichannel signalling and supporting the concept that
ATP release via hemichannels is required for keratinocyte galvanotaxis [30]. By contrast, in the AF
and HNDF cells, SiRNA targeted to Cx43 enhanced scrape wound closure, but treatment with Gap27
was without effect, extending studies where we reported limited effects of Gap27 on adult fibroblast
migration rates [22,23]. Profound differences in cell migration, proliferation and the TGF-β1/pSmad3
signalling axis occurred between the cells isolated from different skin compartments. The data provides
new insights into the controversy surrounding Cx43 channel versus non-channel functions in cell
migration and wound repair responses [16] and suggests that inhibition of hemichannel signalling
alone is insufficient to modify cell migration events in adult dermal fibroblasts.
Within epithelial tissues, including the skin and cornea, it is widely accepted that downregulation
of Cx43 is favourable to wound closure, as reported in the skin of connexin-deficient mice [19] and
by the development of Cx43 anti-sense oligonucleotides, that have proven effective in rat models
and in human clinical trials [18,26,31,32]. Other studies by Gourdie and colleagues used a peptide
targeting the carboxyl tail of Cx43 and its binding site with the PDZ domain to improve wound healing,
resolve inflammation and reduce scarring in rat models and recently in human clinical trials [33–35].
Studies using Pep5, based on the Gap27 sequence, have shown remarkable effects on tissue repair
and inflammation in the retina, cornea and spinal cord [36–38]. Recent studies using Gap27 have also
shown that this peptide is effective in improving rabbit corneal wound healing [39] and in primary
human gingival fibroblasts, isolated from donors aged 26–48 years of age [29]. A further peptide
TAT-Gap19, has also recently been reported to enhance scrape wound closure of human gingival
fibroblasts [40]. TAT-Gap19, targeted to the intracellular loop of Cx43, was designed as a cell permeant
peptide and has been extensively used to characterise interactions between the intracellular loop of
Cx43 and the carboxy terminal tail [41,42]. This peptide effectively blocks hemichannel activity but has
no effect on gap junction coupling, in contrast to Gap27 which blocks all forms of connexin mediated
communication. Thus, inhibiting Cx43 gene expression and blocking channel function both have a
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positive influence on wound closure events; however, comparisons of the mechanisms underlying the
modes of action of these different means of remodelling Cx43 remains unresolved.
In the present study we have identified profound differences in wound healing events in skin
cells isolated from different sources, and between adult epidermal and stromal derived fibroblasts,
which relate to whether Cx43 channel function or gene expression is regulated.
In the case of JFF cells, derived from juvenile foreskin discards (a thin layer of tissue) and in adult
keratinocytes, both Gap27 and SiRNA targeted to Cx43 enhanced scrape wound closure. Further, in
both of these cell types at the end point of the migration time course, neither knockdown of Cx43
expression or inhibition of channel function by Gap27 had any effect on cell proliferation as monitored
by Ki67 gene expression. This re-enforces our previous findings where irradiated juvenile fibroblasts
were used and Gap27 effectively enhanced wound closure [22]. Hence in JFF cells and keratinocytes
proliferation factors are not involved in the enhanced cell migration response, suggesting hemichannel
signalling plays an important role in co-ordinating cellular responses [30,40].
By contrast, in ADF and HNDF while SiRNA targeted to Cx43 accelerated the rates of scrape
wound closure, exposure to Gap27 had a limited effect on cell migration rates. In AF cells, Gap27
did not influence the gene expression of Ki67 but decreasing Cx43 gene expression enhanced cell
proliferation. In the HNDF cells, exposure to Gap27 and to SiRNA targeted to Cx43 enhanced cell
proliferation, but only SiRNA targeted to Cx43 enhanced cell migration rates. It is also noteworthy
that at the end point of the migration assays, while SiRNA targeted to Cx43 reduced Cx43 gene
and protein expression in all cell types by >50% exposure to Gap27 had no effect on Cx43 protein
levels in AF cells. By contrast, in the JFF and AK cells Gap27 reduced the level of Cx43 protein
expression by ~50%, however it had a limited effect on Cx43 gene expression, suggesting Cx43 changes
were post-transcriptional. A similar effect was also observed in adult human gingival fibroblasts
where Gap27 also enhanced wound closure rates [29]. Studies using mouse NIH3T3 fibroblasts also
determined that Gap27 reduced Cx43 protein expression in line with our observations in JFF cells [43].
Studies in our lab also determined that Gap27 improved cell migration rates in primary neonatal
mouse fibroblasts [27] and keratinocytes [44]. Taken together, this data suggests that in human adult
dermal fibroblasts and neonatal fibroblasts, non-channel functions of Cx43 may be more important
than acute hemichannel signalling in regulating cell migratory behaviour.
Previously, we identified changes in expression of a panel of genes associated with extracellular
matrix (ECM) deposition in JFF cells following exposure to Gap27, including metalloproteinase 9
(MMP-9) and connective tissue growth factor (CTGF) [23]. Several other reports have indicated a link
between altered Cx43 expression and ECM regulation, including in fibroblasts isolated from a patient
harbouring a non-functional Cx43 mutation associated with the Cx-channelopathy oculodentodigital
dysplasia [45]. Modifying Cx43 expression or function by antisense oligonucleotides and peptide αCTI
have also been associated with alterations in ECM deposition [20,33]. Further studies by Tarzemany et
al. systematically reviewed the impact of Gap27 and more recently TAT-Gap19 on gene expression and
cell signalling pathways involved in wound closure events in human adult gingival fibroblasts [29,40].
Both peptides effectively enhanced wound closure rates and gene array analysis after 24 h indicated
changes in expression of a panel of genes related to ECM deposition including a number of MMP
proteins and CTGF, in agreement with our previous studies on JFF cells [23].
The TGF-β signalling pathway is important in controlling cell migration events, and a number of
studies have suggested links between TGF-β1 and Cx43 expression in wound healing scenarios [20,46].
Treatment with either Gap27 or SiRNA targeted to Cx43 enhanced the gene expression of TGF-β1 in
JFF cells, but had little impact following 24 h exposure to these reagents in the adult keratinocytes
and fibroblasts. However, it remains possible that expression of TGF-β1 is transiently induced at
earlier time points, since TGF-β1 has been reported to stimulate chemotactic migration of human
fibroblasts [47].
The TGF-β/Smad3 signalling axis plays an important role in cell migration events, and has been
linked with Cx43 expression. In line with this in both JFF and ADF cells, levels of pSmad3 were
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increased following 24 h exposure to Gap27 and SiRNA targeted to Cx43. A profound increase in
pSmad3 was also reported in gingival fibroblasts exposed to Gap27 for 24 h [29]. Smad3 and the
carboxyl terminal tail of Cx43 both compete for a similar ‘microtubule binding domain’ [48]. Thus,
alteration in Cx43 expression levels or function may modify the interaction. Upon translocation to the
nucleus, Smad3 is phosphorylated to pSmad3 and exerts transcriptional control on a range of genes
involved in regulation of inflammation, cell proliferation and re-epithelisation in both positive and
negative tissue-specific ways. Given the diverse pathways that pSmad3 can regulate, it is highly likely
that in the ADF cells, where Gap27 did not influence cell migration, other key cellular events may be
affected. Although no evidence of induction of pSmad3 expression was observed in the keratinocytes,
a host of other signalling pathways including the ERK1/2 and JNK pathways may be influenced [49]
and this is subject to further investigation. In the present studies, the influence of modulation of Cx43
was assessed in monocultures. In the future it will be important to exploit our 3D organotypic models
as it is well established that keratinocytes and fibroblasts can influence responses of adjacent cells as
part of a coordinated tissue event [50].
4. Materials and Methods
4.1. Cell Culture
Primary juvenile human dermal fibroblasts (JFF cells) were derived from paediatric foreskins
discarded at surgery following informed consent with ethical approval by Yorkhill Hospital Trust
Research Ethics Committee, Glasgow, or were kindly gifted by Prof J Brandner, University Hamburg,
with their use approved by the ethics committee of the Aerztekammer Hamburg (060900) as
previously described [22]. Human neonatal dermal fibroblasts (HNDF) were sourced from Invitrogen
(Cat No.: C0045C, Paisley, UK) and human adult dermal fibroblasts (AF) and keratinocytes (AK) were
obtained from the GCU Skin Research Tissue Bank, which has NHS and GCU research ethical approval
(NHS REC Ref 16/ES/0069). Fibroblasts and keratinocytes were isolated from tissue explants and
cultured as previously described [22,24]. All cells were maintained at 37 ◦C, 5% CO2. Monolayers of
all fibroblasts were maintained in DMEM (Lonza, Wokingham, UK) supplemented with 10% (v/v)
foetal calf serum, 2 mM glutamine, 50 Units/mL penicillin/streptomycin (Lonza, Wokingham, UK),
hereafter termed ”complete” DMEM (cDMEM). Keratinocytes were maintained in EPILIFE medium
as previously described [51] (Thermo Fisher, Paisley, UK). Cells were seeded at appropriate densities
on 24-well plates for ATP assays (~0.5 × 105 per well) or 6-well plates (~1 × 106 cells per well) for all
other assays.
4.2. Inhibition of Connexin Mediated Communication
For the purpose of this study, Gap27 (MW 1305) (Zealand Pharma, Glostrop, Denmark) was used
in aqueous solution at doses ranging from 1–100 μM for 15 min–48 h depending on experimental
requirements. The peptide and media were replaced at 8 h intervals.
4.3. Knockdown of Cx43 Expression by siRNA
SiRNA duplex sequences targeted to Cx43 (TriFECTa®RNAi Kit from Integrated DNA
Technologies (Tyne & Wear, UK)) along with a fluorescently-labelled scrambled transfection control
duplex: TYE 563™ was used to knockdown Cx43 expression. SiRNA transfection was carried out using
Lipofectamine 3000 transfection reagent (Invitrogen, Paisley, UK). Transfection reagents and siRNAs
were combined and incubated for 20 min at room temperature for complex formation. Cells were
transfected with a final concentration of 5 nM siRNA diluted in 1.5 mL of EPILIFE medium for primary
keratinocytes and serum free DMEM (SFM) for fibroblasts. Twenty hours post transfection scrape
wound assays were performed and cells subsequently harvested for endpoint analysis as described
below. Transfection efficiency of control SiRNA, determined by fluorescent microscopy analysis of the
scrambled SiRNA control was ~90% for all cell types.
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4.4. Hemichannel Functionality Assays
Hemichannel activity was assessed by ATP release assays with minor modifications to that
previously described [51]. Briefly, cells were seeded on 24-well plates and grown to ~80% confluency
overnight. Cells were then washed three times in SFM and incubated in SFM for 1 h prior to exposure
to Gap27 for 90 min. Following this, one half of the plate was challenged with Ca2+ and Mg2+ free PBS
in the presence or absence of Gap27 for 15 min. Supernatants were collected and microcentrifuged at
10,000 rpm for 5 min prior to addition of 25 μL of supernatant to a well of an opaque-walled Nunc
96 well plate containing 25 μL ATP assay mix diluted 1:10 with ATP dilution buffer (Sigma-Aldrich,
Gillingham, UK). ATP standards (25 μL) 0–10 nM diluted in SFM, and in PBS, were also added in
duplicate. Luminescence was measured in relative luminescence units (RLU) using the Fluostar
Optima plate reader (BMG Labtech, Aylesbury, UK). Experiments were performed in triplicate per
treatment group, and each experiment was carried out a minimum of three times (n = 3). Data is
represented as the fold change in ATP released between control and peptide treated wells.
4.5. Scrape Wound Assays and Time-Lapse Microscopic Analysis of Cell Migration
Cells were pre-exposed to peptide or SFM for 90 min, or were transfected with SiRNA targeting
Cx43 for 20 h, prior to introducing a scrape wound to confluent cell monolayers using a sterile 100 μL
pipette tip. Cell migration was monitored by taking triplicate images of wound area 0, 6, 12 and 24 h
post scraping on a CMEX-3200 camera [51]. The scrape wound area was measured at each time point
using Image J software. Values were normalised by comparing with the corresponding initial wound
size. For time-lapse microscopy analysis, images were recorded on a Zeiss Axiovert 100 microscope
(Cambridge, UK) linked up to a CCD camera (Nikon Eclipse TS10, Kingston Upon Thames, UK). Image
capture was controlled by AQMsoftware (Kinetic Imaging Ltd., Nottingham, UK). Images were captured
every 15 min for up to 48 h [52]. The movement of 18 individual cells for each set of JFF time-lapse
images in the presence or absence of 100 μM Gap27, were tracked using Image J software tracking plug-in.
The size of each image was 512 × 512 pixels with a diameter of ~500 μm, therefore, at ×100 magnification
each pixel represented approximately 1 μm. This value was used as the x/y calibration value with a
time interval value of 15 min. Cells were tracked by clicking on the leading edge of a cell on sequential
images representing every 15 min over the 48 h period. Six cells were randomly chosen from each of
(1) wound edge; (2) 0–50 μm from the wound edge and (3) 50–100 μm from the wound edge. The data
output produced by Image J software included the XY co-ordinates together with distance and velocity
values. The XY co-ordinates were plotted on a graph using Excel software, providing an individual track
for each cell, enabling visualisation of cell movement over 48 h.
4.6. RNA Extraction and Real Time PCR
The Bioline ISOLATE RNA Kit (Bioline, London, UK) was used according to manufacturer’s
instructions to extract RNA from cell monolayers (usually 2 wells for a 6 well plate). RNA concentrations
were determined using a Nanodrop ND-100 at 260/280 nm. cDNA was prepared from the RNA
samples using cDNA synthesis kit from Primerdesign and real-time PCR was performed using
Primerdesign Master Mix kit (Primer Design, Chandlers Ford, UK). Primers amplifying human
Cx43, human Ki67, human TGF-β1 and the house keeping gene GAPDH were purchased from IDT
(Tyne & Wear, UK) (Table S1). All reactions were performed in an ABI 7500 FA Real-Time PCR system
(Applied Biosystems, Warrington, UK). The mRNA expression level for each gene was determined
using the ΔCt method and each sample was run in triplicate.
The CT value obtained for the target gene in all samples was first normalised with the CT value
obtained for the housekeeping gene. The resulting change in CT (ΔCt) calculated for test samples
was then normalised with the ΔCt calculated for the control sample, giving a ΔΔCt value. The gene
expression ratio was calculated using 2−ΔΔCt, providing a fold increase or decrease in gene expression
compared to the control sample. Gene fold changes ≥±2 were considered significant.
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4.7. Western Blot Analysis
Protein was harvested from cells in 100 μL lysis buffer (1% (v/v) SDS, 30 mM Na3VO4, 1 μM DTT,
protease inhibitor cocktail (Sigma-Aldrich) and phenylmethanosulfonylfluoride (PMSF)) prepared in
1xPBS as previously described [52].
Equivalent amounts of protein (30–80 μg) were mixed with 5 μL loading buffer (NuPAGE® LDS
Sample Buffer (4X)) and the volume adjusted to 20 μL with lysis buffer. Samples were mixed for
15 min at 20 rpm followed by brief centrifugation and separated by 4–12% sodium dodecyl sulphate
polyacrylamide gel electrophoresis (SDS-PAGE) (NuPAGE® Novex® Bis-Tris Mini Gels; Thermo
Fisher) followed by electrophoretic transfer to a nitrocellulose membrane using an I-Blot transfer
system (Invitrogen) following manufacturer’s instructions. Transfer efficiency was determined by
staining the blots with Ponceau S (0.1% (w/v) in 5% acetic acid) (Sigma-Aldrich) for 15 s, prior to rinsing
in distilled water and probing for relevant protein expression using appropriate primary antibodies as
previously described [52]. Membranes were probed with primary antibodies to detect Cx43 (Rivedal
polylclonal antibody 1:2000 dilution, kindly gifted by Edward Leithe [53]), GAPDH (mouse monoclonal
antibody, Santa Cruz (LOCATION) (1:5000 dilution)) and pSmad3 (rabbit polyclonal antibody Abcam
(Cambridge, UK) (1:2000 dilution)) expression as appropriate. Secondary antibodies were IRDye®
800CW goat anti-rabbit IgG or IRDye® 680CW goat anti-mouse IgG (Licor 1:15,000 dilution) as
appropriate. Blots were developed by exposing the image for a period of 15 s to 5 min according to the
intensity of the signal using an Odyssey FC Dual Mode Licor imaging system (LI-COR Biosceinces
UK Ltd, Lincoln, UK). Densitometric values were quantified using the Odyssey software. To enable
normalisation of the blots and comparison of the effect of different treatments on protein expression,
the intensity of the protein bands were compared to the house keeping protein.
4.8. Statistical Analysis
Experiments were performed in triplicate per setting and on three separate occasions with at least
2 different patient samples. Results were compiled in GraphPad Prism software (La Jolla, San Diego,
CA, USA) and all data is expressed as mean ± SEM unless otherwise stated. Statistical tests were
performed on the data using Student’s unpaired t-test or one-way ANOVA and Dunnett’s post-test as
appropriate, with statistical significance inferred at p < 0.05.
5. Conclusions
In conclusion, we provide an in-depth study on the comparative effects of Gap27 with a
Cx43-SiRNA knockdown approach to improve wound healing and identify significant differences in
the cell signalling pathways that are controlled by Cx43 in fibroblasts and keratinocytes. Further work
is now warranted to define the molecular pathways by which Cx43 exerts its effects in the skin which
will aide in identifying new therapeutic strategies and applications for specific types of wounds.
Supplementary Materials: Supplementary materials can be found at www.mdpi.com/1422-0067/19/2/604/s1.
Acknowledgments: We thank Professor Joanna Brandner, University of Hamburg for the supply of the Juvenile
Foreskin Fibroblasts used in the latter part of this project. Chrysovalantou Faniku and Claire Lorraine were funded
by GCU studentships and Erin O’Shaughnessy by a Ph.D. studentship from the Psoriasis Association (Grant No.:
ST3 15). We thank, Professor Rachel Errington (University of Cardiff) for access to time lapse microscopy,
Dr. Bjarne Due Larsen (Zealand Pharma) for supply of Gap27 and a grant from Animal Free Research (AG) for
support of the GCU Skin Research Tissue Bank. We are also indebted to Professor Malcolm Hodgins for helpful
discussions and inputs. No funds for covering the costs to publish in open access were awarded.
Author Contributions: Patricia E.M. Martin, Claire Lorraine, Chrysovalantou Faniku conceived and designed
the experiments; Claire Lorraine, Chrysovalantou Faniku and Erin O’Shaughnessy performed the experiments
and Scott R. Johnstone performed the initial timelapse experiments; Claire Lorraine, Chrysovalantou Faniku,
Erin O’Shaughnessy and Patricia E.M. Martin analysed the data; Sebastian Greenhough, Annette Graham and
Scott R. Johnstone contributed reagents/materials/analysis tools and Sebastian Greenhough, funded by Animal
Free Research, did not participate in any experiments involving animals or animal tissue; Claire Lorraine and
Chrysovalantou Faniku contributed initial drafts and Patricia E.M. Martin wrote the final manuscript that was
critically proof read by Annette Graham.
343
Int. J. Mol. Sci. 2018, 19, 604
Conflicts of Interest: The authors declare no conflicts of interest.
Abbreviations
Cx connexin
CMP connexin mimetic peptide
CMC connexin mediated communication
JFF human juvenile foreskin derived fibroblasts
HNDF human neonatal dermal fibroblasts
AF adult dermal derived fibroblasts
AK adult keratinocytes
SFM serum free media
References
1. Evans, W.H.; Martin, P.E. Gap junctions: Structure and function (Review). Mol. Membr. Biol. 2002, 19,
121–136. [CrossRef] [PubMed]
2. Evans, W.H.; Bultynck, G.; Leybaert, L. Manipulating connexin communication channels: Use of
peptidomimetics and the translational outputs. J. Mem. Biol. 2012, 245, 437–449. [CrossRef] [PubMed]
3. Evans, W.H.; Leybaert, L. Mimetic peptides as blockers of connexin channel-facilitated intercellular
communication. Cell. Commun. Adhes. 2007, 14, 265–273. [CrossRef] [PubMed]
4. Willebrords, J.; Maes, M.; Crespo Yanguas, S.; Vinken, M. Inhibitors of connexin and pannexin channels as
potential therapeutics. Pharmacol. Ther. 2017, 180, 144–160. [CrossRef] [PubMed]
5. Chaytor, A.T.; Evans, W.H.; Griffith, T.M. Peptides homologous to extracellular loop motifs of connexin 43
reversibly abolish rhythmic contractile activity in rabbit arteries. J. Physiol. 1997, 503 Pt 1, 99–110. [CrossRef]
[PubMed]
6. Chaytor, A.T.; Martin, P.E.; Evans, W.H.; Randall, M.D.; Griffith, T.M. The endothelial component of
cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication.
J. Physiol. 1999, 520, 539–550. [CrossRef] [PubMed]
7. Dora, K.A.; Martin, P.E.; Chaytor, A.T.; Evans, W.H.; Garland, C.J.; Griffith, T.M. Role of heterocellular Gap
junctional communication in endothelium-dependent smooth muscle hyperpolarization: inhibition by a
connexin-mimetic peptide. Biochem. Biophys. Res. Commun. 1999, 254, 27–31. [CrossRef] [PubMed]
8. Hutcheson, I.R.; Chaytor, A.T.; Evans, W.H.; Griffith, T.M. Nitric oxide-independent relaxations to
acetylcholine and A23187 involve different routes of heterocellular communication. Role of Gap junctions
and phospholipase A2. Circ. Res. 1999, 84, 53–63. [CrossRef] [PubMed]
9. Griffith, T.M.; Chaytor, A.T.; Edwards, D.H. The obligatory link: Role of gap junctional communication in
endothelium-dependent smooth muscle hyperpolarization. Pharmacol. Res. 2004, 49, 551–564. [CrossRef]
[PubMed]
10. Straub, A.C.; Zeigler, A.C.; Isakson, B.E. The myoendothelial junction: connections that deliver the message.
Physiology 2014, 29, 242–249. [CrossRef] [PubMed]
11. Verma, V.; Hallett, M.B.; Leybaert, L.; Martin, P.E.; Evans, W.H. Perturbing plasma membrane hemichannels
attenuates calcium signalling in cardiac cells and HeLa cells expressing connexins. Eur. J. Cell. Biol. 2009, 88,
79–90. [CrossRef] [PubMed]
12. Boitano, S.; Evans, W.H. Connexin mimetic peptides reversibly inhibit Ca2+ signaling through gap junctions
in airway cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 2000, 279, L623–L630. [CrossRef] [PubMed]
13. Yoon, J.J.; Nicholson, L.F.; Feng, S.X.; Vis, J.C.; Green, C.R. A novel method of organotypic brain slice culture
using connexin-specific antisense oligodeoxynucleotides to improve neuronal survival. Brain Res. 2010, 1353,
194–203. [CrossRef] [PubMed]
14. Oviedo-Orta, E.; Errington, R.J.; Evans, W.H. Gap junction intercellular communication during lymphocyte
transendothelial migration. Cell. Biol. Int. 2002, 26, 253–263. [CrossRef] [PubMed]
15. Oviedo-Orta, E.; Evans, W.H. Gap junctions and connexins: potential contributors to the immunological
synapse. J. Leukoc. Biol. 2002, 72, 636–642. [PubMed]
16. Kameritsch, P.; Pogoda, K.; Pohl, U. Channel-independent influence of connexin 43 on cell migration.
BBA-Bioenergetics 2012, 1818, 1993–2001. [CrossRef] [PubMed]
344
Int. J. Mol. Sci. 2018, 19, 604
17. Brandner, J.M.; Houdek, P.; Husing, B.; Kaiser, C.; Moll, I. Connexins 26, 30, and 43: Differences among
spontaneous, chronic, and accelerated human wound healing. J. Investig. Dermatol. 2004, 122, 1310–1320.
[CrossRef] [PubMed]
18. Becker, D.L.; Thrasivoulou, C.; Phillips, A.R. Connexins in wound healing; perspectives in diabetic patients.
BBA-Bioenergetics 2012, 1818, 2068–2075. [CrossRef] [PubMed]
19. Kretz, M.; Euwens, C.; Hombach, S.; Eckardt, D.; Teubner, B.; Traub, O.; Willecke, K.; Ott, T. Altered connexin
expression and wound healing in the epidermis of connexin-deficient mice. J. Cell. Sci. 2003, 116 Pt 16,
3443–3452. [CrossRef] [PubMed]
20. Mori, R.; Power, K.T.; Wang, C.M.; Martin, P.; Becker, D.L. Acute downregulation of connexin43 at wound
sites leads to a reduced inflammatory response, enhanced keratinocyte proliferation and wound fibroblast
migration. J. Cell. Sci. 2006, 119 Pt 24, 5193–5203. [CrossRef] [PubMed]
21. Mendoza-Naranjo, A.; Cormie, P.; Serrano, A.E.; Hu, R.; O′Neill, S.; Wang, C.M.; Thrasivoulou, C.;
Power, K.T.; White, A.; Serena, T.; et al. Targeting Cx43 and N-cadherin, which are abnormally upregulated in
venous leg ulcers, influences migration, adhesion and activation of Rho GTPases. PLoS ONE 2012, 7, e37374.
[CrossRef] [PubMed]
22. Pollok, S.; Pfeiffer, A.C.; Lobmann, R.; Wright, C.S.; Moll, I.; Martin, P.E.; Brandner, J.M. Connexin 43 mimetic
peptide Gap27 reveals potential differences in the role of Cx43 in wound repair between diabetic and
non-diabetic cells. J. Cell. Mol. Med. 2011, 15, 861–873. [CrossRef] [PubMed]
23. Wright, C.S.; Pollok, S.; Flint, D.J.; Brandner, J.M.; Martin, P.E. The connexin mimetic peptide Gap27
increases human dermal fibroblast migration in hyperglycemic and hyperinsulinemic conditions in vitro.
J. Cell. Physiol. 2012, 227, 77–87. [CrossRef] [PubMed]
24. Wright, C.S.; van Steensel, M.A.; Hodgins, M.B.; Martin, P.E. Connexin mimetic peptides improve cell
migration rates of human epidermal keratinocytes and dermal fibroblasts in vitro. Wound Repair Regen. 2009,
17, 240–249. [CrossRef] [PubMed]
25. Ghatnekar, G.S.; Grek, C.L.; Armstrong, D.G.; Desai, S.C.; Gourdie, R.G. The effect of a connexin43-based
Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial. J. Investig. Dermatol.
2015, 135, 289–298. [CrossRef] [PubMed]
26. Qiu, C.; Coutinho, P.; Frank, S.; Franke, S.; Law, L.Y.; Martin, P.; Green, C.R.; Becker, D.L. Targeting connexin43
expression accelerates the rate of wound repair. Curr. Biol. 2003, 13, 1697–1703. [CrossRef] [PubMed]
27. Lorraine, C. The role of connexins in skin wound healing events. Ph.D. Thesis, Glasgow Caledonian
University, Glasgow, UK, available through British Library Electronic Theses Online System. 2015.
28. Wright, J.A.; Richards, T.; Becker, D.L. Connexins and diabetes. Cardiol. Res. Pract. 2012, 2012, 496904.
[CrossRef] [PubMed]
29. Tarzemany, R.; Jiang, G.; Larjava, H.; Hakkinen, L. Expression and function of connexin 43 in human gingival
wound healing and fibroblasts. PLoS ONE 2015, 10, e0115524. [CrossRef] [PubMed]
30. Riding, A.; Pullar, C.E. ATP Release and P2 Y Receptor Signaling are Essential for Keratinocyte Galvanotaxis.
J. Cell. Physiol. 2016, 231, 181–191. [CrossRef] [PubMed]
31. Grupcheva, C.N.; Laux, W.T.; Rupenthal, I.D.; McGhee, J.; McGhee, C.N.; Green, C.R. Improved corneal
wound healing through modulation of gap junction communication using connexin43-specific antisense
oligodeoxynucleotides. Investig. Ophthalmol. Vis. Sci. 2012, 53, 1130–1138. [CrossRef] [PubMed]
32. Ormonde, S.; Chou, C.Y.; Goold, L.; Petsoglou, C.; Al-Taie, R.; Sherwin, T.; McGhee, C.N.; Green, C.R.
Regulation of connexin43 gap junction protein triggers vascular recovery and healing in human ocular
persistent epithelial defect wounds. J. Memb. Biol. 2012, 245, 381–388. [CrossRef] [PubMed]
33. Ghatnekar, G.S.; O′Quinn, M.P.; Jourdan, L.J.; Gurjarpadhye, A.A.; Draughn, R.L.; Gourdie, R.G. Connexin43
carboxyl-terminal peptides reduce scar progenitor and promote regenerative healing following skin
wounding. Regen. Med. 2009, 4, 205–223. [CrossRef] [PubMed]
34. Moore, K.; Bryant, Z.J.; Ghatnekar, G.; Singh, U.P.; Gourdie, R.G.; Potts, J.D. A synthetic connexin 43 mimetic
peptide augments corneal wound healing. Exp. Eye Res. 2013, 115, 178–188. [CrossRef] [PubMed]
345
Int. J. Mol. Sci. 2018, 19, 604
35. Soder, B.L.; Propst, J.T.; Brooks, T.M.; Goodwin, R.L.; Friedman, H.I.; Yost, M.J.; Gourdie, R.G. The connexin43
carboxyl-terminal peptide ACT1 modulates the biological response to silicone implants. Plast. Reconstr. Surg.
2009, 123, 1440–1451. [CrossRef] [PubMed]
36. Danesh-Meyer, H.V.; Kerr, N.M.; Zhang, J.; Eady, E.K.; O′Carroll, S.J.; Nicholson, L.F.; Johnson, C.S.;
Green, C.R. Connexin43 mimetic peptide reduces vascular leak and retinal ganglion cell death following
retinal ischaemia. Brain 2012, 135 Pt 2, 506–520. [CrossRef] [PubMed]
37. Guo, C.X.; Mat Nor, M.N.; Danesh-Meyer, H.V.; Vessey, K.A.; Fletcher, E.L.; O′Carroll, S.J.; Acosta, M.L.;
Green, C.R. Connexin43 Mimetic Peptide Improves Retinal Function and Reduces Inflammation in a
Light-Damaged Albino Rat Model. Investig. Ophthalmol. Vis.Sci. 2016, 57, 3961–3973. [CrossRef] [PubMed]
38. Mao, Y.; Nguyen, T.; Tonkin, R.S.; Lees, J.G.; Warren, C.; O′Carroll, S.J.; Nicholson, L.F.B.; Green, C.R.;
Moalem-Taylor, G.; Gorrie, C.A. Characterisation of Peptide5 systemic administration for treating traumatic
spinal cord injured rats. Exp. Brain Res. 2017, 235, 3033–3048. [CrossRef] [PubMed]
39. Elbadawy, H.M.; Mirabelli, P.; Xeroudaki, M.; Parekh, M.; Bertolin, M.; Breda, C.; Cagini, C.; Ponzin, D.;
Lagali, N.; Ferrari, S. Effect of connexin43 inhibition by the mimetic peptide Gap27 on corneal wound
healing, inflammation and neovascularization. Br. J. Pharmacol. 2016, 173, 2880–2893. [CrossRef] [PubMed]
40. Tarzemany, R.; Jiang, G.; Jiang, J.X.; Larjava, H.; Hakkinen, L. Connexin43 Hemichannels Regulate the
Expression of Wound Healing-Associated Genes in Human Gingival Fibroblasts. Sci. Rep. 2017, 7, 14157.
[CrossRef] [PubMed]
41. Abudara, V.; Bechberger, J.; Freitas-Andrade, M.; De Bock, M.; Wang, N.; Bultynck, G.; Naus, C.C.;
Leybaert, L.; Giaume, C. The connexin43 mimetic peptide Gap19 inhibits hemichannels without altering gap
junctional communication in astrocytes. Front. Cell. Neurosci. 2014, 8, 306. [CrossRef] [PubMed]
42. Iyyathurai, J.; Wang, N.; D′Hondt, C.; Jiang, J.X.; Leybaert, L.; Bultynck, G. The SH3—Binding domain of
Cx43 participates in loop/tail interactions critical for Cx43—hemichannel activity. CMLS 2017. [CrossRef]
[PubMed]
43. Glass, B.J.; Hu, R.G.; Phillips, A.R.; Becker, D.L. The action of mimetic peptides on connexins protects
fibroblasts from the negative effects of ischemia reperfusion. Biol. Open 2015, 4, 1473–1480. [CrossRef]
[PubMed]
44. Kandyba, E.E.; Hodgins, M.B.; Martin, P.E. A murine living skin equivalent amenable to live-cell imaging:
Analysis of the roles of connexins in the epidermis. J. Investig. Dermatol. 2008, 128, 1039–1049. [CrossRef]
[PubMed]
45. Kelly, J.J.; Esseltine, J.L.; Shao, Q.; Jabs, E.W.; Sampson, J.; Auranen, M.; Bai, D.; Laird, D.W. Specific
functional pathologies of Cx43 mutations associated with oculodentodigital dysplasia. Mol. Biol. Cell. 2016,
27, 2172–2185. [CrossRef] [PubMed]
46. Hills, C.E.; Siamantouras, E.; Smith, S.W.; Cockwell, P.; Liu, K.K.; Squires, P.E. TGFbeta modulates cell-to-cell
communication in early epithelial-to-mesenchymal transition. Diabetologia 2012, 55, 812–824. [CrossRef]
[PubMed]
47. Postlethwaite, A.E.; Keski-Oja, J.; Moses, H.L.; Kang, A.H. Stimulation of the chemotactic migration of
human fibroblasts by transforming growth factor beta. J. Exp. Med. 1987, 165, 251–256. [CrossRef] [PubMed]
48. Dai, P.; Nakagami, T.; Tanaka, H.; Hitomi, T.; Takamatsu, T. Cx43 mediates TGF-beta signaling through
competitive Smads binding to microtubules. Mol. Biol. Cell. 2007, 18, 2264–2273. [CrossRef] [PubMed]
49. Leivonen, S.K.; Lazaridis, K.; Decock, J.; Chantry, A.; Edwards, D.R.; Kahari, V.M. TGF-β-elicited induction of
tissue inhibitor of metalloproteinases (TIMP)-3 expression in fibroblasts involves complex interplay between
Smad3, p38α, and ERK1/2. PLoS ONE 2013, 8, e57474. [CrossRef] [PubMed]
50. Huang, P.; Bi, J.; Owen, G.R.; Chen, W.; Rokka, A.; Koivisto, L.; Heino, J.; Hakkinen, L.;
Larjava, H. Keratinocyte Microvesicles Regulate the Expression of Multiple Genes in Dermal Fibroblasts.
J. Investig. Dermatol. 2015, 135, 3051–3059. [CrossRef] [PubMed]
51. Wright, C.S.; Berends, R.F.; Flint, D.J.; Martin, P.E. Cell motility in models of wounded human skin is
improved by Gap27 despite raised glucose, insulin and IGFBP-5. Exp. Cell. Res. 2013, 319, 390–401.
[CrossRef] [PubMed]
346
Int. J. Mol. Sci. 2018, 19, 604
52. Johnstone, S.R.; Best, A.K.; Wright, C.S.; Isakson, B.E.; Errington, R.J.; Martin, P.E. Enhanced connexin 43
expression delays intra-mitotic duration and cell cycle traverse independently of gap junction channel
function. J. Cell. Biochem. 2010, 110, 772–782. [CrossRef] [PubMed]
53. Leithe, E.; Rivedal, E. Ubiquitination and down-regulation of gap junction protein connexin-43 in response to
12-O-tetradecanoylphorbol 13-acetate treatment. J. Biol. Chem. 2004, 279, 50089–50096. [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access
article distributed under the terms and conditions of the Creative Commons Attribution
(CC BY) license (http://creativecommons.org/licenses/by/4.0/).
347
 International Journal of 
Molecular Sciences
Article
Knockout of Pannexin-1 Induces Hearing Loss
Jin Chen, Chun Liang, Liang Zong, Yan Zhu and Hong-Bo Zhao *
Department of Otolaryngology, University of Kentucky Medical Center, 800 Rose Street, Lexington,
KY 40536, USA; catkin19832002@163.com (J.C.); chunliang13@yeah.net (C.L.); cell-099@163.com (L.Z.);
yan.zhu@uky.edu (Y.Z.)
* Correspondence: hzhao2@uky.edu; Tel.: +1-859-257-5097
Received: 12 March 2018; Accepted: 23 April 2018; Published: 30 April 2018
Abstract: Mutations of gap junction connexin genes induce a high incidence of nonsyndromic hearing
loss. Pannexin genes also encode gap junctional proteins in vertebrates. Recent studies demonstrated
that Pannexin-1 (Panx1) deficiency in mice and mutation in humans are also associated with hearing
loss. So far, several Panx1 knockout (KO) mouse lines were established. In general, these Panx1 KO
mouse lines demonstrate consistent phenotypes in most aspects, including hearing loss. However,
a recent study reported that a Panx1 KO mouse line, which was created by Genentech Inc., had no
hearing loss as measured by the auditory brainstem response (ABR) threshold at low-frequency
range (<24 kHz). Here, we used multiple auditory function tests and re-examined hearing function
in the Genentech Panx1 (Gen-Panx1) KO mouse. We found that ABR thresholds in the Gen-Panx1
KO mouse were significantly increased, in particular, in the high-frequency region. Moreover,
consistent with the increase in ABR threshold, distortion product otoacoustic emission (DPOAE)
and cochlear microphonics (CM), which reflect active cochlear amplification and auditory receptor
current, respectively, were significantly reduced. These data demonstrated that the Gen-Panx1 KO
mouse has hearing loss and further confirmed that Panx1 deficiency can cause deafness.
Keywords: Panx1; deafness; hearing; gap junction; inner ear; ABR; DPOAE; CM
1. Introduction
Gap junctions play a critical role in hearing. It has been found that mutations in the Connexin26
(Cx26, GJB2) gap junctional gene induce a high incidence of hearing loss, accounting for more than 50%
of the cases of nonsyndromic hearing loss [1–5]. The pannexin gene family also encodes gap junctional
proteins in vertebrates. So far, three pannexin isoforms (Panx1, 2, and 3) have been cloned from the
human and mouse genomes [6,7]. Like connexins, pannexins have ubiquitous expression in almost
all tissues. In the mammalian inner ear, pannexins also have extensive expression; all three pannexin
isoforms have expression in the inner ear [8]. Panx1 predominantly expresses at the supporting cells in
the organ of Corti, the interdental cells in the spiral limbus, inner and outer sulcus cells, and fibrocytes
in the cochlear lateral wall. Panx2 predominantly expresses at the basal cells in the stria vascularis, and
Panx3 mainly expresses at the bony structure of the cochlea. However, auditory sensory hair cells have
no expression of pannexins [8]. These distinctive cellular distributions strongly suggest that pannexins
may have important functions in hearing.
Unlike connexins that form intercellular gap junctional channels, pannexins usually function as
undocked gap junctional channels on the plasma membrane to provide an intracellular-extracellular
conduit. Due to the relatively large pore size, Panx1 channels in many organs and tissues act as
conduits that allow small molecules, such as ATP [9–11], to pass through in order to participate in many
physiological functions and pathological processes [12–20]. Our previous study also demonstrated
that Panx1 channels dominate ATP release in the cochlea [20,21]. ATP in the cochlea can mediate hair
cells’ sound transduction and neurotransmission [22], outer hair cell (OHC) electromotility [23,24],
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hearing dynamic range [25], synchronization of auditory nerve activity during development [26,27],
gap junctional coupling [28], K+-sinking [29], and endocochlear potential (EP) generation [21].
It is well-known that mutations in connexin genes can induce hearing loss [1–5]. However, it was
for a long-time undetermined whether Panx deficiency can induce hearing loss, until recent studies
showing that Panx1-deficient mice [21,30] and mutation in humans [31] are associated with deafness.
So far, several Panx1 knockout (KO) mouse lines have been established [15,21,30,32,33]. In general,
these Panx1 KO mice demonstrated consistent phenotypes. However, one Panx1 KO mouse line,
which was created by Genentech Inc. (South San Francisco, CA, USA) [15], was reported to have no
hearing loss, as measured by auditory brainstem response (ABR) recording at low-frequency range
(<24 kHz) [34]. In this study, we re-examined hearing function of this Genentech Panx1 (Gen-Panx1)
KO mouse line using multiple auditory functional tests. We found that the Gen-Panx1 KO mice
have hearing loss, particularly in the high-frequency region, which is consistent with hearing loss
observed in Foxg1-Panx1 conditional knockout (cKO) mice (a line which was created by crossing
with a Foxg1-Cre line) [21], and in Pax2-Panx1 cKO mice (a line which was created by crossing with
a Pax2-Cre mouse line) [30]. These new data further confirmed that Panx1 deficiency can induce
hearing loss.
2. Results
2.1. Panx1 Deletion in the Cochlea in Gen-Panx1 KO Mice
As previously reported [8], Panx1 had predominant expression in the cochlea, including the organ
of Corti and the lateral wall (Figure 1a). In the Gen-Panx1 KO mouse, Panx1 expression at the cochlear
lateral wall was deleted (Figure 1b,d); Panx1 labeling was completely absent at the spiral ligament
(SPL). However, Panx1 labeling at the organ of Corti (OC), the spiral limbus (SLM), and outer sulcus
cells (OSCs) remained intense (Figure 1b–d). This deletion pattern in the Gen-Panx1 KO mice is similar
to Panx1 deletion in the cochlea in the Foxg1-Panx1 cKO mice [21]. This location- and cell-specific
knockout pattern also provided direct evidence for the specificity of the anti-Panx1 antibody used in
this study.
Figure 1. Deletion of Panx1 in the cochlea of Gen-Panx1 knockout (KO) mice. (a): Double
immunofluorescent staining for Panx1 (green) and Cx30 (red) in the wild-type (WT) mouse cochlea.
(b–d): Panx1 expression and deletion in the cochlea of Gen-Panx1 KO mice. White asterisks in panel (b)
indicate the absence of Panx1 labeling at the spiral ligament (SPL) in the lateral wall of the Gen-Panx1
KO mice. OC: organ of Corti; OSC: outer sulcus cell; SLM: spiral limbus. Scale bars: (a,b): 50 μm,
(c,d): 25 μm.
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Co-labeling for Cx30 showed that there was no apparent difference between Gen-Panx1 KO mice
and wild-type (WT) mice (Figure 1). Cx26 expression in the cochlea also appeared normal in the
Gen-Panx1 KO mice (data not shown).
2.2. Hearing Loss in Gen-Panx1 KO Mice
Figure 2a-c shows ABR recording in the Gen-Panx1 KO mice. ABR thresholds at 8, 16, 24,
32, and 40 kHz were 60.0 ± 2.28, 50.0 ± 2.28, 57.1 ± 3.30, 86.4 ± 3.21, and 93.9 ± 0.77 dB SPL,
respectively (Figure 2b). In comparison with WT mice, ABR thresholds at 8, 16, 24, 32, and 40 kHz
in the Gen-Panx1 KO mice were significantly increased by 14.0 ± 2.88, 15.5 ± 2.88, 12.1 ± 3.30,
34.4 ± 3.21, and 38.4 ± 1.77 dB SPL, respectively (p < 0.001, one-way ANOVA with a Bonferroni
correction). In the high-frequency region, ABR thresholds had larger increases in comparison with
those in the low-frequency region (Figure 2b). However, there was no significant difference in ABR
thresholds between male and female Gen-Panx1 KO mice (Figure 2c). Thus, we did not separate
different genders in data analyses in the following experiments.
Figure 2. Hearing loss in Gen-Panx1 KO mice. (a): auditory brainstem responses (ABRs) in Gen-Panx1
KO and WT mice. The ABR was evoked by a 16 kHz tone burst. (b): ABR thresholds measured in
Gen-Panx1 KO and WT mice. ABR thresholds in Gen-Panx1 KO mice were increased. *** p < 0.001 as
determined by one-way ANOVA with a Bonferroni correction. (c): There is no significant difference in
ABR thresholds between different genders in the Gen-Panx1 KO mice.
2.3. Reduction of Distortion Product Otoacoustic Emission in Gen-Panx1 KO Mice
Consistent with increases in ABR threshold (Figure 2), distortion product otoacoustic emission
(DPOAE) in the Gen-Panx1 KO mouse was significantly reduced (Figure 3a-d). DPOAEs at f 0 of
20 kHz in the Gen-Panx1 KO mice and WT mice were 25.6 ± 2.76 and 37.1 ± 1.83 dB SPL, respectively
(Figure 3c). In comparison with WT mice, DPOAEs in the Gen-Panx1 KO mice at f 0 = 4, 8, 16, and
20 kHz were reduced by −1.32 ± 0.63, −4.43 ± 2.18, −8.71 ± 2.76, and −11.5 ± 2.73 dB, respectively
(Figure 3b). As shown in our previous publication [30], the reduction was increased as sound intensity
was increased (Figure 3c,d). In I-O plot (Figure 3c), DPOAEs in the Gen-Panx1 KO mice at the stimulus
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intensity range from 40 to 60 dB SPL were significantly reduced. In comparison with WT mice,
the reduction was ≥10 dB SPL (p < 0.001, one-way ANOVA with a Bonferroni correction) (Figure 3d).
However, at the stimulus intensity lower than 40 dB SPL, DPOAEs in the Gen-Panx1 KO mice and WT
mice were not apparently different (Figure 3c,d).
Figure 3. Distortion product otoacoustic emission (DPOAE) reduction in Gen-Panx1 KO mice.
(a): Evoked spectra of acoustic emission in Panx1 KO mice and in WT mice. Inset: High-magnification
plot of 2f 1 − f 2 and f 1 peaks. (b): Reduction of DPOAE in frequency responses in the Panx1 KO mice.
Magnitudes of 2f 1 − f 2 in the Panx1 KO mice ware normalized to those in WT mice. (c,d): I-O function
of DPOAE in Panx1 KO and WT mice. DPOAEs in panel (d) were normalized to those in WT mice.
* p < 0.05, ** p < 0.01, and *** p < 0.001 as determined by one-way ANOVA with a Bonferroni correction.
2.4. Reduction of Auditory Receptor Potential in Gen-Panx1 KO Mice
Cochlear microphonics (CM) is the auditory receptor current/potential. Figure 4 shows that
the CM in the Gen-Panx1 KO mice was reduced. CM in WT mice was 40–60 μV, while CM in the
Gen-Panx1 KO mice was 10–30 μV, thus showing a reduction by more than 50% (p < 0.001, one-way
ANOVA with a Bonferroni correction).
Figure 4. Cochlear microphonics (CM) reduction in the Gen-Panx1 KO mouse. (a): CM waveforms
recorded from Gen-Panx1 KO and WT mice. (b): Reduction of CM in the Panx1 KO mouse. *** p < 0.001
as determined by one-way ANOVA with a Bonferroni correction.
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2.5. No Apparent Hair Cell Loss in Gen-Panx1 KO Mice
Figure 5 shows that there was no substantial hair cell loss in Gen-Panx1 KO mice. The loss of
hair cells in the Gen-Panx1 KO mice was less than 5%. There was no significant difference of hair cell
loss between WT and Gen-Panx1 KO mice. This is consistent with the previous report that there is no
significant hair cell loss in Foxg1-Panx1 cKO mice [21].
Figure 5. No apparent hair cells in Gen-Panx1 KO mice. (a,b): The cochlear sensory epithelia of
the Gen-Panx1 KO mice in whole-mounting preparation with staining of phalloidin-Alexa Fluor-488
(green) and propidium iodide (red). OHCs: outer hair cells; IHCs: inner hair cells. Scale bars: 20 μm.
(c): There is no apparent hair cell loss in the Gen-Panx1 KO mice.
3. Discussion
In this study, we found that the Gen-Panx1 KO mouse had hearing loss. ABR thresholds were
significantly increased, and DPOAE and CM were significantly reduced (Figures 2–4). These data
are consistent with previous findings that Panx1-deficient mice have hearing loss [21,30] and are also
consistent with the fact that Panx1 mutation in humans can cause deafness [31].
In this experiment, in addition to the increases in ABR threshold, we found that DPOAE in the
Gen-Panx1 KO mice was reduced (Figure 3). This finding is consistent with our previous findings
of DPOAE reduction and hearing loss in Pax2-Panx1 cKO mice [30]. DPOAE reflects the activity
of active cochlear amplification, which can increase hearing sensitivity and is required for normal
hearing. DPOAE reduction suggests that active cochlear amplification is impaired, which can induce
hearing loss and increase ABR threshold (Figure 2). Moreover, in line with the observed reduction
of CM in the Foxg1-Panx1 cKO mice [21], CM in this Gen-Panx1 KO mouse line was also reduced
(Figure 4). CM is the auditory receptor current/potential. CM reduction can consequently decrease
active cochlear amplification, thereby eventually leading to hearing loss. Thus, consistent with ABR
recordings, these auditory function tests also demonstrated hearing loss in the Gen-Panx1 KO mice.
However, these findings are inconsistent with a recent report that the Gen-Panx1 KO mice had no
hearing loss in ABR recordings [34]. Several factors could contribute to this discrepancy. First, ABR in
that report [34] was recorded at frequency range <24 kHz. However, as shown in Figure 2 and in our
previous reports [21,30], the Panx1 deficiency-induced hearing loss was most severe at high-frequency
(>24 kHz). By recording at these low frequencies, hearing loss at higher frequencies may have been
missed by the authors. Second, the study used C57BL/6 mice rather than WT littermates as control.
Although the Gen-Panx1 KO mice have similar genetic backgrounds with C57BL/6 mice, this still could
produce significant differences in hearing functional tests. In particular, hearing loss in the Gen-Panx1
KO mice in the middle- and low-frequency range is not as large as that in the high-frequency range
(Figure 2b). Third, unlike in the previous report [34], which only considered ABR recordings, in the
present study, we also recorded CM and DPOAE (Figures 3 and 4). All of these auditory functional
tests demonstrated hearing loss in the Gen-Panx1 KO mouse.
352
Int. J. Mol. Sci. 2018, 19, 1332
In the previous report [34], the susceptibility of the Gen-Panx1 KO mouse to noise was also
examined. Mice were exposed to a high intensity tone (12 kHz, 115 dB SPL, 1 h), and there was no
significant difference in ABR thresholds between the Panx1-deficient mice and WT mice measured
at the post-exposure day 7 [34]. However, since both WT and KO mice had large ABR threshold
shifts for this high-intensity exposure, the susceptibility of Panx1 KO mice to noise could not be
assessed. In order to assess susceptibility, low- or moderate-intensity noise exposure could be used
to test whether the Panx1-deficient mice have larger threshold shifts than WT mice. In addition,
only recording ABR thresholds at the seventh day after noise exposure [34] may have been too short
a time to assess a permanent threshold shift (PTS).
Recently, another Panx1 KO mouse line (B6;129-Panx1tm1.Fam/Cnrm, European Mouse Mutant
Archive (EMMA): E11476) [32] has also been reported to have no hearing loss [35]. However, it has
been reported that the brain tissues of this EMMA Panx1 KO mouse line showed no negative reaction
to Panx1 in Western blotting using several anti-Panx1 antibodies [36], including a chicken anti-human
Panx1 antibody used in this study, whose specificity was widely validated in previous experiments
by multiple assays in different Panx1 KO mouse lines [8,9,21,30,37,38]. This suggests that this EMMA
Panx1 KO mouse line may have a hypomorphic phenotype. As shown in our immunofluorescent
staining in this study (Figure 1) and also in previous studies in other Panx1 KO mouse lines [21,30],
the location- and cell-specific deletion of Panx1 is clearly visible in the cochlea. This cell-specific deletion
pattern also provides direct and unequivocal evidence that the used chicken anti-human antibody
is specific to Panx1. Indeed, a hypomorphic phenotype has been found in the KOMP (Knockout
Mouse Project, University of California, Davis, CA, USA) Panx1 KO mouse line, in which Panx1 is
not completely deleted [33]. Finally, Panx1 deficiency-induced hearing loss is progressive [20,30];
the increase in ABR threshold is small at postnatal day 30 (P30) and becomes large and apparent
after P60 [20,30]. The ABR threshold in the previous report [35] was averaged from P30 to P90.
This could also attenuate the potential difference. Thus, as suggested by these inconsistent results and
reports, Panx1 function including characterization of Panx1 KO mice and the specificity of anti-Panx1
antibodies still needs to receive further study in the future.
Our previous study demonstrated that the Panx1 deficiency reduced ATP release and EP
generation in the cochlea [21]. Positive EP in the cochlear endolymph is generated in the cochlear lateral
wall [21,39] and a driving force for K+-ions passing through the mechano-transduction channels in hair
cells to produce CM [39], although hair cells have neither connexin [40,41] nor pannexin expression [8].
EP reduction can reduce CM, thereby leading to the reduction of active cochlear amplification and
eventually hearing loss. In this study, we did not measure EP and ATP release in the Gen-Panx1
KO mice. However, CM and DPOAE were reduced in the Gen-Panx1 KO mice (Figures 3 and 4).
Thus, the Gen-Panx1 KO mice may share the same mechanism to reduce CM and active cochlear
amplification, thereby leading to hearing loss.
4. Materials and Methods
4.1. Panx1 KO Mice and Genotyping
Gen-Panx1 KO mice were created by Vishva Dixit at Genentech Inc. with the loxP-Cre
technique [15]. In this transgenic mouse strain, Exon2 of Panx1 was floxed with FLP recombinase
and was deleted by crossing to the C57BL/6-Gt(ROSA)26Sortm16(Cre) Arte Cre deleter strain (Taconic
Artemis, Rensselaer, NY, USA). Mice were genotyped by tail genomic DNA with PCR primers: 5′-TGA
CCA CAG ACA GCA CTTAAG-3′ and 5′-CGT CTG AGA GCT CCC TGG CG-3′, which yield a 651-bp
WT band and a 335-bp knockout band [15]. WT littermates served as control. All recordings were
performed under anesthesia with Ketamine and Xylazine (8.5 mL saline + 1 mL (100 mg/mL) Ketamine
+ 0.55 mL (20 mg/mL) Xylazine, 0.1 mL/10 g body weight, ip) to minimize suffering. The experimental
procedures were approved by the University of Kentucky’s Animal Care and Use Committee (Protocol
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No. 00902M2005, May 9, 2010) and conducted according to the standards of the NIH Guidelines for
the Care and Use of Laboratory Animals.
4.2. Data Processing and Statistical Analysis
A total of 16 Gen-Panx1 KO mice (4 females and 12 males) were used in this study. Littermate WT
(6 females and 8 males) mice were used as control. Mouse ages were between P60 to P90. For ABR,
DPOAE, and CM recordings, 14 (4 females and 10 males), 16 (4 females and 12 males), and 16 (4 females
and 12 males) of Gen-Panx1 KO mice were used, respectively. Exact numbers of mice used in each
experiment were also indicated in the corresponding figures. Since there was no significant difference
in ABR threshold between different genders in Gen-Panx1 KO mice (Figure 2c), we did not do gender
analyses in other experiments.
The statistical analyses were performed by SPSS v18.0 (SPSS Inc., Chicago, IL, USA) using one-way
ANOVA with a Bonferroni correction. The level of statistical significance was set at p < 0.05. Data were
presented as mean ± SEM and plotted by SigmaPlot v10 (SPSS Inc., Chicago, IL, USA). All sample size
and P values were reported in the figures or the figure legends.
4.3. ABR, CM, and DPOAE Recordings
As described in our previous publications [21,42–46], ABR was recorded by a Tucker-Davis ABR
& DPOAE workstation with ES-1 high frequency speakers (Tucker-Davis Tech., Alachua, FL, USA).
Mouse body temperature was maintained at 37–38 ◦C. ABR was measured by clicks (rate: 20/s) in
alternative polarity and series tone pips (5 ms duration with 1 ms up and down ramp, rate: 20/s) from
80 to 10 dB SPL in a 5-dB step at 8, 16, 24, 32, and 40 kHz. The signal was amplified (50,000×), filtered
(300–3000 Hz), and averaged by 500 times. The lowest level at which the ABR could be recognized
was defined as the threshold. The high levels of acoustic stimuli (100 to 70 dB SPL) were used if the
threshold was >75 dB SPL.
CM was recorded with the same electrode configuration as the ABR recording, i.e., one electrode
was inserted at the vertex, one electrode was ventrolaterally inserted to the right or left ear, and the
ground needle electrode was inserted in the right leg [42,46]. However, the signal evoked by tone
bursts was amplified (50,000×), filtered (3–50 kHz), and averaged by 250 times, as described in our
previous publications [42,46].
For DPOAE recording, an ear-plug that contained a small microphone and two small tubes was
plugged into the outer ear cannel. Two-testing sounds were separately induced into the ear through
two-small tubes [30,44–46]. The frequencies of two-testing sounds were determined by a geometric
mean of f 1 and f 2 (f 0 = (f 1 × f 2)1/2) at f 0 = 4, 8, 16, and 20 kHz with f 2/f 1 = 1.22. The intensity of f 1 (I1)
was set at 5 dB SPL higher than that of f 2 (I2). The distortion product was recorded with an average of
150 times. A cubic distortion product of 2f 1 – f 2 was measured as DPOAE.
4.4. Cochlear Preparation and Immunofluorescent Staining
The detailed methods and procedures of immunofluorescent staining can be found in our previous
reports [8,41]. After decapitation, the cochlea was isolated and fixed with 4% paraformaldehyde for
0.5–1 h. After decalcification with 10% EDTA for 2 days, the cochlea was embedded with OCT
(Cat # 4583, Sakura Finetek USA Inc., Torrance, CA, USA), and cut into 10-μm thick sections at
−22~ 24 ◦C by a cryostat (Thermo Electron Corp., Waltham, MA, USA). For immunofluorescent
staining, the sections were incubated in a blocking solution, which was composed of 10% goat serum
and 1% bovine serum albumin, with 0.1% Triton X-100 for 30 min, and then reacted with chicken
anti-human Panx1 antibody (1:500; #4515, a gift from Gerhard Dahl at the University of Miami Medical
School) and polyclonal rabbit anti-Cx30 antibody (1:400, #71-2200, Invitrogen, Carlsbad, CA, USA) or
monoclonal mouse anti-Cx26 (1:400, # 33-5800, Invitrogen, CA) at 4 ◦C overnight. The specificity of
this Panx1 antibody was verified in previous publications by Western blotting and Panx1 KO mouse
tissues in our laboratory and other laboratories [8,9,21,30,37,38]. After washout with PBS for three
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times, the sections were incubated with corresponding secondary antibodies (Alexa Fluor 488- and
568, 1:500, Molecular Probes, Eugene, OR, USA) at room temperature (23 ◦C) for 2 h to visualize the
staining. The staining was observed under a fluorescence microscope (Nikon 2000, Nickon, Melville,
NY, USA).
4.5. Cochlear Epithelium Whole-Mounting and Hair Cell Loss Accounting
As reported in our previous publications [21,44,45], the cochlear epithelia were isolated and
stained with phalloidin-Alexa Fluor-488 and propidium iodide in the whole-mounting preparation.
Hair cells were accounted under a 20× lens.
5. Conclusions
Our present study demonstrated that Gen-Panx1 KO mice have hearing loss. These data are
consistent with previous observations from other Panx1 KO mouse lines [21,30] and the known
occurrence of Panx1 mutation-induced hearing loss in humans [31]. These new data further confirm
that Panx1 deficiency can induce hearing loss. However, Panx1 function in hearing still remains largely
undetermined and needs to be further studied in the future. Also, as demonstrated by this study,
multiple auditory function tests, careful characterization of Panx1-deficient mice, and specificity of
anti-Panx1 antibody are important and required for assessing the role of Panx1 in hearing and other
Panx1 functions.
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Abstract: The most ubiquitous gap junction protein within the body, connexin 43 (Cx43), is a target of
interest for modulating the dermal wound healing response. Observational studies found associations
between Cx43 at the wound edge and poor healing response, and subsequent studies utilizing
local knockdown of Cx43 found improvements in wound closure rate and final scar appearance.
Further preclinical work conducted using Cx43-based peptide therapeutics, including alpha connexin
carboxyl terminus 1 (αCT1), a peptide mimetic of the Cx43 carboxyl terminus, reported similar
improvements in wound healing and scar formation. Clinical trials and further study into the mode
of action have since been conducted on αCT1, and Phase III testing for treatment of diabetic foot
ulcers is currently underway. Therapeutics targeting connexin activity show promise in beneficially
modulating the human body’s natural healing response for improved patient outcomes across a
variety of injuries.
Keywords: gap junctions; hemichannels; connexins; skin; wound healing; scar formation; peptide
1. Gap Junctions, Connexins, and Skin Wound Healing
Gap junctions (GJs) are complexes of intercellular channels composed of proteins encoded by
the connexin multigene family [1]. Gap junctions enable direct cytoplasmic coupling between cells,
permitting the intercellular exchange of small molecules (<1000 Da). Additionally, undocked gap
junctional connexons or hemichannels are also increasingly recognized as having roles in homeostasis
and disease [2–5]. A number of connexin gene family members have been reported to be expressed in
skin, including connexin 26 (Cx26), Cx30, Cx31.1, Cx30.3, Cx37, Cx40, Cx45 and Cx43 [6–10]. Of these,
Cx43 (Figure 1) is the most abundant and ubiquitous, being present in both the epidermal and dermal
cutaneous layers.
Wound healing typically progresses in four stages: Hemostasis, inflammation, proliferation,
and maturation [11]. Hemostasis begins immediately after injury, with platelets and various clotting
factors invading the wound space to create a fibrin clot that prevents further bleeding. After hemostasis
is achieved, inflammation begins within an hour of the original injury. Blood vessels dilate and become
more porous, enabling inflammatory leukocytes to invade the wound and phagocytize bacteria and
dead/damaged cells. It is this inflammatory stage that is the key target of many wound healing
Int. J. Mol. Sci. 2018, 19, 1778; doi:10.3390/ijms19061778 www.mdpi.com/journal/ijms359
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experiments. Fetuses, which do not mount a mature inflammatory response, are able to heal wounds
without leaving a lasting scar, particularly during mid-gestational stages [12–14]. Research has also
found that eliminating the inflammatory response in an adult mouse resulted in wounds that healed
efficiently with reduced scarring [15]. On the other hand, failure of the inflammatory phase to resolve
appears to be an important aspect of why pathological skin wounds, such as diabetic foot ulcers,
are slow to heal [16].
 
Figure 1. A diagram of connexin 43 (Cx43) spanning the cell membrane, with approximate locations
highlighted from which several memetic peptides were derived. αCT1: alpha connexin carboxyl
terminus 1.
Gap junction channel function and connexin activity have long been recognized as having
important assignments in nearly all phases of skin wound healing, including in the coordination of the
inflammatory response, propagation of injury signals between cells, wound closure, granulation-tissue
formation, and scar remodeling after injury [6–10,17–28]. In this short review, we will summarize key
findings on basic research into GJs and connexins in skin wound healing as well as recount recent
progress on translating this fundamental knowledge to the clinic.
2. Early Work on the Role of Cx43 in Cutaneous Wound Healing
A key initial set of findings on the role of connexins in cutaneous wound healing was made in the
laboratory of Paul and co-workers [26]. In studies in rodent models, it has been determined that Cx26,
Cx31 and Cx43 undergo characteristic cell-specific changes during the wound healing progression [26,
27]. Of particular note, Cx43 expression, as well as GJ-mediated intercellular communication, decreases
transiently in epidermal cells at the wound edge over the first 24 h following injury [26,27]. Cx43 was
downregulated not only in the epidermis of the wound immediately following injury but in the
epidermis surrounding the wound as well. A contrasting observation was made in the deep dermis.
Here, Cx43 was found to be transiently upregulated in fibroblasts and other tissues in the hours
immediately following wounding. After one week, and at later time-points associated with granulation
tissue formation and remodeling, increased Cx43 was associated with increases in granulation tissue
formation andmaturity. Taken together, these results indicated the possibility that localizedmodulation
of Cx43 levels, or certain aspects of Cx43 function, could be a potential method for beneficially altering
the cutaneous healing response. This prospect is also suggested by studies of the buccal mucosa,
the tissue that lines the inside of the cheeks and floor of the mouth [29], and gingival tissues lining the
gum [24,30,31]. In these mucosal tissues, both of which heal more quickly and with significantly less
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scarring than skin, this relatively fetal-like healing response occurs in association with a rapid and
strong downregulation of Cx43.
The first in vivo study of the potential benefits of manipulating wound-localized Cx43 levels
was conducted by Green, Becker, and colleagues, who topically applied Cx43 antisense directly to
healing wounds [20]. Application of a Cx43 antisense gel to adult rat wounds immediately after
wounding increased the rate of Cx43 downregulation in the epidermis and prevented the upregulation
of Cx43 in the dermis. This had the remarkable macroscopic effect of reducing inflammation at the
wound site, increasing the rate of wound closure, and reducing the appearance of scars at 12 days
post-wounding. These effects were particularly noticeable for incisional wounds, although excisional
wounds were also improved. The transient upregulation of Cx43 in the smooth muscle cells and
endothelial cells of the blood vessels after wounding has been suggested to increase vasodilation and
allow the infiltration of inflammatory cells. The Cx43 antisense prevented this upregulation, resulting in
a decrease in inflammatory neutrophil numbers and a reduction in the overall inflammatory response
in the antisense-treated tissue. The granulation tissue area was also significantly decreased in the
treated wounds. In a follow-up study, the group reported decreases in leukocytes and macrophages
in Cx43 antisense-treated wounds, concomitant with reduced expression of CC chemokine ligand-2
and Tumor Necrosis Factor alpha, suggesting that the observed enhanced regeneration may have been
mediated in part by attenuating inflammation at the wound site [32].
More recently, Martin and co-workers have used an alternate gene knockdown approach,
short interfering RNAs (siRNAs) targeted to Cx43, together with the Cx43 mimetic peptide Gap27,
to study channel-dependent and independent effects of Cx43 in the response of dermal cells to
injury [33]. Their data indicates that the response to targeting Cx43 varies between cell types
(keratinocyte versus fibroblast) and between cells of the same type (skin fibroblasts), but of different
tissue origins. The knockdown of Cx43 via siRNA enhanced both scrape wound closure and cell
proliferation in dermal fibroblasts of human adults and neonates, indicating roles for Cx43 in cell
proliferation and migration in these cell types. By contrast, in adult keratinocytes and juvenile foreskin
fibroblasts, only scrape wound closure was enhanced, indicating that in these tissue types Cx43 still
has a significant effect on cell migration, but its knockdown does not enhance proliferation.
Similar to the Cx43 knockdown/anti-sense experiments, excisional wound studies of a Cx43
heterozygous knockout (Cx43+/−) mouse showed decreased inflammation and increased wound
closure in the Cx43+/− mouse model compared to wildtype littermates [23]. While no difference was
reported in the collagen deposition of the granulation tissue, increased numbers of active dermal
fibroblasts were found in the wound space of the Cx43+/− mice, indicating increased fibroblast
infiltration/proliferation and activation. Gene expression of extracellular remodeling proteins,
including collagen I and III, was also significantly increased in the Cx43+/− mice seven days post-injury;
a time-point consistent with the initiation of the remodeling phase of scar tissue.
Research on chronic wounds, such as venous leg ulcers and diabetic foot ulcers, have shown that
Cx43 may be a key participating protein in these conditions [8,17,21,34–42]. Studies of diabetic wounds
found Cx43 persistence at the wound edge in these chronic wounds [34], while another study by the
Becker group on biopsies taken from human venous leg ulcers determined that Cx43 was significantly
overexpressed, not just at the edge of these chronic wounds, but throughout the entire dermis of the
biopsies [35]. Cx43 over-expression has also been reported to show strong correlations to varicose vein
severity in patients—a precursor to leg ulceration from venous insufficiency [36].
3. Preclinical Studies of αCT1 Peptide in Skin Wound Healing
During the last decade, a number of peptides targeting specific activities and functions of Cx43
have been developed and studied in the context of wound healing. These include peptides such as
alpha connexin carboxyl terminus 1 (αCT1), Gap19, Gap26, Gap27, and more, each targeting different
binding sites with varying specificity and size in attempts to narrow down the mode of action and
assess therapeutic opportunity [7–9,20,30,37–42]. Although many of these peptides have been studied
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in depth for years, only one peptide thus far, αCT1, has moved forward to pivotal Phase III clinical
testing (NCT02667327).
αCT1, also referred to as aCT1 or ACT1 in publications, incorporates the last nine amino acids
of the Cx43 carboxyl terminus (CT) with an amino terminal antennapedia internalization vector to
enable the peptide to penetrate the cell cytoplasm [43]. Originally developed to study the effects
of binding between Cx43 and the actin-binding protein zonula occludens-1 (ZO-1), αCT1 peptide
competitively inhibits the interaction between the Post synaptic density Drosophila disc large tumor
suppressor Zonula occludens-1 (PDZ)-binding domain at the CT of Cx43 and the second PDZ domain
of ZO-1 [43,44]. Ongoing work has indicated that the peptide also influences interactions within and/or
between Cx43 molecules, with effects on the Cx43 phosphostatus [45,46]. Unlike Cx43 antisense and
knockout models, αCT1 does not appear to affect Cx43 protein levels [7,43]. This suggests that its
mode of action in wound healing is unlikely to be mediated by the direct effects on the abundance
of Cx43, although the influence of αCT1 may well involve downstream alterations in the network
of protein-protein interactions that flow from a decrease of Cx43 protein levels at the wound edge.
The prevention of Cx43 recycling and transport facilitated by ZO-1 caused by αCT1, as well as non-PDZ
based interactions involving αCT1, including binding the Cx43 molecule itself [45], are two likely
candidates for causing this alteration.
Early observations in scratch wound assays of 3T3 fibroblasts treated with αCT1 noted that treated
fibroblasts appeared more active, migrating with greater speed across the scratch [6]. When mouse
excisional woundswere treated withαCT1, inflammationwas reduced, and thewound closure rate was
increased [7,10,47], mirroring the results of the Cx43 antisense and knockout experiments. Additionally,
strength testing analyses of scar tissue 90 days post-wounding revealed that αCT1 treated scars had
significantly improved mechanical properties compared to control [7]. Interestingly, the improvement
in scar mechanical properties seen at 90 days was more marked than that at 30 days post-wounding,
suggesting that the acute treatment by αCT1 had effects that continued long into the remodeling phase
of scar formation [7,47]. Additional studies of αCT1 skin wound healing were conducted in a pig
model [7]. Porcine models are considered the gold standard for wound healing studies as pig skin
is thought to be the closest analogue to human skin [48]. Porcine dermal wounds treated with αCT1
showed decreased granulation tissue area size and increased sub-epidermal vascularity, somewhat
regenerating the patterns of blood vessel distribution found in unwounded skin [7].
Additional therapeutic opportunities beyond undiseased dermal wound healing have been
identified for αCT1. Topical ophthalmic delivery of αCT1 resulted in decreased inflammation and
accelerated healing in both a standard rat model of corneal injury [49] and a diabetic rat model
of corneal injury [50]. The Cx43-based peptide has also been found to modulate the biological
response to silicone implants, attenuating neutrophil infiltration and increasing vascularity of the
specialized internal scar tissue that forms around implants, also reducing the density of activated
fibroblasts (myofibroblasts) and type I collagen deposition in this tissue [51]. Application of αCT1
directly to an infarcted heart improved cardiac contractility, reduced the propensity for arrhythmia,
and maintained action potential conduction velocity at normal speeds [46,47]. As we will discuss in
detail in the following section, treatment of chronic diabetic foot ulcers and venous leg ulcers with
αCT1 significantly reduced ulcer size, increased the likelihood of complete ulcer closure, and decreased
the time to ulcer closure [37,41].
4. Clinical Trials
Given the efficacy of αCT1 in animal studies, multiple Phase I and Phase II clinical trials have
since been conducted on the wound healing and scar reduction capabilities of αCT1 [37–39,41,42]—see
also Table 1. These clinical trials have studied the safety and efficacy of αCT1 in the treatment of
venous leg ulcers, diabetic foot ulcers, and surgical wounds, with the peptide being tested as the active
ingredient of a gel formulation branded as Granexin®.
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Table 1. Summary of completed alpha connexin carboxyl terminus 1 (αCT1) clinical trials.
Clinical Trial Phase Phase I Phase II






Treatment Regimen Immediately afterwounding and 24 h later
Twice during the
1st week and once
a week thereafter
Twice during the
1st week and once
a week thereafter
Immediately after
wounding and 24 h later
Patients 49 92 92 91
No Adverse Effects    
Mean Percent Ulcer Area
Reduction at 12 Weeks -
79% αCT1 vs. 36%
control
94% αCT1 vs. 52%
control -
Incidence of Complete
Ulcer Closure at 12 Weeks -
57% αCT1 vs. 28%
control
81% αCT1 vs. 50%
control -
Comparative Vancouver
Scar Scale Scores at
9 Months
- - -
47% better for αCT1
compared to
within-patient controls
The initial clinical trial on the effect of αCT1 on human dermal wound healing was performed on
49 healthy human volunteers in Switzerland in a randomized, double-blind Phase 1 study. As shown in
Figure 2, on Day 1 a biopsy punch was used to create a wound in the unblemished skin underneath both
arms. One underarm wound from the patient was treated with an αCT1 gel formulation, while the
wound on the patient’s other underarm was treated with a vehicle gel, enabling within-patient
comparisons. Treatments were applied immediately after injury and again 24 h later. The αCT1
dosage in the gel depended on the cohort. Cohort 1 received a gel with 20 μM of αCT1; Cohort 2,
50 μM; Cohort 3, 100 μM, and Cohort 4, 200 μM of αCT1. Cohort 3, which received a gel with 100
μM of αCT1, was given the same dosage that was used in Phase II clinical trials and is considered the
therapeutic dosage. Wound healing was followed for 29 days and recorded photographically. On Day
29, following final photograph collection, the healed scars were biopsied to permit examination of
the histological features of the scar tissue. The biopsies were washed, placed in paraformaldehyde
for 24 h, and embedded in paraffin for sectioning. Data collected from these biopsy sections revealed
improved healing outcomes, in terms of collagen order, density and maturity, with αCT1 treatment
and has formed the basis of ongoing studies into the αCT1 mode of action. Importantly, from the
perspective of the safety focus of Phase I clinical testing, αCT1 usage showed no local or systemic
adverse effects associated with treatment.
Continuing onto Phase II, two of the Phase II clinical trials involved studies of chronic skin
wounds characterized by chronic inflammation and retarded re-epithelialization: Venous leg ulcers
and diabetic foot wounds [37,41]. For treatment of chronic wounds, αCT1 was topically applied to
the wound area twice during the first week, and then on a weekly basis thereafter. In the venous
leg ulcer trial, n = 92 patients were randomized for study [37]. αCT1 treatment was associated with
a significantly greater reduction in the mean percent ulcer area by 12 weeks (79% wound closure
in the treatment group compared to 36% in the control), and a doubling in incidence of complete
wound closure by 12 weeks (57% of the treatment group had completely healed wounds by the study
end point of 12 weeks compared to only 28% of the control group). Venous leg wounds treated with
αCT1 also showed a shorter time to 50% (p = 0.014), and 100% (p = 0.041) wound closure than the
control group. The median time to 50% and 100% wound closure in the treatment group was 2.9 and
6.0 weeks, respectively, while the control group took an average of 6.9 and 12.1 weeks to reach the
same milestones.
Similar results were found for diabetic foot ulcers in a separate clinical trial, in which n = 92
patients were randomized for study [41]. The mean percent ulcer area at 12 weeks was 94% for the
treatment group versus 52% for the control, and the incidence of 100% wound closure at the study
end point of 12 weeks was 81% for treatment versus 50% for control. Median time to complete wound
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closure was 6.0 weeks for the treatment group while the control group’s estimated median time to
closure was 14.6 weeks. Time to 50% ulcer closure for this study was not significantly different.
To summarize the results of these two clinical trials, chronic wounds treated with αCT1 heal more
quickly and are more likely to completely resolve within 12 weeks than the control group of chronic
wounds treated with the current standard of care only.
Figure 2. Alpha connexin carboxyl terminus 1 (αCT1) Phase I clinical trial sampling scheme, performed
on healthy human volunteers.
In a third Phase II clinical trial, the potential of αCT1 in reducing post-surgical scarring was
assessed [39]. Unlike the weekly αCT1 application protocol applied in the treatment of chronic
wounds, αCT1 was applied to surgical wounds immediately after injury and then again 24 h later.
This treatment regime was followed by scarring assessment over a nine-month study period. This acute
treatment regime was similar to that used in the earlier animal studies involving therapeutic evaluation
of the Cx43 antisense as well as αCT1 [7,20]. The clinical trial involved 91 patients who had received
laparoscopic abdominal surgery involving two or more incisions, allowing within-patient controls
with the surgical wound on one side of the abdomen treated with αCT1 and the control wound on
the opposite side. Treatment versus control was randomized to patient sides, and both wounds were
treated with identical conventional standard of care protocols. [39]. Scar appearance, as judged by the
Vancouver Scar Scale clinical standard, was equivalent between treatment groups after one month,
but after nine months αCT1 treated scars showed a highly significant, 47%, improvement (p < 0.005)
in scar appearance (Figure 3). Since αCT1 was only applied in the first two days, the results raise
interesting questions about the mechanism by which brief, transitory targeting of Cx43 and/or its
activities after injury is able to induce a long-term modification in scarring outcome.
Preclinical results found improvements in the tensile strength of αCT1 treated wounds—a
property directly linked to extracellular matrix composition and structure [7,47]. In line with this,
we have identified structural changes in the extracellular matrix of αCT1 treated wounds from biopsies
collected in Phase I clinical trial that suggest the peptide is prompting the deposition of an initial
collagen matrix more similar to unwounded skin (Figure 4). Work exploring this hypothesis is
currently ongoing.
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(a) (b) 
Figure 3. (a) Photographs of a single patient’s αCT1 and control treated wounds immediately after
surgery and at the study end point of nine months; (b) Mean percentage difference between treatment
and control scar scores for the Phase II scar appearance clinical trials [35].
 
Figure 4. H&E stainedwhole sections of Phase I biopsies from a single patient at 29 days post-wounding.
The left arm was treated with a vehicle (left), while the right arm was treated with 100 μM αCT1 (right).
The boxed regions highlight areas of subtle variance in tissue organization deep within the dermis
between the control and treated scars—magnified 4.67× from upper panels.
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5. Conclusions
Preclinical and clinical studies of αCT1 have indicated that this peptide, based on the CT-most
sequence of Cx43, beneficially modulates the healing of both undiseased and diseased, chronic skin
wounds without detrimental side-effects. However, important work remains to be undertaken to
characterize the details of the molecular and cellular mechanisms by which therapies targeting Cx43
function, such as αCT1, improve wound healing and mitigate scar formation. Identifying key parts of
the cascade may allow the development of improved, targeted therapeutics, reducing the potential for
off-target effects. Connexin-based therapeutics are also being explored in preclinical studies of injury
to other organ systems and tissues, including the heart, eye, brain, and lungs [52–59]. Moving from
topical delivery of drugs like αCT1 to internal administration in tissues such as the heart or brain will
pose significant challenges. The regulatory bar for safety will be necessarily higher. There will also be
questions on optimal route and mode of delivery, treatment regime, the stability of the drug in body
fluids, the negotiation of the immune system, and obstacles such as the blood-brain barrier that will
need to be addressed. This being said, ongoing research provides encouragement that connexin-based
therapeutics could be a promising path towards future medical interventions in the healing of the
human body.
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